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Abstract 
Introduction: Patients with severe chronic obstructive pulmonary disease (COPD) 
experience breathlessness leading to exercise limitation and impacting on Quality 
of Life (QOL). Pulmonary rehabilitation (PR) may improve QOL, but those with the 
severest disease are frequently hospitalised and cannot readily access PR. 
Previous studies have trialled positive pressure as a means of relieving ventilatory 
load in one off exercise tests, allowing patients with more severe COPD to exercise 
(Maltais, Reissman and Gottfried, 1995). Other studies have assessed either mixed 
pathology or patients with stable COPD (Menadue, et al. 2010, Dyer et al. 2011). 
Therefore there was a need to investigate the feasibility of allowing patients with 
severe unstable COPD to exercise using non-invasive ventilation (NIV). 
Aim: To evaluate the feasibility (including acceptability) of applying NIV during 
exercise in both the hospital environment and at home with patients who have 
severe COPD who had been hospitalised for an acute exacerbation with acidotic 
respiratory failure.  
Methods: A mixed methods approach was applied. Patients were recruited when 
medically stable and randomised into three limbs: 1. Standard Care; 2. Exercise on 
NIV in hospital for length of admission and 3. Exercise on NIV in hospital and 
continued at home for three months. Blinding of the participants or researcher was 
not possible. Quantitative outcome measures were collated for all groups including: 
six minute walk test (6MWT); St George’s respiratory questionnaire (SGRQ); 
European quality of life - 5 Dimensions - 5 Levels (EQ-5D-5L); The London Chest 
Activity of Daily Living Questionnaire (LCADL); Borg breathlessness score 
(MBORG); Modified Medical Research Council (MMRC) dyspnoea score; activity 
levels (ActiCal monitor); self-reported medication use, access to healthcare and 
hospital admissions. Semi-structured interviews were performed with patients in 
limb three to assess acceptability. 
Results: Sample size recruited for the trial was n = 18. At the end of the trial n = 15 
remained (n = 6 standard care, n = 5 exercise on NIV in hospital and n = 4 exercise 
on NIV in hospital and home). Three patients died during the trial. No other 
participants dropped out of the trial. All outcome measures were completed except 
the activity monitor (ActiCal). There was a trend for improvement in 6MWT, SGRQ, 
LCADL and EQ-5D-5L in the exercise on NIV from hospital to home group.  Data 
from the semi-structured interviews revealed that the trial was acceptable to the 
participants in the exercise on NIV in hospital and home group. 
Conclusions: This novel trial has shown that it is feasible and acceptable to patients 
with severe COPD to exercise on NIV. A further multi-centre RCT is required to 
achieve sufficient numbers to detect whether there is statistical significance in the 
primary outcome of the 6MWT, to identify the clinical relevance of any changes, and 
to evaluate cost effectiveness. 
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Glossary 
Acid base balance: Blood acidity increases when the level of acidic compounds 
in the body increase or when the level of alkaline compounds in the body decrease 
(both caused by intake or production, or decreased through elimination). Blood 
alkalinity increases with the opposite processes. The body's balance between 
acidity and alkalinity is referred to as acid-base balance (Levitzky, 1991). The 
acidity or alkalinity of any liquid is shown on the pH scale. The blood's acid-base 
balance is meticulously controlled because even a slight variation from the normal 
range can damage organs. The aim of acid-base balance is to achieve a stable 
concentration of hydrogen ions in body fluids (Mosby, 2012). 
Acidosis: Increased acidity in the blood and tissues caused by an increased 
hydrogen ion concentration. This causes a fall in pH to less than 7.35. If the pH of 
arterial blood falls below 6.8 there is irreversible cell damage and death (Levtizky, 
1991). 
Accessory muscles: These are additional muscles that assist with inspiration. 
They include the external intercostals, sternomastoids, trapezium, pectoralis 
minor and the scalene muscles (Dempsey et al., 2006).  
Airway Obstruction (airflow obstruction): In COPD the airways can collapse 
on exhalation because of a loss of stable alveolar walls, preventing air from 
moving out of the lungs. Additionally there may be chronic inflammation and 
mucus causing a blockage to the airway. In the case of COPD pathology the 
airway obstruction is chronic and not, or only partially, reversible. The amount of 
obstruction is measured by Spirometry (Mitchell, 2015). 
Anaerobic threshold (AT): The point during cardiopulmonary exercise test 
beyond which the demand of the muscles for oxygen exceeds the amount 
delivered to them, so that they start to add aerobic with anaerobic uptake 
(Dempsey et al., 2006).  
Alveolar ventilation (VA): Is the volume of air that reaches the alveoli and is 
available to take part in gas exchange (movement of oxygen into the blood and 
carbon dioxide from the blood). When VA is low this is referred to as 
hypoventilation (Dorland, 2011).  
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Carbon dioxide (CO2): The waste gas breathed out in expiration (Mosby, 2012). 
CO2 is essential for regulating breathing levels and maintaining body pH (Mosby, 
2012). PaCO2 is the partial pressure of CO2 in the arterial blood, the overall blood 
gas pressure applied by CO2.The normal level of CO2 is 4.7-6.0kPa (kilopascal). 
High CO2 levels are referred to as hypercapnia. If the CO2 exceeds the normal 
level blood becomes more acidic (Frew and Doffman, 2008). 
Carbon dioxide output (VCO2): The volume of CO2 (mL/min) breathed out 
through the lungs (Mosby, 2012). 
Cardiac output: This is the volume of blood pumped by the heart per minute and 
is the product of the amount of blood per heart beat (called the stroke volume) 
multiplied by the number of heart beats in a minute (heart rate (HR)) (Aliverti and 
Macklem, 2008). 
Cellular respiration: For muscles to contract they need energy, which they get 
by burning fuel. Carbohydrate is the fuel which is ‘burnt’ using O2.  The waste 
products produced are CO2 and water (H2O) (Levitzy, 1991). 
Continuous Positive Airways Pressure (CPAP):  is a mild positive pressure 
which splints open the airways decreasing breathing effort and allowing time for 
gas exchange (Kinnear, 2008). 
Dead space ventilation (VD): Not all of the air that passes the lips reaches the 
alveolar unit where gas exchange happens. Part of the gas from each breath 
remains in the conducting airways (trachea and bronchi) and therefore does not 
participate in gas exchange (Laszlo, 1994). Physiological dead space (VD) is the 
anatomical dead space and areas of lung ventilated but not perfused so no gas 
exchange occurs (Laszlo, 1994). 
Dynamic lung hyperinflation (DLH): This is a temporary increase in operating 
lung volumes above their resting values, caused by a limitation in expiratory flow 
(O’Donnell, Revill and Webb, 2001). 
End-expiratory lung volume: The volume of air remaining in the lung at the end 
of spontaneous expiration. If increased this volume can contribute to gas trapping 
and DLH (O’Donnell, Revill and Webb, 2001).  
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Exacerbation: Increase in severity of disease and/or signs and symptoms (Kim 
et al., 2004). 
Expiration: Breathing out, the movement of air out of the lungs (Mosby, 2012). 
Forced Expiratory Volume in one second (FEV1): The volume of gas exhaled 
in the first second following full inspiration. It is a sign of airway obstruction.  
Forced Vital Capacity (FVC): The greatest volume of gas that can be exhaled 
following full inspiration by breathing out as vigorously and quickly as possible. 
Golgi tendon organ: Is a neurotendinous organ (spindle) within the muscle 
sensing changes reported from the tendon regarding muscle tension and inhibits 
movement if tension is high to protect against injury. (American Thoracic Society 
(ATS), 1999) 
Humoral stimulus: Is when a hormone is released in response to change in the 
blood or other body fluids (ATS, 1999). 
Hyperpnoea: Increased depth and rate of breathing in response to exercise 
(Dempsey, 1985). 
Hypoventilation: This is when ventilation is low caused by either a reduced 
respiratory breathing frequency (RR) or by reduced depth of breathing. It causes 
an increased amount of CO2 in the blood (Frew and Doffman, 2008). 
Inspiration: Breathing in, the movement of air into the lungs (Mosby, 2012). 
Inspiratory capacity (IC): The maximum amount that can be inspired at the end 
of a tidal expiration (Laszlo, 1994). 
Inspiratory Pressure Support (IPS): Positive pressure via a face mask to 
increase depth of breathing (Tidal volume (VT)) (Kinnear, 2008). 
Maximum Oxygen uptake (VO2max): Oxygen uptake (VO2) is the volume of 
oxygen (mL/min) taken up from the lungs into the blood and utilized in metabolism 
in the body primarily, in mitochondria (Laszlo, 1994). The highest value of oxygen 
that could be used during a cardiopulmonary exercise test, rarely achieved in 
clinical practice. A VO2max of < 80% predicted is abnormal. The lower the VO2 max 
the worse the outcome. VO2peak is the highest value of oxygen consumption 
observed during an exercise test. VO2Resp is the highest value of oxygen 
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consumed in healthy people during quiet breathing (O’Donnell, Revill and Webb, 
2001). 
Minute Ventilation (VE): (L/min) sum of the volume of all the breaths in one 
minute. It is the product of the frequency (f) and depth of breathing (TV) (Dempsey 
et al., 2008).  
Mitochondria: Is a membrane bound organelle found in cells. These structures 
are sometimes described as "the powerhouse of the cell" because they generate 
most of the cell's supply of adenosine triphosphate (ATP) used as a source of 
energy. In addition to supplying cellular energy, mitochondria are involved in other 
tasks such as cell signalling, cellular differentiation, cell death, as well as 
maintaining the control of the cell cycle and growth (Allaire et al., 2004).  
Muscle dysfunction: Is defined as: 
“the loss of at least one of the two main muscle properties: Strength and 
endurance. The former corresponds to the capacity to develop a short 
maximal contractile effort, whereas the latter is characterized by the ability to 
maintain a submaximal exercise load throughout a more prolonged period of 
time”.  
(Gea, Agusti and Roca, 2013, p.1222) 
Normal Quiet Breathing (NQB): Normal breathing at rest/ relaxed breathing 
(Laszlo, 1994). 
Non-invasive ventilation (NIV): Provides both inspiratory positive pressure and 
a continuous splinting (expiratory) pressure via a face mask (Kinnear, 2008).  
Oxygen: O2 gas essential for the body to convert into energy for use in cell 
metabolism, essential for cell, tissue and organ life (Mosby, 2012). The partial 
pressure of O2 (PaO2) is the amount of overall blood gas pressure applied by O2. 
Normal PaO2 is 10.7-13.4kPa (Frew and Doffman, 2008).  
Parenchyma: The working parts of the lung only related to gas exchange: alveoli, 
terminal bronchioles and vessels. However the term may include any form of lung 
tissue including bronchioles, bronchi and interstitium (Mattison and Christensen, 
2006). 
PEEPi: Intrinsic Positive Expiratory End Pressure (AutoPEEP) is incomplete 
expiration prior to the initiation of the next breath causing progressive air trapping 
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(hyperinflation). This accumulation of air increases alveolar pressure at the end 
of expiration (Fleury, 1985). 
pH: A figure stating the acidity or alkalinity of a solution on a scale on which seven 
is neutral, lower values are more alkaline. On an arterial blood gas (ABG) the 
normal pH is 7.35 (Mosby, 2012). 
Pleural Pressure (PPL): The pressure surrounding the lung within the pleural 
space (Laszlo, 1994). 
Polycythaemia: Excessive haemoglobin and haematocrit within the red blood 
cells. The symptoms can be fatigue, high blood pressure and headaches. It can 
cause blood clots causing cerebral vascular attack (stroke), myocardial infarction 
(MI) (heat attack), deep vein thrombosis (leg/arm clot) and pulmonary embolism 
(Lung clot) (Mosby, 2012). 
Proportional Assisted Ventilation (PAV): Mode of ventilation via a face mask 
which provides inspiratory flow and volume to meet the demands of increased 
ventilation despite any changes in lung compliance or resistance (Hernandez et 
al., 2001).  
Pulmonary hypertension: This is when the pressure in the blood vessels in the 
lungs (the pulmonary vasculature) is abnormally high. The pulmonary vasculature 
carries blood that is low in oxygen through the pulmonary arteries from the right 
side of the heart to the lungs. At this location red blood cells collect oxygen. The 
blood is then pumped back to the left side of the heart and around the body. With 
pulmonary hypertension the higher pressure in the blood vessels means the right 
side of the heart needs to work harder to pump the blood. Chronically this causes 
the right side of the heart to fatigue with this extra work, and pumps less 
effectively. The symptoms include dyspnoea, swollen ankles, fatigue, dizziness 
and chest pain (British Lung Foundation (BLF), 2013). 
Positive End Expiratory Pressure (PEEP): Applied positive pressure from a 
ventilator to maintain airways pressure above atmospheric pressure to stop end 
expiratory alveolar collapse and improve respiratory gas exchange. 
Respiratory Acidosis: Uncompensated respiratory acidosis is when the arterial 
blood pH is less than 7.35 and the partial pressure of carbon dioxide (PaCO2) 
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greater than 6kPa in an ABG (BTS, 2002). This condition is caused by low VA 
(shallow breathing). This causes PaCO2 build up, which subsequently combines 
with water in the body to make carbonic acid, therefore reducing plasma pH. 
Respiratory acidosis can be caused by medullary trauma, neuromuscular 
disease, spinal injuries, chest injury, pneumonia, pulmonary oedema, COPD, and 
cardiac arrest (Mosby, 2012).  
Respiratory failure: is defined as: 
“the failure to oxygenate the blood to achieve an arterial partial pressure of 
oxygen (PaO2) > 8kPa whilst breathing room air at sea level (fractional 
inspired oxygen concentration; FiO2 = 0.21). It is further sub-classified into 
two types, which describe the adequacy of ventilation in clearing carbon 
dioxide from the blood. There are two types: 
Type 1: Respiratory failure without ventilatory failure and PaO2 < 8.0kPa with 
PaCO2 < 6.5kPa 
Type 2: Respiratory failure with ventilatory failure and PaO2 < 8.0 kPa with 
PaCO2 > 6.5kPa” 
(Burt and Arrowsmith, 2009, p. 475). 
Tidal volume (VT): size of each breath or the volume of gas inspired or expired 
during an unforced full breathing cycle (Kinnear, 2008).  
Ventilatory Drive (respiratory drive, or respiratory control): Process by which 
detected changes in the body's hydrogen, through changes in pH and 
PCO2 levels, are responded to by the central nervous system's stimulation of the 
rhythm, effort and rate of breathing (Levitzsky, 1991).  
Ventilatory limitation (VL): In lung disease a person will stop exercising because 
of VL. This is normally experienced as severe breathlessness. The person stops 
before maximum cardiac capacity is reached (HR < 80% predicted) (O’Donnell 
and Webb, 2008). 
Vital Capacity (VC): The maximum amount of gas that can be exhaled after a 
maximum inhalation or inhaled following a maximal exhalation (Laszlo, 1994). 
Work load (Maximum workload (Wmax)/peak workload (WLpeak)): The effort 
during exercise testing or training. Can relate to HR, CO2, metabolic equivalent of 
resting O2 consumption (METS) and other physiological products. 
  
35 
 
Acknowledgements 
I cannot express enough thanks to my Supervision team for their continued 
support and encouragement.  I would like to express gratitude to Professor Shea 
Palmer, my Director of studies, for his willingness to take me and my project on, 
for his patience, motivation and immense knowledge. Special thanks and 
recognition, I would like to offer, to my supervisor and colleague Dr Adrian 
Kendrick. Without the guidance of Dr Kendrick my thesis may just have been an 
idea, I once had, as a clinician. Dr Kendrick provided initial support and 
encouragement to undertake this research. Further thanks go to Professor 
Margaret Fletcher for her suggestion and encouragement to embark on a PhD, 
without which I would never have ever considered this as a possible option. 
Professor Margaret Fletcher provided the voice of calm, reason and sensible 
suggestions throughout my PhD journey. Finally to Kathy Badlan, who provided 
in-depth clinical understanding, empathy to my juggling of roles of full time job, 
PhD and Mother. Kathy Badlan encouraged me through the whole PhD process, 
never once made me feel incapable and helped shape me into the beginnings of 
a qualitative researcher. I could not have imagined a better team to advise and 
mentor me for my PhD. 
Additionally I would like to thank the faculty who supported our postgraduate 
training days and led the M-level modules I undertook. Special thanks go to Dr 
Fiona Cramp and Dr Richard Gray for their encouraging feedback at progression 
points which have directed me to completion. 
Special thanks to my participants, for allowing me a glimmer into your lives and 
reminding me of the importance of looking at situations with fresh vision and the 
importance of re-examining my clinical practice. I hope I have been able to offer 
a true reflection of your experiences. 
My completion of this project could not have been accomplished without the 
funding and support of Philips-Respironics and the NHS funded Clinical Academic 
Training Programme. The project relied upon the willingness and support of my 
Therapy management team and colleagues within the Respiratory Medicine team 
and Home NIV team, thank you all.  
36 
 
I would also like to thank my peers Tori Salmon and Serena Halls, what 
amusement we have had along the way (most of which I am guilty of providing). I 
thought this PhD would bring many opportunities but I had not considered finding 
friendship. 
Additional thanks go to a few key professionals, who have influenced my early 
career: Dr Leyla Osman who deserves a special mention. Leyla was a true 
inspiration and role model, who ensured I would always question clinical practice 
and strive for perfection; Alex Harvey, who taught me the importance of 
thoroughness and enhanced my clinical practice; Maria Buxton, for demonstrating 
what I could achieve in my career and lastly to Craig Brown, who taught me to 
think outside the box, embrace extended roles and also taught me to have fun 
along the way. 
To my family: My kind, gentle Dad who taught me to try my best; my special Mum, 
who I took my work ethos from and who works so hard. Mum you have supported 
me at every stage of my life, encouraged me through disappointment to be able 
to begin again. You make nothing seem impossible; my loving, calm and patient 
sister who has taught me the importance of seeing the person behind the long 
term condition. Additional gratitude to my Australian editors, my in-laws Diane and 
Ian, who managed to edit my thesis on an IPAD camping in the Bush! Special 
thanks to my brother-in-law Phil, who made time to edit despite caring for many 
little folk. 
Finally but most importantly to my caring, loving husband Joel and my wonderful 
little boy, Noah. Joel, you are my rock who always supports my crazy ideas 
including this one. As my chief editor and IT whizz, you have encouraged and 
helped out in all ways possible, and I can’t thank you enough. Noah, my little fish, 
you were the best surprise miracle and came along while I was busy looking the 
other way. You have proved a welcome distraction even when you decided you 
had had enough of Mum working and turned the computer off. It is all turned off 
now, so we can finally play with your animals. 
  
37 
 
Chapter 1 Background 
 
1.0 Introduction 
The purpose of this chapter is to provide the background to the research idea, 
subsequent research project and thesis. The chapter addresses the following 
topics: 
 Introduces the epidemiology of Chronic Obstructive Pulmonary Disease 
(COPD) and how it impacts on the lives of patients with the condition.  
 Examines the treatment options available to these patients with focus 
placed on discussing Pulmonary Rehabilitation (PR), including the content 
and structure of such intervention programmes.  
 Discusses the pathophysiology of COPD and why exercise is limited. 
 Explains the problems with access to PR and identifies other possible 
forms of delivery. One realistic treatment option discussed is non-invasive 
ventilation (NIV).  
 Describes the history of NIV and how it is currently used and the potential 
for it to be used to assist PR.  
 The chapter ends by summarising the thesis structure. 
 
1.1 Chronic obstructive pulmonary disease (COPD) 
1.1.1 Definition 
COPD is an umbrella term used to describe numerous chronic conditions 
including chronic bronchitis, emphysema, chronic obstructive airways disease 
and chronic airflow limitation (CAL) (National Institute of Health and Care 
Excellence (NICE), 2010). This is illustrated in Figure 1.1 
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Figure 1.1 The overlap of disease with different pathophysiology within a COPD 
diagnosis 
Reprinted with permission of the American Thoracic Society. Copyright © 2016 American 
Thoracic Society. American Thoracic Society (1995) Standards for the diagnosis and care 
of patients with chronic obstructive pulmonary disease. American Journal of Respiratory 
Critical Care Medicine.152:S77–121, Figure 1. 
 
COPD is distinguished by damage to the small and large airways and lung 
parenchyma (lung tissue) and its vasculature, caused by chronic inflammation 
(NICE, 2010; O’Donnell, Revill and Webb, 2001). This causes non-reversible 
progressive airflow obstruction (see Glossary, p.25) demonstrated by a decline in 
lung function tests over time (Jones and Ostrem, 2011; NICE, 2010). 
Impairments caused by COPD include airflow obstruction (difficulty exhaling air), 
which, in more advanced disease, occurs even during normal quiet breathing (see 
Glossary, p. 32); increased work of breathing; deconditioning; and skeletal muscle 
dysfunction (see Glossary, p. 32) (O’Donnell, Revill and Webb, 2001). This 
causes the symptoms of worsening breathlessness, chronic productive cough, 
and limited exercise tolerance (NICE, 2010) and these contribute to a negative 
impact on psychological state and social engagement (British Thoracic Society 
(BTS), 2013; O’Donnell, Revill and Webb, 2001). 
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1.2 Diagnosis of COPD 
Diagnosis is made from a combination of clinical judgements from the patient’s 
presentation including patient subjective history, reported symptoms, physical 
assessment and spirometry testing to confirm airflow obstruction (NICE, 2010). 
COPD usually only occurs in people over 35 years of age and many people are 
not diagnosed until after they are 50 years old (NICE, 2010). 
Airflow obstruction is defined as a decreased FEV1/FVC ratio after bronchodilators 
(where FEV1 is forced expired volume in 1 second and FVC is forced vital 
capacity, see Glossary, p. 31). If FEV1/FVC is less than 0.7 or if FEV1 is ≤ 80% of 
the predicted normal this is indicative of airflow obstruction (NICE, 2010). This is 
the current working definition of COPD but it is considered to be flawed and could 
lead to misdiagnosis, which is why history and symptoms must also be considered 
(Rennard et al., 2013; Qaseem et al., 2011). The differences between normal 
spirometry and a patient with COPD are demonstrated in figure 1.2.
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Figure 1.2 Spirometry demonstrating post bronchodilator FEV1 and FVC in two 
male patients of similar age and height, one with COPD and one patient without 
COPD. 
Figure reproduced with permission from Dr Adrian Kendrick, Association of Respiratory Technology and 
Physiology, NIV course, Holiday Inn, Birmingham, COPD presentation, October 2014. 
Abbreviation key: COPD Chronic obstructive pulmonary disease, FEV1 
Forced expiratory volume in one second, FVC Forced vital capacity. 
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1.3 Severity of COPD 
The patient must present with clinical symptoms for a diagnosis of ‘mild’ COPD 
and all diagnosed cases must have FEV1/FVC < 0.7. See Table 1.1 for NICE 
(2010), definition of disease severity. 
Table 1.1 NICE guideline 2010 of COPD severity 
FEV1 (% predicted) Definition 
< 80 Mild 
50-79 Moderate 
30-49 Severe 
< 30 or  
< 50 but with additional 
respiratory failure (see 
glossary, p. 34) 
Very Severe 
Abbreviation key: FEV1 Forced expiratory volume in one second 
 
1.4 Pathophysiology of COPD 
Traditionally COPD was seen as a disease that predominantly affected the 
respiratory system (Calverley and Walker, 2003). However it is now known that 
COPD affects the skeletal muscles, the cardiovascular system and contributes to 
depression, weight loss and osteoporosis (Anderson and MacNee, 2009; 
Norwood and Balkissoon, 2005; Sin, 2003; Biskobing, 2002; Prescott et al., 2002). 
This is an important consideration because disability experienced does not always 
correspond with FEV1 (Doherty, 2008). A more comprehensive assessment of 
severity would also include frequency of exacerbations, dyspnoea level, exercise 
capacity, six minute walk test (6MWT), body mass index (BMI) and evaluation of 
heart failure (NICE, 2010). Additionally FEV1 within large powered studies has not 
been demonstrated to respond to medication including inhaled bronchodilators 
and steroids (Tashkin, Celli and Senn, 2008; Calverley, Anderson and Celli, 
2007). 
COPD includes three different subgroups of emphysema, chronic bronchitis and 
chronic asthma that overlap to a different degree in each patient, previously 
demonstrated in figure 1.1 (ATS, 1995). The pathophysiology of each subgroup 
is described below. 
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 1.4.1 Emphysema:  Pathophysiology 
This is defined by abnormal, permanent widening of air spaces distal to the 
terminal bronchioles, with additional obliteration of alveolar walls (Mattison and 
Christensen, 2006). The natural elasticity of the lungs is also lost causing 
hyperinflation and elimination of the alveolar walls. This leads to reduced gas 
exchange because of a decrease in the alveolar surface area (Mattison and 
Christensen, 2006). 
1.4.2 Chronic Bronchitis: Pathophysiology 
Chronic inflammation causes an increase in mucus production, a normal 
defensive response. This leads to an increase in the number of goblet cells that 
secrete mucus, further contributing to hyperplasia of the mucus gland and 
resulting in infections (Innes et al., 2006). This all leads to narrowing of the small 
airways and airway obstruction. 
1.4.3 Chronic Asthma: Pathophysiology 
Pathophysiologically there is smooth muscle constriction combined with 
inflammation of the bronchi (Fanta, 2009). Some patients may have allergic 
asthma which means that their airways react to allergens or irritants. In response 
to the allergen there is a release of histamine and prostaglandin, which cause 
constriction of the smooth muscle in the airway, inflammation of mucosa and 
increased secretion, all leading to airway obstruction (Frew and Doffman, 2008). 
When there is little or no reversibility of obstruction on lung function testing then 
asthma has evolved to become a diagnosis of COPD. 
1.4.4 COPD: A multi-system disease 
More recent thought is that COPD is actually a multi-system disease (Decramer 
et al., 2008). This is because COPD is not just associated with airway obstruction 
but is also an inflammatory process (Jones and Ostrem, 2011). COPD is a 
catabolic process and individuals are at risk of becoming underweight, which is a 
poor prognostic clinical feature (Chailleux, Laaban and Veale, 2003). It is well 
documented that COPD is associated with not only pulmonary but systemic 
inflammation. A systematic review (SR) by Gan et al. (2004) demonstrated 
increased levels of systemic inflammatory markers including C-reactive protein, 
IL-6 and fibrinogen in patients with COPD compared to controls. Exacerbations 
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further enhance this inflammation contributing to other systems being exposed to 
inflammation (Agusti et al., 2012). A fuller exploration of COPD pathophysiology 
is beyond the scope of this thesis. The reader is directed towards Calverley and 
Walker (2003) for a more comprehensive overview.  
1.4.5 COPD and skeletal muscles 
Quadriceps muscle dysfunction has been identified in patients with COPD even 
at the early stages of the disease (Seymour et al., 2010). This is a term used to 
describe the decreased muscle strength, decreased endurance and increased 
fatigability of the muscle (Mador, Bozkanat and Kufel, 2003; Gosselink, Troosters, 
Decramer, 1996). Additionally, quadriceps strength and rectus femoris muscle 
cross-sectional area are significantly reduced (Shrikrishna et al., 2012). Fatigue 
is also increased in patients with COPD compared to age matched controls 
(Mador et al., 2000), fatigue will be discussed further in section 1.10.3, fatigue and 
reduced activity in COPD. Exacerbations worsen quadriceps strength and this can 
persist up to one month post discharge (Crul et al., 2007; Pitta et al., 2006: Spruit 
et al., 2003). There are many potential causes of the decline in muscle function. 
Genetics, smoking, lack of oxygen (O2), increased carbon dioxide (CO2) leading 
to a pH imbalance and acidosis (these terms are explained in the Glossary on 
p.25, also refer to acid base balance for further information, p.28), testosterone 
and vitamin D deficiency have all been implicated (Barreiro and Gea, 2014). Other 
contributing factors to decreased quadriceps strength and reduced muscle mass 
are systemic inflammation, co-morbidities, exacerbations, reduced physical 
activity, the ageing process and medication (Shrikrishna et al., 2012; Gea, 
Martinez-Llorens and Barreiro, 2014; Gayan-Ramirez and Decramer, 2013; Gea, 
Augusti and Roca, 2013; Pitta et al., 2006; Spruit et al., 2003; Decramer, 1996). 
Whilst debate surrounds the cause of the changes to lower limb muscle, what is 
clear is that muscle strength, in particular the quadriceps, is an important systemic 
marker in COPD and weakness is associated with increased mortality and 
healthcare utilisation (Decramer et al., 1997; Swallow et al., 2007). 
1.4.6 Cardiovascular system 
Cardiovascular disease is more prevalent in patients with COPD than the general 
population (Mapel, Dedrick and Davis, 2005). Cardiovascular disease increases 
in severity with increasing severity of COPD (Sin and Man, 2005; Anthonisen et 
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al., 2002). It is difficult to isolate the cause of cardiovascular disease in COPD, as 
smoking is a confounding causal factor for both conditions (Maclay and MacNee, 
2013). Other proposed causes include physiological stress on the cardiovascular 
system caused by low O2 levels (Maclay and MacNee, 2013). Evidence suggests 
these causes relate to abnormalities of the vascular wall, and changes in cellular 
production, sympathetic nerve supply, atherosclerosis and heart rate (HR) 
(Kameda et al., 2003; Savransky et al., 2007; Aoki et al., 2001). 
1.4.7 Skeletal system 
Osteoporosis is a disease caused by low bone mass and destruction of the bone 
tissue (World Health Organisation (WHO), 1994). Osteoporosis traditionally was 
thought to be a later stage disease caused by smoking, steroid use, vitamin D 
deficiency and inactivity (Lehouck et al., 2011; Riancho et al., 1987, Seeman et 
al., 1983), however, research is now focusing on the presence of osteoporosis in 
mild cases of COPD, suggesting that physiological changes from COPD may also 
contribute (Bolton et al., 2009; Bolton et al., 2004). Cross-sectional population 
studies have demonstrated a greater prevalence of bone mineral loss in patients 
with COPD compared to age matched controls (Iqbal et al., 1999; Engelen et al., 
1998). As the severity of COPD advances the number of patients with 
osteoporosis increases (McEvoy et al., 1998). The exact mechanisms for 
osteoporosis are unclear but it is possible systemic inflammation plays a part 
(Bolton et al., 2009). 
1.4.8 Other considerations 
Significant pathophysiology separate to the respiratory effects and co-morbidities 
also contribute to the severity of the disease (Jones and Ostrem, 2011). Patients 
with greater than two co-morbidities have a greater chance of repeated hospital 
admissions and may die earlier than other patients with COPD who do not have 
co-morbidities (Yohanne and Alexpoulos, 2014; Sode, Dahl and Nordestgaard, 
2011). 
1.4.9 Conclusions 
Patients with COPD have a multi-system pathology (Sinden and Stockley, 2010). 
It is not always clear whether symptoms are caused as a direct result of COPD 
pathology or as a consequence of inactivity and medication. What is clear is that 
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outcomes for patients with COPD worsen through inactivity (Garcia-Aymerich et 
al., 2006). Therefore it is important that interventions consider COPD as a multi-
system pathology and look at interventions that can act on multiple systems. 
There is little that can be done to improve lung function so interventions which 
seek to encourage activity should be further developed. However COPD patients 
may find it difficult to exercise for pathophysiological reasons, and these will be 
explored in the next section. 
1.5 Causes of COPD 
COPD is mostly caused by tobacco smoke in the western world (Pauwells and 
Rabe, 2004), however 20% of cases are not caused by smoking. Whilst smoking 
rates have declined in developing countries, they are increasing in developing 
countries and this means that the future prevalence of COPD may rise as smokers 
develop the disease (Mannino and Buist, 2007). Conversely the link between 
COPD and smoking is not completely understood, because only a minority of 
heavy smokers will go on to develop significant disease (Mannino, Brown and 
Giovano, 1997; Lacasse, Brooks and Goldstein, 1995).  Controversially modern 
researchers report that COPD may in some cases have little to do with cigarette 
smoking. Recent research has been investigating other causes. Current research 
is looking at the possibility of a COPD gene (Berndt, Lerne and Shapiro, 2012).  It 
has been argued that a large cause of COPD worldwide is the burning of biomass 
fuels for cooking (Salvi and Barnes, 2009). Another cause of 1-2% of emphysema 
is a genetic lack of alpha-1 antitrypsin, a protein that inhibits neutrophil elastase, 
which protects the lungs (Strange, 2013). 
1.6 Incidence (Number of new diagnosis/year) and prevalence (% 
of population) of COPD 
Globally the incidence rate is unknown as most data relates to high income 
countries (Gershon et al., 2010). The incidence of COPD in England is 2.0 per 
1000 people per year (Simpson, Hippisley-Cox and Sheikh, 2010).  
COPD has a prevalence rate of 1.6% globally (Menezes et al., 2008). Data from 
the quality and outcomes framework (QOF) report the prevalence of diagnosed 
COPD as 1.6% in England. Approximately 900,000 people have been diagnosed 
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with COPD in England and Wales, although it is thought that there are 
considerably more undiagnosed (NICE, 2010; Healthcare Commission, 2006). A 
study undertaken in 2006 demonstrated a prevalence of spirometry-diagnosed 
COPD at 13.3% within the 8215 participants (Shahab et al., 2006). There are 
estimated to be 2.8 million people with undiagnosed COPD in the UK (British Lung 
Foundation (BLF), 2007). 10% of patients with COPD are first diagnosed when 
they attend hospital as an emergency (National Health Service (NHS) Medical 
Directorate, 2012). 
Prevalence is increasing in women while it has levelled out in men (Global 
Initiative for Obstructive Lung Disease (GOLD) 2016; NICE, 2010). COPD is also 
more common in more disadvantaged areas (Department of Health (DH), 2011b; 
NICE, 2010). Prevalence increases with age and it is not commonly seen in 
people under 35 years of age (Pauwells and Rabe, 2004). 
1.7 Mortality and morbidity of COPD 
COPD is associated with high mortality and morbidity rates (Mathers and Loncar, 
2006; Jemal et al., 2005). Globally COPD is the fourth leading cause of death and 
is predicted to be the third by 2030 (Mathers and Loncar, 2006), and it kills more 
people each year than any other non-communicable chronic disease (Jamal et 
al., 2005). COPD is the fifth most common reason for death in England and Wales, 
causing more than 25,000/year (DH, 2011b). Death rates for COPD in the UK are 
higher than the European and European Union averages (NHS Medical 
Directorate, 2012). The disease is the second leading cause of emergency 
admission in the UK and patients with COPD occupy over one million 'bed days' 
yearly in hospitals in the UK (NICE, 2010). 
1.8 Economic Cost 
There is a high medical and social economic cost. COPD is challenging to 
diagnose, medications are expensive, repeated worsening flare ups are costly 
and there are social costs from patients not being able to work and having 
increased social care needs (Simeons, 2010). 
The medical cost is high because of the need for substantial and ongoing medical 
treatment. The total annual cost of COPD to the NHS is estimated to be over £800 
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million for direct healthcare costs, which equates to £1.3 million per 100,000 
people (Health Care Commission, 2006).  
In the late 1990s, 24 million working days per year were lost due to COPD, and 
the cost of lost productivity has been estimated at around £2.7 billion (DH, 2010b). 
44% of people diagnosed with COPD are below the retirement age, 24% of these 
are unable to work because of their symptoms, and a further 9% are limited at 
work because of COPD (DH, 2010a). The number of lost working days through 
people of working age caring for patients with COPD is unknown (Britton, 2003). 
There are other social costs related to decreased quality of life (QOL). Restricted 
mobility leads to social isolation and the development of psychological conditions 
(DH, 2010b). A BLF survey found that 90% of participants felt that they could not 
contribute to society (BLF, 2007). 
There is limited evidence about the overall costs of treating COPD exacerbations 
or ‘flare ups’. This is because there is a discrepancy on what constitutes an 
exacerbation, how this may be recorded, and variability in possible treatment 
(Simoens, 2010). A study in the NHS demonstrated that the total primary care 
cost associated with acute exacerbations of chronic bronchitis in the COPD-
diagnosed population was £35.7 million (McGuire et al., 2001)  compared to total 
annual cost of COPD at £491,652,000 direct costs and £982,000 indirect costs 
(24 million lost work days) (Healthcare commission, 2006). The cost of COPD per 
patient per year is £819.42 (54% hospital care, 18.6% medication, 16.4% General 
Practitioner (GP) visit, 57% Accident and Emergency (A&E) visit and 5% 
laboratory tests) (Britton, 2003). Punekar, Shukla and Mullerova (2014) suggest 
from their observational study that the overall cost increases with increasing 
disease severity. It is thought that to reduce the cost of this disease future 
management should focus on prevention of exacerbations requiring 
hospitalisation (Punekar, Shukla and Mullerova, 2014).  
1.9 The clinical course of COPD 
The clinical course of COPD over time is progressive because it causes 
increasing airflow obstruction, demonstrated in declining lung function and an 
abnormal inflammatory reaction in the lungs to noxious gases (GOLD, 2015); 
Fletcher and Peto, 1977). Severity is also affected by co-morbidities, age, and 
systemic changes (Jones and Ostrem, 2011; Decramer et al., 2008).  
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1.9.1 Early symptoms 
The initial symptoms are often an unproductive cough and breathlessness 
(Georopoulos and Anthonisen, 1991). However most patients do not present at 
their GP until their breathlessness is disrupting activities of daily living (Pauwells 
and Rabe, 2004). The breathlessness on exertion results in less everyday activity. 
The continued inactivity causes deconditioning of muscles and further inactivity 
leading to social isolation (GOLD, 2015; Decramer, Rennard and Troosters 2008). 
This is discussed further in section 1.10 on living with the disease. As the disease 
progresses, weight loss and anorexia are common symptoms (Schols et al., 
1993). In advanced COPD patients commonly develop cor pulmonale, an 
alteration of right cardiac ventricular function, with right ventricular dilation and 
hypertrophy as a result of secondary pulmonary hypertension (Calverley, 1996).  
The presence of right sided heart failure decreases the 5 year survival rate to only 
27-33% (MacNee, 1994). 
1.9.2 Exacerbation 
COPD has a fluctuating progressive trajectory (Murray, Kendall, Boyd and Sheikh, 
2005) caused by repeated exacerbations (Pauwels et al., 2001). See figure 1.3 
for a diagram of the disease course. 
 
Figure 1.3 COPD disease trajectory 
Reproduced with permission: Figure 2. (Typical end-of-life disease trajectory in COPD and chronic 
heart failure) from: Lehman R. How long can I go on like this? Dying from cardiorespiratory 
disease. 2004; Br J Gen Pract 54(509): 892-893. 
<http://www.ncbi.nlm.nih.gov/pubmed/?term=lehman+2004+Dec+Br+J+Gen+Pract#>  
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Exacerbations are defined as an acute onset of continued worsening of symptoms 
beyond those normally experienced that need additional medical treatment 
(GOLD, 2015; Burge and Wedzicha, 2003). However, every patient’s symptoms 
are different, making it difficult to standardise classification of an exacerbation. 
This has implications for the way the illness may be coded, leading to a 
discrepancy in hospital data (Lopez-Campos, Caleu and Quintana-Gallego, 2013; 
Stein et al., 2010). As COPD progresses the frequency and severity of 
exacerbations increases (Burge and Wedzicha, 2003). COPD patients typically 
suffer from one to four exacerbations per year, with the frequency of 
exacerbations increasing with the severity of COPD (Simeons, 2010). 
Exacerbations are correlated with persisting deteriorating symptoms and health-
related QOL, increased healthcare consumption and death (BTS, 2013). Exercise 
ability and physical activity are reduced during and after an exacerbation, causing 
skeletal muscle dysfunction, especially of the legs (BTS, 2013). Severe 
exacerbations present with Type II respiratory failure and an acidotic pH on 
arterial blood gas (ABG). If not corrected this can lead to cell death and organ 
failure (Calverley and Gorini, 2008). 
1.9.3 Respiratory failure 
During acute respiratory failure, respiratory rate (RR) increases causing 
expiratory time to decrease which adds to an increase in lung volume and intrinsic 
positive end expiratory pressure (PEEPi) (see Glossary, p. 33), which can lead to 
decreased cardiac output (see Glossary, p. 30) (Fleury et al., 1985). For patients 
in uncompensated respiratory failure, who do not respond to standard care of oral 
steroids, antibiotics and bronchodilators it has been recommended that NIV (see 
Glossary, p. 32) is used (NICE, 2010; Royal College of Physicians, 2008; BTS, 
2002).  
1.10 Living with the disease  
As the symptoms worsen, QOL is impaired and sleep may be disturbed (Calverley 
and Walker, 2003). Patients become unable to carry out everyday activities, 
including work and participating in social activities, leading to reduced social 
interaction. Anxiety and depression may emerge as the patient becomes 
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increasingly isolated and physically disabled by their disease (BTS, 2013; 
Wagena et al., 2005).  
1.10.1 Stigma 
In one interview study participants with COPD expressed a prevalence of blame 
towards them related to their smoking. This was experienced from others 
including health care workers and inwardly they blamed themselves (Berger, 
Kapella and Larson, 2011). Symptoms of COPD can be embarrassing for patients 
to deal with publicly, extending to their medications including inhaler use and O2 
outside of the home (Johnson et al., 2007; Earnest, 2002). Patients with COPD 
are particularly embarrassed by their physical limitations especially to do with 
falling behind others (Berger, Kapella and Larson, 2011). Stigmatisation may 
contribute to social isolation and depression, further contributing to inactivity 
(Berger, Kapella and Larson, 2011). 
1.10.2 Anxiety and depression 
A recent literature review of the prevalence rate of anxiety within the COPD 
population identified rates between 6-74% (Yohannes, Willgoss and Baldwin, 
2010). It has been suggested that the vast variation in prevalence rate may have 
been because of poor methodological quality of the studies and the differences in 
the objective measures used, with up to 13 different types used, including the 
Hospital Anxiety and Depression Scale (HADS) and the Anxiety Based Interview 
Schedule (Vogele and von Leupoldt, 2008). An alternative suggestion is that it is 
difficult to distinguish between symptoms of anxiety and those of respiratory 
disease. The presence of anxiety (assessed by HADS and Spielberger State Trait 
Anxiety Inventory) and COPD is associated with reduced functional status and 
QOL (St Georges Respiratory Questionnaire (SGRQ), lower walking distance 
(6MWT) and lower ergometer peak workload (WLpeak) (Giardino et al., 2010; Di 
Marco et al., 2006). Anxiety can also lead to more utililisation of health services, 
increased risk of exacerbation and readmission to hospital (Laurin et al., 2012; 
Laurin et al., 2009). There is little research investigating anxiety and physical 
activity in patients with COPD, however one study found an association between 
increased anxiety and increased activity levels (Nguyen et al., 2013). It is unclear 
whether the anxiety caused the increased levels of activity or being more active 
made the participants more anxious (Nguyen et al., 2013). In depth interviews 
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with patients with COPD showed that some participants were afraid of carrying 
out activity for fear of the breathlessness it may cause and thus avoided activities. 
Planning their days to avoid activities however made them feel more frustrated 
and anxious (Willgoss et al., 2010). 
The prevalence of depression in patients (assessed using the Centre for 
Epidemiological Studies Depression score; Geriatric Depression Scale; Geriatric 
Mental State Schedule; Brief Assessment Schedule Depression Cards) with 
COPD is reported as between 10-42% (Maurer et al., 2008; van Manen et al., 
2002; Lacasse, Rousseau and Maltais, 2001; Yohannes et al, 2000). The 
prevalence is so variable because of the different use of outcome measures and 
variation of disease severity in the studies. Depression is almost twice as likely to 
occur in patients with COPD compared to an aged matched cohort (Ng et al., 
2007). Depression is undertreated in patients with COPD, with an estimate that 
only one third of patients with depression receive the correct treatment (Kunik et 
al., 2005; Kim et al., 2002). Depression leads to lower treatment adherence, 
reduced walking distance (12 minute walk test (12MWT) and decreased QOL 
(Hopkins Symptoms Checklist-20; Medical Outcome Short Form - 36) (Felker et 
al., 2001; Bosley et al., 1996; Light et al., 1985).  
Depressed patients with COPD have a diminished daily and maximum exercise 
capacity when compared to non-depressed patients with COPD (di Marco et al., 
2014). Anxiety and depression cause decreased QOL and decreased 
concordance with medication (Yohannes, Wilgoss and Baldwin, 2010). Patients 
with anxiety and depression have a greater chance of re-hospitalisation and 
mortality (Ng et al., 2007; Gudmundsson et al., 2005; Dahlen and Jansen, 2002). 
Harris et al., (2008) reported that patients with COPD who scored highly for 
anxiety and depression were more likely to report breathlessness and to be afraid 
of exercise, regardless of their Medical Research Council (MRC) breathlessness 
score. 
1.10.3 Fatigue and reduced activity in COPD 
Fatigue is the second most common symptom in patients with COPD after 
dyspnoea (Blinderman, Homel and Billings, 2009). Fatigue is more prevalent in 
patients with COPD than in the general population (Lewko, Bidgood and Garrod, 
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2009) and leads to an increased hospitalisation risk (Paddison et al., 2013). This 
fatigue could make participating in physical activity more difficult. 
QOL and exercise tolerance are commonly reduced and physical activity levels 
are lower compared with those of healthy people of a similar age (Menadue et al., 
2014; Pitta et al., 2005). The literature demonstrates that reduced activity in 
patients with COPD leads to reduced exercise capacity, less QOL, higher use of 
healthcare including hospital admissions and reduced life expectancy (Watz et al., 
2008; Garrod et al., 2006; Pitta et al., 2006; Garcia-Aymerich et al., 2006).  
Exacerbations have a detrimental effect on physical activity. This is because there 
is less time spent by a patient outdoors immediately prior to an exacerbation and 
for up to five weeks after an exacerbation (Pitta et al., 2006; Donaldson et al., 
2005). Physical activity deteriorates with disease progression (Watz et al., 2009). 
1.11 Dyspnoea - breathlessness 
Breathlessness is defined as: 
“A subjective experience of breathing discomfort that is comprised of 
qualitatively distinct sensations that vary in intensity”  
(American Thoracic Society, 1999, p.321).  
Dyspnoea is the main symptom of COPD (Viegi et al., 2007) and is more common 
in severe disease (Killian et al., 1992). Patients frequently describe their 
dyspnoea as a sense of increased effort to breathe, heaviness, air hunger, 
gasping and suffocation (Strang, Ekberg-Jansson and Henoch, 2014; Simon, 
1989). Patients with COPD often experience anxiety in combination with their 
breathlessness (Strang, Ekberg-Jansson and Henoch, 2014). This experience is 
greater than in other pathologies (Pantilat et al., 2012; Bausewain et al., 2010; 
Gore et al., 2000). In interviews with patients with very severe COPD the fear of 
breathlessness meant that the participants did not take part in usual activities or 
leave the house. Shortness of breath, fatigue and a lack of energy were reported 
as making it impossible for the participants to perform their activities of daily living 
(Stranng, Ekberg-Jansson and Henoch, 2014). 
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1.11.1 Patient Management of Breathlessness 
Dyspnoea can lead to a cycle of activity evasion, deconditioning and reduced 
participation in activities (Garrod et al., 2006). This is illustrated in figure 1.4. 
 
Figure 1.4 Cycle of dyspnoea and activity avoidance (Adapted) 
Permission obtained: This research was originally published in Clinical Science. Man, W., D., C., 
Kemp, P., Moxham, J. and Polkey, M. Skeletal muscle dysfunction in COPD: Clinical and 
Laboratory observations. Clinical Science. 2009; 117: pp251-pp264 © the Biochemical Society. 
Interviews with patients with severe COPD demonstrated that patients used 
individual strategies to manage their breathlessness including slowing the pace 
of activities, sitting down for activities, controlled breathing exercises and activity 
avoidance (Dunger et al., 2015; Stranng, Ekberg-Jansson and Henoch, 2014). 
The importance of exercise as an intervention will be discussed later (section 
1.15.2 Why PR is beneficial), but it seems appropriate that interventions should 
seek to address the anxiety and symptoms of becoming breathless on exercise, 
as this may encourage the patient to participate in exercise.  
Breathlessness 
on exertion
Decreased 
physical activity
Deconditioning
Muscle wasting
Fatigue
Activity 
avoidance
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1.12 Social Deprivation 
COPD is related to poverty with an  increased prevelance in lower socio-economic 
groups. Factors associated with poverty include poor diet, damp housing and 
increased frequency of chest infections (Russell et al., 2011). Deprivation has 
been linked with increased mortality in outpatients with COPD after one year 
(Collins et al., 2010). There is also an increased risk of exacerbation and 
admission to hospital with lower social economic status (Calderon-Larranaga et 
al., 2010; Healy, 2003). Smoking is associated with deprivation leading to overall 
worse outcomes (Shohaimi et al., 2013; Osman et al., 2007). 
1.13 Treatment and management of COPD 
1.13.1 Introduction  
A number of national and international respiratory societies have developed 
guidelines for the management of COPD. The Global Initiative for Chronic 
Obstructive Pulmonary Disease (2015) guidelines are internationally recognised 
and were developed jointly by the National Heart Lung and Blood Institute and the 
WHO to increase awareness of COPD (GOLD, 2015). Additional guidance was 
developed by the International Primary Care Respiratory Group based on five 
recommendations but with the aim of being more appropriate to the primary care 
physician (Jones and Ostrem, 2011; Bellamy et al., 2006). 
Although there is no known cure for COPD (Jones and Ostrem, 2011) the main 
effective interventions in the treatment of COPD exacerbations are increased 
doses of inhaled bronchodilators, systemic corticosteroids, antibiotics and NIV for 
respiratory failure (NICE, 2010). Advice on smoking cessation is also important 
(Willemse et al., 2004; Scanlon et al., 2000) as 33% of all COPD patients in the 
UK continue to smoke (NICE, 2010). The management recommendations for 
each stage of disease severity is demonstrated in table 1.2 (GOLD, 2015).  
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Table 1.2 Management of COPD: Multidisciplinary approach 
(Adapted from the GOLD: Multidisciplinary management of COPD. Reproduced from the Global 
Strategy for the Diagnosis, Management and Prevention of COPD) (GOLD, 2015). Available from: 
http://www.goldcopd.org/ and van Eeden and Burns, 2008. A multidisciplinary approach to the 
treatment and management of COPD, volume 50, number 3, pp 144.). 
Stage of COPD 
Severity: GOLD 
Lung Function Management Clinician 
Mild: GOLD I FEV1/FVC < 0.7 
and FEV1 > 80% of 
predicted with or 
without symptoms 
Spirometry testing 
Smoking cessation 
Vaccination 
Flu/pneumonia 
GP 
Physiologist 
Respiratory nurse  
Physiotherapist 
Moderate: GOLD II FEV1/FVC < 0.7 
and FEV1 50-80% 
of predicted 
Short-acting 
bronchodilators 
PR 
Nutritional advice 
GP 
Pharmacist 
Physiotherapist 
Dietician 
Severe: GOLD III FEV1/FVC < 0.7 
and FEV1 30-50% 
predicted 
Long acting 
bronchodilators and 
inhaled 
corticosteroids 
PR 
Respiratory 
consultant 
GP 
Physiotherapist 
Very Severe: Gold 
IV 
FEV1/FVC < 0.7 
and FEV1  < 31% of 
predicted or 
presence of 
respiratory failure 
or right sided heart 
failure 
O2 Therapy 
Surgery 
End of life 
management 
 
GP 
Thoracic Surgeon 
Palliative care 
Social services 
Abbreviation Key: GOLD Global Initiative for chronic obstructive lung disease, 
FEV1/FVC Forced expiratory volume in one second/ forced vital capacity, O2 Oxygen 
 
1.14 Medication 
Maintenance medication consists of both short and long acting bronchodilators 
and inhaled steroids to relieve the symptoms of airways obstruction where it is still 
reversible (NICE, 2010). It is now thought these should be initiated at the very 
early stages of disease (Jones and Ostrem, 2011). 
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1.14.1 Long term O2 therapy (LTOT) and ambulatory O2 (AOT) 
There are two well publicised RCTs demonstrating that 15 hours per day of LTOT 
improves survival in patients with COPD and hypoxaemia (low concentration of 
O2 in the blood, (Mosby, 2012; Medical Research Council Working Party, 1981; 
Nocturnal oxygen therapy group, 1980). LTOT is indicated in patients with a PaO2 
< 7.3kPa, peripheral oedema (seen as swollen ankles), pulmonary hypertension 
(pulmonary artery wall damage causing right sided heart failure, see Glossary, 
p.33) and polycythaemia (Increased quantity of haemoglobin (Hb) in the blood, 
this can thicken the blood, see Glossary, p. 33) (BTS, 2015). However the effects 
of LTOT on QOL are inconclusive. In one trial there were no statistically significant 
changes in QOL (SGRQ) scores demonstrated in patients with COPD six months 
after starting LTOT (Okubadejo et al., 1996) compared to a trial by Borak et al. 
(1996) which demonstrated a significant improvement in mood after one year of 
initiating LTOT. From the literature one study undertook in-depth interviews with 
people who had been carers of recently deceased patients with COPD, reported 
that although LTOT improved symptoms and mobility in the home, the cylinders 
used meant that the patients did not like to be far from their O2 source and felt 
restricted (Elkington et al., 2004).  
AOT is used during exercise and activities of daily living (BTS, 2015). The addition 
of AOT during exercise can improve exercise tolerance and dyspnoea during 
exercise programmes. It is recommended for use if patients decrease their SpO2 
during exercise training (BTS, 2015; Bradley et al., 2007; Nonoyama et al, 2007; 
Bradley and O’Neill, 2005), however the disadvantages of using the O2 cylinders 
may outweigh the benefits. A large double blinded placebo controlled RCT 
involving n = 139 participants with stable COPD with PaO2 > 7.3kPa comparing 
O2 via cylinder with air via a cylinder at 6L/minute for use on any activity that 
provoked dyspnoea. The study demonstrated no improvements in dyspnoea, 
QOL or functional capacity with the use of O2 (Moore et al., 2011). Additionally at 
the end of the trial, when surveyed, 50% of the participants reported difficulties 
using the equipment and 46% of the O2 group reported that they would prefer to 
stop using the O2 altogether. Some participants felt embarrassed using the 
cylinders and were anxious of becoming dependent on them. Interestingly the use 
of the air cylinders provided similar comments. Therefore it may be the weight and 
type of cylinder that limited beneficial use (Moore et al., 2011). 
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When considering interventions for patients with severe COPD, it is therefore 
important that the intervention improves QOL and does not add to the burden of 
disease, whilst maintaining activity levels. If an intervention is proven to decrease 
hospital admissions and length of stay then this may have a positive effect on 
improving QOL. PR is an intervention that can improve health status and walking 
distances (McCarthy et al., 2015). PR will be discussed in depth in the next 
section. 
1.15 Pulmonary Rehabilitation (PR) 
1.15.1 What is PR? 
PR describes programmes that are designed to provide a structure for the delivery 
of physical training sessions for patients with COPD. PR also includes education 
sessions on disease, nutrition and medication. The primary aim of PR is to 
improve the symptoms of patients with COPD (BTS, 2013). 
1.15.2 Why is PR beneficial? 
There is very good quality evidence to support the effectiveness of exercise 
training within PR on exercise capacity (BTS, 2013). The most recent SR included 
65 RCTs involving 3822 participants with COPD for meta-analysis (McCarthy et 
al., 2015). This demonstrated that PR in comparison to usual care offered clinical 
and statistical improvements in 6MWT and health-related QOL including 
dyspnoea, fatigue and emotional function (McCarthy et al., 2015). The limitations 
of most of the studies are that they were all unblinded due to the nature of the 
intervention, potentially leading to bias, and most of the sample were men which 
may not be reflective of today’s COPD population (McCarthy et al., 2015; NICE, 
2010). The current evidence supports the use of PR in patients with COPD, 
however more research is needed into the content and structure of PR. 
Dyspnoea and health status is also improved by PR, with a meta-analysis of 
twenty trials using SGRQ (McCarthy et al., 2015). The minimal clinically important 
difference (MCID) was defined as the smallest difference in a measurable clinical 
parameter that indicates a meaningful change in the patient’s condition (either 
better or worse) decided by the patient, clinician or researcher (Kiley et al., 2005). 
The meta-analysis demonstrated that the weighted mean difference was greater 
than the MCID of 4 units for total, symptoms, impact and activity domains 
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(McCarthy et al., 2015).  The weighted mean difference is often used in meta-
analysis when comparing the average difference between the treatment group 
and the control group across studies. Within mean weighted analysis some of the 
studies contribute more to the average than others (Cochrane Library, 2012). 
Physiological benefits of exercise training in rehabilitation of patients with COPD 
include reduced HR, minute ventilation (VE) (see Glossary, p. 32) and acidosis, 
and superior action of mitochondrial enzymes (see Glossary, p. 32) with increased 
capillary concentration in trained muscles (Cassaburi et al., 1997). More recently 
research has identified that PR decreases the frequency of hospital admissions 
following an exacerbation (Puhan et al., 2011). PR may improve activity levels, as 
demonstrated by a recent SR, but further evidence is needed because of a lack 
of comparison control groups (Cindy et al., 2012). A large RCT also demonstrated 
improvement in psychological health with improvements in anxiety and 
depression (Griffiths et al., 2000).  
PR also appears to represent good value for money compared to many drug 
treatments (see table 1.3). 
Table 1.3 The costs of treatment of COPD (Patel and Baxter, 2014) 
Ranking 
(cost) 
Treatment Cost (£/QALY) 
1. Telehealth 92,000 
2. Triple Therapy 7,000-187,000 
3. Long acting Beta-agonist medication 8,000 
4. Tiotropium (bronchodilator to relax smooth 
muscle in airway, opening the airway) 
7,000 
5. PR 2,000-8,000 
6. Smoking cessation support with medication 2,000 
7. Flu vaccination 1,000 (in at risk 
population) 
Abbreviation Key: PR Pulmonary rehabilitation, QALY Quality adjusted life year. 
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There are many problems with medication including non-adherence (Rand et al., 
1995; Dolce et al., 1991), side effects (Calverley et al., 2007; Reilly, 2014) and 
poor administration techniques (Vincken, Dekhuijzen and Barnes, 2013). 
Therefore PR provides a more cost effective treatment, although despite the 
benefits and low cost of PR it is still under-utilised in patients with COPD (see 
section 1.15.10) (Yohannes and Connolly, 2004; Brooks et al., 2007; Puhan et al., 
2011).  
1.15.3 What should the duration of the training programme be? 
Three studies have assessed rehabilitation duration and demonstrated greater 
improvement in health status and function in the groups carrying out rehabilitation 
of a longer duration (Berry et al., 2003; Foy et al., 2001; Swerts et al., 1990). 
Longer training duration may be more beneficial for the patients with more severe 
disease who are more deconditioned. One RCT indicated that 18 months duration 
of a supervised exercise programme may be more beneficial than three months. 
The study demonstrated improvements in self-reported disability scores and 
physical function compared to three months (Berry et al., 2003). Therefore it is 
recommended that PR duration be longer than three months if costs allow (BTS, 
2013), however a longer training programme may have a cost and resource 
implication which has not been evaluated.   
1.15.4 How many sessions should there be? 
The BTS PR quality standards (2014) suggest that based on available evidence, 
programmes should consist of a minimum of two supervised sessions per week 
for at least six weeks. The most beneficial number of supervised sessions during 
a programme of PR has not been confirmed in the literature. McCarthy et al. 
(2015) SR and Griffiths et al. (2000) RCT supported the benefits of PR 
incorporated two supervised sessions and either a third supervised or 
unsupervised exercise session. 
1.15.5 Type of training 
It has been suggested that the exercise component of PR may consist of strength 
and endurance training in the form of progressive muscle resistance exercises 
and aerobic training (BTS, 2013). Lower limb endurance training commonly 
includes either walking or cycling. This is to target lower limb weakness that may 
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be associated with a poor prognosis (Swallow et al., 2007). Walking and cycling 
may be easily reproduced in an outpatient environment although they may not be 
considered as enjoyable by some patients as other pursuits, which may lead to a 
reduction in motivation, which in turn can lead to reduced exercise tolerance (ATS 
and ERS, 2006). One RCT considered Nordic walking as an alternative means of 
delivering PR in a three month programme.  The Nordic walking group improved 
their 6MWT distance compared to baseline and control group, this was sustained 
at six to twelve months post completion of the course (Breyer et al., 2010).  
Another possible means of exercise is Tai Chi Qigong which incorporates 
breathing and whole body movement. An RCT compared Tai Chi Quigong with a 
walking group and a control group. Tai Chi increased the mean 6MWT distance 
from 298 to 349 m. This was significantly greater than the walking or control group 
(Chan et al., 2013), however a limitation was the high drop-out rate in the control 
group. A potential problem with more specialist exercise regimens are that they 
often need skilled practitioners to deliver and may require space or equipment not 
readily available.   
In summary, the exercise component of PR may consist of progressive muscle 
resistance exercise and aerobic training. This could include cycling or walking.  A 
patient’s preference for exercise should be considered when planning the 
exercise to facilitate motivation to exercise. 
1.15.6 Training Intensity 
It is recommended that the exercise programme should also be individualised in 
terms of training intensity. Vallet et al., (1997) carried out an RCT demonstrating 
the importance of individualised training for patients with chronic airflow limitation 
(CAL) (synonymous with COPD). In this study, patients with COPD were randomly 
allocated to four weeks of individualised (n = 12) or standardised (n = 12) 
stationary bike training. The individualised training was carried out at the 
individually measured gas exchange threshold (anaerobic threshold), and in the 
standardised group was carried out at 50% of the calculated maximal HR reserve. 
The results demonstrated that the target training level was similar between the 
two groups, however there were greater physiological improvements 
demonstrated in the individualised group (greater submaximal cardiorespiratory 
responses with lower ventilation). Therefore the results of this study suggest that 
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individualised training may lead to greater physiological improvements than 
standardised programmes. 
The BTS PR guidelines (2014) recommend a minimum target intensity of 60% 
peak work rate, however the optimum intensity is unknown. The recommended 
duration of the exercise is between 30 - 60 minutes per session. Some patients 
with severe disease may not be able to exercise for 30 minutes and shorter 
sessions will still be beneficial (BTS, 2013). Although there is weak evidence for 
resistance training it can be used within PR programmes. Muscles trained should 
include quadriceps, with individualised weights of two to four sets of 10 - 15 
repetitions (BTS, 2013; O’Shea, Taylor and Paratz, 2009; Houchen, Steiner and 
Singh, 2009). To achieve the physiological benefits, patients need to train at a 
level which exceeds their anaerobic threshold (see Glossary, p. 29). High-intensity 
exercise training may produce greater physiological improvement compared with 
lower-intensity exercise training in people with COPD (Gimenez et al., 2000; 
Casaburi et al., 1991).  
Severe COPD patients are unable to train at this level due to ventilatory limitation 
(VL) (Cassaburi, et al., 1997). Some individuals may have difficulty performing 
exercise at an adequate intensity for the required duration (Maltais et al., 1997) 
and may not achieve the same benefit from exercise training as those without a 
significant VL to exercise, particularly if peripheral muscle strength is relatively 
preserved (Garrod et al., 2006; Plankeel, Mcmullen and MacIntyre, 2005; 
Troosters, Gosselink and Decramer, 2001). 
In summary, the literature has suggested that the exercise intensity should be 
60% of peak work rate for durations between 30 - 60 minutes, but shorter sessions 
may also be beneficial. Some patients may have very severe lung disease and be 
deconditioned so they may be unable to train at a high intensity or for a long period 
of time. Therefore the exercise component of PR should be individualised in terms 
of the intensity and the duration of training. 
1.15.7 Activity 
It is recommended that all adults should take 150 minutes of moderate intensity 
aerobic exercise per week to maintain a healthy lifestyle (WHO, 2010). The DH 
(2009) recommended this to be five sessions of 30 minutes of activity a week. 
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Individuals hindered by illness and disease are advised to carry out as much 
physical activity as their health allows (WHO, 2010). The GOLD strategy (2015) 
recommended that patients with COPD should participate in daily physical activity, 
although the details of this are not described.  
A study undertaken in Sweden demonstrated that patients with COPD carry out 
less than the recommended physical activity levels compared with patients with 
other conditions and the healthy population (Arne et al., 2009). Katajisto et al. 
(2012) carried out a study which sent out a postal questionnaire to 719 patients 
with COPD to establish their activity levels and exercise participation. The study 
had a good response rate (87%) and found that, as anticipated, activity and 
exercise decrease with disease severity. Interestingly the reported barriers to 
exercise were dyspnoea (66%), pain (36%), other illness (42%), dislike of 
strenuous exercise (20%) and poor weather (17%). Although the research relied 
on self-reported data and did not encompass very severe patients (65% predicted 
of FEV1/FVC), it did demonstrate that dyspnoea was the main barrier to exercise 
and this needs to be addressed to enable patients to be active. 
Whilst it is recommended that patients with COPD need to train at a certain 
intensity to gain optimum physiological benefit, studies suggest that patients may 
gain health benefits participating in activity. One study explored the relationship 
between baseline activity and mortality, demonstrated that a small increase in 
physical activity in people who are sedentary may have similar health benefits to 
a greater change in the more physically active population (Minton et al., 2013). 
1.15.8 How should PR be evaluated? 
NICE (2010) quality standards for COPD advised that PR is evaluated by a 
validated outcome measure, for example the 6MWT. The BTS Quality standards 
for PR (2014) suggested that PR is evaluated by, as a minimum, measures of 
exercise capacity, other body systems (for example, physical activity) and health 
status. The research recommendation of the BTS (2013) regarding PR evaluation 
suggested that measures should evaluate other body systems, not just the 
respiratory system. The BTS (2013) suggested that research was needed into the 
use of physical activity measures to evaluate PR. The outcome measures used 
need to be easy for clinicians to carry out in clinical practice and not expensive so 
as to be available for local hospitals and centres. The majority of the 
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recommended evaluation of PR is therefore through quantitative outcome 
measures. However, as PR is individualised it would seem important to capture 
some rich data about the acceptability and perceived benefits of the intervention 
in the form of qualitative research.  
In summary, the exercise component of PR should be evaluated by both HRQOL 
measures and exercise capacity. Outcomes measuring activity levels following 
PR are under researched and need to be evaluated. Qualitative information would 
be useful to inform clinicians of acceptability of PR to patients. This would help 
inform exercise programmes to improve adherence and ensure they remain 
patient focused. 
1.15.9 Who should be offered PR? 
It has been recommended that PR should be offered to all patients with COPD 
with a MRC breathlessness score of > 3 (NICE, 2010). PR is also recommended 
for patients with moderate to severe COPD, or those who have mild lung function 
but experience shortness of breath on activity, including patients who have been 
hospitalised for an exacerbation (BTS, 2013; NICE, 2010). The contraindications 
to PR are those patients who have had a recent Myocardial Infarction (MI), 
unstable angina or who are unable to walk (BTS, 2013).  
1.15.10 PR attendance 
Approximately 33% of patients offered PR refuse to attend and a further 33% fail 
to complete due to sickness, reduced motivation, depression or logistical 
problems (BTS, 2011; Keating, Lee and Holland, 2011; Taylor et al., 2007; 
O’Shea, Taylor and Paratz, 2007; Fischer et al., 2007; Arnold, Bruton and Ellis-
Hill, 2006). Therefore it is estimated that less than 5% of the patients with COPD 
who would benefit from PR actually receive it (Brooks et al., 2007; Yohannes and 
Connolly, 2004). This is problematic as patients who are less active are more 
commonly admitted to hospital and more likely to relapse following discharge 
(Garcia-Aymerich et al., 2006; Kim et al., 2004). It is important to consider different 
ways of administering PR to patients with severe COPD. This could include the 
timing of PR, the environment in which PR is delivered and also adjuncts to 
exercise that may relieve dyspnoea allowing patients to train. 
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The NICE COPD guidelines (2010) state that PR should be available for all who 
need it. Problems with incompletion of PR include accessibility in rural areas, 
waiting lists and problems with logistics including hospital transport. It is often 
house bound patients with very severe COPD who are unable to access or 
complete the PR course (Harris, Hayter and Allande, 2008; Sabit et al., 2007).  
1.15.11 Post exacerbation PR 
The BTS quality standards for PR (2014) suggested that patients should be 
referred to PR on discharge from hospital following an exacerbation and attend 
within one month of hospital discharge. 
Often research on PR is carried out with the stable COPD population, however 
more recently research has focused upon rehabilitation post exacerbation. One 
Cochrane review aimed to assess the effects of ‘early’ PR within three to eight 
days after COPD exacerbations (Puhan et al., 2011). The review considered nine 
RCTs involving 432 participants. The programmes had variable participant 
completion rates of 40-94%. PR significantly reduced the number hospital 
admissions and also reduced mortality, although the effect of the intervention may 
have been overestimated due to the small sample size of the trials. Nevertheless, 
no study reported any serious adverse events (SAE) with the intervention. There 
were also statistically and clinically significant improvements in SGRQ and 
Chronic Respiratory Questionnaire (CRQ) and 6MWT, although there was a 
considerable difference in mean results between the trials in 6MWT (mean 
difference 77.70m, 95% Confidence Interval (CI) (12.21-143.20). 
An RCT undertaken by Ko et al., (2011) compared early post-exacerbation PR 
within two to three weeks of hospital discharge with usual care.  HRQOL as 
measured by SGRQ (the higher the score the worse the HRQOL experienced) 
was improved in the post-exacerbation PR group (mean total score ±standard 
deviation (SD) 40.15 ±19.10 versus 46.91 ±18.21 in the usual care group, with a 
statistical significance of p = 0.01 and 42.3 ±20.06 in the post exacerbation PR 
group versus 51.44 ±18.98 in the usual care group with a statistical significance 
of p = 0.01 at three and six months respectively). There were no differences 
between usual care and the post exacerbation group in SGRQ scores observed 
at 12 months post discharge.  
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Behnke et al. (2003) compared two groups of patients after recovery from an 
exacerbation of COPD requiring a hospital admission. The two groups were a 
control group (n = 14) with no exercise and an intervention group (n = 12) that 
performed a 10-day walking training in the hospital, followed by 18 months of 
supervised individualised training at home. The exercise was initiated at four to 
seven days after hospital admittance. The results showed that during the 18-
month period patients in the training group showed a reduced frequency of 
hospital admissions (total, n = 3 versus n= 14, p = 0.026; disease-related, n = 3 
versus n = 12, p = 0.050) and administered less short-acting ß2-agonists than the 
control group - (mean [95% CI)], 2.4 [1.4 - 3.4] versus 5.7 [4.2 - 7.2] puffs per day, 
p < 0.001). The results also showed improved walking distance, with decreased 
levels of breathlessness, and improved HR QOL in all domains of CRQ. However 
the control group showed a deterioration in CRQ scores over all domains with a 
worsening of the reported fatigue score (mean ±SD) from 16.7 ±1.6 at baseline to 
23.7 at 18 months for the rehabilitation group compared to 13.9 ±1.1 at baseline 
and 11.2 ±1.3 at 18 months for the control group. The six minute treadmill walk 
test demonstrated a significant improvement from baseline to 18 months in the 
rehabilitation group (p < 0.001) compared to the control (rehabilitation group 
baseline walking distance was 273m improving to 597m at 18 months versus 
baseline measure of 226m decreasing to 208 at 18 months in the control group). 
The literature therefore suggests that it may be advantageous to begin the 
exercise component of PR in hospital following an exacerbation of COPD. The 
literature suggests exercising post exacerbation is safe and beneficial to patients 
with COPD. 
1.15.12 Home based exercise 
Traditionally PR takes place in an outpatient clinic either at a hospital or in the 
community, for example a community centre. But home PR needs to be 
considered due to the poor uptake of outpatient PR discussed earlier (see section 
1.15.10, PR attendance). There was one UK-based study looking at home PR but 
this was in the form of brief advice after a one hour outpatient attendance and not 
comparable to a formal supervised exercise programme at home (White et al., 
2002).  
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Home based rehabilitation programmes may offer an alternative way of delivering 
PR in patients with severe COPD who can not access PR. However most of the 
literature in support of PR is based on supervised outpatient programmes (BTS, 
2013). The evidence surrounding home PR is conflicting.  
A randomised, placebo-controlled trial of patients with COPD (n = 60) with MRC 
Grade 5 who were housebound due to their breathlessness demonstrated there 
was no benefit from supervised exercise training in their home (Wedzicha et al., 
1998).  
In a large retrospective observational study (n = 146/450) of patients with COPD 
graded as MRC 5, but who were able to attend and complete outpatient PR, 
gained the same significant improvement (p < 0.0005) in incremental shuttle walk 
test (ISWT) compared to patients who had MRC grade of 3 who completed the 
same outpatient PR (n = 103/450) (Evans et al., 2009). The ISWT results of 
patients graded MRC 5 increased by 54m (CI 43 - 64) post PR compared with 
MRC grade 3 participants increased by 63m (CI 50 - 75). However more unstable 
patients (exacerbation in last 3 months) were excluded and the drop out number 
was high (n = 55) and this consisted of participants with worse lung function, 16% 
were MRC grade 5 compared with 8% grade 4, thus severity of disease may be 
a barrier to outpatient PR.  
There have been four studies that attempted to make a comparison between 
hospital and home based rehabilitation (Guell et al., 2008; Maltais et al., 2008; 
Puente-Maestu et al., 2000; Strijbos et al., 1996), however on review they 
evaluated supervised versus non-supervised rather than home versus outpatient 
location.  The studies demonstrated that it was safe to carry out home based 
rehabilitation in patients with COPD. None of the home based programmes were 
completely carried out at home. Some of the self-management, monitoring and 
education sessions were carried out in the hospital (Guell et al., 2008; Maltais et 
al., 2008; Puente-Maestu et al., 2000). Only one study was a powered non-
inferiority study (Maltais et al., 2008; BTS, 2013). All of the other studies were 
underpowered to have detected any statistically significant differences between 
the supervised and unsupervised groups. 
One small numbered study did include regular home visits from clinicians to 
supervise exercise (Strijbos et al., 2008). This compared a 12 week hospital 
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programme (n = 18) with a 12 week supervised home programme (n = 17) and a 
control group (n = 15) of no rehabilitation. Both PR groups demonstrated 
improvement in maximal work level and walking distance, but the hospital PR 
group only improved their maximal work load (see Glossary, p. 35) on an exercise 
cycle test up to six months after the programme. In contrast the home group 
continued to improve their maximum work level and walking distance up to 18 
months after the programme. This may be because they were accustomed to 
exercising in their own environment unlike the hospital based patients. However 
a possible limitation of the study was it did not interview the participants to 
understand why they had continued or not continued with the exercise. This may 
have offered more understanding of why the improvements were maintained at 
18 months. 
Murphy, Bell and Costello, (2005) provided supervised home rehabilitation 
immediately on discharge demonstrating improvements in walking distance, leg 
strength and QOL compared to usual care. Therefore there may be some benefit 
for patients exercising at home who are unable to access PR, but the fear of 
exercise and dyspnoea they experience may still prevent them from training and 
achieving health benefits. 
A well cited RCT (Griffiths et al., 2000) demonstrated that the positive effects of 
PR deteriorate over time and in the PR treatment group were only marginally 
better than the control group at one year. One possible reason for this may be 
that patients do not continue an exercise programme over time. Therefore it could 
be speculated that a possible benefit of home based rehabilitation may be that 
patients develop ways of exercising in their own environment that are easier to 
maintain.   
In conclusion, the effects of outpatient PR reduce over time, so one suggestion is 
to base the exercise rehabilitation in the patient’s home environment to facilitate 
continued exercise at home following cessation of the programme. A home based 
programme may mean that it is accessible to patients with severe lung disease 
and housebound patients can be included. 
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1.16 PR and Behaviour change interventions. 
Whilst there are clear short term benefits of PR the longer term benefits are 
unclear and studies suggest they only last for one year (Guell et al., 2000; 
Troosters et al., 2000; Hill et al. 2008). Therefore it is appropriate to consider 
methods of delivering PR that ensure uptake and adherence to longer term 
physical activity. A theoretical underpinning of behaviour change in PR 
interventions may be important in creating and supporting effective behaviour 
change. Behaviour change can be defined as a: 
“Coordinated set of activities designed to change specified behaviour 
patterns”  
(Michie, van Stralen and West, 2011, p.1).  
There are many frameworks of behaviour change interventions. Michie, van 
Stralen and West (2011) produced from their SR of behaviour change frameworks 
an accessible and complete model of behaviour change called the COM-B system 
see (figure 1.5). 
 
Figure 1.5 COM-B system of behaviour change Reproduced with permission of 
BioMed Central 
This model has the potential to be useful when designing and evaluating 
interventions.  
 A recent SR considered studies that used interventions to increase physical 
activity in patients with COPD (Wilson et al., 2015). It is uncertain what length, 
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intensity and method of delivering the intervention is needed to facilitate change 
in physical activity behaviour in COPD. The review included n = 20 studies 
including n = 31 physical activity interventions varying in type, timing and duration 
of intervention. The range of exercise duration was 150-180 minutes per week. 
Most included moderate aerobic exercise for physical activity and included 
behaviour advice, self-monitoring and goal setting for activity behaviour. Most of 
the studies used a pedometer or accelerometer to measure activity. Unfortunately 
because of the wide variety of interventions and outcome measures a meta-
analysis for type of intervention or outcome assessment was not feasible. For a 
sub-group n = 7/16 demonstrated between group differences in favour of a 
walking based intervention.  
It is challenging for patients with COPD to carry out physical activity for many 
complex reasons. To enable an intervention to change behaviour in regards to 
exercise and activity it is important that these reasons are understood. As part of 
this exploration it is valuable to review physiologically what may contribute to 
those causes. 
1.17 The pathophysiology of COPD and exercise 
One of the most debilitating aspects of COPD is that it hinders a patient’s ability 
to exercise. The physiological response of patients with COPD to exercise is 
complex. The main difference is that people with normal lungs stop exercising 
because of cardiovascular limitation, but there are several possible theories 
suggesting that VL, causing dyspnoea, is the reason for cessation of exercise in 
patients with COPD. VL is described as when the patient can no longer exercise 
due to breathlessness (Mador et al., 2000; Polkey et al., 1995). VL is a 
complicated response related to pathophysiological mechanisms in the lungs, 
peripheral muscles and psychological factors relating to motivation and dyspnoea. 
This section of the theses will address some of the key suggested causes of VL, 
however due to the extensive physiology literature surrounding this debate a full 
review is beyond the scope of this thesis.  
Garcia-Rio et al. (2009) described an association between Dynamic Lung 
Hyperinflation (DLH) (see Glossary, p. 30) and reduced daily activity regardless 
of severity, however, there are studies that found no relationship between DLH 
and muscle load and breathlessness (Freedman, Lane, Guz, 1987; Potter, 
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Olafsson and Hyatt, 1971). DLH resulted in a biomechanical disadvantage, 
shortening the inspiratory muscles and results in breathing at higher absolute lung 
volumes compounding breathlessness sensations (Gorini et al., 1996). Patients 
with DLH will be positioned physiologically at the top of the curve and thus 
disadvantaged by limited lung compliance to respond to exercise. See Figure 1.6 
demonstrating this physiological disadvantage. 
 
 
Figure 1.6 Pressure (P) volume (V) curve of the respiratory system for a patient 
with dynamic lung hyperinflation 
Figure reproduced with permission from Dr Adrian Kendrick, Association of Respiratory 
Technology and Physiology, NIV course, Holiday Inn, Birmingham, COPD presentation, October 
2014. 
COPD patients with DLH are unable to increase their tidal volumes (VT) (see 
Glossary, p. 34) in response to amplified ventilatory drive on exercise (see 
Glossary, p. 34) (O’Donnell, Revill and Webb, 2001). This means that there is 
alveolar hypoventilation (see Glossary, p. 25 on alveolar ventilation (VA). 
Therefore the body responds by increasing the RR leading to shortening of the 
inspiratory muscles (O’Donnell and Webb, 2008).  
Another possible suggestion as to why patients with COPD were unable to 
exercise was because the diaphragm becomes fatigued. Aliverti et al. (2004) 
Abbreviation Key: Pressure P (cmH2O), Volume V (L) 
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suggested that diaphragm fatigue was caused by expiratory muscle activity. This 
activity negatively affects the cardiovascular system and the interaction between 
the respiratory and peripheral muscle systems (Aliverti et al, 2004; Potter, 
Olaffson, Hyatt, 1971). This may have caused diaphragm fatigue but this had not 
been demonstrated conclusively at the point of VL (Mador et al., 2000; Polkey et 
al., 1995). 
Patients with COPD often have reduced elasticity and compliance of the lung 
parenchyma. There is also a chronic change in the diameter of the airways 
(Decramer et al., 2012). These pathological changes may mean that patients with 
COPD are unable to use effectively a feedback system from receptors within the 
lung parenchyma (stretch) (see Glossary, p. 32), airway receptors (flow), muscle 
spindles (tension) and Golgi tendon organs (tension) (see Glossary, p. 31) in the 
chest wall (Remmers and Bartlett, 1977). These combine with neural humoral 
stimuli related to tissue CO2 yield causing an exact homeostatic reduced 
expenditure exercise hyperpnoea (see Glossary, p. 31) (Dempsey, 1985).  
Therefore the patient is unable to respond to the exercise as efficiently with 
increased VT, vital capacity (VC) (see Glossary, p. 34) and expiratory flow rates 
(Powers and Howley, 1997). 
O’Donnell, Revill and Webb (2001) found that COPD patients who stopped 
exercising because of dyspnoea had significantly greater resting airflow limitation 
and thoracic hyperinflation than those who stopped for leg discomfort. Therefore 
the patients with more severe lung disease are more limited by breathlessness on 
exercise. DLH creates a mismatch between drive to breathe and incapacity to 
meet ventilator requirements. O’Donnell, Hamilton and Webb (2006) referred to 
this as neuro-muscular uncoupling of the ventilation system. This leads to 
circumstances where, despite putting in the most forceful of inspiratory effort, 
minimal air goes into the lungs on inspiration. This causes the patient to 
experience intolerable breathlessness (O’Donnell and Webb, 2008). 
An alternative hypothesis was that over time COPD causes increased energy 
demands and a decrease in the available O2. This was argued to be primarily 
caused by excessive recruitment of the expiratory muscles (Aliverti and Macklem, 
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2008). The theory was that energy demands increased because of the high O2 
cost consumed by the respiratory muscles (VO2Resp) (see Glossary, p. 31, 
maximum O2 uptake) of breathing in COPD. In normal subjects this is 1 – 3mLO2/L 
but in patients with COPD it is 6.3 - 16.4mLO2/L (Levison and Charnick, 1968). 
Patients with COPD recruited their expiratory muscles during exercise to improve 
their VE, however, this was futile due to high pleural pressures (Ppl) (see Glossary, 
p. 33) limiting potential expiratory flow. Patients who do successfully recruit their 
expiratory muscles have an increased VO2Resp. If this is subtracted from VO2max 
(maximum volume of O2 that can be used) (see Glossary, p. 31) then there is very 
little energy left for peripheral muscles and other body tissues. In the patients who 
did not recruit their expiratory muscles the respiratory muscles took 17% of VO2max 
compared to 53% in patients who used their expiratory muscles (Babcock et al., 
2002). Although the patients who did not recruit their expiratory muscles had 
better exercise tolerance their resting lung function worsened. Aliverti et al. (2008) 
hypothesised that patients with COPD learn to de-recruit their abdominal muscles 
as their disease progresses, but this causes DLH. Overall an imbalance may be 
present between energy provision and use causing VL. 
A different theory that investigated why COPD patients stop exercising considered 
that pathophysiological consequences of COPD are not just confined to the lungs 
(Decramer et al., 2005). Respiratory impairment is not enough to explain exercise 
limitation in COPD (Debigare and Maltais, 2008). There was only a weak link 
between lung function and exercise tolerance, implying that other systems must 
be involved (O’Donnell, Lam and Webb, 1999). COPD may be associated with 
weight loss and muscle dysfunction (Decramer et al., 2005). Chronic inflammation 
may lead to muscle dysfunction because there was evidence of local inflammation 
in the muscle of patients with COPD including cytokines, macrophages and T-
Cells, and these may have contributed to the pathogenesis of skeletal muscle 
(Montes de Oca et al., 2005). Leg discomfort was often stated as a reason for 
stopping exercise (Debigare and Maltais, 2008; Gosselink, Troosters and 
Decramer, 1996).  Killian et al. (1992) studied the influence of leg muscles on 
exercise intolerance in COPD. They concluded that leg discomfort was a frequent 
exercise-limiting symptom when cycling, however in the study by O’Donnell, Revill 
and Webb (2001) only n = 18 of 105 patients stopped exercising because of leg 
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discomfort, much less than the n = 61 of 105 patients who stopped because of 
breathlessness. Hamilton et al. (1996) evaluated the relationship between the 
perception of leg fatigue, work capacity and muscle strength in both normal 
participants and patients with COPD. They concluded that weaker patients had 
leg fatigue and reduced peak exercise capacity. They also found that quadriceps 
strength determined exercise capacity independent of lung function. 
In contrast Mahler and Wells (1988) demonstrated that their participants (n = 153) 
with mild COPD stopped with leg symptoms whereas those with severe disease 
stopped because of dyspnoea. A smaller (n = 84) but more recent study reported 
that breathlessness limited exercise as opposed to leg fatigue following walking. 
A comparison between those patients who stopped because of dyspnoea 
compared to leg discomfort revealed no difference in age or FEV1. The 
participants in the study that reported dyspnoea performed less well in the interval 
walking test than those who reported leg discomfort (Man, Soliman and Gearing, 
2003). 
The response to sub-maximal exercise could have been shaped by the strength 
and aerobic capacity of the leg muscles. Lower limb atrophy in patients with 
COPD ranges from 21 - 45% of muscle bulk (Vermeeran et al., 2006; Schols et 
al., 1993) and muscle limb weakness is established in patients with COPD 
(Bernard et al., 1998; Killian et al., 1992). Evidence has suggested that patients 
with COPD have weaker leg muscles that fatigue more quickly than the muscles 
of healthy people (Debigaire and Maltais, 2008). There is also a reduction in the 
number of Type I muscle fibres that provide a slow contraction action and are very 
resistant to fatigue. There is a reduction in the cross sectional area of both Type I 
and Type II (the faster acting) muscle fibres and also contractile protein deficiency. 
The resulting muscle inefficiency contributes to exercise limitation (Gosker et al., 
2002; American Thoracic Society, 1999b; Bernard et al., 1998). Similarly, there is 
lower myosin and oxidative enzyme activity (Gosker et al., 2002; Maltais et al., 
2000) affecting muscle endurance (Allaire et al., 2004). This suggested that 
patients with COPD have muscle changes that influenced their deconditioning, 
making it more difficult to rehabilitate them. However it might be too simplistic to 
consider physiological causes of breathlessness in isolation. It is also important 
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to consider how psychological factors may influence dyspnoea on exercise. 
Dyspnoea is a complex multidimensional experience that is very individual hence 
why patients with the same pathology perceive it differently.  
Traditionally dyspnoea was viewed as a simple concept measured by numerical 
scoring. The understanding of dyspnoea has progressed and there is a growing 
body of literature citing psychological factors as impacting on the perception of 
dyspnoea including emotion, anxiety, previous experience, attributions and 
context. More recently a school of thought has suggested interpreting dyspnoea 
was similar to how we view the complexity of pain (Lansing et al., 2009). The 
Lansing et al. (2009) model of different breathlessness sensations and causes fits 
more easily with the complexity of dyspnoea experienced by patients with COPD. 
This model of Lansing, et al. (2009) reflects 3 specific qualities of dyspnoea 
gathered from previous research literature (Harver et al., 2000; Schwartzstein, 
1998; Banzett et al., 1996; Elliott et al., 1991; Simon et al., 1990; Banzett et al., 
1989). The three suggested descriptors are: 
1) Air hunger: This is driven by brainstem motor control and is an automatic 
stimulus of breathing, not caused by a mismatch between drive and ventilation. 
This would be similar to the dyspnoea experienced for physiological reasons 
previously discussed. 
2) Tightness sensation: This relates to bronchospasm and is as a result of 
bronchoconstriction of the airways. It is a localised sensation to the chest (Moy 
et al., 1998). 
3) Work: Increased work of breathing is influenced by an increased motor 
command in response to an activity or exercise. The increased motor 
commands influence the muscle afferent pathways and perceived cortical 
command, leading to an increase in VE. 
The first two dyspnoea descriptors seem to relate more to the physiological 
causes previously discussed, however the sensation of work seems to fit in more 
with voluntary interaction. This would seem to relate more to motivation and 
emotions. Carrieri-Coleman et al. (1996) identified a relationship between the 
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affective dimension and sensory dyspnoea. They identified that supervised 
exercise training can decrease dyspnoea-related anxiety in the same individuals, 
even if the same intensity of breathing is sustained. Leopold et al., (2009) used 
cards conveying a negative affective state or those with a positive affective state 
during cycle ergometry in patients with COPD. A higher level of dyspnoea was 
expressed by the group viewing the negative affective cards, although this was 
not significant. As the sample was elderly with more co-morbidities it may be that 
both groups exposed were more deconditioned. This research was further 
developed by Jannsons et al., (2011) who evaluated dyspnoea-related fear before 
and during PR and demonstrated that those with increased baseline anxiety and 
dyspnoea-related fear had a higher baseline dyspnoea score. This was the group 
who also had the steepest improvement in dyspnoea during PR. However in these 
studies there was no validated measure for dyspnoea-related fear. 
This section has demonstrated that there are numerous interconnecting 
physiological causes that may contribute to dyspnoea limiting exercise. These 
include DLH, respiratory and peripheral muscle dysfunction, and pulmonary gas 
exchange deficits causing arterial hypoxaemia (O’Donnell and Webb, 2008; 
Aliverti and Macklem, 2008). It would seem sensible to conclude that all systems 
play a role because of the multi-system pathology of COPD.  
Exercise is important for maintaining activity levels (Decramer et al., 2005). 
Therefore it is important to consider treatments that encourage exercise and 
treatments that may overcome both the pathophysiological changes and the 
psychophysiological changes in patients with COPD that prevent them exercising. 
Adjuncts to exercise will be considered in the next section. 
1.18 Are there any methods or adjuncts that could improve PR? 
1.18.1 Lung volume reduction surgery (LVRS) 
LVRS is a proven palliative procedure for patients with COPD who have 
emphysema in the upper lobes of the lungs. This surgery removes 20 – 30% of 
each lung’s most damaged segments. This reduces dead space (see Glossary, 
pp. 30 dead space ventilation) and gas trapping (see Glossary, p. 31 end 
expiratory lung volume) allowing for improved breathing biomechanics on 
exercise (Ernst and Anantham, 2011). When comparing LVRS and three months 
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of PR to three months of PR alone there were improved benefits in static lung 
function, gas exchange and QOL with a trend for improved walking distance in the 
group that received both LVRS and PR (Criner et al., 1999). In another study 
exercise endurance and QOL significantly improved at 24 months post-operative 
procedure compared to the control group (Fishman et al., 2003). However LVRS 
is a highly selective treatment, therefore it is not suitable for all patients with 
severe COPD. There is also a risk of post-operative mortality (7.9%) and post-
operative complications are at > 50% (DeCamp et al., 2008). Thus this kind of 
surgical management is not necessarily appropriate and the high risk of the 
procedure may outweigh the benefits. Therefore there is a need to look at other 
low risk and low selection criteria interventions that may act as an adjunct for PR. 
1.18.2 Inspiratory muscle training (IMT) 
IMT attempts to improve respiratory muscle strength and endurance. IMT uses 
devices that permit inhalation against resistance at a certain threshold. A pilot 
study (n = 36) of patients with COPD demonstrated that the use of IMT in addition 
to an exercise programme led to greater improvement in walk test distance than 
those who undertook exercise alone (Winer, Azgad and Ganam, 1992). Similarly, 
another pilot study (n = 32) found that IMT led to greater improvement in 
cardiopulmonary exercise test parameters after an exercise programme (Wanke 
et al., 1994). 
Two subsequent RCTs in patients with COPD found no additional benefit from 
IMT with exercise compared to exercise alone in regards to dyspnoea 
experienced by the participants or performance. (Berry et al., 1996; Larson et al., 
1999). The positive studies in favour of IMT have limitations due to small samples, 
no randomisation, not blinded, there was a high participant drop-out rate and a 
lack of detail of the intervention and exercise training (Wanke et al., 1994; Weiner, 
Azgad and Ganam, 1992). IMT is not recommended as a routine adjunct to PR 
(BTS, 2013). 
1.18.3 Other Adjuncts 
Other adjuncts have been advocated including hormonal supplements, nutritional 
supplements and heliox (80% Helium, 20% O2) but are not currently 
recommended with PR due to a lack of appropriate evidence (BTS, 2013). There 
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may also be evidence for the addition of neuro-muscular electrical stimulation 
(NMES) of the quadriceps if there is available expertise. Some patients, with low 
BMI and with evidence of quadriceps weakness, that are unable or unwilling to 
participate in PR could be considered for NMES (BTS, 2013; Vivodtzed et al., 
2006).  
In conclusion, PR seems to be supported by evidence in patients with very severe 
COPD. The problem of access to PR and fear of participation in exercise because 
of the sensation of dyspnoea means that many patients with severe COPD are 
unable to use this intervention. Adjuncts to PR have been considered but are not 
currently recommended due to a lack of appropriate evidence (BTS, 2013). Thus 
there is a need to consider other ways of providing exercise to this group of 
patients. Exercise on NIV may provide a means for enhancing the ability for these 
patients to engage with exercise.  
1.19 Non-invasive ventilation (NIV) 
It is relevant to this study to understand how NIV was established as a treatment 
for COPD. Non-invasive ventilation methods have been key to the history of 
respiratory care, although having early origins, they were initially superseded by 
invasive methods. In the last 30 years the use of NIV ventilation has escalated 
globally in both acute and chronic use, for multiple pathology and novel uses. This 
is because there are disadvantages to using invasive ventilation (ventilating via 
an endotracheal tube) that may often be avoided with NIV, this will be further 
discussed in section 1.19.2 The birth of NIV. 
1.19.1 Negative pressure ventilation 
The first well recognised feasible way of sustaining life in patients unable to 
breathe independently was by the use of negative pressure applied with tank 
ventilation, developing into the iron lung (Simonds, 2001; Woolam, 1976a; Drinker 
and Mckhann, 1929). Cuirass jackets eliciting negative pressure were created in 
the 1930s (Woolam, 1976b). The emergence of ventilation occurred during the 
polio epidemic of the 1940s-1950s (Colice, 1994; Morch, 1990; Lassen, 1956). 
Iron lung ventilation was rolled out all over the UK and former Empire (Simonds, 
2001). Unfortunately, despite the use of the iron lung, mortality remained high. 
Therefore new ways of ventilating patients were trialled including manual 
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intermittent positive pressure ventilation. This doubled the chance of survival and 
led to the replacement of negative pressure ventilation with positive pressure 
(Young and Sykes, 1994). This was soon superseded by more advanced ways of 
invasive ventilation (Pierson, 1990). 
By the 1970s ventilation was a routine part of intensive therapy unit (ITU) 
management for all pathologies requiring support to the respiratory system. 
Invasive ventilation became more sophisticated and improved with the 
introduction of novel ways of taking physiological measures e.g. ABG analysis 
(Pierson, 1990). However, awareness of the complications of invasive mechanical 
ventilation and artificial airways led to investigations into ventilatory support with 
fewer side effects (Tremblay and Slutsky, 2006; Slutsky, 2005; Pierson, 1990; 
Stauffer and Silvsetri, 1982).  
1.19.2 The birth of NIV 
Searching for new methods of ventilation led to a renewed interest in NIV and 
mask ventilation was successfully used with continuous positive airways pressure 
(CPAP) to treat obstructive sleep apnoea (OSA) (Sullivan et al., 1981). In 1987 
Delaubier et al. used NIV to treat a young man with Duchenne’s muscular 
dystrophy. The arrival of NIV as a treatment for chronic hypercapnic respiratory 
failure changed the normal trajectory of neuromuscular and chest wall diseases 
(Lobato and Alises, 2013; Piper and Sullivan, 2006). NIV functioned to reduce the 
work of breathing of the respiratory muscles by decreasing the RR and increasing 
Tv leading to an improvement in VA (Elliott, 2005). It can be applied with a nasal 
or full face mask without reducing the defence of the airway. This method can be 
used safely outside of the ITU (Plant, Owen and Elliott, 2000). Initially volume 
modes were used to ventilate patients but this then changed to inspiratory 
pressure modes. This was further developed into Bi-level inspiratory positive 
airways pressure (BIPAP) (Respironics) made up of two pressures inspiratory 
positive airways pressure (IPAP) to change the depth of breathing and expiratory 
positive airways pressure (EPAP) was added to treat a collapsing/floppy upper 
airway in sleep or overtake resistance in the breathing tube to allow for mask leak 
ventilation (Simonds, 2001). This also allowed for a patient to spontaneously 
trigger a breath, in spontaneous timed (S/T) mode, rather than the machine 
triggering and generating a controlled breath (Elliott, 2009). This allowed for more 
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comfort and concordance with the device (Simmonds, 2001). More recently 
research has considered its use in other conditions. Obesity hypoventilation 
syndrome (OHS) required treatment with NIV. This was caused by obesity leading 
to extra work for the diaphragm meaning hypoventilation can result. OHS is 
commonly diagnosed in addition to OSA and COPD, referred to as crossover 
syndrome. This mixed pathology often meant patients needed a mix of inspiratory 
and expiratory pressures called hybrid modes to treat their symptoms. More 
recently NIV has been used to palliate the respiratory symptoms in Motor Neuron 
Disease (MND), which commonly include breathlessness on lying flat and during 
sleep caused by poor innervation to the respiratory muscles causing 
hypoventilation (NICE, 2010). 
NIV using inspiratory Pressure Support (IPS) was a mode of ventilator support 
that demonstrated pioneering positive results when treating COPD patients with 
acute respiratory failure (Plant, Owen and Elliott, 2000). NIV enabled patients not 
to be intubated and suffer the potential risk of nosocomial infections and 
complications arising from the use of paralysing agents. This is because NIV 
allows for speaking, swallowing and airway defence mechanisms, for example 
preserved cough (Nava and Hill, 2009; Elliott, 2005). Two meta-analyses 
confirmed the effectiveness of NIV in acute exacerbations of COPD (Lightowler 
et al., 2003: Peter et al., 2002). It improved survival and also decreased length of 
hospital stay (Ram et al., 2004a).  
The use of NIV for chronic hypercapnia is controversial. Long term RCTs are 
currently being undertaken across Europe, including the UK version ‘The Hot 
study’, but results are yet to be published. Results to date have been variable. 
One study suggested a marginal improvement in survival but this decreased after 
three years (McEvoy et al., 2009).  
Researchers have used the knowledge of the therapeutic effects of NIV and 
applied this to investigate the benefits of using NIV during exercise in patients with 
COPD. NIV may offload the respiratory muscles, improving the experience of 
dyspnoea during exercise and allowing patients to train at a higher intensity, 
gaining health benefits.  
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1.19.3 Patients using NIV to exercise 
Physiological studies have researched the addition of positive pressure via a face 
mask to patients with COPD when exercising. Initial studies focused on CPAP to 
unload the respiratory muscles (Petrof, Calderini and Gottfried, 1990; O’Donnell, 
Sanii and Younes, 1988; O’Donnell et al., 1988). This applied Positive end 
expiratory pressure (PEEP) (See Glossary p. 34), which acts to splint open the 
airways, reducing the work of breathing (Lopes, Nery and Sousa, 2011). It was 
thought that CPAP lowered the inspiratory threshold load on the inspiratory 
muscles in hyperinflated patients (Ambrosino and Strambi, 2004). This rectified 
the PEEPi, improving neuromuscular coupling, therefore lessening dyspnoea, 
and increasing exercise tolerance (Lougheed, Webb and O’Donnell, 1995). 
O’Donnell, Sanii and Younes (1988) demonstrated that CPAP applied to patients 
with COPD significantly improved submaximal endurance time by 48% (mean 
time 8.82 minutes in the CPAP group compared to 5.98 minutes in the control 
group) and reduced dyspnoea scores compared to the control group at iso-time 
in the CPAP group to BORG score of 5.5 compared to 7.83 in the control group. 
This same research group confirmed that CPAP counterbalanced PEEPi during 
cycling (O’Donnell et al., 1988). They hypothesised that inspiratory muscle 
performance determined exercise endurance and that CPAP may relieve 
dyspnoea by unloading the overburdened respiratory muscles. They suggested a 
connection between elevated inspiratory muscle action, increasing central 
command output and creating dyspnoea (Leblanc et al., 1988). A further 
supporting study on patients with COPD demonstrated that CPAP maintains 
oxygenation and decreases the pressure time interval of the respiratory muscles, 
thus reducing the O2 consumption of the muscles (Petrof, Calderini and Gottfried, 
1990). 
A recent study using CPAP on COPD patients climbing stairs did not support 
these previous results. The findings demonstrated no improvement in lung 
hyperinflation, deoxygenation, hypoventilation, blood lactate production, 
dyspnoea or completion time (Walterspacher et al., 2013), however the patients 
carried the CPAP up the stairs, which may have added to their muscle burden. 
The patients were not screened for DLH so may not have been physiologically 
disadvantaged to benefit, as in other studies (Soares, Oliveira and Franca, 2008). 
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Nevertheless the patients in the study by Walterspacher et al. (2013) did develop 
significantly less limb discomfort when on CPAP. They hypothesised that the 
CPAP caused a decreased work of breathing, boosting peripheral blood flow and 
therefore improving oxygenation of the limb muscles (Romer and Polkey, 2008; 
Petrof, Calderini and Gottfried, 1990).  
Overall the existing evidence suggests that CPAP may be beneficial in some 
patients with severe COPD, however CPAP did not influence VT and whilst aiding 
inspiration it may add to inspiratory load and increased respiratory effort if the 
pressure is too high (Keilty, 1994).  
1.19.4 Using the mode of pressure support (PS) to exercise 
IPS is a type of mechanical ventilation that can effectively aid breathing when 
applied non-invasively to patients with respiratory failure. PS is a pressure-
targeted mode where the patient initiates each breath which is supported by a 
pre-set pressure (Kinnear, 2008). NIV is a combination of PS and PEEP 
synchronised with the inspiratory effort of the patient (Simonds, 2001). NIV works 
acutely to reduce inspiratory effort and dyspnoea while increasing VA (Plant, 
Owen and Elliott, 2000). Other studies have used the mode of proportional 
assisted ventilation (PAV) (see glossary, p. 33), which provides partial ventilatory 
assistance providing changing inspiratory flow and pressure in proportion to the 
patient’s effort (Ambrosino and Strambi, 2004). 
Maltais, Reissman and Gottfried (1995) studied PS versus no PS in patients with 
COPD on an exercise bike. PS increased VE through changes to both VT and RR. 
Physiologically this was unrelated to reductions in inspiratory effort, evidenced by 
oesophageal and transdiaphragmatic pressure-time intervals. Dyspnoea 
significantly improved when PS was used and deteriorated on removal.   Slowing 
of the maximal muscle relaxation of skeletal muscle is an early marker of fatigue 
(Kyroussis et al., 1996). When PS was applied to COPD patients during treadmill 
walking, oesophageal maximum relaxation rate was significantly lower than 
walking without IPS. This therefore suggests that IPS unloads inspiratory muscles 
counteracting fatigue.  This was further validated in study by Kyroussis et al., 
(2000) involving patients with severe COPD who exercised on a treadmill. 
Unsupported oesophageal and transdiaphragmatic pressure rose early in 
exercise and remained high until dyspnoea stopped exercise. When the patients 
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walked the same distance with NIV a reduction was observed in the inspiratory 
and expiratory time products throughout the walk. Therefore it would seem PS 
substantially unloads all parts of the respiratory muscle pump (De Backer et al., 
2010). 
Another theory of how PS may physiologically aid exercise in COPD was 
investigated by Polkey et al. (1996). Patients with severe COPD exercised on a 
treadmill with and without PS. Plasma lactate levels were compared for both 
walks. The walk with PS showed no difference in lactate levels compared to the 
unsupported walk, however, patients were able to walk for longer with PS. 
Hernandez et al. (2001) trial involved a sample of patients with severe COPD who 
exercised using proportional assisted ventilation (PAV); a mode of ventilation that 
provides a level of support irrespective of any changes in lung compliance or 
resistance. They showed similar improvements in exercise duration, VT and VE, 
with improvements in ABG and dyspnoea, however there also seemed to be an 
overall improved breathing pattern. Therefore it could be that NIV regulates and 
paces breathing as well as offloading the respiratory muscles.  
An alternative hypothesis on how NIV may delay VL was offered. The theory is 
that using NIV during training of patients with COPD led to unloading of the 
respiratory muscles. This may minimise the impact of increased respiratory 
muscle blood flow, enabling more effective physiological adaptations of the 
peripheral muscles. This results in less perceived leg effort, increased leg 
oxygenation, decreased exercise lactate and improved exercise tolerance (Borghi 
Silva et al., 2010; Borghi Silva et al., 2008). This hypothesis was based on the 
work by Harms et al. (1997) on the use of NIV during exercise in normal subjects 
which showed that respiratory muscle effort improved blood flow distribution. The 
growth of inspiratory muscle strength in the NIV group may be accounted for by 
the decreasing of mechanical load and a pause in the onset of respiratory muscle 
fatigue (Polkey et al., 1996; Nava et al., 1993) causing a reduction of inspiratory 
muscle metaboreflex activity. It is possible that increased walking distance was 
caused by improved respiratory muscle strength contributing to less leg fatigue. 
The decrease in lactate/speed ratio also advocates better oxidative capacity of 
the exercising muscles, and possible true beneficial physiological adaptations 
(Borghi Silva et al., 2010). Alternatively there have been some studies 
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demonstrating negative results when ventilation is applied during exercise 
(Highcock, Shneerson and Smith 2003; Revill, Singh and Morgan, 2000).  
In the prospective randomised study carried out by Revill, Singh and Morgan 
(2000) the effect of AOT versus PS on an endurance shuttle walk was evaluated. 
The participants (n = 10) with severe COPD (FEV 1 < 40% predicted) performed 
the endurance shuttle walk test under five test conditions: baseline walk (no 
support); PS at 14cmH2O, PEEP set < 3cmH2O from a portable ventilator (HIPPY, 
Friday Medical, U.K.) using a full face mask (over nose and mouth); sham PS < 8 
cmH2O PEEP < 3cmH2O; AOT at 2L/min; and sham O2 (carrying the portable 
cylinder but breathing in air). The results demonstrated a significant improvement 
in the mean walk time compared to baseline (172 seconds) with the addition of 
AOT (242 seconds) but a worsening in time with the HIPPY ventilator (84 
seconds). The authors concluded that a more powerful machine, in terms of 
inspiratory flow, is required to support exercise when higher levels of ventilation 
are reached. Therefore inspiratory flow needs to be considered and assessed 
when choosing a ventilator to support the exercise programme.  
Highcock, Shneerson and Smith (2003) evaluated three different makes of 
ventilator (BiPaP S/T 30, Nippy 2 and VPAP ST using bi-level mode). No details 
were given to EPAP values, only that they were set as a minimum. The average 
IPAP pressure used was 12.2cmH2O on (n = 8) patients with COPD (severity 
FEV1/FVC < 70% predicted) whilst exercising during a submaximal treadmill 
exercise. The participants walked to exhaustion with each of the ventilators, and 
one with just breathing through a mouthpiece, in a random order. As a control four 
treadmill walks were performed unaided. The mean distance of the unaided walks 
were 259m, mouthpiece alone was 211m, and only 145m with the addition of the 
ventilators. There was no difference found between each make of ventilator, 
however the VT and VE achieved were greater in the ventilator walks. The authors 
did attempt to apply a control walk and counteract learnt behaviour of walks by 
using multiple walks. The authors attempted to reduce bias with randomisation, 
although blinding of participants and researchers was not attempted.  
The negative results of this study may have been because the pressure, circuit 
and equipment were inadequate to meet the inspiratory flow rates or pressure 
needed to offload the respiratory muscles to result in physiological change 
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(Menadue et al., 2009). The circuit used in Highcock, Shneerson and Smith’s 
(2003) study used an inefficient expiratory valve so up to 60% of expired air may 
remain in the circuit at the end of expiration (Lofaso et al., 1996). Therefore the 
authors’ conclusions were that exercise capacity in patients with COPD was not 
improved with the addition of ventilatory support using a mouth piece and whisper 
valve in the circuit (Highcock, Shneerson and Smith, 2003). The authors 
commented on asynchrony between patient and ventilators as the patients were 
breathing out before the ventilator had achieved the set IPAP. The ventilators 
used in that study are now dated and modern ventilators are more sensitive and 
have improved synchronisation with patients. The disease severity of the 
participants in the Highcock, Shneerson and Smith’s (2003) study was not very 
severe. Although the authors did consider whether their exercise was limited by 
breathlessness and excluded participants if they could walk for more than 10 
minutes on the treadmill at their individual maximum speed. There was also only 
a 30 minute rest in-between walks. The number of participants recruited in these 
negative studies are small but comparable with those recruited in the positive 
studies.  
Recent studies have considered upper limb exercise in COPD with the use of NIV 
compared to unsupported exercise. NIV improved unsupported arm exercise 
(UAE) endurance time possibly because of reduced dyspnoea and perceived 
exertion, and improvement in oxygenation (Menadue et al., 2010; Menadue et al., 
2009). Physiologically during UAE some accessory muscles (see Glossary, p 29) 
have two jobs of executing the upper limb activity, as well as helping inspiration. 
Consequently some of the ventilator load is shifted to the diaphragm and 
abdominal muscles. Previously arm elevation was shown to increase inspiratory 
muscle work in patients with chronic respiratory failure (Poggi et al., 2006). The 
reduction in dyspnoea that was observed with NIV during UAE suggests that NIV 
may have improved exercise performance by unloading the inspiratory muscles. 
The added EPAP used in Poggi, et al.’s (2006) study has been shown to 
counterbalance PEEPi (Nava et al., 1993). The decrease in perceived dyspnoea 
may have allowed patients to exercise for longer, although both groups stopped 
because of arm tiredness. This may again relate to the competition for blood flow 
between muscles of locomotion and respiratory muscles (Debigare and Maltais, 
2008). 
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1.19.5 NIV on exercise conclusion 
Overall the evidence has suggested that the use of NIV during exercise in COPD 
may be beneficial. NIV may reduce breathlessness during exercise as a result of 
one or more physiological processes, allowing for higher levels of exercise 
intensity. It would seem that only suggesting that physiological factors influence 
dyspnoea on exercise may be too simplistic. Dyspnoea is an individual experience 
developing from physiological, psychological and social factors. Given that there 
is a multi-factorial reason as to why patients with COPD could not exercise, it 
would seem feasible to suggest that the reason NIV allowed patients with COPD 
to exercise harder and for longer was also multi-factorial. On reviewing the 
methodological quality of the studies the biggest problem was the small sample 
sizes used and lack of RCTs (De Backer et al., 2010).  
1.20 Current political health climate in the UK  
It is important to consider how the current political health climate influenced the 
environment in which the current research was carried out to enable the results 
to be interpreted in context. The NHS was driven by a government target which 
sought to decrease waiting times to under four hours in A&E departments and 
facilitate the flow of patients through the hospital system (DH, 2002; DH, 2000). 
Additionally there had been government and health guideline drives to move care 
provision back into the community (DH, 2014; DH 2010c; National Collaborating 
Centre for Chronic Conditions, 2004). This policy had impacted upon COPD 
patients because it had driven early discharge schemes for patients admitted with 
exacerbations. This potentially meant that patients spent less time in the hospital 
and were less at risk of developing hospital acquired infections. An SR concluded 
that 30% of patients admitted with a COPD exacerbation were considered for 
early discharge (Ram et al., 2004b). A SR and two audits demonstrated that early 
discharge was safe and effective, mortality and re-admission rates were the same 
for both groups of patients (Ram et al., 2004b; Candy et al., 2005; Quantill et al., 
2003). Early discharge schemes could potentially affect the amount of time 
available for recruitment and establishing an exercise on NIV intervention, 
however these schemes are aimed at patients who are less acutely unwell (for 
example, do not have a pneumonia or respiratory failure treated with NIV). 
Therefore the patients with more severe COPD treated with NIV have a longer 
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hospital stay which allows for a longer duration for recruitment and immediate 
initiation of exercise on NIV post exacerbation. These severe patients are also 
identified as those less able to access or partake in community PR.  
COPD patients with severe and end-stage COPD previously received very little 
palliative input (Curtis, 2008; Gardiner et al., 2010). Hospice and palliative care 
services were primarily offered to patients with cancer because the prognosis of 
COPD is difficult to predict (Pountney, 2006). NICE (2011) guidance has 
recommended an improved palliative care service for patients with COPD. Within 
the last five years palliative input for COPD patients has improved within Bristol. 
There has been a drive for improved completion of advanced care decisions, ‘do 
not resuscitate’ forms and palliative symptom control forms. This has also 
included an increase in referral to palliative care for patients with severe COPD 
who have had repeated admissions. If someone is referred to palliative care 
services it often means that the level of active care is reconsidered. This may 
include whether someone is offered antibiotics or treatment with NIV. What is 
challenging is that these patients may live a further six to twelve weeks with 
frequent admissions. Their mobility may deteriorate further and they are not 
considered for PR, exercise or physiotherapy as this may be considered to be too 
aggressive. Patients with severe end-stage COPD may benefit from increasing 
their activity levels through supported exercise on NIV and possibly gain QOL 
benefit from increased activity within this later stage of disease.  
1.21 Motivations for undertaking the study 
1.21.1 Personal Perspective 
In recent years I have witnessed a change in clinical practice towards patients 
with COPD. Previously it was not common for palliative care to be offered to 
patients with severe COPD until they were considered to be dying. However in 
the last five years patients are frequently referred and considered to be palliative 
if they have had multiple admissions. Previously each patient with COPD had an 
exacerbation treated as an isolated acute event up until their death, often in 
hospital. They were unable to access the support of palliative care, Macmillan 
nurses and hospice care. Over time, thanks to well publicised recommendations, 
this approach has changed to an almost over-zealous approach to referral to 
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palliative care. Now on frequent admission patients are advised that there is little 
else to be done, and they are referred to palliative care, given Oramorph 
medication for breathlessness and advised on advanced planning related to end 
of life care. COPD is a disease with a difficult to predict prognosis, therefore early 
referral does ensure that a dying patient receives appropriate palliative support, 
however I couldn’t help but feel palliative care should not be the only treatment 
option for this group. 
In the past, whilst working within respiratory, health care professionals have often 
expressed a helplessness to treat patients who are frequently admitted with 
exacerbations of COPD. Occasionally terms like “repeat admission”, “social 
admission”, “panicker” and, more recently “palliative” have been used to describe 
these patients. Occasionally it seemed that reasons for hospital admission were 
even associated with the patient with suggestions such as “still smoking”, 
“declined social services”, “never attended the clinic appointments”, “declined PR” 
and “turned their O2 up”. This possibly meant that these patients may not be 
considered suitable for early discharge schemes, PR or smoking cessation, as it 
may have been assumed they would decline to attend or fail the intervention. 
As a more junior physiotherapist I remember feeling a sense of responsibility and 
a sense of personal failure if a patient was readmitted soon after discharge. I felt 
I must have missed a new infection or failed to meet all their rehabilitation needs. 
Then later I became hardened to this and maybe shared the frustration of my 
colleagues. More recently the sense of failure returned and I felt I wanted to 
address more than palliative care in these patients. I wanted to help them access 
other treatment options. I think this probably came to the forefront when I 
witnessed a new junior physiotherapist happily completing a smoking cessation 
referral and PR referral for a regular attender after the patient consented. I 
probably would not have even offered those things to this patient knowing that 
they had declined previously. 
The patients with very severe COPD were frequently bed bound on admittance 
into hospital in an unresponsive state. They were previously deconditioned and 
often housebound. They repeatedly became dependent on the NIV used to treat 
their acute respiratory failure and became breathless with removal. Using my 
clinical knowledge of balancing wean and rehabilitation it made sense to me to 
87 
 
continue rehabilitation on the ventilator. The practicalities of this were very 
individual to each patient. I increased the pressures in response to breathlessness 
and desaturation. It seemed to be an effective way to rehabilitate this very 
breathless group, however I had no clear idea of the physiology behind it, whether 
it did really clinically benefit the patient or if there was a preferred method for 
delivery. Therefore I was keen to create a study that investigated whether 
exercising on NIV was feasible out of hospital and if it had any clinical benefit. I 
also wanted to give the patients with severe COPD another chance at treatment. 
1.21.2 Clarification of the role of the PhD student 
To enhance understanding it is important to clarify my role throughout the thesis. 
I thought out the research question and developed the design and protocol. I 
sought out commercial funding and applied for ethical approval. I am the 
researcher who undertook recruitment and consented participants into the study. 
I am the physiotherapist who treated the participants with the intervention and I 
am the researcher who assessed the outcome measures. I completed the 
quantitative data analysis. I undertook the interviews, transcribed and coded the 
content. I evaluated the intervention and research design. 
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1.22 Aims of the Research and Thesis 
1. To evaluate the acceptability of applying non-invasive ventilation (NIV) during 
exercise in both the hospital environment and at home to patients with severe 
COPD who have been hospitalised for an acute exacerbation with acidotic 
respiratory failure.  
2. To gather qualitative data to aid understanding of the patient experience of 
participation in the intervention arm of the research trial to enhance quantitative 
acceptability data. 
3. To evaluate the feasibility of a randomised controlled trial design including: 
Ability to complete the design in clinical environment with available resources 
Availability of the participant sample pool 
Recruitment numbers and recruitment time period 
Randomisation process and acceptability 
Participant retention in the trial, drop-out rate and reasons 
4. To evaluate the feasibility of collation and completion of the quantitative outcome 
measures to inform a future trial of the potential primary outcome and secondary 
outcomes. These measures include:   
Six minute walk test (6MWT) 
St George’s Respiratory Questionnaire (SGRQ) 
European Quality of Life - 5 Dimensions - 5 Levels (EQ-5D-5L): Utility score and 
visual analogue score 
The Activity of Daily Living Questionnaire (LCADL) 
Activity levels 
Medication use, access to healthcare and hospital admissions 
1.23 Objectives 
1. To review and critically evaluate the existing literature regarding exercising 
patients with severe COPD on NIV. To inform the development of the feasibility 
study design. Focusing on the reasoning behind the study question, sample 
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characteristics, recruitment and retention of participants, trial design and 
hypothesis, outcome measure choice, SAEs and duration of follow up. 
2. To review and critically evaluate the existing literature regarding the planned 
intervention of the practicalities of exercising patients with severe COPD on 
NIV. To understand which modes, pressures, circuitry of ventilation and type, 
duration, intensity of exercise to use. 
3. To review and critically evaluate the existing literature regarding exercising 
patients with severe COPD on NIV. The research question was shaped in 
clinical practice but the researcher wanted to be certain that the research was 
novel. 
4. To design and carry out a research protocol for patients with severe COPD to 
exercise on NIV documenting clearly the methodology to inform future studies. 
To develop an outline of the future research protocol justified by the feasibility 
trial. 
5. To evaluate the feasibility of the research design, research method, process 
and intervention as a whole to inform the outline of a protocol for the future 
trial. The scope of this evaluation includes recruitment and retention of 
participants, and implementation of an individualised exercise programme on 
patients who have been seriously ill and are deconditioned. Evaluation of the 
intervention arm of applying NIV during exercise at a high PS. Evaluation of 
the outcome measures and sample size calculation for statistical significance 
of the chosen primary outcome. 
6. To evaluate whether it is feasible to deliver the intervention in everyday 
practice. The feasibility of recruiting participants who have been acutely unwell 
from the hospital environment and exercising them on NIV for a three month 
period in both the acute care and community environment with the available 
resources. 
7. To evaluate the acceptability of the research to participants. 
8. To explain the experience of the participants of the research and intervention. 
9. To evaluate the process and timing of collating the outcome measures and 
their completion, including the description of any trends in changes in the 
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outcome measures recorded between treatment groups, to inform primary and 
secondary outcome measures in a future trial. 
10. To fully integrate both the quantitative results and qualitative results to ensure 
a complete evaluation of feasibility. 
1.24 Structure of thesis 
To assist the reader with navigation of this thesis the following paragraphs provide 
a brief description of each chapter’s content. 
Chapter 2 provides a critical analysis of the literature on exercise on NIV in 
patients with COPD. The literature review informs the planned feasibility study 
design and intervention. 
Chapter 3 outlines the chosen mixed methods methodology and the justification 
for this. It chronicles the development of key methodological decisions including 
the change in research study aim to feasibility. It goes on to discuss the strengths 
and weaknesses of the chosen methodology. 
Chapter 4 reports the quantitative method from initial design, gaining funding, 
ethical approval and intellectual property rights. It goes on to discuss the choice 
of outcome measures and briefly discusses why alternatives were not considered.  
Chapter 5 describes the qualitative method of semi-structured interviews used 
and how analysis was carried out using a step by step approach using thematic 
analysis (TA).  
Chapter 6 presents the quantitative results. In particular it seeks to answer the 
aim of feasibility focusing on recruitment retention, outcome measure completion 
and presentation of any trends in the data. 
Chapter 7 portrays the findings and analysis from the qualitative semi-structured 
interviews. It seeks to offer an insight into the patient experience by presenting as 
many of the participants’ voices as possible. Themes are presented under 
concepts based on the research aims and objectives. 
Chapter 8 explains how the researcher saw herself as influencing and interacting 
with the research. The chapter describes how this was present and how it evolved 
at each stage of the research process. It goes on to demonstrate the researcher’s 
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learning journey. By presenting this information in an open and honest way the 
researcher hopes to improve rigour and offer further insight into the qualitative 
findings. 
Chapter 9 is the discussion integrating both the quantitative and qualitative data 
to answer the original question of feasibility. It discusses the feasibility of all 
aspects of the research trial from recruitment to undertaking the outcome 
measures. It also discusses the acceptability of the research and intervention to 
participants, a valuable component of feasibility. It discusses the strengths and 
limitations of the research and alternative methods that could have been used. It 
goes on to outline how a definitive RCT may look based on the findings of this 
feasibility study. 
Chapter 10 concludes the thesis. It reviews the research aims and objectives, 
evaluating the extent to which they have been achieved. 
1.25 Conclusion 
This chapter has laid the foundation and set the scene for the research project 
and thesis by reviewing the historical background, definitions, pathophysiology 
and personal perspectives that have inspired the research and provided 
motivation for this thesis. It included a detailed account of COPD including 
prevalence, cause and pathology. It discussed the symptoms and impact of 
COPD on patients’ lives. It discussed how the pathophysiology of COPD limits 
exercising. It then focused on available treatment, in particular PR. Unfortunately 
PR is not accessible to all patients with COPD, especially those with severe 
disease, thus this required further investigation. One possible intervention 
available was exercising on NIV. In clinical practice the researcher had witnessed 
patient reported benefits of exercising on NIV. The next chapter of the literature 
review sought to evaluate the quality of the research available on exercise on NIV 
in patients with COPD and highlight missing research in the literature to inform 
the development of the planned feasibility study 
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Chapter 2 Literature Review 
 
2.1 Introduction 
This thesis differs from some traditional theses because the research question 
has been directly derived from clinical practice, thus the literature review has been 
carried out following the initial research development. The purpose of the literature 
review was to inform and develop the design of the feasibility study and 
intervention. A further extended review of studies that were not included in the 
SRs was also included to further inform the study and intervention. 
The literature review was composed of two parts: 
Part A: Reviewed the high quality evidence from SRs regarding exercise on NIV 
in patients with COPD (to inform the design of the research study and 
intervention). 
Part B: Reviewed any literature not included within Part A (to inform the design of 
the research study and intervention). 
 
2.2 Aims: Part A 
The literature review for Part A sought to meet the following aims: 
1. To carry out a literature search for SRs on exercise on NIV in COPD. 
2. To evaluate the quality of the evidence reviewed. 
3. To inform the development of the feasibility study. Focusing on the reasoning 
behind the study question, sample characteristics, recruitment and retention of 
participants, trial design and hypothesis, outcome measure choice, SAEs and 
duration of follow up. 
4. To inform the design of the complete intervention. Focusing on type and mode 
of ventilation, ventilation settings and interface, location of intervention, type of 
exercise, duration and timing of intervention. 
5. To establish whether the research question formed in clinical practice was 
novel.  
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2.3 Methods: Part A 
2.3.1 Search strategy 
The initial search began in 2012 and it was continually updated. Updated 
searches were based on the Menadue et al., (2014) SR search strategy. A 
literature search was performed using the following electronic databases: 
Cochrane central register of controlled trials (CENTRAL), the Allied and 
Complimentary Medicine database (AMED), Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), Excerpta Medica database (Embase) (1974-
2001), Medical Literature and Analysis and Retrieval  System Online (MEDLINE), 
Physiotherapy Evidence Database (PEDro), Psychological Information Database 
(PsycINFO) and PubMed. This was searched between the dates of 2000 to 2015. 
This was because the literature pre-dating this had been discussed during 
Chapter 1 (Introduction) and because of advances in ventilator technology. 
Articles were screened for inclusion criteria based on their titles; duplicates were 
removed; and the abstracts and finally the full articles were reviewed and 
analysed. The reference lists of each reviewed article were screened to identify 
any other relevant articles. Careful notice was taken at key conferences (ERS 
2013, ERS 2014, ERS 2015, BTS 2013, BTS 2014, BTS 2015 and European 
Respiratory Care Association Congress (ERCA) 2015) for any unpublished data 
by key authors. Boolean operators of AND/OR were used to combine the search 
terms as Exercis* OR pulmonary rehabilitation AND COPD AND BIPAP OR NIV 
OR CPAP OR non-invasive ventilation OR PAV OR proportional assist ventilation 
OR NIPPV. Table 2.1 shows the key words used in the search. 
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Table 2.1 Key search terms 
COPD NIV Exercise Review 
Chronic 
Obstructive 
Pulmonary 
disease 
Non-invasive 
ventilation 
Rehabilitation Meta-analysis 
CAL NIPPV Pulmonary 
rehabilitation 
Systematic 
Chronic airflow 
limitation 
Ventilation PR Review 
 Pressure support Exercise* Overview 
 Positive pressure Exercise therap* Literature 
 PAV   
 Proportional Assist 
ventilation 
  
 
2.3.2 Inclusion/exclusion criteria 
Only SRs and meta-analyses were considered. This was because SRs and meta-
analyses are considered to be the most reliable source of evidence when 
evaluating the effectiveness of interventions in healthcare (Scottish Intercollegiate 
Guidelines Network (SIGN), 2010). SRs from the year 2000 were included 
because ventilator technology had advanced significantly over recent years and 
thus newer data were more likely to be relevant and applicable to the intended 
study. SRs not written or translated in to English were excluded because of the 
potential difficulty of obtaining correct translation. This may have introduced 
language bias into the review, however bias may be reduced as some of the 
reviews themselves included non-English studies. Only SRs on adults were 
included as COPD is only diagnosed in adults (see Chapter 1 Introduction, section 
1.2). The final inclusion criteria were: 
1. Full SRs and meta-analyses of exercise on NIV 
2. Dates from 2000 to present 
3. Treatment was positive pressure on exercise 
4. Included patients > 18 years old 
5. The full review was published in English 
There was a limited number of articles relating to NIV on exercise therefore specific 
exclusion criteria were deliberately limited. The only exclusion criterion was not 
including paediatric studies. 
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2.3.3 Methodological quality assessment 
The SRs are presented using the 27-item checklist for Preferred Reporting Items 
for SRs and Meta-Analyses (PRISMA) tool (Moher et al., 2009). The PRISMA tool 
was considered useful to present the content of the SRs but an additional critical 
evaluation of the quality of the reviews was presented using the Critical Appraisal 
skills programme (CASP) tool (CASP, 2014). Initially both the CASP and Scottish 
intercollegiate guidelines network (SIGN) (Scottish Intercollegiate Guidelines 
Network, 2012) tools were considered as these were both familiar to the 
researcher from evidence evaluation in clinical practice. The use of an appraisal 
tool is important for maintaining a consistent approach. The tools were useful 
because they were aimed at reviewing a particular type of research for example, 
SRs (Aveyard, 2010). There is no gold standard critical appraisal tool developed 
for allied health research (Katrak et al., 2004). The researcher chose the CASP 
tool because it was more relevant to clinical practice and demonstrated the 
researcher’s thought processes more effectively. The CASP tool was concise, 
encompassed a wide range of appraisal questions, had pragmatic content and 
was useful for investigating the rigour of methods and reporting of the research 
evaluated (Nadelson and Nadelson, 2014). The CASP tool consists of three parts: 
Assessing whether the results are valid; what the results are and if it will help 
locally. There are ten questions within the tool answerable with yes, no, or can’t 
tell. Within each question there are prompts to help the evaluation. The quality 
assessment will be further discussed in the Discussion. 
2.4 Results: Part A 
2.4.1 Introduction 
This section will present the results of the literature search, tabular data detailing 
the included SRs and the results of the assessment of their methodological 
quality. The quality of the SRs will be further discussed in the Discussion: Part A, 
section 2.5.1 
2.4.1 Included SR results 
There were three SRs that met the inclusion criteria and were analysed for 
methodological quality. Of the ten studies that did not meet the inclusion criteria 
two full studies were not documented in English (Gravier et al., 2015; Vargas et 
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al., 2011). One SR was not included because it was just an abstract (Correia, 
Tomas and Carolino, 2014). Five were excluded because they were narrative 
reviews (Ambrosino and Cigni, 2015; Corner and Garrod, 2010; De Backer et al., 
2010; Dreher, Kenn and Windish, 2008; Araujo et al., 2005). Two reviews were 
excluded because the intervention was not exercising with NIV (Dretzke et al., 
2015; Struick et al., 2013). The results of the literature search are presented in 
figure 2.1 
 
Figure 2.1 Literature search flow diagram 
2.4.2 Methodological quality assessment. 
The detail of the three SRs included from the literature search are presented in 
Table 2.2 using the PRISMA checklist followed by Table 2.3 using the CASP tool 
for further methodological quality evaluation of the SRs. 
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Table 2.2 Review of SRs using the PRISMA checklist for the reporting of SRs 
PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
1. Title  Acute effects of NIV during exercise on 
exercise endurance and dyspnoea in 
patients with COPD: a SR. 
Physical Training and NIV in COPD 
Patients: A Meta-Analysis. 
Non-invasive ventilation during exercise 
training for people with COPD 
(Cochrane Review: Intervention review) 
2. Abstract:  Yes: No registration number. Yes: No registration number. Yes: Registered: Cochrane database. 
3. Introduction: 
a)Rationale and 
b)Review 
Rationale 
a) 1. Benefits of high intensity PR 
training and why COPD inhibits this. 2. 
NIV and use in exercise. b) Variability of 
NIV protocol. 
a) 1.Benefits of high intensity PR 
training and why COPD inhibits this. 2. 
NIV and use in exercise. b) 
Methodological quality of studies. 
a) 1. Benefits of high intensity PR 
training and why COPD inhibits this. 2. 
NIV and use in exercise. b) NIV use 
during multiple exercise sessions. 
4. Objectives Evaluate the effectiveness of different 
modes of NIV during exercise to reduce 
exertional dyspnoea and improve 
exercise endurance acutely, in patients’ 
with COPD.  
1. Evaluate the physiological effects of 
exercise training with NIV after PR in 
patients with COPD; 2. Investigate dose 
response relationship of benefit and 
total training time with NIV.  
Does NIV during exercise training (as 
part of PR) affect exercise capacity, 
HRQOL and physical activity in COPD 
compared with exercise training alone 
or exercise training with sham NIV? 
5. Methods: 
Protocol & record 
Protocol not documented or located. Protocol not documented or located. Cochrane number.CD007714. 
Published protocol & amendment 
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
6. Eligibility criteria:  
(PICO-Patient, 
intervention, 
comparison and 
objective measure) 
Patient: COPD: ERS definition 
(Siafakas, et al.1995)  
Intervention: NIV 
Comparison: Cross over trial (control). 
Randomisation of intervention order 
(NIV versus placebo). 
Objective measure: Borg-scale during 
cycling or walking exercise test at 50% 
or 80% VO2peak or 50% of W max. 
Endurance time at 50% VO2peak  test), 
50–60% W max, 60–70% W max, On 80% 
W max, on 75% W max, 80% VO2peak. 
Walking distance at a comfortable 
speed. 
 
Other: Published in the English, Dutch, 
or German language. 
Patient: Stable COPD (received PR) 
Intervention/comparison: Comparative: 
effect of NIV and exercise training 
Outcomes: Lactate production, heart 
rate (HR), walking or physical exercise 
performance, respiratory outcomes, and 
training characteristics (number of and 
duration per session of sessions, and 
rehabilitation schedule) 
 
Other: Published in the English 
language. 
Patient: 1. Stable diagnosed COPD, no 
exacerbation in past month. 2. 
FEV1/FVC < 70% and FEV1 < 80% 
predicted GOLD stage II to IV (GOLD 
2013). 3. Excluded: non-COPD, NMS, 
restrictive/thoracic or cardiac disease. 
Intervention and Comparison: NIV (bi-
level, PS and PAV) via 
mask/mouthpiece during supervised 
exercise. Control: exercise training 
with/without sham NIV. O2 provision 
(both groups). Nocturnal NIV included 
(in both groups). Training: arm and/or 
leg endurance and > 4 (no < 2) 
supervised sessions/week.  
Objective: Exercise capacity (peak 
capacity, constant work rate, 
endurance, functional capacity) post 
exercise training, without NIV). HRQOL 
(disease specific/generic instrument). 
Physical activity measure.  
99 
 
PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
7. Information 
sources 
Medline (1966-2001), Cochrane Library 
(1993-2001), Embase (1974-2001), and 
CINAHL (1982-2000). Existing reviews 
were found and lists of references of 
articles were scanned. 
 
Medline, Embase and CINAHL 
additionally a manual search of 
reference lists was carried out of 
included studies, reviews, meta-
analyses, and guidelines on NIV and 
pulmonary disease. 
 
AMED, CENTRAL, CINAHL, EMBASE, 
LILACS, MEDLINE, PEDro, PsycINFO 
and PubMed. ANZCTR 
(www.anzctr.org.au); 
www.ClinicalTrials.gov; International 
Standard Randomised Controlled Trial 
Number Register (www.controlled-
trials.com/isrctn/); Netherlands Trial 
Register 
(www.trialregister.nl/trialreg/index.asp); 
UMIN (www.umin.ac.jp/ ctr/index/); 
Google Scholar 
(http://scholar.google.com.au/); and 
Web of Science 
(http://thomsonreuters.com/web-of-
science/). Hand searching of ATS; ERS; 
BTS. Register coded ’COPD’ 1/1/1987-
24/11/2013. Screened reference lists 
asked authors/ experts in NIV  
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
8.  Search Following thesaurus (MeSH) terms were 
used: pulmonary rehabilitation, 
noninvasive ventilatory support, 
inspiratory PS, 
CPAP, PAV, COPD. 
“noninvasive ventilation,” “training 
exercise,” and “chronic obstructive 
pulmonary disease” as key words.  
(exercis* or physical* or train* or 
rehabilitat* or conditioning or ergometry 
or treadmill or endurance or “upper 
limb”) AND (non-invasive* or 
noninvasive* or “non invasive*” or NIV 
or “positive pressure” or NIPPV or 
NPPV or “pressure support” or IPS or 
“assist* ventilation” or PAV or 
“ventilatory support” or bilevel or BVS or 
“mechanical ventilation” or “artificial 
ventilation” or “artificial respiration” or 
mask* or BiPAP or IPAP or EPAP or 
nasal* or NIV during exercise training 
for people with chronic obstructive 
pulmonary disease or “positive airway*” 
1/1/1987, NIV delivered via mask 1987. 
9. Study selection Abstracts were included if reported 
detailed method and results. 
 
Controlled trials included. RCTs compared NIV during exercise 
training versus exercise training alone 
or with sham NIV in people with COPD. 
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
10.  Data collection 
process 
After consensus meetings: studies 
evaluated quality independently by two 
reviewers (a third if required). 
  
Conducted independently, copied by 
two reviewers. Independently selected 
studies for inclusion. Disagreements 
resolved by consensus or third senior 
author. Data extract sheet: piloted on 
three randomly selected articles. 
Extracted author, study year, 
participants, country, outcomes, training 
schedule characteristics, and dropouts. 
Second reviewer checked accuracy.  
Two reviewers independently included 
studies. Titles/ abstracts were reviewed; 
kept or discarded. Kept papers were 
evaluated. Kappa coefficient calculated: 
Agreement between authors on 
inclusion from initial and second 
selection, Two reviewers independently 
extracted data: Pre-set form: Methods; 
sample; intervention; outcomes; and 
results. Post training data: extracted if 
participants were evaluated off NIV. 
Discrepancies resolved by consensus. If 
no numerical data: (Engauge Digitizer, 
http:// digitizer.sourceforge.net/) 
converted graphical images. Two 
reviewers independently manually 
extracted data from graphs. Authors 
contacted for missing data. 
11. Data items: 
Outcome 
Exertional dyspnoea & exercise 
endurance 
Post training physiological effects. 1. Exercise capacity, HRQOL and 
physical activity. 2. Training intensity, 
physiological changes, dyspnoea, 
dropouts, AE, cost. 
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
12. Risk of bias in 
individual studies 
Quality screening: Delphi) (Verhagen et 
al., 1998): Patient characteristics, 
randomization procedure, blinding 
procedure, control for co-intervention(s), 
reliability and validity of the assessment 
procedures, description of the 
intervention & description of 
withdrawal/dropout. 
Two reviewers: PEDro scale 
(Physiotherapy Evidence Database, 
1999): study design, statistical analysis 
and intention to treat. Age, gender, and 
FEV1 random effects comparison, and 
comparisons between NIV and placebo 
at isotime were reported.  
Two reviewers: Cochrane Handbook for 
SRs of Interventions (Higgins, 2011): 
randomisation sequence generation; 
allocation concealment; blinding; 
completeness of outcome assessment; 
selective reporting; and other bias. 
Included: Un-blinded studies. Graded: 
high, low or unclear risk of bias.  
13. Summary 
measures 
 
For effect size of each study: calculated 
the difference between the means of the 
experimental and control phases, 
divided by SD of control phase. 
Baseline age, gender, and FEV1 
compared by means of random effects 
comparison, and comparisons between 
NIV and placebo at isotime  
Mean post-intervention values, changes 
from baseline values and SDs for 
continuous variables from both groups 
within each study. MD and 95% CI were 
used when combining continuous data 
measured on the same scale. SMD 
used when studies reported data 
measured on different scales that could 
not be converted to a common scale. 
When possible, estimates of treatment 
effect NIV during training for people with 
COPD (and confidence limits were 
related to the MID for each outcome. 
103 
 
PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
14. Synthesis of 
results 
 
Results: Pooled and combined after 
each study was weighted to estimate 
variance of the summary effect size. Z 
statistics & P values: Calculated from 
totals of the added values in 
experimental and control groups and 
the estimated variances for the total 
group. Summary effect sizes: 
Calculated Borg and cycling time or 
walking distance/time. 
For different modes summary effect 
sizes (best-case, worst-case scenario, 
greatest and lowest effects reported, 
were pooled separately). Post hoc 
analysis and summary effect sizes 
calculated: Effects of different modes on 
endurance. For each summary effect 
size, the homogeneity (or 
heterogeneity) test (Q statistics) was 
examined to see if studies shared a 
common effect size to explain if 
variance was from sampling error alone, 
justifying the fixed effects model. For 
any statistically significant heterogeneity 
found: random-effects model was used 
to decide significance. The value for 
rejecting H0 was 0.05. 
Analysis: compared results between 
PAV and PS ventilation; variable 
modification at isotime after training in 
the NIV arm using a meta-analytical 
approach. If the heterogeneity 
evaluated by I2 was > 50%, the random 
effects model was selected over the 
fixed effects model. 
 
Dichotomous data combined, treatment 
effect was defined as odds ratio (OR) 
with 95% CI. Unit of analysis = 
participant. Missing data: If dropouts (> 
15%), and results from ITT and per-
protocol analyses were reported, data 
extracted from ITT analyses: if not 
reported, data from the per-protocol 
analyses were used for meta-analysis. If 
incomplete statistical results reported in 
an included study for a given outcome 
the missing data was requested. If still 
unavailable then not used for that 
outcome. Effect of heterogeneity: Using 
I2 statistic, indicated the percentage of 
the total variation in observed 
intervention effects across studies 
caused by heterogeneity not chance 
alone. If included studies were clinically 
homogeneous, data were combined 
using software: Forest plots created. A 
fixed-effect model for all analyses 
unless a moderate or greater degree of 
heterogeneity was detected (I2 > 30%): 
a random-effects model used. 
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
15. Risk of bias 
across studies 
 
Bias: Scoring totals provided. 
 
Bias: Small study & publication bias 
effect: funnel plot. Harbord & Egger 
tests applied if > 5 studies included 
Small number of included trials meant 
no funnel plots to assess publication 
bias. 
16. Additional 
analysis 
No additional analysis If training duration influenced changes 
in outcome in the NIV arm, used 
random effects meta-regression 
approach and evaluated training 
duration as explanatory covariate. Study 
weight from meta-analysis was used in 
the regression analysis as a weight 
variable. p < .05 was significant, and all 
statistical were two-tailed. Performed 
Meta-analysis, meta-regressions, and 
Harbord & Egger asymmetry tests. 
No subgroup analysis. 
 
17. Results: Study 
selection 
10 articles & 5 abstracts evaluated 
1 article & 2 abstracts not included: No 
exercise endurance or dyspnoea, 3 
articles excluded: No BORG. 2 studies 
excluded: No randomisation of order of 
exercise with NIV and then control. 
5 articles & 2 abstracts included.  
107 results selected. 53 excluded: 
Duplicates or not comparative studies. 
33 excluded: not stable COPD. 21 
papers remaining: only 8 detailed 
training. 
. 
12,392 studies, excluded 12,299 by 
title/abstract (substantial agreement: 
Kappa 0.78), 1 from a reference list, 
6/94 studies included (perfect 
agreement Kappa 1.0). Exclusions: 38 
not RCT, 37 not exercise training, 6 not 
COPD. 4 NIV not used during exercise, 
1 not stable COPD.  
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
18. Study 
characteristics 
65 patients with COPD, mean age of 64 
years and FEV1 of 35% predicted.  
6 studies: exercise endurance: 
Measured endurance time (cycle), 1: 
exercise endurance: maximal walking 
distance (treadmill). 5 studies: the 
effects of 2 or more modes.4 studies: 
Exertional dyspnoea (BORG). One 
mode of NIV reported.  
174 patients with stable COPD, mean 
age 67 years. FEV1 26-48% predicted. 
8 Studies: 12-36 training sessions and 
6-12 weeks duration. Studies: 6 NIV v 
control, 1 NIV v O2, 1 NIV v heliox. 
Training: cycle ergometer, treadmill and 
endurance walking. Different NIV 
protocols. Measures: HR at Isotime, 
lactate post exercise and VO2. 
126 patients with COPD (control n = 63 
v NIV n = 63) FEV1 range 26-48% 
predicted. Individual study size n = 18-
29. Mean age = 63-71 years. Training in 
outpatients; 2 hospital based. Training 
6-8 weeks duration, 2-3 sessions/week 
of 45 minutes exercise at moderate 
intensity. Different NIV protocols. 
19. Risk of bias 
within the studies 
All studies: lung function, randomization 
and co-interventions were applied 
equally and NIV protocol described well. 
All studies: No description of: 
randomization, or blinded observer or of 
the reliability & validity of the outcome 
measure, withdrawals and dropouts. 
All studies: satisfactory score on PEDro 
% predicted FEV1: heterogeneous (not 
statistically significant) 
Duration of training: homogenous 
Session duration: heterogeneous 
 
Quality of evidence low for exercise 
capacity and moderate for QOL, training 
intensity and isoload blood lactate. 
Randomisation sequence: adequate in 
50% of studies (not reported in 3). 
Blinding: trainers & participants not 
blinded: High risk of performance bias 
5/6 studies. 50% studies blinded 
assessor to evaluate clinical outcomes. 
5/6 studies reported drop outs. 2 studies 
did not report full results. 
20. Results of 
individual 
studies. 
Reported 7 studies: Analysed FEV1, 
outcome, effect size and SD and p 
value. 
Reported 8 studies: Analysed mean 
age, FEV1, training protocol. NIV v 
placebo: trend for differences in HR or 
VO2 but not statistical. 
Reported 6 studies: Analysed 6MWT, 
SGRQ, endurance, lactate levels, work 
capacity and respiratory muscle 
strength. 
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
21. Synthesis of 
results  
Statistically significant summary effect 
size: Dyspnoea (0.57; CI 0.04-1.07; p = 
0.03). Heterogeneity statistic: Not 
significant (χ2 = 0.28; p = NS). Average 
(weighted) improvement in Borg on 
exercise with NIV was < 2 units during 
isotime control phase. Best-case: Effect 
of NIV on endurance, a statistically 
significant summary effect size was 
found (0.58; CI 0.29-0.87; P < 0.001). 
Overall heterogeneity: Not significant (χ2 
= 3.95; p = NS). Summary effect size: 
Mean (weighted) improvement in 
endurance of 3.3 min. Worst-case: 
Summary effect size on exercise 
endurance was still statistically 
significant (0.33; CI 0.05-0.62; p = 0.02), 
an average (weighted) increase in 
exercise endurance: 1.7min.  
Sub-analysis by ventilation protocol did 
not show statistical significance in the 
pooled analysis. 
After training NIV arm: HR at isotime 
improved by 6 beats/minute (95% CI 
0.98-11.01, p = 0.02). Work load (fixed 
effect mean change 242.11(95% CI 
154.93-329.9), p = 0.001). Lactate: not 
statistically significant but trend for 
improvement (fixed effect mean change 
0.21 (95% CI -0.1 to 0.54), p = 0.205). 
Effect of training intensity on patient 
performance: Meta-regressions 
reported: positive relationship between 
variable modification and training time 
for all outcomes considered. 
 
NIV on exercise arm: Comparative risk 
(95% CI) and relative effect size (95% 
CI) of the intervention: Exercise 
capacity (% change in peak work rate 
incremental cycle/treadmill test) n = 48 
(3 studies): 17% higher (95% CI 7-
27%). Exercise capacity (% change 
constant work rate cycle endurance test 
cycle endurance test) n = 48 (2 studies): 
59% higher (95% CI 4-114% higher) 
Exceeds 34% the minimally important 
difference). Endurance time (minutes) 
(constant work rate cycle exercise test): 
n = 48 (2 studies): 3.62 minutes higher 
(0.17 minutes lower to 7.41 minutes 
higher). HRQOL: SGRQ mean score: n 
= 48 (2 studies) 2.45 points higher (2.3-
7.2 points higher). 
Physical Activity: not measured. 
22. Risk of bias 
across studies 
Agreement between reviewers on 78/91 
criteria scored (Cohen’s kappa = 0.86). 
The methodological quality score was 
31% to 54% 
Agreement between reviewers 
satisfactory > 95%. Funnel plots & 
Harbord & Egger test did not exclude 
small study or publication bias effect. 
Small number of included trials meant 
no funnel plots to assess publication 
bias. 
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
23. Additional 
analysis 
Heterogeneity statistic: not significant 
(χ2 = 2.3; p=NS) when CPAP, PS, and 
PAV on endurance pooled separately. 
Significant, homogeneous (χ2 = 0.02; p 
= NS) summary effect size only for PS 
(0.41; CI 0.06-0.77; p = 0.03): Average 
(weighted) improvement: Time 2.2min. 
A statistically significant effect on slope 
found when considering HR, work load 
as response variables: random effects 
estimates of these slopes were: 0.015 
(95% CI 0.008-0.22) for HR 0.01 (95% 
CI 0.0002-0.0215) for work load. 
Isoload blood lactate (mmol/L) n = 37 (2 
studies) -0.97 mmol/L lower (1.58 to 
0.36 lower). 
 
24. Discussion: 
Summary of 
evidence 
 
Caution acknowledged: Small 
significant effect size: use of PS over 
other modes. Further research: NIV 
during training is required. 
Similarities (training) between studies 
and differences (Ventilator protocol) 
Further large numbered, based on 
power calculations, RCTs needed. 
Effect on exercise capacity is unclear. 
NIV in training may improve the % 
change in peak and endurance 
capacity. Further good quality, large 
numbered RCT are needed, with 
assessment of outcome measures with 
known MID & economic evaluation and 
long term impact. 
25. Limitations Differences in PS and outcome 
measure (BORG) unclear on MCID. 
 
Drop out heterogeneity and small 
sample sizes. 
No assessment of publication bias: 
small numbers, could not contact all 
authors. 
26. Conclusions NIV during exercise in COPD results in 
acute improvements of exertional 
dyspnoea and exercise endurance 
The Meta-analysis: no evidence of 
superiority of using NIV to train. The 
trend for improvements in HR and VO2 
post training with NIV suggest benefit. 
Longer training duration in PR leads to 
improved physiological outcomes 
No clear conclusions made. NIV in 
COPD during leg training may allow 
patients to exercise at higher training 
intensities and achieve greater 
physiological training effect compared 
with training alone or with sham NIV. 
27. Funding  The Dutch Asthma Foundation (grant 
3.2.99.28) 
Not disclosed: no conflict of interest 
reported. 
Royal Prince Alfred Hospital, Australia. 
Commercial funding: author declaration. 
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PRISMA Checklist van’t Hul, Kwakkel and Gosselink 
(2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and Wong  
(2014) 
Abbreviation key: ANZCTR Australian New Zealand Clinical Trials Register, CI Confidence interval, CINAHL Cumulative Index to Nursing and Allied 
Health Literature, EMBASE Excerpta Medica Database, FEV1/FVC Forced Expiratory Volume in 1 second/Functional Residual Capacity, H0 Null 
Hypothesis, HRQOL Health Related Quality of Life, ITT Intention-to-treat, LILACS Latin American and Caribbean Health Science, MD Mean Difference, 
MID Minimal Important Difference, Min Minute, NMS Neuromuscular, NS Non Significant, PAV Proportional Assist Ventilation, PEDro Physiotherapy 
Evidence Database, PS Pressure Support, SD Standard Deviation, SMD Standardised mean difference UMIN University Hospital Medical Information 
Network, VO2peak Peak oxygen uptake, Wmax Maximum Workload. 
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Table 2.3 Evaluation of the quality of the SRs using the Critical Appraisal Skills Programme (CASP) tool for SRs 
 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue et al. (2014) 
1. Evidence of a clear focused 
question? 
Yes: Clear population: Adult 
patients with COPD (Siafakas et 
al., 1995). Clear intervention v. 
control group, clear outcomes  
Yes: Clear aims, clear 
population: Stable COPD, clear 
intervention, clear outcomes  
Problem: 1) COPD: no 
definition. 
2) Multiple objectives (6)  
Yes: Clear population: Stable 
COPD, clear intervention and 
clear outcome measures. 
2. Did the authors look at 
correct papers? 
Yes: RCTs and crossover 
studies. 
Yes: RCTs but included one 
other, focused on aims of SR 
with intervention appropriate. 
Yes: RCTs focused on aims of 
SR and intervention. 
3. Were all the important, 
relevant studies included? 
Yes: Good search strategy: 
Cochrane Airways group for RCT 
(2002). Detailed search terms. 
References were scanned and 
abstracts were included.  
Problem: 1. No authors 
contacted for extra studies. 
2. No unpublished data. 
No: No clear protocol, used 
electronic databases and manual 
search of reference lists. 
Problem: 1. No authors 
contacted for extra studies.  
2. No unpublished data. 
3.  Excluded 11 papers: no detail 
on training regime but no 
clarification sought. 
4. Only included English studies  
Yes: Good strategy, clear search 
criteria and all search terms 
documented, used a wide range 
of electronic databases, including 
hand searching reference lists, 
personally contacting experts, 
and also screened conference 
abstracts. There were no 
language restrictions on studies. 
4. Did the review’s authors do 
enough to assess the quality 
of the included studies? 
Yes: Scoring system based on 
Delphi list, a criteria for quality 
assessment of RCTs (Verhagen 
et al., 1998). Independently 
assessed by 2 reviewers and 3rd 
if disagreement.  
Yes: PEDro scale. Independently 
assessed: 2 authors. 
Problem: Details of bias 
described but not tabulated. 
Yes: 2 authors assessed internal 
validity and rigour of the studies. 
Strategy from Cochrane (Higgins, 
2011), authors contacted. 
Problem: Did include unblinded 
studies. 
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 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue et al. (2014) 
5. If the results combined was 
it reasonable to do so? 
Yes: Pooled and calculated best 
and worst case scenario. 
Calculated summary effect size 
for different modes of ventilation. 
Problem: Did not consider 
differences in PS used. 
Yes: For HR, workload, lactate 
and VO2. Sub-analysis of pooled 
data for differences in mode of 
ventilation used. 
Problem: Not the same NIV, 
mode and settings. Did consider 
mode but not level of PS used. 
Yes: Same objective measures, 
same intervention. Results 
displayed and discussed. Tested 
combined results with/without a 
study of mild COPD severity. 
Problem: Not the same NIV, 
mode or settings. 
6. Are the overall results of the 
review clear and precise?  
Yes: Results are clear Yes: Majority of results clear. 
Problem: Clearer figure needed 
to demonstrate the random 
effects meta-regression and 
paired comparison effect 
estimation in the NIV arm.  
Yes: Results are clear.   
7. How precise are the results? Not sure. 
Problem: CI % is: not 
documented. 
Yes: Expressed as 95% CI. Yes: Expressed as 95% CI. 
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 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue et al. (2014) 
8. Can the results be applied to 
the local population? 
Not sure: COPD, FEV1 25-39% 
predicted. Age range 59-69years. 
Problem: 1. Recruitment location 
not documented to decide if any 
patients were missed. Stability of 
patients not classified. 2. Not 
elderly so may exclude sicker 
group. 
Not sure: Moderate-severe 
COPD with FEV1 26-48% 
predicted, only Bianchi, et al.  
(2002) study is moderate 
severity. Age range 64-72years 
would fit with some of population 
of COPD seen in the UK. 
Problem: 1. Did not consider 
very elderly patients, therefore 
sicker patients with more co-
morbidities not represented. 
2. Did not consider unstable 
patients. 
3. No recruitment location detail 
Not sure: Severe COPD (mean 
FEV1 26%-41% predicted + 1 
moderate severity study FEV1 
48%) and an age range 63-
71years. 
Problem: 1. Studies selected 
participants from outpatient 
clinics or PR referrals. This may 
miss non-attendees. 
2. Stable patients, co-morbidities, 
elderly not included so may have 
excluded sickest population. 
3. Drop outs included patients 
having an exacerbation therefore 
excluding sickest population. 
 
9. Were all important outcomes 
considered? 
No: Only considered exercise 
endurance and dyspnoea. 
Problem: 1. Did not consider 
common clinical measures e.g. 
6MWT. 
2. Did not consider QOL. 
3. Did not consider activity levels. 
4. Did not consider economic 
evaluation 
5. Did not consider hospital 
admission or exacerbation rate. 
No: Only considered 
physiological measures. 
Problem: 1. Did not consider 
common clinical measures e.g. 
6MWT.  
2. Did not consider QOL 
3. Did not consider activity levels. 
4. Did not consider economic 
evaluation. 
5. Did not consider hospital 
admission or exacerbation rate. 
Yes: Considered both physical 
and QOL measures. 
Problem: 1. Did not consider 
common clinical measures e.g. 
6MWT. 
2. Did not consider admission or 
exacerbation rate.  
3. Did not consider economic 
benefit outcome. 
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 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue et al. (2014) 
10. Are the benefits worth the 
harms and costs? 
There is benefit detected, but not 
enough evidence to offset harm 
or cost. 
Not enough evidence to detect 
harm, cost or benefit of using NIV 
during exercise. Further research 
is required. 
Not enough evidence to detect 
harm, cost or benefit to use NIV 
during PR. Further research is 
required. 
Abbreviation Key: CI Confidence interval, COPD Chronic Obstructive Pulmonary Disease, CPAP Continuous positive airways pressure, 
ERS European Respiratory Society, FEV1 Forced expiratory volume in one second, HR Heart rate, HRQOL Health related quality of life, RCT 
Randomised controlled trial, PEDro Physiotherapy evidence database, PS Pressure support, QOL Quality of life, SR systematic review, UK 
United Kingdom, VO2 Measure of oxygen consumption, 6MWT Six minute walk test. 
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2.4.3 How did the SRs inform the proposed research study design 
The information as to how the SRs informed the proposed research study design is presented in Table 2.4 
Table 2.4 How the SRs may inform the proposed research study design. 
 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and 
Wong (2014) 
Sample Characteristics  Stable COPD. 
Mean age 64 years.  
Mean FEV1 of 35% predicted. 
1 trial: less disease severity and 
no statistical or perceived effect. 
Sample size range n = 6-39. 
Stable COPD recently carried out 
PR. 
Mean age 67 years. 
Mean FEV1 of 34% predicted. 
Sample size n = 7-15 patients. 
 
Stable COPD, no exacerbation in 
the past month.  
FEV1 26-48% predicted. 
Sample size range n = 19-33. 
 
 
Recruitment location/method Not recorded. Not recorded. 2 trials from referrals to 
outpatient PR.  
1 from Respiratory clinic. 
1 trial referral to respiratory 
physical therapy. 
 2 trials not recorded. 
Number screened/ % 
recruitment 
Not recorded. Not recorded. Number of patients screened: 34-
89. Not recorded in 3 trials. 
Recruitment %: 35-85%. 
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 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and 
Wong (2014) 
Participant retention/ 
Attrition rate 
None of the studies described 
withdrawals or drop outs. 
Drop outs 0-50% (difference 
between arms not discussed). 
No details about participants who 
declined trial. 
Drop outs in NIV arm range from 
21-44%.Drop outs in control arm 
range from 15-40%.1 trial not 
recorded. 
Reason for drop out  
(n = number of patients) 
Not recorded. Not recorded. Intolerant of NIV n = 8,  
Acute exacerbation COPD = 15, 
Exercise Hypertension = 2, 
Unexplained coronary = 2, Non-
pulmonary hospital Admissions = 
2,  
Exertion of angina = 1, 
Non-concordance = 1, 
Liver disease = 1, 
Tibial  fracture = 1, 
Conflict of schedule =1,  
CCF = 1, 
Back pain = 1,  
Transplant = 2,  
CVA = 1,  
Fatigue = 1.  
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 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and 
Wong (2014) 
Outcome measure timing Not reported. Not reported. 2 baseline assessments the 
week before training and 2 
assessments in the week training 
completed. 1 baseline the week 
before and within 1 week of 
ending training. Baseline 2 
weeks before start and final 
within 2 weeks of completion. 
Outcome measure that 
reflected change? 
Exertional dyspnoea (BORG) 
decreased by 2 units (p = 0.3) 
and exercise endurance 
increased by 1.7(best case) - 3.3 
minutes (worse case) (p < 0.001 
to < 0.02). 
PS increased exercise 
endurance by 2.2 minutes (p = 
0.03). 
No clear benefit. 
The trend for improvements in 
HR and VO2 post training with 
NIV suggest NIV may be of 
benefit. 
Increase in percentage change 
peak and endurance exercise 
capacity with NIV during training.  
HRQOL: SGRQ possible effect. 
Physical activity was not 
assessed. 
Increase in training intensity with 
NIV and isoload lactate was 
lower with NIV.  
Effect of NIV on dyspnoea 
uncertain. 
 
Outcome measure 
complications 
Not described Not described Not described 
AEs (other problem) Not described Not described No AEs and no cost information. 
Abbreviation key: AE Adverse Event, CCF Congestive Cardiac Failure, COPD Chronic obstructive pulmonary disease, CVA Cerebral 
vascular accident, FEV1 Forced expiratory volume in one second, NIV Non-Invasive ventilation, PS Pressure support.  
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2.4.4 How did the SRs inform the proposed intervention 
Table 2.5 demonstrates how the reviewed SRs informed the proposed intervention. 
Table 2.5 How did the SRs inform the proposed intervention 
 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and 
Wong  
(2014) 
Type of ventilator/mode/circuit Mode: 1 study: CPAP.  
1 study: PAV versus CPAP 
versus CPAP and PAV. 
1 study: PS versus CPAP. 
1 study: PS versus CPAP versus 
PAV. 
1 study: CPAP versus CPAP and 
PAV. 
1 study: PS. 
Mode: PAV: 2 studies. 
PS: 6 studies. 
 
 
Mode: PAV: 2 studies. 
PS: 1 study. 
Bi-Level: 3 studies.  
Two studies also entrained O2. 
To keep SpO2 at 90% in one 
study and SpO2 at 92% in the 
other study. 
Ventilator Settings Treatment pressure CPAP 4 -
10cmH2O. 
PAV 2/1, 8/3, 6/3, 10/3. 
PS 10-16cmH2O. 
Small significant effect size for 
PS over other modes in 
improving exercise endurance. 
PAV (FA 3.6, 0.7cmH2O 
VA 12.7, 1.5cmH2O) 
(FA 3.5,1.6cm H2O 
VA 6.6, 2.2cm H2O) 
PS range: 4-11cmH2O 
EPAP range: 0-8cmH2O 
FA 3.5 (1.6) cmH2O/L/s, VA 6, 
EPAP 2cmH2O. 
FA 3.6 (0.7) cmH2O/L/s, VA 12. 
7 (1.5) cmH2O/L during exercise 
training. 
PS range 5-10cmH2O. 
EPAP range 0-6cmH2O. 
Research setting Not reported Not documented 1 study: Hospital outpatient 
4 studies: Outpatient centre. 
1 study: No information. 
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 van’t Hul, Kwakkel and 
Gosselink (2002) 
Ricci et al. (2014) 
 
Menadue, Piper, van’t Hul and 
Wong  
(2014) 
Exercise type 6 studies: Cycle ergometer.  
1 study: Treadmill. 
 
Tread mill training, cycle 
ergometry and endurance 
walking/cycling. 
Cycle ergometry. 
Intensity, duration, number of 
sessions 
One off exercise test. Intensity not documented. 
12-36 sessions. 
20-60 minutes. 
6-12 weeks duration. 
Cycle ergometry: 3 studies: 50-
70% of peak work capacity, 65% 
peak work capacity.  
Treadmill training: 50-60% 
maximum METS, 65-70% initial 
walking speed, Or 70% 
maximum baseline speed,  
Training session of 12 weeks led 
to greater training effect size. 
Intervention 
participation/training session 
attended 
One off test. Not documented. 3 studies: Not documented. 
1 study: all attended 
1 study: 10/12 sessions 
attended. 
1 study: Extended weeks if 
patient missed session. 
Reported problems/changes to 
intervention 
Not documented. Not documented. Mask intolerance led to drop 
outs. 
Abbreviation Key: CPAP Continuous positive airways pressure, EPAP End positive airways pressure, FA Flow assist, METS Metabolic 
equivalents, PAV Proportional assist ventilation, PS Pressure support, SpO2 Saturation of arterial blood with oxygen, VA volume assist. 
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2.5 Discussion: Part A 
2.5.1 Introduction 
This discussion focused on the results of the SRs including the quality of the 
research methods used. It combined the results of the SRs and informed the 
planned feasibility. 
2.5.2 Aims and outcome measures of the SRs 
The SRs all had clear questions, aims and population group that they intended to 
review. The outcome measures of exercise endurance (van’t Hul et al., 2002), 
exercise capacity (Menadue et al., 2014) and physiological measures (Ricci et al., 
2014) may not be that relevant to patients because it may be hard for them to 
translate the benefits into their everyday lives. The outcome measures that may 
be considered more relevant to patients are exertional dyspnoea on exercise 
(van’t Hul, Kwakkel and Gosselink, 2002), as breathlessness is a common 
symptom experienced by patients with COPD, and the HRQOL measures 
evaluated (Menadue et al., 2014). 
2.5.3 Quality of the search methods 
Ricci et al. (2014) was the only review that did not have a documented search 
protocol which may have biased the search resulting in missed studies. Menadue 
et al. (2014) carried out the most rigorous search of the literature that included 
unpublished data and approaching key authors for access to unpublished data. 
This may have resulted in the variation for the initial list of studies to search with 
12,392 in Menadue et al.’s (2014) review compared to 107 in Ricci et al.’s (2014) 
review and only 15 in van’t Hul, Kwakkel and Gosselink (2002) review. Ricci et al. 
(2014) was the only review that did not consider English papers but the reasons 
for this were not recorded. All three studies used a third author to resolve any 
differences between the initial reviewers regarding inclusion and exclusion of 
studies. Menadue et al. (2014) demonstrated good methodology for searching as 
they also assessed for statistical agreement with the Kappa coefficient, achieving 
a substantial agreement score (Kappa = 0.78) for the initial selection and perfect 
agreement score (Kappa = 1.0) for the final selection. This is a robust method for 
reviewing inter-rater agreement for categorical points (Gwet, 2014). 
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2.5.4 The SRs’ quality assessment 
All three reviews used a research evidenced scoring system to assess quality. 
Menadue et al. (2014) presented the most detailed quality review in the SR, Ricci 
et al. (2014) presented the least complete quality review with no details of the 
quality scoring for each study. 
2.5.5 Quality of the results 
All of the SRs combined the results but this may have been inappropriate because 
all of the studies used different NIV models, modes and PS, therefore the 
intervention could have been quite different. Whilst van’t Hul, Kwakkel and 
Gosselink (2002) and Ricci et al. (2014) considered different modes they did not 
consider different models or PS. 
2.5.6 How do the SRs reviewed inform the current study design and 
intervention? 
Although the reviewed studies’ involved patients diagnosed with severe COPD, 
the samples may not be reflective of patients usually treated in acute clinical 
practice. This is because the studies reviewed recruited stable patients from the 
outpatient setting who had not experienced recent exacerbations and who did not 
suffer from extensive co-morbidities. Both Menadue et al. (2014) van’t Hul, 
Kwakkel and Gosselink (2002) commented on the observation that there were 
three studies who recruited patients with less severe lung disease. These studies 
did not demonstrate statistical or perceived benefit.  
Only one SR recorded the number of participants screened and recruitment 
location. No time duration was recorded for screening. There was a variation in 
the percentage of participants recruited from the samples, from 35-85%. No 
details were given regarding inclusion/exclusion numbers or reasons given for 
declining to participate (Menadue et al., 2014). Drop-out rates were sought by two 
SR’s, van’t Hul, Kwakkel and Gosselink (2002) reported that this was not 
documented in the reviewed included studies. It was difficult to predict time of 
recruitment and screening numbers required from the reviewed SR’s. The lack of 
detailed documentation informed the planned feasibility study and it was noted 
that good documentation of recruitment and retention was an important 
consideration.  
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Menadue et al. (2014) reported that eight participants dropped out because of 
being intolerant to NIV and three of the eight were because of mask discomfort. 
In the planned feasibility study consideration was required for the time allocated 
to allow tolerance of NIV and mask comfort. An alternative consideration was 
recruiting participants that had already tolerated NIV acutely in hospital because 
this may have led to less drop outs. The other main reason for dropping out (n = 
15 participants), in both the treatment and control arms, was an acute 
exacerbation of COPD. Whilst not unexpected this was concerning because the 
sample was a stable group of patients. Therefore if the planned feasibility study 
involved a less stable group then they could experience more exacerbations.  
 Two of the SRs supported the use of exercise endurance as an effective outcome 
measure to show change (Menadue et al., 2014; van’t Hul, Kwakkel and 
Gosselink, 2002). van’t Hul, Kwakkel and Gosselink (2002) demonstrated that 
BORG dyspnoea score may evidence change when evaluating studies of exercise 
on NIV. Therefore these were considered as potential outcomes for the feasibility 
trial. The discussion resulting from the SRs contemplated using outcome 
measures which are commonly used in clinical practice to measure the effects of 
exercise on NIV (for example the 6MWT) so the results are clinically meaningful. 
The results for HRQOL were inconclusive (Menadue et al., 2014). Thus it was 
valuable to consider HRQOL measures to review whether exercising on NIV is 
perceived by patients as being beneficial. The validity of each outcome measure 
should be documented in the research methods of the planned trial to ensure it 
measured what it intended to measure.  
The SR’s informed the future intervention by detailing the mode and PS used. 
There was limited information about circuitry and mask used. van’t Hul, Kwakkel 
and Gosselink (2002) demonstrated a small significant effect size for the use of 
PS over other modes. When reviewing the exercise content cycle ergometry and 
treadmill were used as the intervention. The exercise sessions varied in length, 
intensity and number. These aspects were not evaluated in relation to exercise 
on NIV but one SR reported a greater training effect size in the 12 week 
programme (Menadue et al., 2014). Therefore the planned feasibility study may 
have benefited from undertaking a 12 week programme. 
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The overall reported quality of the studies varied. Menadue et al. (2014) reported 
the evidence to be of low quality for exercise capacity, moderate quality for 
HRQOL, training intensity and post training blood lactate levels (Menadue et al., 
2014). For the proposed feasibility study consideration was undertaken to ensure 
clear documented methods would be used including recruitment, randomisation 
procedure and calculation of a prospective sample size for the selected primary 
outcome.  
 
2.6 Conclusion: Part A 
This literature review has demonstrated that a further RCT was necessary on the 
effects of exercising with NIV on patients with COPD. The review demonstrated 
that there was a gap in the literature considering exercising with unstable patients 
with COPD on NIV who have recently experienced an exacerbation. 
The literature findings are inconclusive on using NIV to exercise patients with 
COPD. There were a number of methodological limitations identified that need to 
be addressed in future research to improve the available evidence. Therefore the 
intention of this doctoral research is to address these. Further evaluation was 
required to develop the research design and intervention, reviewed in Part B. 
2.7 Aims: Part B 
The literature review for part B sought to meet the following aims: 
1. To carry out a literature search for studies on exercise on NIV in COPD that 
were not included in the SRs (reviewed in Part A). 
2. To evaluate the quality of the evidence reviewed. 
3. To inform the development of the feasibility study. Focusing on the reasoning 
behind the study questions, sample characteristics, recruitment and retention of 
participants, trial design, hypothesis, outcome measure choice, possible AEs and 
duration of follow up. 
4. To inform the design of the complete intervention. Focusing on the type of 
ventilation, mode, settings, mask, location of intervention, type of exercise, 
duration and timing of intervention. 
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2.8 Methods: Part B 
2.8.1 The search criteria 
The initial search began in 2012 and it was continually updated. The search was 
completed using the same methods used for Part A, see section 2.3.1, Search 
strategy. Individual studies were sought rather than reviews. Table 2.6 shows the 
key words used in the search. 
Table 2.6 Search terms for literature review Part B 
COPD NIV Exercise 
1.Chronic 
Obstructive 
Pulmonary 
disease 
Non-invasive 
ventilation 
Rehabilitation 
2.CAL NIPPV Pulmonary 
rehabilitation 
3.Chronic airflow 
limitation 
ventilation PR 
 Pressure support Exercise* 
 Positive pressure Exercise therap* 
 PAV  
 Proportional Assist 
ventilation 
 
 
2.8.2 The search inclusion criteria 
The search inclusion criteria were: 
1. Full studies of exercise on NIV 
2. Published between 2000 to January 2016 
3. Treatment was positive pressure on exercise 
4. Included patients > 18 years old 
5. The study was published in English 
6. Not included in the SRs by van’t Hul, Kwakkel and Gosselink (2002), Ricci et 
al. (2014) and Menadue et al. (2014) 
2.8.3 The search exclusion criteria 
The search exclusion criteria were: 
1. Paediatric studies 
2. Not published in English 
3. Not positive pressure use during the actual exercise 
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4. Included in the SRs by van’t Hul, Kwakkel and Gosselink (2002), Ricci et al. 
(2014) and Menadue et al. (2014) 
2.8.4 Methodological quality assessment  
The quality of each of the studies were critically evaluated using the CASP tool 
(CASP, 2014). The CASP was chosen because it is relevant to clinical practice 
and demonstrated the researcher’s thought processes more effectively. 
 
2.9 Results: Part B 
2.9.1 The results of the literature review 
The results of the literature search are presented in figure 2.2. A list of the 
excluded studies can be found in Appendix 1.  
 
Figure 2.2 Flow diagram of the results of the literature search of part B 
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2.9.2 Summary of the studies within the results of literature search B 
There were 21 studies included in the results. The publication dates ranged from 
2000 to 2014. The investigations were predominantly crossover designs and three 
were feasibility studies. The sample size of the studies ranged from n = 4 to n = 
45, with a mean sample size of n = 14. In 19 of the studies one-off exercise tests 
were performed, two of the studies considered exercising with positive pressure 
during more than one exercise session. In nine of the studies cycle ergometry was 
the chosen exercise test. The other tests used included 6MWT, 12MWT, treadmill 
walking, endurance shuttle walk test (ESWT), UAE’s and knee extensor 
exercises. The two studies that attempted to undertake a longer programme of 
exercise both used cycling. The primary outcome measures used included 
endurance time, workload and limit of tolerance for cycle ergometry, ESWT and 
UAE. A few of the studies chose distance walked measured 6MWT. It included 
physiological values of respiratory including PaO2 and muscle’s including IL-6 
plasma levels. There were 13 studies that demonstrated statistical improvement 
of their primary outcome. Summaries of the included studies are presented in 
Table 2.7. 
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Table 2.7 The description of the included studies including reporting any statistical improvement 
Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Allan et al. 
(2009) 
 
n = 12. 
Mean age 70 
± (Standard 
deviation) 3 
years 
Mean FEV1 
42 ±10% 
predicted 
Mean 
FEV1/FVC 41 
±7% 
predicted 
Feasibility sequential 
randomised, 
placebo-controlled 
crossover. Cycle 
exercise test at (80% 
of maximal 
workload) with: 
1. Air via mask 
2. Sham NIV: PS 
3cmH2O 
3. NIV  
4. 60:40 (Helium: O2 
ratio) heliox with 
sham NIV  
5. 60:40 heliox with 
NIV.  
Primary: Total 
exercise time.  
Secondary: HR, 
SpO2, RR. 
 
Primary: Partial: NIV and Heliox (13.53 ±11.57 mins) duration was 
significantly more (p = 0.01) than heliox alone (10.10 ±10.04 mins) or 
NIV alone (p = 0.007) (0.95 ±10.14) but not significantly greater (p = 
0.009) than sham treatment (05.57 ±05.50 mins). 
Secondary: Partial: With Heliox and NIV SpO2 was significantly 
greater than just NIV (p < 0.001) or sham (p < 0.001). 
Authors reported the RR for sham was significantly greater than all of 
the treatment arms at peak exercise, but p-value was not reported. 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Barakat et al. 
(2007)   
 
N = 12 Mean 
age 64 ±8 
years 
Mean FEV1 
0.8 ±0.42L 
Mean 
FEV1/FVC 
0.31 ±0.07L 
Crossover trial of: 
1. 10 sessions x 
25min of static 
cycling at 25-50% of 
their maximum 
power without NIV.  
2. Followed by 10 
sessions with NIV. 
PS 14-17cmH2O, 
EPAP 3-4cmH2O. 
Primary: Work load 
and exercise time. 
6MWT. 
Secondary: 
Dyspnoea: BORG, 
SGRQ, 
Cardiovascular 
variables, CRQ. 
Primary: Yes. Maximal mean workload was 50 W max (p < 0.05) with 
NIV and 27 W max without NIV. 
Primary: Yes. Mean exercise time 33.75 ±3.4min with NIV (p < 0.05) 
and 19.37 ±3.4min without NIV). 
Primary: Yes. 6MWT increased by mean 38m (p < 0.01) with NIV 
(245 ±87 to 282±111) verses 14m unsupported (231 ±97 to 245 ±87). 
Secondary: Yes. Mean BORG score improved from 4.7 ±1.81 to 1.3 
±0.6 (p < 0.01) with NIV and from 6 ±2.6 to 4.7 ±1.81 without NIV. 
NIV group showed SGRQ clinical improvement (< 4 units) in total 
scores: 63.71 ±12 to 58.39 ±17 with NIV verses 60.69 ±10 to 63.71 
±12 in unsupported group (p-value not documented). 
 
No change: Impact scores, cardiovascular variables and CRQ. 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Borghi-Silva et 
al. (2008) 
n = 16 
Mean age 59 
±6 years 
Mean FEV1 
42 ±14% 
predicted 
FEV1/FVC 43 
±15% 
predicted 
Blinded crossover. 
Constant work rate 
(70-80% peak) cycle 
ergometry tests with:  
1. PAV  
2. Sham NIV: PS 
5cmH2O and PEEP 
of 2cmH2O. 
Primary: Exercise 
tolerance: Time. 
Secondary: 
Deoxyhaemoglobin 
levels, Dyspnoea 
(BORG), 
Leg discomfort. 
Cardiovascular & 
SpO2. 
Primary: Yes. PAV significantly increased time: mean 337±189 
seconds versus sham NIV 273 ±142 seconds (s) (p = 0.01). 
Secondary: Yes. PAV lowered deoxyhaemoglobin concentration and 
significantly lessened the decrease in oxyhaemoglobin concentrations 
at 75% isotime and cessation. (PAV -85.4 ±19.4 to -70.4 ±18.8 versus 
sham -87.7 ±18.7 to -69.3 ±19.4. (p < 0.05). 
Secondary: No. No significant difference in dyspnoea; leg discomfort; 
cardiovascular or SpO2 response. 
128 
 
Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Borghi-Silva et 
al. (2009) 
n = 24 
Mean age 68 
±8 years. 
Mean FEV1 
33 ±10% 
predicted 
FEV1/FVC 56 
±9% 
Predicted 
n=18 healthy 
(added 
control) 
Prospective cross 
over double blinded 
RCT. 
Maximum isokinetic 
dynamometer testing 
of concentric knee-
extensor strength 
and 1min endurance 
test on: 1. Bi-level: 
(PS 8cmH2O) 
2. Sham Bi-level: 
IPAP 3cmH2O and 
EPAP 2cmH2O) (PS 
of 1cmH2O) 
Primary: Fatigue 
Index of the 
Quadriceps muscle. 
Secondary: SpO2. 
 
Primary: Yes. Group 1. Bi-level had significantly less muscle fatigue 
36.3 ±11.7 (mean % fatigue index score) than with 2. Sham 29.9 
±11.5% (p = 0.003).  
Secondary: Yes. Group 1. Bi-level significantly improved SpO2 to 89 
±5% compared to using sham at 84 ±4% during isokinetic exercise (p 
= < 0.0001). 
Carrascossa et 
al. (2010) 
n = 20 
Mean age 62 
±7 years 
Mean FEV1 
39 ±10% 
predicted 
FEV1/FVC 
0.46 ±0.14L 
Randomised 
crossover. Constant 
load (75-80% peak 
work rate) cycle 
ergometry to the limit 
of tolerance whilst:  
1. Mask only 
2. Using PAV  
Primary: Tlim 
Secondary: SV, HR, 
CO. 
Primary: Partial. PAV had a statistical improvement in Tlim median 
252s (range 163-645) compared to 219s (range 144-1200) p=0.05 
(seen in n = 8/20 patients but n=12/20 Tlim decreased -20.5 (range -4 
to -9).  
Secondary: Partial. SV slowed with PAV in n = 13 participants at the 
onset of exercise (p < 0.05).  
Secondary: Partial. HR remained unaltered in 9/20 (p > 0.05) with 
PAV.  
Secondary: Partial. CO reduced in n = 9/20 (p = 0.01). 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Dreher, Storre 
and Windisch, 
(2007) 
n = 20 
Mean age 65 
±9 years 
Mean FEV1 
27 ±8% 
predicted 
 
Feasibility 
randomised cross-
over 6MWT test with 
rollator with NIV and 
O2 verses just O2. 
Mean IPAP 29 
±4cmH2O and mean 
EPAP 4 ±0.4cmH2O. 
Primary: PaO2 
Secondary: BORG, 
6MWT 
Primary: Yes. With NIV PaO2 increased by 10.5 ±10.8mmHg (95% CI 
5.4 to 15.6mmHg; p < 0.001) but decreased without NIV by 10.8 
±8.0mmHg (95% CI -14.5 to -7.1mmHg; p < 0.001). Secondary: Yes. 
BORG significantly (p < 0.001) decreased after walking with NIV from 
6 (IQR 4.5-10) to 4 (IQR 1.5-4.5). 
Secondary: Yes. 6MWT distance significantly (p = 0.027) increased 
from 209m (IQR 178-279) to 252m (IQR 203-314) in favour of NIV 
assisted walking. 
Dreher et al. 
(2009) 
n = 19 
Mean age 63 
±10 years 
Mean FEV1 
26 ±19% 
predicted 
FEV1/FVC 39 
±7% 
predicted 
Randomised cross 
over, three x 
12MWTs. 1. Walk 
with usual O2. 2. 
Walk with double the 
dose of O2. 3. Walk 
with NIV and usual 
O2. Mean IPAP 29 ± 
4cmH2O and mean 
EPAP 2 ± 1cmH2O. 
Primary: PaO2 
Secondary:12MWT, 
BORG 
 
Primary: Yes. PaO2 decreased with O2 by 8.2 ±10.9 and with the 
double O2 by 4.2 ±10.9mmHg. PaO2 increased by 14.0±16.66 mm Hg 
with NIV and O2 compared to O2 alone (p < 0.003).  
Secondary: No. Distance was less with NIV and O2 (555 ±227 m) 
compared with usual O2 (619 ±210 m) and double dose O2 (622 ±215) 
(p < 0.024). 
Secondary: No. The median change of Dyspnoea (BORG) for O2 was 
4 (2.25-6.375), for Double O2 was 3 (2-5.875) and for NIV was 4 
(2.375-5.75). There was no significant difference p = 0.266). 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Dyer et al. 
(2011) 
Part A: n = 
12. (No 
COPD). Part 
B: n=4  
Mean age 72 
±12 years 
Mean FEV1 
not recorded 
Cycle 20 min on 
static bike at 20 
watts at 40-60 
revolutions per min. 
NIV Mode ST IPAP 
15cmH2O 
EPAP 5cmH2O 
+/- O2 if desaturation. 
Part B: Recruit into 
trial NIV on exercise. 
Primary: Part A: 
effect of NIV on a 
single exercise test of 
exercise time and 
work done. 
Primary: Part B: 
Feasibility of enrolling 
patients into a trial of 
NIV on exercise.  
 
Primary: Part A: Not relevant: as no COPD. On NIV (n=5) median 
increase in exercise time of 854.4 seconds, median total work done 
significantly increased (p = 0.016) from 1560 (600-9720) J – 8336 
(1200-21960) J.  
Primary: Part B: No. Not feasible to recruit to trial. 
Hannink et al. 
(2014) 
n = 8  
Mean age 62 
±2 years 
Mean FEV1 
42 ±17% 
predicted 
FEV1/FVC 33 
±12% 
predicted 
Pilot cross over of 
40W constant work-
rate cycle exercise 
until symptom 
limitation or 20 min: 
1. 1. Unaided. 
2. 2. NIV aided. 
IPAP 12.0 
±0.8cmH2O (range 
10-14cmH2O) and 
mean EPAP 5.0 
±0.4cmH2O (range 
4-6 cmH2O). 
Primary: IL-6 plasma 
levels, 
oxidative stress 
response to ROS, 
PaO2. 
Secondary: Mean 
duration of exercise. 
HR, PCO2, blood 
lactate. Leukocyte 
plasma 
concentrations, 
neutrophil plasma 
levels, dyspnoea 
(BORG) and leg pain. 
Primary: Yes. IL-6 plasma levels increased significantly on control 
exercise, pre exercise 2.7 ±2.1pg/mL and response to exercise was 
+0.4 ±0.3pg/ml. IL6 plasma levels did not rise significantly upon 
exercise on NIV, pre-exercise 2.8 ±2.3pg/mL and response to 
exercise was +0.0±0.6pg/mL (p<0.05).  
Primary: Yes. The oxidative stress response of ROS increased 
significantly in the NIV on exercise group by a response of +22.6 
±14.8 relative light units/second (RLu/s) compared to the unsupported 
group response of -6.6 ±40.5 RLu/s (p < 0.05).  
Primary: Yes. PaO2 decreased significantly more with NIV by -1.2 
±1.0kPa than unaided exercise by -0.5 ±1.0kPa (p < 0.05). 
Secondary: No. Mean duration of exercise was similar in both tests 
12.9 ±2min. Both tests caused increased HR, PCO2, blood lactate 
levels, leukocyte plasma concentrations, neutrophil plasma levels, 
dyspnoea and leg pain but there were no significant difference. 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Highcock, 
Shneerson 
and Smith 
(2003) 
 
n = 8  
Mean age 66 
±8 years 
Mean FEV1 
36 ±15% 
predicted 
FEV1/FVC 34 
±13% 
predicted 
Crossover. 
Compared three NIV 
devices (Nippy2 
(B=D Electrical Ltd., 
UK), BIPAP ST 30 
(Respironics Inc., 
USA), Vpap II ST 
(Resmed Ltd., UK)) 
during submaximal 
treadmill verses an 
unaided walk and 
mouthpiece walk. 
NIV: Mean IPAP 
12.2 ±2.2cmH2O. 
Primary: Mean 
distance walked. 
Secondary: VT, VE. 
Primary: No. No significant difference between the unsupported 
walks (mean distance walked 259 ±123m). Mouthpiece walk mean 
distance was 211 ±96 m. NIV walk mean distance was 145 ±76m. 
There was a significant difference between the groups (p = 0.02). Post 
hoc analysis: only significant difference was between the 
unencumbered walks and the ventilator walks (p < 0.01). There was a 
significant difference (p < 0.05) in the last 20s of exercise between 
mean Ti: Bipap 0.85 ±0.14, Nippy2 1.0 ±0.13 and Vpap 0.89 ±0.14 s. 
There was a significant difference (p < 0.05) in the last 20 s of the test 
between mean IPAP: Bipap 12 ±2cmH2O, Nippy2 15 ±3 cmH2O and 
Vpap 13 ±2 cmH2O. No difference between ventilators pre-exercise. 
Secondary: Yes. VT was significantly higher (p < 0.04) in all NIV 
walks (119 ±371mL) compared to mouthpiece walk (1035±284). VE 
was significantly higher (p < 0.03) during the NIV walks (32.7 
±13.8mL) than mouthpiece walk (27.4 ±10.3mL). 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Hussain et al. 
(2011) 
n = 13 
Mean age 65 
±10 years 
Mean FEV1 
28 ±10% 
predicted 
FEV1/FVC 39 
±13% 
predicted 
Three submaximal 
constant-load cycle-
ergometry test equal 
to 80% of the 
highest work rate 
(Watts) achieved 
were selected on: 
1. 30% O2. 
2. 30% O2 and 70% 
He 
3. 30% O2 with PS. 
Mean PS 9 
±2cmH2O (start) – 
19 ±2cmH2O (end). 
EPAP 0cmH2O.  
Primary: IC (measure 
of DLH) 
Secondary: RR, VE, 
Ti, TE, PTPdi/min and 
index of drive to 
breathe, dyspnoea 
(BORG), exercise 
duration. 
Primary: Yes. IC was significantly less (p ≤ 0.03) with He-O2 or PS 
than O2 after 1 min. At end-exercise decrease in IC was significantly 
greater (p < 0.03) with PS and O2 than with He-O2. VT was significantly 
greater (p < 0.04) with PS than O2.  
Secondary: Yes. At isotime RR and VE were significantly less wih PS 
(p ≤ 0.003) than with He-O2 or O2.  At end-exercise PS V’E was 
significantly less (p = 0.008) than with He-O2. At isotime TI and TE 
were significantly (p ≤ 0.007) longer duration with PS ergometry than 
with He-O2 or O2 alone. At end exercise only TI was significantly (p = 
0.001) longer duration with PS than with He-O2. 
Secondary: Yes. Dyspnoea median (IQR) (BORG) at isotime 
decreased from 9 (4.5-10.0) with O2 to 4 (2.5-5.0) with He-O2 and 
reduced to 3 (2.5-5.0) with PS (significance p = 0.01).  
Secondary: Yes: At PTPoes/min and index of drive to breathe was 
significantly less (P ≤ 0.02) with Helium-O2 or with PS than O2. 
Secondary: No. At end-exercise inspiratory effort/breath and 
inspiratory effort/litre were significantly less (p ≤ 0.03) with Helium-O2 
than PS.  
Secondary: Yes. Helium-O2 and PS ergometry had significantly (p = 
0.003) longer duration than O2 alone (O2 6.9 ±0.8min; helium-O2 10.7 
±1.4min and PS 11.2 ±1.6min). 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Kyroussis et 
al. (2000) 
n = 12 
Mean age 64 
±7 years 
Mean FEV1 
27 ±11% 
predicted 
Constant speed 
exhaustive treadmill 
walks: 1. Free walks 
2. Free walk with 
PS. 3. PS assisted 
exhaustion walks. 
Primary Outcome:  
Respiratory muscle 
use by PTPdi, PTPoes, 
PTPga. 
Primary: No just trend. PS caused a decrease on PTPdi and PTPoes 
of n = 6 compared to free walk and prevented the increase in PTPga. 
In PS exhaustive walk PTPdi and PTPoes did not reach the same 
levels as free walk. 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Menadue et al. 
(2009) 
UAE: Mixed 
n = 17 (mixed 
n = 9 COPD 
n = 8 other) 
Mean age 62 
±12 years 
FEV1 20 ±5% 
predicted 
FEV1/FVC 55 
±19% 
predicted 
ESWT: n = 
15 (n = 10 
COPD, n = 5 
other) 
Mean age 
62 ±7 years 
FEV1 28 
±12% 
predicted 
FEV1/FVC 55 
±19% 
predicted 
Randomised cross 
over study. Part A: 
Two UAE tests. 1. 
UAE unsupported  
2. UAE on NIV. 
Part B: ESWT at 
85% of the 
maximum walking 
speed stopped by 
fatigue, dyspnoea or 
time: 1: ESWT with 
NIV.  
2. ESWT 
unsupported. 
Settings: EPAP 3-
5cmH2O, IPAP 13-
15cmH2O (set 
10cmH2O above 
EPAP)   
PS 10-13cmH2O. 
(O2 to maintain SpO2 
at 93% at rest). 
Primary: Exercise 
endurance time in 
UAE and ESWT. 
Secondary: Isotime 
and end time 
dyspnoea (BORG). 
Isotime and end time 
SpO2 in UAE and 
ESWT. 
  
 
Primary: UAE: Yes. UAE on NIV significantly increased endurance 
time by a mean 91 s (95% CI: 10-172, p = 0.031) compared with 
unsupported. 
Primary: ESWT: No. Just trend: For increased endurance time on 
NIV compared with unsupported (119s, 95% CI: -17 to 254, p = 
0.081). 
Secondary: Yes. UAE on NIV led to less dyspnoea (-2.3 Borg, 95% 
CI: -3.7 to -1.0, p = 0.002). End exercise dyspnoea was statistically 
lower after UAE on NIV (1.9 Borg, 95% CI: -3.3 to -0.5, p = 0.010) 
compared with unsupported UAE. 
Secondary: Yes. Isotime SpO2 was greater (1.7%, 95% CI: 0.2-3.3, p 
= 0.033) with UAE on NIV compared to unsupported. 
End exercise SpO2 remained higher (1.8%, 95% CI: 0.3-3.4, p = 
0.023). 
Secondary: No. No difference in isotime dyspnoea between exercise 
with NIV or unsupported (-1.0, 95% CI: -3.0 to 1.0, p = 0.29). End time 
dysnoea was not reported. 
Secondary: Yes. Significant improvement in SpO2 at isotime with NIV 
(3.6%, 95% CI: 0.3 to 6.9, p = 0.033) was maintained at end exercise 
(3.8%, 95% CI: 0.1-7.5, p = 0.045). 
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Menadue et al. 
(2010) 
6MWT: n = 
18 (n = 12 
COPD) 
Median age 
65 years 
Interquartile 
range (IQR) 
61-68 
Median FEV1 
21 (IQR 16-
27) % 
predicted 
FEV1/FVC 46 
±17% 
predicted 
UAE: n = 16 
(n = 12 
COPD) 
Median age 
64 years 
(IQR 56-66) 
Median FEV1 
21 (IQR 16-
24) % 
predicted. 
FEV1/FVC 43 
±13% 
predicted 
Randomised cross 
over study. Two 
6MWT’s and two 
UAE’s with: 1. NIV: 
EPAP 4-5cmH2O 
IPAP 14cmH2O  
(PS = 10cmH2O and 
O2. 2. O2 alone. 
 
 
Primary: 6MWT: 
Distance walked. 
Secondary: 6MWT: 
Distance and time to 
first rest. 
Primary: UAE: 
Endurance time. 
Secondary: UAE: 
Isotime SpO2 and 
dyspnoea (BORG). 
 
Primary: 6MWT: Yes. NIV and O2 significantly increased total 
distance walked by mean 43.4m (95% CI 14.1 to 72.8, p = 0.006) 
compared to exercise with O2. 
Secondary: 6MWT: Just Trend. For improvement with NIV for 
distance and time to first rest. 
Primary: UAE: Yes. Statistically significant improvement in UAE 
endurance time with NIV and O2 compared to exercise with O2 alone 
(median 201s (IQR 93-414) versus 157s (90-342), p = 0.033) 
Secondary: UAE: No. There was no difference demonstrated for 
isotime SpO2 and dyspnoea (BORG). 
Moga et al. 
(2014) 
N = 10 
Mean age 68 
±6 years 
Randomised cross-
over. Comparison of 
3 symptom limited 
Primary: WLpeak. Primary: No. WLpeak significantly lower with PS 0cmH2O EPAP 
4cmH2O (30.5 ±13.00watts) and PS 10cmH2O (33 ±16.70 watts) than 
no PS (43 ±19.50 watts) significance was p < 0.001.  
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
FEV1 53 
±22% 
predicted 
FEV1/FVC 46 
±13% 
predicted 
cycle ergometry 
tests: 
1: No PS 
2: PS 0cmH2O 
(IPAP 0cmH2O 
EPAP 4cmH2O) 
3: PS 10cmH2O 
(IPAP 14cmH2O 
EPAP 4cmH2O). 
Secondary: 
Dyspnoea (BORG), 
VT, VE, VO2, VCO2. 
Secondary: No. Dyspnoea (BORG) was similar between groups at 
peak exercise but lower with no PS compared with PS 0cmH2O and 
PS 10cmH2O p < 0.01.  
Secondary: Unclear meaning. VT and VE were highest with PS 
10cmH2O (1.29 ±0.32L) and lowest with no PS (1.04 ±0.38L) both at 
peak exercise and isoload (p < 0.001).  
Secondary: Unclear meaning. VO2 and VCO2 were significantly 
highest with PS 10cmH2O compared with no PS EPAP 4cmH2O (p < 
0.001) at both peak exercise and isoload. 
Oliveira et al. 
(2010) 
n = 21 
Mean age 63 
±8 years 
FEV1 40 
±11% 
predicted 
FEV1/FVC 50 
±15% 
predicted 
Randomised to two 
high-intensity 
constant work rate 
cycle ergometry 
tests at 70-80% 
peak to tolerance 
limit with: 1. Assisted 
supported breath 
mode: PS 16cmH2O 
and PEEP 5cmH2O.  
2. Unaided.  
Primary: Exercise 
endurance 
Secondary: HR, 
SV, CO. 
Primary: Partial. In n = 11 patients (Group A) exercise endurance 
significantly improved (p < 0.05) with PS 115 seconds (-210 to 909) 
but not in n = 10 (Group B) when endurance was 51 seconds (-60 to 
486).  
Secondary: Partial. PS reduced HR compared with non-assisted 
exercise. SV and CO was variable with PS. Group A. had stable or 
higher SV compared with group B. who were more hyperinflated had 
lower SV with PS. 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Pessoa et al. 
(2012)  
n = 32 
Mean age 69 
±7 years 
FEV1 42 
±13% 
predicted 
FEV1/FVC 42 
±12% 
predicted 
Randomised cross 
over trial of lifting 
containers (from 0.6-
5 kg) repeated 5min: 
1. No NIV. 
2. NIV IPAP 
10cmH2O and EPAP 
4cmH2O. 
Primary: IC 
Secondary: 
Dyspnoea (BORG) 
Primary: No. No significant difference in IC (indication of DLH) post 
exercise between intervention (1.69 ±0.60L) and control (1.73 ±0.57L) 
p = 0.30. 
Secondary: No. No significant difference in dyspnoea intervention 
(BORG score 2.67) and control (BORG score 2.67) post exercise. No 
P value documented. 
Poggi et al. 
(2006) 
n = 8 
Mean age 65 
±11 years 
FEV1 0.72 
±0.23L 
 
Randomised 
crossover of: 1. 
Spontaneous 
breathing.  
2. Spontaneous 
breathing with arm 
elevation.  
3. Arm elevation with 
PS.  
4. Arm elevation with 
PAV.  
5. PS only.  
6. PAV only. 
Primary: VE 
Secondary: VT, RR, 
PEEPidyn, PTPdi  
 
Primary: Yes. Arm elevation performed with PAV and PS mean VE 
were 50% significantly greater (p < 0.05) than unsupported. The rise in 
VE with PAV (3.96 ±1.34L/min was significantly greater than both 
spontaneous breathing (1.11 ±1.34L/min) and PS (2.32 ±2.15L/min (p 
< 0.05).  
Secondary: Yes. PS increased VT by mean 48% (p < 0.05) (0.46 
±0.15L spontaneous breathing, PAV 0.72 ±0.72L and PSV 0.77 
±0.4L).  
Secondary: No. Just trend. Arm elevation PEEPidyn decreased by 
30% with PS (3.8 ±4.3cmH2O) or PAV (1.3 ±0.9cmH2O) compared to 
unsupported (3.8 ±4.3cmH2O). 
Secondary: Yes. PTPdi decreased to - 44% with PAV (268 
±170cmH2Omin) and - 54% with PS (219 ±75cmH2Omin) compared to 
unsupported (478 ±27cmH2Omin).  
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Polkey et al. 
(2000) 
n = 8  
Mean age 70 
±8 years 
FEV1 24 ±7% 
predicted 
 
Cross-over of two 
treadmill walks until 
severe dyspnoea: 
1. Free walk 
2. PS provided 
Primary: Walking 
time. 
Secondary: PaCO2, 
Peak lactate level. 
Primary: Yes. Mean (SD) free walking time was 5.5 (1.5) min and in 
PS walk 13.6 (6.0) min, increase of 149% (p = 0.01).  
Secondary: Yes. End mean PaCO2 was higher in free walk 6.32kPa 
compared to 5.86kPa with PS (p < 0.04).  
Secondary: Yes: Mean peak lactate level was significantly higher at 
the end of the free walk 2.96 than PS 2.42 (p = 0.01). 
Revill, Singh 
and Morgan 
(2000) 
 
n = 10  
Median age 
63 (IQR 58-
81) years 
FEV1 0.60 L 
(IQR 0.35-
0.45) 
 
Performed four 
ESWT’s, following 
an ISWT to assess 
for speed of ESWT 
with: 
1. PS 14cmH2O 
(range 8-20cmH2O) 
PEEP 3cmH2O. 
2. Sham PS < 
8cmH2O. 
3. O2.  
4. Sham O2 
Primary: ESWT 
duration. 
Secondary: SpO2. 
 
Primary: No. The mean ESWT walk distance was worse than 
baseline (172sec) with sham PS (84sec), PS (84 sec), sham O2 
(150sec). It improved with O2 (242sec) 
Secondary: No. The mean SpO2 85% (standard error (SE 2.0) of the 
O2 walk was significantly higher than the PS (80% (SE 2.0) and the 
baseline walk (80% (SE 2.0) (p < 0.05). 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
van’t Hul et al.  
(2004)  
n = 45  
Mean age 67 
±7 years 
FEV1 39 
±14% 
predicted 
 
Three constant-load 
endurance tests 
were performed on a 
cycle ergometer at 
75% of previously 
determined at Wmax: 
1. PS 10cmH2O.  
2. PS 5cmH2O.  
3. PS 0cmH2O.  
Primary: Exercise 
endurance: Time. 
Secondary: VT, VE, 
VCO2, VO2, RR. 
Primary: Yes. PS 10cmH2O compared with PS 5 cmH2O led to a 
significant increase in duration (6.3 ±6.7 versus endurance was 
2.2min, p < 0.01). PS 10cmH2O compared to PS 0cmH2O was 
significantly longer (6.3 ±6.7 versus 4.3 ±2.6min, p < 0.01No statistical 
difference was found in endurance between PS 5cmH2O and PS 
0cmH2O (4.4 ±2.9 versus 4.2 ±2.6min), p = 0.70).  
Secondary: Yes. PS 10cmH2O had a significantly higher VT at isotime 
than PS 5cmH2O at end-exercise (1.5 ±0.40 versus 1.38 ±0.36L p = < 
0.05).  
Secondary: Yes. PS 10cmH2O had a significantly lower RR at isotime 
than PS 5cmH2O at end–exercise (21 ±5 breaths.min-1 versus 23 ±5 
breaths.min-1.  
Secondary: No. VE did not differ.  
Secondary: Yes. VO2 and VCO2 were significantly lower at isotime for 
PS 10cmH2O compared to PS 5cmH2O (VO2 0.76 ±0.25L.min-1 versus 
0.80 ±0.26L.min-1 p < 0.05 and VCO2 was 0.74 ±0.29 L.min-1 versus 
0.77 ±0.30 L.min-1. VE, VO2 and VCO2 were also significantly higher at 
end exercise with PS 10cmH2O (VE 34.0 ±10.0, VO2 0.83 ±0.25 and 
VCO2 0.81 ±0.29) compared with PS 5cmH2O (p < 0.05). 
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Author/ 
Date 
published 
Sample size, 
age and 
lung 
function 
Design Outcome measure Clinical or statistical improvement 
Abbreviation key: CO Cardiac output, CO2 Carbon Dioxide, CRQ Chronic respiratory questionnaire, DLH Dynamic Lung Hyperinflation, ESWT 
Endurance shuttle walk test, He Helium, HR Heat rate, IC Inspiratory Capacity, IQR Interquartile range, IL6 Interleukin 6, ISWT Incremental shuttle walk 
test, O2, Oxygen, PaCO2 Partial pressure of arterial carbon dioxide, , PaO2 Partial pressure of arterial oxygen,  PAV Proportional assisted ventilation, 
PEEPi Intrinsic positive end expiratory pressure, PEEPi,dyn Dynamic intrinsic positive end expiratory pressure, PS Pressure support, PTPdi Pressure/time 
products of transdiaphragmatic pressure, PTPga Pressure/time products of gastric pressure, PTPoes Pressure/time products of oesophageal pressure, 
RR Respiratory rate, ROS Reactive oxygen species, SD Standard deviation, SpO2 Peripheral capillary oxygen saturation, SV Stroke volume, TE 
Expiratory time, Ti Inspiratory time, Tlim Limit of tolerance, UAE Unsupported arm exercise, VCO2 Volume of carbon dioxide breathed out, VE Expired 
minute ventilation, VO2 Oxygen uptake, VT Tidal volume, WLpeak, Peak exercise workload, Wmax maximal workload, 6MWT Six minute walk test, 12MWT 
Twelve minute walk test, IL-6 Interleukin-6. 
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2.9.3 Quality assessment of the individual studies 
Table 2.8 presents the quality assessment of the individual studies. It represents 
the questions asked within the CASP tool. The majority of the studies had a 
crossover design. The CASP tool does not have a specific tool for crossover 
design. There is no known specific quality assessment for crossover design, 
therefore the studies were also evaluated for quality using the suggestions within 
the Cochrane handbook (Ding et al., 2015). 
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Table 2.8 The quality assessment of the individual studies 
Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Allan et al. 
(2009) 
Yes: But 
4 arms is 
a 
complex 
design. 
Yes. Yes: But coin 
toss could be 
biased. 
Partial. 
Yes: 
Patient  
No: 
clinician 
No: 
Study 
team. 
Yes: But 
small. 
Excluded 
n = 
94/110. 
No: 
Sham 
NIV: may 
have 
raised 
dead 
space 
affecting 
effort. 
Used 2 
different 
makes of 
NIV thus 
not equal 
method. 
 
Yes: 
Two 
days. 
Yes. Partial: 
Power 
calculation 
n = 12 (80% 
power) for 
primary 
outcome. 
No P value 
for RR. 
No P value 
of heliox HR 
verses 
placebo 
HR. Sample 
small 
needed 
n=38. 
No: Stable 
group and 
post PR, no 
LTOT users) 
Outcome 
clinically 
relevant but 
may not be 
relevant to 
the patient.  
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Barakat et al. 
(2007) 
Yes. No: 
Crossover 
poor design 
choice 
because trial 
was 10 
sessions that 
may cause 
long term 
change. 
Good detail 
in methods. 
No: Not 
randomised to 
order of 
intervention. 
Lack of detail 
about how 
patient’s 
recruited 
unable to rule 
out selection 
bias 
No. Yes: 
small, only 
n = 2 
female. n 
= 1 on 
home NIV 
could 
influence 
results. 
No: 
Equal 
time but 
patients 
may be 
fitter 
from first 
training. 
No: 
Effect 
could 
carry 
over.  
Yes: 
n = 1 
unable to 
use NIV. 
No: No 
power 
calculation. 
No p value 
for SGRQ. 
No: Stable, 
younger 
group with 
excluded co-
morbidities 
but more 
severe as all 
on LTOT. 
Good 
programme 
length. 
Borghi-Silva et 
al. (2008) 
Yes. Yes. No. Yes: 
Double. 
Sham 
used. 
Yes: 
No data 
shown in 
table of 
baseline 
details. 
Yes. No: 
Poor 
record. 
Yes. No. No 
power 
calculation. 
Exact 
values for 
between 
treatment 
details not 
available 
just p-value 
No: Stable 
group, not 
elderly or 
women.  
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Borghi-Silva 
et al. (2009) 
Yes. Yes: Good 
detailed 
method with 
SOPS, but 
9cmH2O may 
not be 
enough PS. 
Sham NIV 
may have 
increased 
work of 
breathing. 
Yes: 
Intervention 
order with 
sealed 
envelopes. 
Yes: 
Double. 
Sham 
used but 
no basis 
for sham 
settings. 
Yes. Yes. No: 
Only 
30min. 
Yes. Yes, power 
calculation 
for a 
sample size 
of n = 20. 
No: Stable 
group, no co-
morbidities 
although n = 
6 on LTOT. 
Carrascossa 
et al. (2010) 
Yes. Partial: Lack 
of detailed 
information. 
Outcome 
measure may 
be flawed for 
cardiac 
measure. Did 
use SOPS. 
Yes: 
Envelopes 
No. Yes. Yes. No: 
30min. 
Yes, but 
unable to 
use data 
from n = 5 
due to 
poor 
signal for 
SV. 
No: No 
power 
calculation. 
No: Stable 
group, no co-
morbidities, 
no flare up of 
COPD in 3 
months prior 
to study and 
no one on 
oral steroids.  
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Dreher, 
Storre and 
Windisch 
(2007) 
Yes. Yes: Lack of 
detail in 
method. 
Used high 
pressure that 
may only be 
tolerable 
because the 
patients were 
all patients 
with home 
NIV. 
Partial: Lack 
of details to 
decide on any 
possible bias. 
No. Yes. No: Did 
not use 
the same 
circuitry. 
Yes: 
One 
day. 
Yes. Yes, power 
calculation 
collated. 
Yes: Severe 
group with 
multiple 
pathology 
and on home 
NIV, but 
excluded 
bronch-
iectasis. Did 
not use a 
commonly 
used NIV 
device. 
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Dreher et al. 
(2009) 
Yes. Yes. Used 
very high 
pressures 
may only be 
tolerable 
because 
patients were 
all nocturnal 
NIV patients.  
Yes. No. Yes: but n 
= 8 
excluded 
as refused 
to walk 
with heavy 
kit. Drop 
outs had 
higher 
level of 
Hb.  
No: 
patient 
carrying 
kit. 
Weight 
varied. 
Yes: 
One 
day. 
Yes. Yes, power 
calculation. 
Yes: Severe 
on home NIV, 
co-
morbidities 
but no flare 
up’s. Did not 
include 
house bound. 
Pragmatic as 
patients 
usually have 
to carry their 
O2 and NIV.  
Dyer et al. 
(2011) 
Yes. No: different 
pathology, 
different sites 
conflicted 
design. Not 
RCT. 
No. 
Selection bias 
possible as 
part A sample 
selected by 
staff. 
No. No: 
Only some 
of the 
sample 
were NIV 
users.  
N/A as 
study not 
feasible. 
N/A. N/A could 
not recruit.  
No: For part 
B, no power 
calculation.  
No results. 
Yes: Part B: 
acute group 
with hospital 
stay, better 
reflects 
clinical 
context. 
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Hannink et al. 
(2014) 
Yes. Yes: But PS 
used may not 
have been 
enough to 
off-load 
muscles. No 
added O2. 
No. No. Partial: 
Baseline 
ROS not 
recorded. 
Yes. Yes: 
Two 
weeks. 
Yes. Yes, but no 
power 
calculation. 
No: Stable 
group. No 
patients with 
normal or 
high fat-free 
mass. 
Highcock, 
Shneerson 
and Smith 
(2003) 
Yes. Yes: But 
circuits used 
may have led 
to CO2 re-
breathing. 
Yes: Order of 
walks. 
No. Yes. Yes: 
Different 
circuitry. 
No: 
30min. 
Yes. No: No 
initial power 
calculation. 
Post-hoc 
power 
analysis (for 
50%) on 
effect of 
order on 
walking 
difference in 
unaided 
walks. 
No: stable, 
able to walk 
for 10min on 
the treadmill. 
Hussain et al. 
(2011) 
Yes. Yes, but 
added O2 to 
all groups 
may be a 
confounder. 
Yes: Order of 
test. 
No. Yes. Yes. Yes: 
Four 
days. 
Yes: n = 3 
drop outs 
but still 
equal 
groups. 
Yes, but no 
power 
calculation. 
No: invasive 
testing. 
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Kyroussis et 
al. (2000) 
Yes. Yes, but PS 
used may not 
have been 
high enough 
to off-load 
muscles. 
Researcher 
bias in 
choosing 
who did the 
PS walk. 
No. No. Yes. Yes. No: 
Same 
day. 
No: n = 6 
did PS 
walk, but 
only n = 5 
did PS 
walk until 
unable as 
n = 1 
dropped 
out. 
No: No 
power 
calculation. 
No: Sample 
had only one 
female. 
Menadue et 
al. (2009) 
Yes. Partial: 
Mixed 
pathology. O2 
added from 
resting SpO2 
may have led 
to low SpO2 
on walking. 
Yes: Order of 
tests by 
computer, 
closed 
envelope until 
after consent. 
No. No: Mixed 
pathology. 
Yes. No: 
Same 
time. 
No: n = 3 
stopped 
test due to 
low SpO2, 
unclear if 
included in 
results. 
Yes, but no 
power 
calculation. 
No: Stable 
sample and 
mixed 
pathology. 
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Menadue et 
al. (2010) 
Yes. Yes, but 
mixed 
pathology. 
Yes: Order of 
tests by 
computer then 
sealed 
envelopes until 
after consent. 
No. No: Mixed 
pathology. 
Yes. No. 
Same 
day. 
Yes. Yes: 
Powered for 
primary 
outcome n 
= 18 
6MWT, n = 
16 UAE. 
Yes: acutely 
unwell 
patients. 
Moga (2014) Yes. Yes, but PS 
used may not 
have been 
high enough 
to off-load 
muscles. 
No. Exercise 
off NIV always 
before NIV 
exercise. 
No. Yes. Yes. Yes: 48 
hours. 
Yes. No: No 
power 
calculation. 
Small 
sample 
size. 
No: Not 
severe group. 
Oliveira et al. 
(2010) 
Yes. Yes, but lack 
of clarity in 
the results. 
Group A and 
B not clearly 
defined. 
Yes, but no 
details. 
No. No: Not 
clear. 
Yes. Yes: 24 
hours. 
No: Not 
clear. 
No: No 
power 
calculation. 
Not all 
results were 
reported. 
No: No 
women and 
stable group. 
Pessoa et al. 
(2012) 
Yes. Yes, but PS 
used may not 
have been 
high enough 
to off-load 
muscles. 
Yes, but 
occurred after 
baseline 
testing. 
No. Yes. Yes. No: 15-
30min. 
Yes. No: Power 
calculation: 
For sample 
n = 22. No 
p value 
(BORG). 
No: Stable 
patients, but 
good disease 
severity, 
included the 
elderly. 
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
Poggi et al. 
(2006) 
Yes. Yes, but 
balloon 
measure 
invasive, 
some 
patients may 
not tolerate 
this. 
Yes: Order of 
treatment, but 
lack of detail. 
No. No: n = 2 
not 
COPD. 
Yes. No: 
Same 
time. 
Yes. Yes, but no 
power 
calculation. 
No: stable, 
no women 
but all on 
LTOT thus 
more severe 
group. 
Polkey et al. 
(2000) 
Yes. Yes, but no 
details of 
settings used 
on NIV. 
Partial: 
Previously 
chosen 
sample, but 
randomised to 
allocation of 
treatment. 
No. Yes. Yes. No: 
30min. 
Yes. Yes, but no 
power 
calculation. 
No: Previous 
sample used 
so may not 
represent the 
normal 
COPD 
population. 
Only men. 
Revill, Singh 
and Morgan 
(2000) 
Yes. Yes, but NIV 
device had 
low flow 
rates.  
Partial, 
possible 
selection bias 
as sample just 
done PR. 
Randomised to 
allocation of 
treatment. 
Partial: 
Sample 
blinded to 
treatment 
Yes. Yes. No: 
30min. 
Yes. No: No 
power 
calculation. 
No: sample 
just 
completed 
PR, may be 
fitter than 
typical patient 
with COPD. 
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Author Clear  
design 
question 
Good 
design  
and 
outcome  
Randomised Blinding Similar 
groups at 
the start 
Method 
equal 
for each 
group 
Wash-
out 
time   
Similar 
groups 
finish 
Treatment 
effect 
Applicable 
to clinical 
context 
van’t Hul et 
al. (2004) 
Yes. Yes: 
Outcome 
measures 
tested and 
ergometry 
tested for 
standards. 
Partial: Only 
the two tests 
with PS. 
Partial: 
Only the 
sample 
between 
the two 
PS tests. 
Not team.  
Yes. Yes. Yes: 
One or 
two 
weeks. 
Yes. Yes, but no 
power 
calculation, 
but 
reviewed 
the effect of 
small 
sample. 
No, Included 
no co-
morbidities 
that can 
cause 
exercise 
limitation. 
Abbreviation Key: CO2 Carbon Dioxide, COPD Chronic Obstructive Pulmonary Disease, FiO2 Fraction of inspired oxygen, LTOT Long term oxygen 
Therapy, min Minute, NIV Non-Invasive ventilation, O2 Oxygen, PS Pressure Support, RCT Randomised controlled trial, ROS Reactive oxygen species 
Levels, SGRQ St George’s Respiratory Questionnaire, SOP Standard operating procedure, SpO2 Oxygen saturations. 
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2.9.3 How did the individual studies inform the design of the planned 
feasibility study? 
 
Table 2.9 Combined information that informed the design of the planned feasibility 
study from the reviewed individual studies. 
 Studies combined information 
Sample 
characteristics 
n = 4-45 (combined mean n = 14), Mean age range of 62-72 years 
(combined mean age of 65 years), FEV1 (% predicted) mean range 
20-56%, 4 not recorded (combined mean 32%). 
Recruitment 
method 
Not recorded in 9 studies. 
From respiratory clinics in 6 studies, from PR cohort in 3 studies, 
home NIV clinic in 2 studies, and respiratory wards hospital in 2 
studies. 
Number/time 
period of 
screening 
Not recorded in 19 of the studies. 
Allan  et al. (2009) screened 122 patients in 12 months (n = 28 met 
inclusion, 16 of these excluded with less severe lung disease and 
additional lung disease) 
Dyer et al. (2011): n = 60 screened in 4 months. n = 42 excluded 
(56% MSK problems, 13 % dementia, 13 % neurology). n = 18 
included but n = 10/18 declined n = 2/10 did not want to do research, 
n = 8/10 felt unable/did not want to exercise and then n = 4/8 
excluded for logistical reasons. 
Recruitment 
rate 
Not recorded in 16 studies.  
Allan et al. (2009) Patients that met inclusion criteria was 23% of 
patients screened but recruitment rate (due to exclusions) was 10%.  
Dyer et al. (2011): Recruitment rate of patients that met the inclusion 
criteria was 30% but due to logistics, and refusals the final 
recruitment rate was 7%.  
Retention rate All participants completed the trial in 16 studies. 
Barakat et al. (2007) n = 9/12 completed (n = 1 could not tolerate 
NIV, n = 1 developed AF, n = 1 hospitalized exacerbation COPD). 
Dreher, Storre Windisch (2009) n = 11/19 completed (n = 8 withdrew 
as did not want to carry kit).  
Dyer et al. (2011) 2/4 (n = 1 frail, n = 1 breathless on exercise). 
Hussain et al. (2011) n = 10/13 (n = 1 new diagnosis of PVD, n = 1 
new diagnosis of prostate cancer, 1 x knee pain). Kyroussis et al. 
(2000) n = 11/12 completed (n = 1 exacerbation COPD).  
Outcome 
measure 
timing 
Not recorded in 6 studies. 
Most of the studies did baseline tests on a separate day to the 
intervention.  
Timing ranged from every 30 seconds to once before training began 
and one measure the week after 8 week training.   
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 Studies combined information 
Outcome 
measure that 
reflected 
change 
13 studies: Statistical improvement in their outcome measure: 
 Cycle ergometry: Exercise duration (Barakat et al. 2007; 
Borghi et al., 2008; Hussain et al., 2011; van’t Hul et al., 
2004). 
 BORG Dyspnoea score (Barakat et al. 2007; Borghi et al. 
2008; Hussain et al., 2011; Menadue et al., (2009)). 
 6MWT (Barakat et al., 2007; Dreher Storre and Windish 
2007; Menadue et al., 2010). 
 UAE endurance time (Menadue et al., 2009; Menadue et al., 
2010). 
 ESWT endurance time (Menadue et al., 2009). 
 Treadmill walk time (Polkey et al., 2000). 
 Cycle ergometry: increased work load (Barakat et al., 2007). 
 Fatigue index of quadriceps: decreased score (Borghi et al., 
2009). 
 SpO2 (Borghi et al., 2009; Menadue et al., 2009) 
 PaO2 (Dreher et al., 2007; Dreher et al., 2009; Hannink et al., 
2014). 
 IL6 (Hannink et al., 2014) 
 VE (Highcock, Shneerson and Smith, 2003;  Hussain et al., 
2011; Poggi et al., 2006) 
 VT (Highcock, Shneerson and Smith, 2003; Poggi et al. 2006; 
van’t Hul et al. 2004). 
 IC (Hussain et al., (2011)) 
 De-Oxyhaemoglobin: decreased (Borghi et al., 2008). 
 RR decreased (Hussain et al., 2011; Van’t Hul et al., 2004). 
 Lactate decreased (Polkey et al., 2000). 
 VCO2 (van’t Hul et al., 2004). 
 VO2 (van’t Hul et al., 2004). 
Complications 
with outcome 
measures 
None reported in 17 studies. 
Borghi et al. (2008): May not measure what was intended. 
Borghi et al. (2009): May not be sensitive enough.  
Menadue et al. (2009) 3 tests stopped early due to SpO2 <75%. 
Menadue et al. (2010) 3 tests stopped early due to SpO2 <75%. 
AEs None reported in 20 studies. 
Barakat et al. (2007) n = 1 could not tolerate NIV, n = 1 developed 
AF and n = 1 hospitalized COPD exacerbation. 
Abbreviation Key: AE Adverse Event, AF Atrial Fibrillation, COPD Chronic obstructive 
pulmonary disease, ESWT endurance shuttle walk test, IC Inspiratory Capacity, FEV1 
Forced expiratory volume in one second, IL6 Interleukin 6, MSK Musculoskeletal, NIV 
Non-invasive ventilation, O2 Oxygen, PaO2 Partial pressure of arterial oxygen, PR 
Pulmonary rehabilitation, PVD Peripheral vascular disease, RR Respiratory rate, SpO2 
Saturation of arterial blood with oxygen, UAE Unsupported arm exercise, VCO2 Volume 
of carbon dioxide produced in a given time, VO2 Volume of oxygen utilised by the body 
each minute, VE Minute ventilation, VT Tidal volume, 6MWT Six minute walk test. 
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2.9.4 How did the individual studies inform the intervention of the planned 
feasibility study? 
 
Table 2.10 Combined information to inform the intervention of the planned 
feasibility study. 
 Studies combined information 
Type of 
ventilator/mode/circuit 
Ventilator: There were 13 different types of ventilator 
used. 4 studies used EVITA 4, 3 Studies used NIPPY S/T, 
and 2 studies used VPAP III, Vision and BIPAP. 4 studies 
used a battery powered device. 
Circuit: 1 study used humidifier and 2 studies used double 
circuit. 
Capabilities: Oliveira et al. (2010) detailed capabilities: 
Evita 4: dual limb, rise fast 0.4 secs, trigger lowest, VE up 
to 99L/min, rise time 5ms, max inspiratory flow 180L/min. 
van’t Hul et al. (2004) detailed settings/capabilities: 
Raphael: low trigger, VE 50L/min, insp. Rate 180L/min, 
dead space < 15mls. 
Interface: 11 studies used full face masks, 3 used 
mouthpiece and nasal clips, 2 used nasal mask and 2 
studies did not record interface used. 
 
Ventilator settings PS range 6-27cmH2O, 4 studies PS not recorded, 2 
studies used PAV and PS not calculated) (mean PS 
13cmH2O). 
EPAP range 2-5cmH2O, 4 studies EPAP not recorded, 5 
studies did not use EPAP (mean EPAP 4cmH2O) 
Entrained O2 13 studies did not entrain O2.  
Barakat et al. (2007) entrained O2 to achieve SpO2 92%. 
Dreher, Storre and Windish (2007) entrained O2 to match 
home prescription.  
Dreher et al. (2009) O2 entrained same as home 
prescription.  
Hussain et al. (2011) entrained 0.3 FiO2 to all. 
Menadue et al. (2009) maintain 93% at rest.  
Menadue et al. (2010)1-3L/min aim resting SpO2 93%.  
Poggi et al. (2006) entrained O2 to keep SpO2 at > 92%.  
Research setting 4 studies did not clearly document location. 
9 study settings were physiology exercise laboratories. 
4 studies were in lung function laboratories.  
3 studies were in community PR centres. 
1 study was in an acute hospital on the ambulatory 
respiratory ward (Menadue et al. 2010) 
Exercise type Cycle ergometry used in 9 of the reviewed studies. 
3 studies 6MWT and 1 study 12MWT. 
2 studies used treadmill walking. 
2 studies used ESWT. 
4 studies UAE’s.  
1 study knee extensor exercises (Borghi-Silva et al. 2009). 
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 Studies combined information 
Intensity, duration, 
number of sessions 
Number of sessions: 1 study full training programme:   
Barakat et al. (2007) 10 sessions with NIV, 10 sessions no 
NIV. 25-30 min, more if patient able, 2-3 x week for 8 
weeks.  
All of the studies were one off exercise tests. 
Intensity: 13 studies did pre-testing to determine peak 
work rate, peak of limit of tolerance and maximum speed. 
Ranged from 50%-80% maximum speed, 25-50% 
maximum power, to 80% work rate.  
2 studies replicated a brisk walk. 
4 studies exercised to extreme dyspnoea. 
2 studies exercised until fatigue. 
1 study exercised against a metronome timer. 
Duration: For tests that were not limited by symptoms the 
timing ranged from 6min to 40min. 
Intervention 
participation/training 
session attended 
19 studies had no non-attendees and all sessions were 
attended. 
Barakat et al. (2010) n = 3 drop outs. 
Dyer et al. (2011): due to discharge; n =1 only had 1 
session and n = 1 only had 2 sessions. 
 Kyroussis: n = 1 drop out.  
Reported 
problems/changes to 
intervention 
16 studies did not report any problems with intervention. 
Problem: Allan et al. (2009) additional methodological 
variance could be traced to clinician inexperience with the 
use of the device, patient-ventilator asynchrony, 
inadequate inspiratory flow or flow-cycling times, 
unappreciated imposed work of breathing due to 
exhalation valve delays or resistance and poor mask fit. 
Barakat et al. (2010) Nasal mask problematic as they 
concluded most patients experienced oronasal breathing 
during exercise. 
Dreher et al. (2009) Problems with patients carrying 
ventilator (7Kg) led to drop outs. 
Dyer et al. (2011) not feasible to recruit to study.  
Highcock, Shneerson and Smith (2003) swivel valve in the 
circuit caused CO2 rebreathe and there was resistance in 
the circuit with a mouthpiece. The researchers were 
unfamiliar with the NIV circuit. 
Benefit: Allan et al. (2009) individualised participant 
settings, increased by 2cmH20 increased tolerance. 
Borghi et al. (2009) Participants benefitted from 30 min to 
get used to NIV pre-exercise. 
Dreher, Storre and Windish (2007) Dreher et al. (2009) All 
home NIV users so familiar with the device allowed for 
better tolerance.  
Abbreviation Key: CO2 Carbon Dioxide, EPAP End positive airways pressure, ESWT 
Endurance shuttle walk test, FiO2 Fraction of inspired oxygen, NIV Non-Invasive 
ventilation, O2 Oxygen, PS Pressure Support, UAE Unsupported arm exercise, VE 
Minute ventilation, 6MWT Six minute walk test. 
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2.10 Discussion: Part B 
2.10.1 What was the methodological quality of the individual studies? 
The methodological quality of the studies included was reported in Table 2.7. The 
studies were small numbered. Only six studies carried out a power calculation to 
ensure their sample was big enough to detect statistical significance for the 
primary outcome measure (Pessoa et al., 2012; Menadue et al., 2010; Allan et 
al., 2009; Borghi-Silva et al., 2009; Dreher et al., 2009; Dreher et al., 2007). All of 
the studies had a clear research question, two of the studies design was overly 
complex as they were investigating the effects of two interventions (Allan et al., 
2009; Hussain et al., 2011). Five studies did not have equal sample characteristics 
in each group or it was unclear if the groups were homogenous (Poggi et al., 2006; 
Menadue et al., 2009; Menadue et al., 2010; Oliveira et al., 2010; Dyer et al., 
2011). 
The sample selected often had exclusions including co-morbidities to avoid 
confounding factors and only one study had a sample with a mean age of > 70 
years (Allan et al., 2009)  In real world clinical practice a high proportion of the 
patients admitted to hospital are elderly and patients with severe COPD 
commonly experience exacerbations. This may mean that a successfully reported 
intervention may not work in clinical practice. 
19 of the studies were cross-over trials. This was a good design for ensuring that 
the sample for each intervention had the same characteristics. It was important 
with cross over trials to ensure that there is an adequate wash out time of the 
intervention.  The studies ranged from no wash out time (Poggi et al., 2006) to 
four days (Hussain et al., 2011). Baraket et al. (2007) used crossover design 
inappropriately because the training period was too long (ten sessions) and 
physiological changes may have carried over into the second arm of the trial. 
Randomisation was used in 15 of the studies, however the detail of randomisation 
was often omitted from the reported method, including randomisation protocol and 
timing.  
There were only two studies that were double blinded, however not all of the    
researchers involved were blinded to the intervention (Borghi-Silva et al., 2009: 
Borghi-Silva et al., 2008). Three studies used a single blinded design and only 
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blinded participants to intervention arm (Allan et al., 2009; Vant Hul et al. 2004; 
Revill, Singh and Morgan, 2000). True blinding was challenging because there 
was no known piloted sham device for NIV and any change to circuitry or 
pressures may possibly influence breathing and thus results. This was observed 
by three studies who attempted to use invalidated sham comparisons (Allan et al., 
2009; Borghi silva et al., 2009; Revill, Singh and Morgan, 2000). 
2.10.2 How did the individual studies inform the current study design? 
The information that helped to inform the current study was reported in Table 2.8. 
The studies often lacked detail in regards to location, recruitment and methods. 
There was a need to carry out a feasibility study based on RCT design with 
detailed reporting and power calculation of the primary outcome measure.  
The majority of the studies used stable patients without co-morbidities, only two 
studies recruited acutely unwell patients in hospital (Dyer et al., 2011; Menadue 
et al., 2010). 
 
The interventions of the individual studies were performed in an exercise 
laboratory as one off exercise tests. There was only two studies that attempted to 
rehabilitate using the NIV as part of an exercise programme (Dyer et al., 2011; 
Barakat et al., 2007). However the trial by Barakat et al. (2007) may have been 
influenced by inefficient wash out and the trial by Dyer et al. (2011) was unable to 
recruit and retain participants as it was hospital-based and continued only until 
the point of the participant’s hospital discharge. This valuable study demonstrates 
the difficulties of recruiting and retaining within the NHS hospital environment. 
There is a gap of knowledge in the literature on exercising on NIV as a programme 
over time to see if any one-off benefits demonstrated during the exercise tests 
continue. Dyer et al. (2011) also informed the planned study by facilitating 
consideration of recruiting patients who had been more critically ill and were more 
likely to have a longer length of hospital stay, thus continuing to exercise the 
patients from hospital to home may have enabled them to be retained in the study. 
Familiarity with the device was used by the researchers to improve concordance. 
However using nocturnal users of NIV may have been a confounding factor. There 
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have been some improved outcomes from using nocturnal NIV during PR (Garrod 
et al., 2000). 
The outcome measures chosen that demonstrated significant improvement 
assessed for a change in physiological variables for example SpO2, inflammatory 
markers and changes in lactate (Hanninck et al., 2014; Borghi et al., 2009; Polkey 
et al., 2000). Measuring physiological measures are important, but within clinical 
practice using outcome measures that can assess an observable change to both 
patient and clinical practice is important. A few of the studies had statistically 
significant results for endurance tests that may be more easily reproduced in 
clinical practice, are meaningful to both clinician and patient, and are able to 
measure changes associated with NIV on exercise. These included endurance 
time of cycle ergometry, UAE, ESWT and 6MWT (Menadue et al., 2010; Menadue 
et al., 2009; Dreher et al., 2009; Borghi et al., 2008; Dreher, Storre and Windish, 
2007). Four of these studies assessed dyspnoea using the BORG score and 
demonstrated statistical improvement by decreasing dyspnoea with the use of 
NIV. This is an important objective measure because dyspnoea is a symptom that 
is meaningful to patients (Hussain et al., 2011; Menadue et al., 2009; Borghi et al. 
2008; Barakat et al. 2007). Unfortunately none of the studies were able to 
demonstrate statistical improvement with a HRQOL measure. Barakat et al. 
(2007) used the SGRQ as an outcome measure and whilst not demonstrating 
statistical improvement there was clinically significant improvement in total scores. 
None of the reviewed studies considered the economic cost of NIV, or the effects 
on activity levels. 
2.10.3 How did the individual studies inform the planned intervention in the 
future feasibility study? 
There were 13 different makes of ventilator used making comparisons between 
studies difficult. Researcher experience of the ventilator was considered useful to 
ensure familiarity and standardise care.  The other important factor was to choose 
a ventilator, circuit and mask that can support the VE of an exercising patient. 
Resistance in the circuit and mask may have increased the work of breathing 
reducing the ability to exercise (Allan et al., 2009; Highcock, Shneerson and 
Smith, 2003). The weight and portability of the ventilator was considered, too 
heavy and/or without a battery patients may not have been able to exercise with 
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it (Dreher et al., 2009). The use of PAV within three studies led to favourable 
outcomes, because it may have been able to respond to the rises in minute VE 
more efficiently. However, PAV is expensive, large, often driven by high flow gas, 
complex to set up and not suitable for clinical practice. The PS used ranged from 
6cmH2O to 29cmH2O. The mean PS used in studies that demonstrated statistical 
significance when using NIV to exercise was 16cmH2O. Four studies did not 
document the PS used, highlighting the importance of clear intervention 
documentation to allow analysis (Allan et al., 2009; Poggi et al., 2006; Kyroussis 
et al., 2000, Polkey et al., 2000). The amount of PS used could have influenced 
four of the studies that did not achieve statistical significance in their primary 
outcome the range of PS used was low including 6, 8, 10, 12cmH2O (Moga et al., 
2015; Pessoa et al., 2012; Highcock, Shneerson and Smith, 2003; Revill, Singh 
and Morgan, 2000). The majority of studies demonstrated that it was feasible for 
participants with stable COPD to exercise on NIV. Most studies reported no AEs, 
although in two studies participants desaturated and the test was stopped 
(Menadue et al., 2009; Menadue et al., 2010). Therefore it was important for the 
future study to consider when to entrain O2. Fatigue may have contributed to a 
higher drop-out rate therefore individualised exercise was considered (Dreher et 
al., 2009). 
2.11 Conclusion: Part B 
The studies in literature review B informed the planned trial in regards to study 
population, mode, PS and feasibility of undertaking the research. The doctoral 
research planned to evaluate the effects of NIV on exercise following a hospital 
admission for an acidotic acute exacerbation of COPD requiring NIV compared to 
standard care. NIV was planned to be applied over a training period to confirm if 
the benefits of NIV observed on one-off exercise tests may possibly be improved 
upon with a training of a longer duration. The exercise on NIV was planned to 
continue from hospital to home to improve retention of participants into the study. 
Randomisation was to be applied before allocation. The outcome focused on both 
economic and QOL measures. Blinding of the participants and researcher was 
not considered possible because of the lack of credible sham-NIV.   
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2.12 How did the literature reviews in part A and B combined inform 
the decisions for the planned feasibility study? 
2.12.1 Sample characteristics 
The feasibility study was to include participants with a diagnosis of severe COPD. 
The participants were planned to be recruited following an admission with an 
acute exacerbation of COPD with uncompensated type II respiratory failure 
treated with NIV. The sample was planned to include co-morbidities except those 
that prevented the patient from walking and was inclusive of elderly patients. 
Research that involved a sample of patients who had been hospitalised for 
acidotic type II respiratory failure and who had been treated with NIV meant the 
patients had experienced NIV, with high pressure, but they may not be on home 
nocturnal NIV. For the study design to be novel and more clinically transferable it 
was necessary to study patients with more severe COPD who had been 
hospitalised following an acute exacerbation. The literature review informed the 
decision to use this group because of early hospital discharge affecting 
recruitment and retention. It was considered advantageous because they may 
have been hospitalised longer, may have been a sicker group (which the 
researcher had hoped to capture) and additionally the participants would have 
used NIV as treatment for acidosis in hospital so were familiar with the equipment. 
2.12.2 Recruitment 
The sample were to be recruited from acute respiratory hospital wards.  
2.12.3 Design 
The feasibility study was planned as a randomised controlled trial. The patients 
were randomised into three groups: A group of patients who have standard care, 
a group that use NIV on exercise during the length of their inpatient stay and a 
group that continue exercising for a further three months on NIV. 
2.12.4 Outcome measure 
The 6MWT was to be used as a measure of assessment. Dyspnoea was to be 
assessed using the modified BORG score (MBORG) and an additional dyspnoea 
measure. A measure of HRQOL was to be evaluated, this included SGRQ and an 
additional measure. A method for measuring of activity assessment was 
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considered. Additionally how to capture economic benefit was considered. The 
outcome measures were planned to be evaluated at baseline, hospital discharge, 
one month, two month and three months following discharge. 
2.12.5 Exercise type, duration and intensity 
The exercise plan was to be individualised in terms of duration and intensity 
because of the varying fitness levels of the patients. The aim was to exercise for 
30min twice weekly supervised. The exercise was to consist of walking or cycling, 
weights and functional activities including sit to stands. 
2.12.6 NIV intervention 
NIV settings included IPAP and EPAP with S/T mode. The ventilator chosen 
needed to produce high inspiratory flow rates to meet the respiratory demands of 
exercise. A minimum PS of 10cmH2O was considered to offload the respiratory 
muscles. 
2.12.7 Quality and detail of reporting 
The overall quality of reporting in the studies was variable, there was a lack of 
detail surrounding recruitment. The feasibility study attempted to provide a 
detailed report of the research process from recruitment to analysis to fully inform 
other researchers and the future study. 
2.13 Overall conclusion 
The literature reviews completed and documented in this chapter have 
successfully met the aims presented in section 2.2, Aims part A and 2.7, Aims 
part B. A logical system was used to search for both the SRs on exercise on NIV 
in COPD and studies not included in the part A SRs. The methodological quality 
of the SRs and individual studies was critically evaluated methodically using a 
recognised evaluation tool. The limitations of the reviews are that they excluded 
studies not published in English. There were two reviews and five individual 
studies not published in English. This may have meant some important studies 
were missing from the review. Nevertheless two of the SR’s reviewed included 
non-English studies and there were 11/21 individual studies from countries 
where the first language is not English. Another limitation is that there may have 
been publication bias, although the researcher attempted to reduce this by 
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searching abstracts from conferences but these were well known European 
based conferences that were familiar to the researcher, other less well known 
conferences were not searched. Additionally the review of the quality of the 
literature may have been biased because there was only a single researcher so 
no comparison of the quality of results could occur. However, the search was 
undertaken in a methodical way and clearly recorded to openly present the 
researcher's critical evaluation. 
This literature review informed the research design and the intervention of the 
planned feasibility study. The following chapters focus on the study method from 
justification of the methodology (Chapter 3) to focusing on the separate 
quantitative (Chapter 4) and qualitative (Chapter 5) components. 
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Chapter 3 Methodology: Justification 
 
3.1 Introduction  
This chapter outlines the methodology and methods used for this research 
programme, justifies the choices made and examines the strengths and 
weaknesses of the approaches taken. Throughout the early phases of the 
research there have been significant changes to the design and these will be 
rationalised in this chapter. 
The following two chapters (Chapters 4 and 5) chronicle the steps taken during 
both the quantitative and qualitative methodology. These chapters also describe 
the development of the methods used at the design, data collection and analysis 
stages of the research process. 
3.2 Why mixed methods was chosen as a methodology 
In the preliminary stages of the research project the researcher had chosen just 
quantitative methods for data collection. This may have been because the 
researcher had been working within the domain of medicine and possibly reflected 
the positivist influence of RCTs traditionally being seen as the gold standard of 
medical research. In comparison qualitative methods are sometimes viewed as 
less rigorous and unfamiliar (Mays, Pope and Popay, 2005).  
However, following in-depth discussion with the PhD supervisors regarding the 
aims of the research and having gained a deeper understanding of the home 
intervention group, it was agreed that there was a need for additional qualitative 
methods to allow insight into the participants’ experience of the research.  
3.3 Strengths and weaknesses of quantitative design 
Quantitative methodology is objective and associated with a need to understand 
cause and effect. Quantitative methods have an advantage in that historically they 
are valued highly by health care professionals. This means that methods may be 
more easily disseminated and published (Pope and Mays, 1995). Quantitative 
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methods have been invaluable in contributing to the advancement of treating 
disease. The gold standard RCT means that quantitative research methods can 
be valid, reliable and repeatable (Robson, 2011). However quantitative methods 
will not capture the patient experience (Woolf, 2006), nor provide insight into how 
the treatment affects the patient’s life (Denzin and Lincoln, 2000). Quantitative 
methods are good at separating and recognising the cause and effect of 
differences observed at set moments in time, but quantitative researchers can 
only comment on the evidence observed (Borkan, 2004). However modern health 
care is now a very complex arena and quantitative research may no longer answer 
questions regarding organisation, culture and experience (Pope and Mays, 1995). 
3.4 Strengths and weaknesses of qualitative design 
Qualitative methods enable the researcher to ask the patient about their 
experience of the treatment. This may improve understanding of their emotions, 
perceptions and actions (Holloway, 2005). Qualitative skills allow insight into the 
processes building up to the witnessed differences. They add benefit because 
they can provide unforeseen understandings that had not been considered before 
(Borkan, 2004). NHS policy drivers have increased the use of qualitative research 
in health care. Traditionally medicine and health care researchers often only used 
and valued quantitative methods in their research design. The redefining of quality 
to incorporate lay perspectives (DH, 2000) means that there is a need to use good 
qualitative research to capture these views. It is important to not only understand 
if something works but also how and why it worked (Meyrick, 2006). The greater 
demand for qualitative research from the health field (Greenhalgh and Taylor, 
1997) presents a challenge as this new audience comes from a predominantly 
positivist, biomedical standpoint (Meyrick, 2006). Qualitative methodology can 
provide information that is rich, exciting and challenging. It captures the 
complexity, mess and contradiction that makes up the real world and makes 
sense of it through patterns and meanings (Braun and Clarke, 2013). 
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3.5 The merits and challenges of combining both quantitative and 
qualitative design 
The main purpose of this research was to evaluate feasibility of the research 
design and the feasibility of the intervention. Some of the main evaluations of 
feasibility include collating quantitative data regarding recruitment population 
numbers, numbers consented, randomisation process and retention of 
participants into the trial. It also includes evaluating the collation and completion 
of outcome measures (Bowen et al., 2009). Quantitative research methods are 
able to assess these aspects of feasibility. Additionally to these components of a 
feasibility trial it was considered important to evaluate whether the research 
design and intervention were acceptable to participants or not and gain 
understanding from the participants’ experience why this may or may not be. 
Therefore in October 2012 the decision was made to change the methodology to 
mixed methods. Mixed method design is when there is a significant component of 
quantitative data collection and a significant component of qualitative data 
collection in the same research programme (Robson, 2011). This involves 
combining the methods but using different research strategies. 
There are critics who suggest that quantitative and qualitative methodologies do 
not study the same things and so cannot be combined (Guba, 1981; Sale, Lohfield 
and Brazil, 2002). There are theoretical hurdles to mixing both paradigms. Some 
researchers suggest that the two research methodologies are too separate in 
underlying assumptions, world view and epistemology that they cannot combine 
(Borkan, 2004). However a pragmatic view would suggest that the methods used 
should relate to the questions, rather than seeking to be purist in terms of method 
relating to a theological position (Bryman, 2006; Robson, 2011). 
The potential disadvantages of mixed methods are that this is more time 
consuming, the researcher may not do either paradigm justice and it is 
complicated to combine the two methods (Creswell, Fetters and Ivankova, 2004). 
Another problem is that despite some researchers carrying out mixed methods 
studies they do not integrate the results well and often publish the two methods 
and results separately (Borkan, 2004). 
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Creswell and Clark (2007) focused on mixed methods as a research technique, 
which fitted in with the researcher’s aims for this study. The central premise is that 
the use of quantitative and qualitative approaches in combination provide a better 
understanding of the research problems than if either data set had been used 
alone (Creswell and Clark, 2007). 
Mixed methods research has potentially more power in answering and testing the 
research question than just one research paradigm. It gives new insights on 
complex phenomena. Mixed methods let the researcher answer questions from 
the perspectives of both numbers and personal accounts therefore adding rigour 
to the research (Borkan, 2004). 
The research programme underpinning this thesis was undertaken with 
participants with very severe COPD. The researcher felt it was important to 
understand the impact of living with COPD and how the intervention might 
influence their life, thus quantitative measures would not answer all of the 
research questions. There was a need to gain further understanding of the impact 
of living with COPD and how this research interacted with this. The choice of tool 
for the qualitative method was semi-structured interviews and the justification for 
this decision can be found in Chapter 5 (‘Qualitative Method’), section 5.2.3 
Interviews. 
The main aim of the in-depth interviews was to help contextualise the findings 
from the quantitative data, by providing insight into the lives of patients with severe 
COPD. 
3.6 How to make mixed methods work  
Mixed methods often work well when a researcher has knowledge of both. It can 
be challenging if the researcher is drawn more to one paradigm, leading to that 
paradigm being more represented (Bryman, 2006). However the supervision team 
for this research programme was made up of practitioners with experience in 
quantitative and qualitative research, thus providing clear input from both areas 
of research. The researcher had limited experience of either paradigm. Although 
her undergraduate dissertation was in qualitative methods most of her career had 
focused on reading and reviewing quantitative data. However mixed methods 
167 
 
must be more than simply collating the quantitative and qualitative data. The 
results and finding must be combined at some point during the research process 
(Creswell, Fetters and Ivankova, 2004). The researcher focused on 5 standards 
designed by Creswell, Fetters and Ivankova (2004) for designing and evaluating 
mixed methods studies. 
3.6.1 Rationale for mixing the methods 
The aim of this research study was feasibility therefore it was important to 
understand if the research had the potential to work but also why it might work 
and whether it was acceptable to patients.  
3.6.2 Types of methods 
The methods used were quantitative clinical measures and qualitative semi-
structured interviews. These are discussed further (at length) in Chapter 5 and 
Chapter 6. 
3.6.3 Priority given to qualitative or quantitative research 
Often qualitative data is carried out as an exploratory research method prior to the 
initial quantitative research (Wilde et al., 1994; Eastbrooks, Field and Morse, 
1994).  The qualitative method in this study was used at the end of the intervention 
period. Whilst the initial phase was quantitative and there were more quantitative 
clinical outcomes evaluated, the research method for the qualitative component 
was time consuming and the findings from the qualitative research were deep and 
complex. The use of qualitative methods to complement the quantitative data is a 
common model for a mixed-method approach (Creswell, 2002), therefore whilst 
initially on the surface it may seem that priority was given to the quantitative 
methods, the researcher saw them both as having important but different values. 
It was equally important to understand if exercise on NIV might lead to clinical 
improvements and also if the intervention was acceptable to patients. Thus 
numbers can not be directly compared to the voice of the participants. Both are 
powerful in different ways, and to different audiences. 
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3.6.4 Implementation sequence 
The quantitative data were initiated first but the personal reflective accounts 
collated by the researcher, which are an important component of reflexivity and 
qualitative methods began at the start of the study. Then followed the qualitative 
methods. However, the qualitative analysis began before the quantitative 
analysis. The details of the method of analysis can be found in Chapter 5 and 
Chapter 6. 
3.6.5 Phase of study in which integration occurred 
After completion of the data collection in May 2014 the researcher secured six 
weeks of funding explained in Chapter 4 (‘Quantitative methods’), section 4.7 
Funding, enabled detailed analysis and integration of the two research paradigms. 
An explicit account of how the quantitative and qualitative data were collated will 
be explained within each method section separately to allow for a clear and 
coherent account that can be easily reproduced. However special importance will 
be given to ensuring that both quantitative and qualitative data are discussed 
together and related to each other where appropriate (Bryman, 2006). 
3.7 Justification of change of primary outcome to feasibility 
Another major change to the research project was to the primary outcome. 
Originally the primary outcome was to be economic evaluation. However on 
reflection the treatment in the study was complex and the researcher had many 
questions relating to the feasibility of the study and these should be reflected in 
the primary outcomes. The Medical Research Council (MRC) guidelines for 
developing and evaluating complex interventions (2008, pp. 6) defines complex 
interventions as  
“… interventions with several interacting components” 
This study was a complex intervention because it assessed two treatments in 
tandem, both ‘exercise’ and ‘non-invasive ventilation’, and is further complicated 
by using these interventions in both the acute and community environment. 
The guidance suggests that due to the complexity of the intervention enough time 
should be allocated to testing the feasibility and piloting of the intervention to 
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ensure that the intervention works as intended (MRC, 2008). Figure 3.1 
summarises the MRC’s guidance on the process for developing and evaluating 
the complex intervention. 
 
Figure 3.1 MRC Process for developing and evaluating complex interventions. Key 
elements of the development and evaluation process 
(Adapted from MRC, Developing and evaluating complex interventions: new guidance, 2008, p.9) 
The NIV device was already CE marked and not contraindicated for use when 
exercising. Therefore the study was not testing the actual feasibility of the 
equipment. 
It was a debatable issue for the researcher as to whether or not the study was 
classified as a pilot or a feasibility. Often previous studies have used the two terms 
interchangeably (Arrain et al., 2010). A pilot study is a complete version of the full 
study run on a smaller level to see if the parts of the research all work together 
(http://www.netscc.ac.uk/glossary/), however a feasibility study can be a complete 
model of a full study or it can be used to assess individual parts for example, 
adequacy of methods, assess participant recruitment strategies, identify potential 
retention problems, evaluate the protocol for realistic implementation, determine 
study resources and assess the preliminary evidence and its justification for a 
larger-scale study (Cope, 2015). Disadvantages of feasibility studies are that they 
may not be large enough to calculate sample size or response rates (van 
Teijlingen and Hundley, 2002). Another problem is that some peer reviewed 
journals could consider a feasibility study not worthy of being published (Cope, 
2015), however the MRC (2008) suggested that it is essential to publish feasibility 
studies to inform other researchers and clinicians. 
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The change to a feasibility study was a challenging one as the researcher wanted 
to meet the needs of the sponsor company but also to fulfil the PhD requirements. 
However after considerable thought and follow up discussion with the supervision 
team in April 2013 the decision was made to make the primary objective feasibility. 
The secondary outcomes would still look to evaluate possible trends for changes 
in clinical outcome measures. The researchers aimed to publish the feasibility trial 
which should still meet the requirements from the sponsor, detailed in Chapter 4 
Quantitative methods, section 4.3. 
There was also a challenge in evaluating feasibility. There is limited published 
literature on standards to guide the design and evaluation of feasibility studies 
(Bowen et al., 2009). This study was in patients with a severe chronic disease 
who were near end of life and suffered frequent exacerbations and hospital 
admissions (BTS and Primary Care Respiratory Society-UK (PCRS-UK), 2011). 
It was important to investigate whether this research was acceptable to patients 
and whether recruitment was feasible. Hagen et al. (2011) reported a shortage of 
quality, powered clinical studies in palliative care. They reported that feasibility 
studies should be trialled and published to assess if the research is capable of 
being done.  
Bowen et al. (2009) suggested that a design of a feasibility study should relate to 
three key questions: 
1) Can it work?  
2) Does it work? 
3) Will it work? 
Feeley et al. (2009) suggested that feasibility related to the ease of execution - 
how the research is planned, undertaken and completed. However, acceptability 
was described as how favourable the research is from the perspectives of the 
recipients, healthcare professionals and providers (Feeley et al., 2009). Therefore 
the descriptive analysis of the project sought to address both feasibility and 
acceptability. 
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3.8 Explanation of pragmatism: To be able to use the intervention 
in clinical practice 
The researcher worked in a pressurised NHS environment, and patients were 
complex, often elderly and with multiple co-morbidities. The researcher did not 
work in a controlled laboratory with patients who only had one pathology. The 
MRC (2008) reported that a purpose of assessing feasibility of a complex 
intervention should be to evaluate whether the intervention works in every day 
practice. Often RCTs were so focused on eliminating bias that the inclusion 
criteria were so exclusive that they no longer mimicked patients in clinical practice 
(Zwarenstein et al., 2008). A pragmatic approach aspired to increase applicability 
of the trials results to usual care settings (Lee et al., 2001; Zarin, Young and West, 
2005).  
This way of thinking complemented the researcher’s background as a 
physiotherapist. The researcher had a desire to be able to be evidence based but 
realistically put findings into clinical practice. The researcher was keen for this 
research to be something other clinicians may be able to take into clinical practice, 
not just something laboratory-based that did not mimic NHS conditions or include 
participants that due to exclusions you would rarely have seen in clinical practice. 
Nor did the researcher want the research to be about solely producing a theory 
about a patient experience. Therefore the method needed to be pragmatic, real 
world research, using a mixed methods approach. 
3.9 Conclusion 
This chapter has justified the use of mixed methods research to allow for both 
clinical assessment of feasibility and allow a deeper understanding of the patient 
experience. The change of aim of the study to feasibility has been justified. The 
chapter also discussed the importance to the researcher that this was a pragmatic 
study that could be useful to clinicians in the real world. The following chapters 
(Chapter 4 and Chapter 5) will detail the quantitative and qualitative methods used 
to underpin the mixed method design. 
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Chapter 4 Quantitative Methods 
4.1 Introduction 
The literature review in Chapter 2 demonstrated that there was a clear need for a 
feasibility study investigating whether it was possible to use NIV during exercise 
on patients with severe COPD using high PS. This chapter outlines the 
quantitative methods used to answer this research question. 
4.2 Type of study 
A RCT using a mixed methods approach was chosen as the research method to 
assess the aim of feasibility. The reasoning behind this decision and justification 
for it can be found in Chapter 3, section 3.7. It was a pragmatic clinical study which 
randomised patients into three different limbs: 
Limb One: Standard Care: Exercise and additional O2 (if O2 saturation (SpO2) < 
90% or the patient required long term O2 therapy (LTOT) or AOT) for the duration 
of the hospital admission. This was based on the PR guidelines (BTS, 2014) and 
previous studies which had used AOT when the particpants SpO2 levels were < 
90% (Dyer et al., 2012; Emtner et al., 2003; Wadell et al., 2001; Garrrod, Paul and 
Wedzicha, 2000; Rooyackers et al., 1997). The research was carried out prior to 
the publication of the home O2 guidelines including advice regarding prescription 
of AOT (BTS, 2015). 
Limb Two: Exercise on NIV in hospital: Exercise on NIV and additional O2 (if 
SpO2 < 90% or the patient required LTOT or ambulatory O2) for the duration of 
the hospital admission. The reasoning for this second limb was that this currently 
matched what the researcher had been doing clinically within the critical care 
environment prior to the study. Clinically the researcher had seen patients 
respond well to getting out of bed on a ventilator, particularly in the early stages 
of recovery. Thus the researcher wanted to see if adding ventilation to 
rehabilitation in this group in the short term, acute hospital phase, changed 
outcome. 
Limb Three: Exercise on NIV in hospital and home: As per limb two but 
patients would continue exercising on NIV supervised at home twice weekly for 
an additional three months following their discharge. The reasoning for this 
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research limb was that this would mirror an effective PR duration which is known 
to have long term health benefits in COPD (Lacasse et al., 2002). 
The pathway for the study is shown in Figure 4.1. 
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Figure 4.1 Schematic of the research process 
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4.3 Commercial Funding  
The researcher worked in a busy NHS department, therefore there were limited 
funding opportunities to be able to carry out the research. Consequently the 
researcher sought out a commercial company who sells respiratory ventilators, 
Philips-Respironics. She pitched the research proposal and protocol to them in a 
bid for the use of equipment and funding of research time. This involved preparing 
the proposal, preliminary interviews with key research personnel followed by an 
international telephone conference question and answer session with company 
representatives and engineers. The bid was successful and funding was secured 
for 18 months of part time (0.5 full-time equivalent) research time and use of their 
equipment.  
The researcher was aware of the potential negative connotations of undertaking 
commercially funded research; however without this funding the research would 
not have been able to take place. To reduce the potential bias that the commercial 
sponsor might have had on the publishing of the results, the researcher was 
thorough to ensure that she owned the rights to the data. Therefore intellectual 
property contracts were negotiated between University of the West of England 
(UWE), University Hospitals Bristol NHS Foundation Trust (UHBristol) and the 
researcher, however there was an expectation from the company that the study 
would be published and all equipment used that was sourced and manufactured 
by Philips-Respironics would be recognised. This is discussed further in section 
4.6.  
4.4 Ethical Approval 
The Central Bristol Regional NHS Ethics Committee (REC) reviewed the research 
and the committee gave a favourable ethical opinion following some clarification 
regarding the variation in care provided to patients in each limb of the study. 
Official ethical approval was received on 24/9/2012 (Appendix 2a).  A favourable 
ethical opinion was also obtained from the Faculty of Health and Life Sciences 
Ethics Sub-Committee at the University of the West of England, Bristol (UWE) on 
30/10/2012 (Appendix 2c).  
An amendment was submitted on 18/3/2013 to The Central Bristol Regional NHS 
Ethics Committee and Health and Social Care Ethics Sub-Committee at the 
176 
 
University of the West of England, Bristol (UWE) requesting inclusion of the 
qualitative method of semi-structured interviews, and it was subsequently 
approved (Appendix 2b). The reasoning behind this decision was explained in 
Chapter 3 (Justification of the methodology), section 3.5.  
4.5 Ethical considerations 
All patients were given a comprehensive information sheet (Appendix 3) and 
approached in advance when considered to be medically stable by the researcher 
to allow adequate time for the patient to consider the study and ask questions. 
The patients who decided not to participate in the study still received standard 
care. Informed consent was received from all of the patients participating in the 
study (Appendix 4). 
The researcher’s main ethical concern was that the group receiving standard care 
and hospital NIV only would not be referred to PR until the end of the 3 months 
following discharge. The hospital and home NIV on exercise group would be 
receiving supervised rehabilitation for the 3 months post discharge. However it is 
known from previous research that approximately 33% of patients offered PR 
decline and a further 33% fail to complete due to sickness, reduced motivation or 
logistical problems (BTS and PCRS-UK, 2011). Thus the researcher reasoned 
that many of these patients with severe disease, would not have been able to 
access or attend PR. Therefore the risk of this group not receiving PR was 
accepted. The ethics committee agreed with the researcher on this matter. 
Following discussion with PR providers the researcher decided to refer all 
participants at the point of discharge so that they could begin PR immediately on 
ending the trial, thus minimising any possible negative effects from having to wait 
longer for PR. 
4.6. Research and Innovation (R & I) 
There was a two month delay in receiving UHBristol R & I Department approval 
due to resolving an issue of Intellectual Property between the NHS Trust and 
UWE. This was eventually resolved with the exchange of contracts and approval 
granted on 24/1/2013 (Appendix 5). IP was an essential component of the contract 
between the researcher, UHBristol, UWE and Philips-Respironics. This 
established that the researcher owned the data and would be able to publish even 
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if the research produced negative data. It also established Philips-Respironics as 
the Sponsor of the study (Appendix 6). 
4.7 NHS Funding 
The Philips-Respironics funding only supported 18 months of research time for 
0.5 full time equivalent therefore additional funding was sourced to provide back-
fill into the researcher’s clinical post to release the researcher to be able to analyse 
the research data. A National Health Service (NHS) Clinical Academic Training 
Programme Internship was applied for and awarded in March 2014. This was an 
award of £10,000 to be spent supporting an application for higher level study as 
described in the accompanying document. This money can be used to support 
release from clinical practice if required. This allowed for 7 weeks of full time back-
fill to allow for data analysis.  
4.8 Choosing the ventilator 
Before the research protocol was finalised the ventilator and settings were 
decided upon. It was important to use a ventilator that was familiar to the 
researcher, currently licenced and used within the clinical setting but also one that 
would be able to provide the inspiratory flow rates needed to support the 
participants increased breathing effort, both increased RR and increased depth of 
breathing (VT). It would also need to be portable with a battery. Therefore the NIV 
CE marked device used in the exercise on NIV in hospital group and the exercise 
on NIV in hospital and home group was the Trilogy 100 (Philips-Respironics). This 
was a domiciliary device currently used by UHB for overnight treatment; however, 
it was not contra-indicated for use during exercise (Figure 4.2). 
 
Figure 4.2 The Trilogy 100 (Philips-Respironics) 
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The benefits of the Trilogy 100 were that it was able to record the date and time 
of use, breathing frequency and predicted VT and pressure settings. This was 
recorded on an integral SD card and was subsequently downloaded using 
software, Direct View (Philips-Respironics) and reports were generated, to assist 
with analysis. The specifications of the ventilator can be found in Appendix 7. 
4.9 Preliminary Equipment Test 
One of the concerns that the engineers from the commercial company raised 
during a telephone consultation was whether the Trilogy 100 would provide a high 
enough inspiratory flow rate to allow a participant to exercise. This question was 
really asking whether or not the ventilator would meet the increased demands of 
respiration as a response to exercise.  
Therefore a cardiopulmonary exercise test on a treadmill was organised on a 
‘normal’ male, over 50 years with no history of lung disease. The Trilogy ventilator 
and equipment was in situ, and average pressures of an inspiratory positive 
airway pressure (IPAP) of 20cmH2O and an expiratory positive airway pressure 
(EPAP) of 6cmH2O, (thus a pressure support (PS) of 14cmH2O (PS = IPAP - 
EPAP)) were generated. The test was successfully undertaken with no problems 
in flow rate occurring. Therefore if the test was achieved in a normal person whilst 
using the Trilogy 100 then it would very likely meet the demands of the patients in 
the trial who had severely compromised lungs and would not reach the same 
exercise levels (Appendix 8). This is called VL and was previously discussed in 
Chapter 1 Introduction, section 1.16 the pathophysiology of COPD and exercise. 
4.10 Ventilator Settings 
During the actual study the settings were individualised for each patient, with the 
aim of providing a minimum PS of 10cmH2O, titrating this to reach a maximum 
pressure support of 20cmH2O during exercise. The mode used was spontaneous 
to allow for the patient to trigger all the breaths. If the patient did not breathe, no 
air or pressure were provided. If the ventilator detected a small inspiratory flow 
(flow trigger), this then activated the inspiratory pressure initiation (Kinnear, 2008).  
EPAP was used to allow the patient to overcome the resistance of the mask and 
hose. This would also help overcome intrinsic positive end expiratory pressure 
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PEEPi, often experienced in patients with severe COPD. This is further explained 
in Chapter 1 Introduction, section 1.18 Non-invasive ventilation (NIV).  
PS is the pressure achieved when EPAP is subtracted from the IPAP. The 
inspiratory time used was also individualised as this needed to be fast enough to 
meet the demands of an increased breathing frequency but not so fast that there 
was not adequate time to reach the desired PS. Clinical observations including 
RR, SpO2, HR and the MBORG scale sheet at two minute intervals was used to 
assess whether the participant work of breathing was offloaded by the ventilator 
and whether the pressure needed to be increased. Additionally the participants 
were asked if the pressure was enough or too strong at two minute intervals. If 
the settings needed to be increased this was carried out in 2cmH2O increments 
based on the findings in literature review B, section 2.9.4. 
The mask used on the patient was individualised but the comfort gel full face mask 
was trialled in the first instance. This was a commonly used mask in the clinical 
setting and familiar to the researcher. Most people mouth breathe on exercise, 
therefore the full face mask was the primary choice (Figure 4.3A). A nasal mask 
was used in the patients unable to tolerate a full face mask (Figure 4.3B) 
 
Figure 4.3 A) The Comfort Gel full face mask (Philips-Respironics) and B) Swift Fx 
nasal pillows (ResMed) 
Further decision-making criteria behind the type of ventilator and settings are 
discussed within Chapter 2 (‘literature review’), section 2.10.2 How did the 
individual studies inform the current study. 
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4.11 Choosing the type of exercise 
As discussed in Chapter 2 the patients selected for the study had severe lung 
disease. They were likely to be physically de-conditioned with very limited 
mobility. They may also have been afraid of exercising due to fearing the 
sensation of breathlessness. This causes further muscle wasting by the 
problematic cycle of inactivity. Therefore the exercise needed to be individualised. 
The BTS PR guidelines (2013) formed the basis for deciding on the content of the 
exercise plan. However, the exercise needed to be easily reproduced both within 
a busy hospital environment and small private accommodation in the community. 
The main focus of the exercise was on aerobic training through walking and 
cycling. However additional resistance exercises were included as they can lead 
to greater improvement in peripheral muscle strength than aerobic training in 
isolation (BTS, 2013). The exercise was made up of muscle strengthening 
exercises, with particular focus on the lower limbs, and also included walking 
and/or cycling, see Appendix 12. Portable leg weights, arm weights and cycling 
pedals were sourced to enable exercise within a confined space.  
The frequency was decided as three exercise sessions per week with two of the 
three sessions supervised by the researcher. The duration of the session was built 
up to last for 30 minutes, however some of the patients were not able to achieve 
this. The exercise progression was modified according to MBORG score, patient 
verbal feedback and observation by the clinician of RR, HR, SpO2 and overall 
work of breathing. When patients are exercising clinically on the wards and in PR 
a MBORG score of four to five is aimed for (somewhat severe to severe 
breathlessness) (European Lung Foundation and European Respiratory Society, 
2000; Egan et al., 2012). The patients in this study were likely to have a resting 
MBORG score higher than this due to the severity of their lung disease. Therefore 
an individualised approach was taken and if MBORG score was greater than five 
at rest then exercise was completed at one unit higher than their resting score, if 
any greater the exercise intensity was reduced. If SpO2 was < 85% exercise 
intensity was reduced based on safety instructions used during exercise testing 
(Zebathos and Weisman, 2002). The targeted intensity of the walking/cycling was 
at a minimum of 60% peak work rate as recommended by the BTS PR guidelines 
(2013), discussed in Chapter 1 (‘Background’), section 1.15.6 Training intensity, 
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also see Appendix 12. The study duration on discharge, for the patients exercising 
at home on NIV, was decided at three months. This is again based on PR 
guidelines and PR quality standards (BTS, 2013; BTS, 2014). RR was monitored, 
it is expected that RR can reach 50 breaths/minute during exercise in healthy 
individuals (Mcardle, Katch, and Katch, 2006). In combination with the other 
observations and participant feedback a RR of 40 was used by the clinician to 
determine if exercise intensity needed decreasing. If a participant suffered an 
exacerbation of COPD then the participant was reassessed and the intervention 
would be modified accordingly. The participant may have needed a higher PS or 
a lower exercise intensity, repetitions or duration of exercise. If a participant 
suffered an exacerbation requiring hospitalisation this was formally recorded as a 
SAE, SAEs are explained further in section 4.23.2. If a participant was admitted 
to hospital the intervention continued as planned but on the ward rather than at 
home. If a patient was unstable, for example acidotic or cardiovascularly unstable 
then the exercise would begin only when the patient was clinically stable, for 
example not acidotic and with stable cardiovascular measures. The participant did 
not get any extra time in the study and still completed the trial three months 
following the initial hospital discharge. 
4.12 Researcher consideration to reduce bias 
The researcher was a highly specialist respiratory physiotherapist with over 10 
years of experience in both acute NIV and home NIV. Therefore the researcher 
was in a good position to be able to undertake this research. However, there were 
possible difficulties from the clinician being the only researcher conducting the 
study. From the initial design phase to the end analysis the researcher was aware 
of potential bias. Strategies were taken to reduce bias through the design of a 
RCT, the use of validated questionnaires and measures, the use of Standard 
Operating Procedures (SOPs) for objective measures and treatment, the use of a 
blinded additional coder for interviews and a blinded analyser of the quantitative 
data. Care was taken to give all three groups an equal amount of encouragement, 
for example during the 6MWT, to avoid bias during data collection. No quantitative 
data were analysed until the end of the research time period. 
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4.13 Recruitment preliminary data collection 
Prior to designing the protocol an audit had been undertaken at UHBristol on one 
main respiratory ward. This collated data on the number of admissions requiring 
treatment with NIV. It identified 50 patients who had been treated with NIV over a 
6 month period from October 2009 to March 2010 (this did not include other 
clinical speciality areas). It revealed that 33/50 patients who required NIV had a 
primary diagnosis of COPD. This information helped to determine the size of the 
potential recruitment pool. 
4.14 Stakeholder involvement and preparation 
The researcher met with the Bristol Breathe Easy group, a support group for 
patients with COPD, prior to and throughout the project time period. The 
researcher piloted equipment and questionnaires prior to the research project 
beginning to ensure acceptability to this patient group which included COPD 
patients and home ventilation users. 
The researcher created a presentation detailing the specifics of the research and 
presented this to hospital consultants, nursing staff, physiotherapy teams, 
discharge teams and community teams to assist with recruitment and support for 
the study. Posters were put up in key clinical areas reminding staff of the study 
and reminder emails to key clinical staff were sent out prior to recruitment 
initiation. 
4.15 Randomisation 
Prior to any recruitment for the research the randomisation process was carried 
out. The study was randomised prior to recruitment. 30 participants was chosen 
as this was similar in size to other studies involving exercise on NIV, (this is 
detailed in chapter 2 literature review) and this seemed a realistic number to 
attempt to recruit based on the preliminary data, see section 4.13, and would be 
adequate to evaluate feasibility.  
Randomisation software http://www.randomization.com, was used by a 
supervisor to generate the allocation of groups. Following feedback from 
examiners as part of the researcher’s PhD progression viva (which took place on 
23rd October 2013), the randomisation process was adapted. The process was 
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changed to a blinded process using sealed envelopes to ensure that the 
researcher did not know which group the next participant would be randomised 
to. The exact process for this was one of the supervisors carried out the 
randomisation procedure and placed the allocated group into number ordered, 
sealed envelopes and stored securely. The researcher was not involved in that 
process and did not see or have access to the envelope until after a participant 
had been recruited into the trial. The supervisor would release each individual 
order numbered envelope after each successful participant recruitment. 
4.16 Study Location 
The study was carried out within the city of Bristol. The population of Bristol is 
428,100 (Census Office for National Statistics, 2011), the largest city in the South 
West of England. The prevalence of COPD is 1.6%, similar to the national average 
of 1.5% (DH, 2010d). COPD is the second most common reason for a hospital 
admission via A&E at UHBristol, after chest and abdominal pain (NHS England, 
2014) 
The study was carried out at a single research centre, The Bristol Royal Infirmary, 
UHBristol. This was a 500 bedded acute teaching hospital with 10 medical wards. 
A sleep unit supplied home NIV to a caseload of 550 patients, of which 70 needed 
on-going follow up at home and 80 had a diagnosis of COPD. Respiratory patients 
were admitted via A&E, GP assessment unit or directly from respiratory 
consultants through a respiratory assessment clinic. They then transitioned 
through the hospital via the Medical Assessment Unit (MAU) to be treated on two 
respiratory wards. Recruitment was planned to include A&E, MAU, respiratory 
wards and acute medical wards. There were two high care beds in A&E that could 
provide NIV. There were two high care beds on MAU and nine high care beds on 
one respiratory ward (n = 13 total high care beds). There were 38 other respiratory 
beds, however during busy admission periods patients requiring NIV were 
managed on the main ward. The nursing to patient ratio for high care was one 
nurse to three high care patients. The other ward patients were managed by one 
nurse to eight patients. Physiotherapy to cover A&E, MAU, two respiratory wards 
and two general medical wards (52 beds) was provided by one 1.0 full-time 
equivalent (FTE) Band 7 (Senior) physiotherapist, two x 1.0 FTE Band 6 (Senior) 
physiotherapists, two x 1.0 FTE Band 5 (Junior) physiotherapists and two x 1.0 
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FTE Band 3 physiotherapy assistants. The home ventilation service (550 patients) 
was provided by one x 1.0 FTE Band 7 physiotherapist and one x 1.0 FTE clinical 
physiologist. 
4.17 Recruitment screening 
All patients admitted with an acute exacerbation of their COPD causing respiratory 
acidosis and type II respiratory failure treated with NIV in hospital were identified 
by the researcher. The researcher reviewed e-handover records from MAU and 
the two respiratory wards, attended medical rounds Monday to Friday and took 
referrals from nursing staff, physiotherapy staff and medical staff in person, by 
bleep, email or telephone. Weekend physiotherapy staff informed the researcher 
by telephone of any weekend admissions. 
All of these patients were screened for the following inclusion and exclusion 
criteria prior to being approached to consider participating in the study (see 
Appendix 10 for the inclusion and exclusion form). 
4.17.1 Inclusion criterion: 
1. A diagnosis of a COPD exacerbation resulting in a hospital admission for 
respiratory acidosis and type II respiratory failure, requiring treatment with 
NIV during this hospital admission, for any length of time 
4.17.2 Exclusion criteria: 
1. Primary diagnosis not COPD 
2. Not had a respiratory acidosis diagnosed through ABG analysis 
3. Not had NIV treatment 
4. Under 25 years of age 
5. Unable to follow commands or unable to consent  
6. Known contraindication to NIV (Royal College of Physicians, 2008) 
7. Unable to tolerate acute hospital NIV 
8. Unable to or refused to comply with physiotherapy  
9. Had an additional pathology that limited ability to mobilise 
10. Dying/receiving end of life care and not expected to survive hospital 
admission 
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The reasoning behind exclusion criteria one, two and three was to ensure that the 
correct patients were selected for recruitment. There are many reasons a patient 
can receive NIV, for example heart failure, and the researcher wanted to be clear 
that only COPD patients were to participate in the planned research.  
Often patients with severe COPD can present to hospital with an ABG 
demonstrating chronic type II respiratory failure. This means that over time the 
body has compensated for a high CO2 so that their cell pH has normalised. These 
patients do not have a respiratory acidosis on their ABG and do not meet the 
criteria for treatment with acute hospital NIV (BTS, 2002). Thus they were 
excluded from the study. It was important that the patient had been treated with 
NIV in hospital because this demonstrated the severity of their disease and also 
the researcher considered that this group of patients may be more concordant 
with the ventilator equipment because they had just been treated with a similar 
device. 
Patients were screened for age because COPD is predominantly diagnosed in 
those over 35 years of age (NICE, 2015), however within Bristol some of the 
known COPD patients are younger because of increased cigarette smoking, 
known genetic disorders (for example alpha-1-antitripsin disorder), or inhalation 
of narcotics causing earlier non-reversible airway damage and a diagnosis of 
COPD. 
Exclusion five was created because the researcher considered the intervention to 
be complex and a participant must be able to follow commands and understand 
potential side-effects of the equipment. Therefore those patients without mental 
capacity or an ability to follow commands were excluded from the study.  
Exclusion six to nine were created to ensure all aspects of the intervention could 
be safely and consensually applied with a potential participant.  
The final exclusion criterion aimed to preserve a patient’s dignity and not cause 
any additional distress to a patient or relatives. 
The sample size was initially planned to be 30 participants. Therefore 10 
participants would be allocated to each study limb. The full details of the recruited 
sample size and consort diagram are presented within Chapter 5 (‘Quantitative 
186 
 
Results’), figure 7.1. The complexity of the recruitment will be discussed within 
Chapter 9 (‘Discussion’), section 9.2.1 Recruitment sample. 
4.18 Recruitment 
The recruitment period was from the end of January 2013 until the beginning of 
January 2014, over an eleven month period. Recruitment had been planned to 
begin in November 2012, but was delayed due to IP negotiations, discussed 
previously in section 4.6 R & I. The participant recruitment process was that each 
potential participant was issued with an initial verbal invitation by the researcher 
and if interested followed up by issuing a participant information sheet. The 
participant information sheet clearly described the equipment used, potential side 
effects and why participants were being invited to take part (Appendix 3). Potential 
participants were only approached when they were medically stable, and no 
longer had a respiratory acidosis detected by their ABG results. This was because 
the potential participant had to be alert and coherent enough to understand the 
information being offered. The potential participant was given time to think about 
their decision to participate and to discuss it further with friends, family or nursing 
staff. If a person decided to participate in the study they were reminded that they 
would be randomly allocated to one of three groups and that they would not be 
able to choose which group they were allocated to. All participants signed the 
consent form (Appendix 4), this was countersigned by the researcher and three 
copies of the form were taken, one for the medical notes, one for the research site 
folder and one for the participant to keep. A sticker detailing the NHS Trust 
Research & Innovation (R & I) Department number, REC number and key 
research information was put into the participant’s medical notes. The participant 
was issued with a participant identification (ID) number and the randomisation 
envelopes were accessed to reveal the participant group allocation. The 
participant was then informed of the allocation. The participant was allocated a 
case record file (CRF) labelled with their research ID. This was stored on a double 
encrypted Microsoft access file on a NHS Trust computer hard drive. The 
participant’s details were kept in a separate paper file alongside their research ID 
number, locked in a separate filing cabinet. The participant’s recruitment details 
were then entered onto the R & I secure database of research information called 
“The Edge system”. A letter was sent to the participant’s GP informing them of 
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their registered patient’s inclusion into the study and revealing their group 
allocation (Appendix 9). 
4.19 Baseline assessment 
The baseline participant information was collated by the researcher immediately 
following consent. This assessment took place on the hospital ward. This was 
obtained from the participant directly and from their medical notes. This included 
basic information including age, ethnicity, address and contact details. It also 
included direct information regarding their medical history including those related 
to this hospital admission, BMI, smoking and alcohol consumption status, home 
environment and walking tolerance.  
4.19.1 Outcome measures 
The outcome measures were also recorded at baseline. They were as follows: 
6MWT, SGRQ, LCADL, modified Medical Research Council (MMRC) dyspnoea 
score, MBORG and EQ-5D-5L. Further details of these measures are discussed 
and justified later in section 4.22 
4.19.2 Self-reported symptom diaries 
The participants were also issued with symptom diaries (Appendix 11). These 
were to be supplied on discharge for the patients to record their daily symptoms, 
medication use and access to health care services during the study. 
4.20 Allocated treatment  
Following consent the randomly allocated treatment was revealed to the 
participant. The justification for the three limbs was documented in section 4.2 
Type of study. 
4.20.1 Standard care 
If the participant was allocated to standard care, this consisted of standard 
treatment according to the COPD Guidelines (NICE, 2015), tailored to the patient, 
on the basis of medical status and symptoms. From a physiotherapy perspective 
it consisted of a supervised exercise programme at least twice a week. This 
included walking or pedal cycling or lower limb and upper limb weights all on either 
air or O2 if the patient was on LTOT or O2 levels were less than 90% SpO2 at rest. 
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This was based on the ventilator SOP (Appendix 13). In addition any other routine 
physiotherapy was carried out e.g. chest clearance or stairs assessment by the 
ward physiotherapy team. At the point of discharge the patient was given a 
standard hospital discharge home exercise plan including basic chair exercises 
for lower limbs and upper limbs, sit to stand and marching on the spot. They were 
then followed up for outcome measure assessment and referred to PR to start at 
the end of the three month period following discharge. 
4.20.2 Exercise on NIV in hospital 
If the patient was allocated to exercise on NIV in hospital, they were set up on a 
Trilogy 100 ventilator as planned in the ventilator SOP (Appendix 13). They were 
seen twice weekly by the researcher for an individualised exercise programme on 
the ventilator based on the exercise SOP (Appendix 12). At the point of discharge 
the patient was given a home exercise plan (see section 4.20.1), followed up for 
outcome measures and referred to PR to start at the end of the three month period 
following discharge.  
4.20.3 Exercise on NIV in hospital and home 
If the patient was allocated to exercise on NIV in hospital and home, they were 
set up on a Trilogy 100 ventilator as in the SOP (Appendix 13). They were seen 
twice weekly by the researcher for an individualised exercise programme on the 
ventilator based on the exercise SOP (Appendix 12). However at the point of 
discharge they were also seen at home twice weekly by the researcher and 
continued with the supervised exercise programme on the ventilator. The exercise 
plan was individualised and progressed as able. If there were any hospital 
admissions required during the trial then the treatment continued within the 
hospital environment when the patient was medically stable and then continued 
at home on discharge. In such circumstances study participation was not 
extended beyond the original three months. They were also referred to PR to 
begin after the three month trial.  
4.21 Follow up 
All of the patients were followed up for three months following hospital discharge 
from hospital. At the point of hospital discharge outcome measures were 
reassessed. The time between baseline assessment and hospital discharge 
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assessment was different in each participant because of the varying severity of 
acute illness and length of hospital stay. 
4.21.1 The BODE Index score 
The BODE Index score was calculated at discharge for each of the participants. 
This scoring system is a prediction of all-cause mortality and respiratory-related 
mortality. The calculation is based on the Forced Expiratory volume in one second 
(FEV1), Body Mass Index (BMI), 6MWT and MMRC dyspnoea score. The 
calculation for this was sourced from the work of Celli et al (2004). This was 
recorded because it was useful in assessing the severity of the participants’ health 
conditions in the study. 
Additionally participants in all three groups had their lung function recorded in line 
with standard hospital care for this group. This assisted with determining the 
severity of participants’ COPD within the groups. All of the patients in the standard 
care group and exercise on NIV in hospital group were contacted weekly by phone 
to ensure symptom diaries were being completed. At the end of every month, for 
three months, a time and place convenient to the participants was organised and 
the researcher would visit. In cases where a patient could not be reached by 
telephone the patient was sent a letter confirming that the researcher would be 
visiting them at home at a chosen time or date unless otherwise indicated by the 
participant. The researcher collected diaries, checked the ActiCal activity monitors 
(discussed in detail in section 4.22.9 ActiCal Data) were being worn, measured 
6MWT and collated the questionnaires. All the outcome measure data were 
placed within the participant’s CRF and locked away as per research governance 
requirement. No information was analysed until the end of the trial. 
4.22 Outcome measures 
This section outlines the different outcome measures that were used to assess 
the feasibility of the trial and the feasibility of the intervention. They were assessed 
at five time points (baseline: in hospital on the day of enrolment into the trial, 
discharge: in hospital on the day of hospital discharge, month one: one month 
following the hospital discharge date, month two: two months following the 
hospital discharge date and month three: three months following the hospital 
discharge date) within a busy acute hospital environment and within the home 
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environment over a considerable length of time. The time of baseline to discharge 
were individualised for each of the participants because severity of illness and 
length of hospital stay varied for each participant. However the month one, two 
and three measures were all taken after the same amount of time.   
The justification for the timing of the outcome measures was that baseline 
assessment was required as an individual participant starting point following 
stabilisation in hospital (CVS stable, not acidotic and medical team in agreement), 
against which the potential benefit of the intervention could be assessed. This was 
because it would be difficult to predict hospital admission in a given sample and 
assess baseline pre-admission. It was also important to wait until the patient was 
medically stable to ensure that the participant was safe to exercise. The discharge 
time point was chosen to identify if participants would get any benefit from using 
NIV to exercise in hospital. The time points after one month, after two months and 
after three months post-discharge were chosen because of the participants’ levels 
of disease severity. The researcher was unsure of their potential morbidity and 
mortality. Participants may die after the first or second month and potential 
outcome measure data would be lost. There is a 10% mortality risk for patients 
admitted with an acute exacerbation of COPD and a 40% risk of mortality in the 
year following discharge (Groenewegen et al., 2003; Connors et al., 1996; Seneff 
et al., 1995).  As part of the analysis of feasibility of the trial identifying when to 
assess the outcome measures was an important finding for a future trial.  
The primary outcome was feasibility evidenced by recruitment and retention 
(illustrated via the CONSORT diagram), completion of outcomes and trends of the 
measures. 
The outcome measures consisted of activity (measured by ActiCal device), 
symptoms (recorded in a symptom diary), Dyspnoea assessment, QOL (assessed 
by questionnaires) and walking distance (6MWT). It was important that they were 
validated in COPD, routinely used in clinical practice and provided relevant 
information that was easily reproducible by other clinicians. They would be used 
to evaluate any potential trend in clinical outcomes from exercising on NIV 
compared to standard care. Figure 4.4 presents the timing of the outcome 
measures. 
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Figure 4.4 Diagram of the timing of outcome measure assessment 
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4.22.1 Assessment of feasibility 
Recruitment and retention was assessed from the recruitment data. This included 
the number of patients’ screened for inclusion and the time scale of recruitment. 
The number of patients excluded and who declined to participate was also 
captured. This enabled the calculation of the recruitment rate. Retention into the 
trial was recorded including drop outs and deaths. This helped to determine 
whether a larger RCT would be feasible in this group. 
The specific reasons for patients declining to participate or dropping out of the 
study were also recorded to allow for evaluation of acceptability of the trial and/or 
intervention to the participant.  
The ease of completion of outcome measures was evaluated by any 
missing/incomplete data and by the ease of completion reported by the researcher 
and also by the exercise on NIV in hospital and home group from their semi-
structured interviews. Further acceptability of the design and intervention would 
be assessed by the qualitative data discussed in Chapter 5 Qualitative Method. 
4.22.2 Clinical outcomes 
The clinical outcomes used were the SGRQ for assessing HRQOL in COPD, the 
LCADL and the EQ-5D-5L. 
Also used were the MBORG and MMRC Dyspnoea scores for evaluating 
breathlessness in this patient group. 
The other important clinical outcome was the 6MWT to determine any trend for 
improvements in walking distance, which has been linked to mortality (Pinto-Plata 
et al., 2004). The order of the outcome measures was decided following the 
stakeholder feedback, section 4.14. The questionnaires that were the most time 
consuming were carried out first as the Breathe Easy group felt they required 
more concentration. Table 4.1 provides a brief summary of the outcome measures 
used. Following the table each of the outcome measures and the justification for 
their use is discussed.
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Table 4.1 A summary of the outcome measures used in NIV on exercise in COPD 
Outcome Measure Description Minimum clinically 
important difference 
(MCID) 
 (unless otherwise 
documented) 
Range of Scores Number, type of questions, 
and time to complete. 
St George’s 
Respiratory 
Questionnaire (SGRQ) 
Questionnaire that 
measures impairment in 
patients with COPD (Jones, 
2005). 
4 (Jones, 2005). 0-100. 
Symptoms, Activity, Impact and a 
total score 
(Higher score = worse 
impairment), (See Appendix 14b 
for full questionnaire). 
There are 19 questions split 
into two parts, the first part 
relates to symptoms and the 
second part to activities 
limited by dyspnoea and 
activities unable to complete. 
It takes 8-15 min to complete 
(Jones, 2005). 
London Chest Activity 
of Daily Living 
Questionnaire (LCADL) 
15 questions assessing the 
impact of breathlessness on 
daily activity (Garrod et al., 
2000). 
Minimal detectable 
change of 4 (Bisca et al., 
2013; Garrod et al., 
2000). 
0-75. 
(Higher score = worse 
symptoms), (See Appendix 15 for 
full questionnaire). 
There are 16 questions 
evaluating the ability to 
perform a daily activity. It 
takes 1-5 min to complete 
(From stakeholder feedback, 
section 4.22).  
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Outcome Measure Description Minimum clinically 
important difference 
(MCID) 
 (unless otherwise 
documented) 
Range of Scores Number, type of questions, 
and time to complete. 
European Quality of 
Life – 5 Dimensions – 5 
Levels (EQ-5D-5L) 
Patient questionnaire and 
visual analogue score (VAS) 
of QOL (NICE, 2008). 
Utility score is not 
established in the 
literature for EQ-5D-5L 
(Obradovic, Lal and 
Liedgens, 2013). The 
minimally important 
difference for the 
predecessor EQ-5D is 
0.03 (Brooks, 2003). 
VAS = 8 points (Zanini et 
al., 2015). 
Utility score and VAS 0 = 
death/worst possible health to 100 
= best possible health. 
EQ-5D-5L utility scores range 
between -0.594 and 1 (full health), 
(See EuroQual, 2015 for full 
questionnaire and VAS). 
There are 25 questions and a 
VAS score on current health 
status. The questions relate 
to assessing the health state 
of their mobility, self-care, 
usual activities, 
pain/discomfort and 
anxiety/depression. It takes 
2-5 min to complete (From 
stakeholder feedback, 
section 4.22). 
Modified BORG 
Dyspnoea Score 
VAS of breathlessness 
(Wilson and Jones, 1989). 
Not established in the 
literature (Ries, 2005).  . 
 
0 (no breathlessness) to 10 
(maximal breathlessness), (See 
Appendix 16 for VAS) 
One question assessing level 
of breathlessness. Takes a 
few seconds to complete 
(From stakeholder feedback, 
section 4.22). 
Modified Medical 
Research Council 
(MMRC) Dyspnoea 
Score 
Simple measure of 
breathlessness (Bausewein 
et al., 2007). 
Not established in the 
literature (Ozalevli and 
Ucan, 2006). 
0 (breathless only on strenuous 
exercise) to 4 (too breathless to 
leave the house/ too breathless to 
get dressed), (See Appendix 17 
for full measure). 
One question assessing level 
of breathlessness on activity 
with four possible choices. 
Takes a few seconds to 
complete (From stakeholder 
feedback, section 4.14). 
6 minute walk test 
(6MWT) 
Walking test on the flat to 
assess distance covered in 
6 min (ATS, 2002). 
30m (Justified in section 
4.22.7) (Holland and Nici, 
2013). 
Distance (m) walked. N/A 
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Outcome Measure Description Minimum clinically 
important difference 
(MCID) 
 (unless otherwise 
documented) 
Range of Scores Number, type of questions, 
and time to complete. 
ActiCal (Philips-
Respironics)(Activity 
monitor) 
Wrist monitor of step count 
(Pita et al., 2006). 
Not established (Waschki 
et al., 2011). 
Number of steps. 
 
N/A 
196 
 
4.22.3 The St George’s Respiratory Questionnaire (SGRQ) 
The SGRQ (Appendix 14b) measures impairment in patients with COPD, 
permission was sought to use the questionnaire and approval granted (Appendix 
14a). There is a detailed manual that explains how to complete the SGRQ (Jones 
and Forde, 2009). The questionnaire is in two parts; part one has a symptoms 
score and part two has an activity and impacts score. Each questionnaire answer 
has an individual empirically calculated 'weight'. The lowest possible weight is 
zero and the highest is 100.  The higher the score the worse the patient feels. The 
total score is derived from three separate domain scores of Symptoms, Activity 
and Impacts. For analysis there is a specially designed Microsoft Excel calculator 
which calculates the three component scores and the total score for each 
participant. The MCID for SGRQ is 4 units (Jones, 2005).  
The SGRQ is a questionnaire responsive to change, particularly in the total and 
impact score (Ferrer et al., 1997; Jones, 2005). The SGRQ is more responsive 
than most generic questionnaires although some research suggests the Chronic 
Respiratory Questionnaire is more responsive to change than the SGRQ (Puhan 
et al., 2007). Nevertheless the SGRQ is widely used in clinical practice, 
particularly as an evaluation of PR intervention (Ferrer et al., 2002). The SGRQ is 
confirmed as a valid measure of impaired health in patients with COPD (Jones et 
al., 1992). This measure was carried out first following the 6MWT because this 
was the longest questionnaire. 
4.22.4 London Chest Activity of Daily Living Questionnaire (LCADL) 
The LCADL is a questionnaire that measures dyspnoea during routine daily 
activities. It comprises 15 questions which give a total score of 75 (Appendix 15). 
Questions focus on self-care (four questions), domestic (six questions), physical 
(two questions) and leisure activities (three questions) (Garrod et al., 2000). Each 
question is scored out of 5 ranging from 0 (‘wouldn’t do task anyway’) to 5 (‘I need 
someone else to do this’). The highest score represents maximum disability. The 
minimum detectable change (MDC) for total score is a change in 4 points (Bisca 
et al., 2013; Garrod et al., 2000). Within each section the MDC is 0.89 in self-care, 
2.60 in domestic, 0.44 in physical and 0.58 in leisure (Bisca, et al., 2013). The 
MDC is the smallest change in a score used to measure a symptom that can be 
197 
 
seen that falls beyond the measurement error of the measuring tool (Crosby, 
Kolotkin and Williams, 2003). 
The LCADL is intended for use in patients with severe COPD (Garrod et al., 2000). 
It is important that the impact of breathlessness on daily life is evaluated. It is 
validated in patients with severe COPD, reliable and responsive to change. The 
LCADL was validated in 60 patients with COPD and compared with other 
measures of health status (Garrod et al., 2000). The LCADL has been reliably 
used to measure the impact of a course of PR on dyspnoea however, it has not 
been tested in other interventions (Garrod, Paul and Wedzicha, 2002). 
Nevertheless it may be useful to evaluate the effect of exercising on NIV. It is easy 
to carry out and not time consuming. However the scoring for domestic tasks may 
not be as useful in patients with severe disease as they still may not be able to do 
most of these domestic tasks following rehabilitation (Garrod, Paul and Wedzicha, 
2002). This questionnaire was completed after the SGRQ because it is more 
concise. 
4.22.5 The modified BORG Dyspnoea scale (MBORG) 
This is a score which patients use to rate the difficulty of their breathing. It is 
commonly used in clinical practice and quick to score. This measure gives a score 
of breathlessness from 0 (‘nothing at all’) to 10 (‘maximal breathlessness’) (Borg, 
1998) (Appendix 16). 
The MBORG is considered a useful tool for breathlessness (Wilson and Jones, 
1989). It has previously been used in participants enduring a 6-minute treadmill 
walk and was validated as a reliable tool for measuring dyspnoea in this group 
(Belman et al., 1991). Subjects were able to distinguish between different 
sensations of breathlessness using the levels of breathlessness on the MBORG 
during induced breathlessness (Simon et al., 1989). The MCID is unknown (Ries, 
2005). The MBORG has been rated as easy to use by patients (Kendrick, Baxi 
and Smith, 2000). However it has been suggested that it is of most benefit if used 
with other QOL tools (Bausewein et al., 2007). This will be measured at rest and 
then used during the intervention to assist with progression of the intervention and 
optimise the settings of NIV. This was completed after the HRQOL questionnaires 
and EQ-5D-5L because the breathlessness scores were the quickest to complete. 
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4.22.6 The Modified Medical Research Council Dyspnoea scale (MMRC 
Dyspnoea scale) 
The MMRC Dyspnoea scale is a simple measure of breathlessness, used as a 
screening tool for PR, developed from the MRC dyspnoea scale (Bestall et al., 
1999). It is a patient selected score from 0 (‘I only get breathless with strenuous 
exercise’) to 4 (‘I am too breathless to leave the house or I am breathless when 
dressing’). It can be used to assess disease severity in COPD (Nishimura et al., 
2002) (Appendix 17).  
A study comparing the MMRC with a Visual Analogue Score (VAS) of 
breathlessness, baseline dyspnoea index and O2 cost diagram favoured the use 
of the MMRC (Ozalevli and Ucan, 2006). They compared the measures using 40 
patients with COPD and compared them to lung function and symptoms. The 
MMRC correlated most with lung function test results and physical symptoms of 
COPD (Ozalevli and Ucan, 2006). It can assess whether PR will be beneficial and 
PR is recommended for patients who are graded between 3 and 4 (BTS, 2013). 
The MMRC dyspnoea scale has been championed as a valid, simple and useful 
tool (Bestall et al., 1999), but it has been argued that it should be used with other 
measures to identify suitable patients for rehabilitation (Spruit and Wouters, 
2007). This was the final patient completed outcome measure assessed at each 
measure point. 
4.22.7 The Six Minute Walk Test (6MWT) 
This test measures the distance a patient can walk on the flat ground (30m) within 
6 minutes (American Thoracic Society (ATS), 2002). The 6MWT needs few 
resources and it is easy to perform in clinical practice (ATS, 2002). Walking is a 
useful assessment because all but the most debilitated patients can mobilise a 
few steps. It was adapted from the 12MWT to include patients with respiratory 
disease who could not walk for that long (Butland et al., 1982). Other tests like the 
stair climb tests may be too difficult to perform in patients with very severe COPD 
(ATS, 2002). It was a useful measure for this study because it assesses both 
respiratory and other system effects of COPD (Spruit et al., 2010). The researcher 
used a research SOP to ensure the same methods were used each time and to 
try and reduce the bias of the researcher measuring the test (Appendix 18). This 
was a pragmatic measure as it was not possible to bring these patients back to 
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hospital for five assessments of 6MWT. Therefore the measures were carried out 
in the patients’ homes, gardens and public pavements to achieve the required 
measure. This was the first measure assessed, the reason for this was based on 
both the clinical experience of the researcher and feedback from stakeholders, 
(see section 4.14) that walking assessments may increase anxiety in patients 
because of the perceived fear of dyspnoea. Therefore by undertaking the 6MWT 
first may have meant the participants did not rush through the questionnaires 
facilitating careful completion. 
This test is widely used in clinical practice to assess the effectiveness of 
treatments in the COPD population (ATS, 2002). The 6MWT has good reliability 
and validity (Garcia-Rio et al., 2009; Hernandes et al., 2011; Wijkstra et al., 1994). 
The 6MWT has been shown to respond to the treatment of PR. A meta-analysis 
of ten trials including 450 participants demonstrated a mean increase of 49m 
following a course of PR (Lacasse et al., 2002). The walk test does have a learning 
effect which plateaus after two walks (Guyatt et al., 1984), thus the researcher 
carried out a practice test when collating the measure at least one hour before the 
documented test. 
There has been much debate surrounding the change in distance which is the 
threshold for MCID (Holland and Nici, 2013). Earlier studies cited 54m as required 
to show change (Redelmeier et al., 1997). Following further research which 
demonstrated poor clinical change, researchers questioned whether 54m was too 
high. Thus other MCID were proposed to range between 25-35m (Polkey et al., 
2013; Puhan et al., 2008; Schunemann and Guyatt, 2005). The researcher 
thought that the lower score of 25-35m seemed a more reasonable figure 
particularly for patients with very severe COPD. There had been differing opinions 
regarding whether the MCID existed for the 6MWT. The 6MWT did not tally with 
other anchor based measures, for example QOL (QOL) measures (Holland and 
Nici, 2013), however a more recent large cohort study has reintroduced a figure 
for MCID which identifies an MCID for decline not just improvement, with an 
indication for an increased risk of mortality with a loss of > 30m in 6MWT (Polkey, 
et al., 2013). It has been suggested that to assess differences in individuals 40m 
should be used but 30m in clinical trials for between group analysis (Holland and 
Nici, 2013). Therefore this study will use 30m to define the MCID in the 6MWT. 
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The 6MWT was easy to carry out by the clinician and meaningful to both patients 
and clinicians; therefore it was highly likely to be retained for a future definitive 
trial. 
4.22.8 EQ-5D-5L 
There is a cost and resource implication of using NIV for exercise in the home, 
therefore it is important to justify the cost effectiveness of the intervention. For 
example the equipment cost is at least £3,500 per NIV device and additionally 
there are consumables, maintenance and professional supervision expenses. 
There are also societal costs and the impact on patients’ QOL that need to be 
considered. The EQ-5D-5L questionnaire is completed by the patient which 
results in a single index value for health status. It allows for cost-utility analyses 
by Quality Adjusted Life Years (EuroQol, 2015; Herdman et al., 2011; NICE, 
2008). 
The EQ-5D-5L measures self-reported health status at the time of completion. It 
consists of two pages; the descriptive page and the EQ visual analogue scale (EQ 
VAS). The descriptive page measures the dimensions of mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression. Each dimension is described 
by five answers of ‘no problems’, ‘slight problems’, ‘moderate problems’, ‘severe 
problems’, and ‘extreme problems’. The measure also incorporates the EQ VAS. 
The EQ VAS scores the respondent’s self-rated health on a 20cm vertical VAS 
with endpoints marked ‘the best health you can imagine’ and ‘the worst health you 
can imagine’. The participant’s answers are translated into a preference-based 
score, yielding an index score based on a scale from 0.000 (death) to 1.000 
(excellent health). EQ-5D-5L is free to use in clinical practice but because this 
study had commercial funding there is a charge to use the measure. Therefore 
Philips-Respironics purchased the permission to use the EQ-5D-5L for the 
purpose of this and other research projects. The sample EQ-5D-5L and handbook 
for use can be found on the EuroQuol website (EuroQol, 2015) 
It has previously been used with and is validated for patients with COPD  in both 
stable disease and during exacerbations (Menn, Weber and Holle, 2010; Stahl et 
al., 2005). In a study comparing HR QOL measures 117 patients with COPD 
during a hospitalised exacerbation were assessed (Menn, Weber and Holle, 
2010). They compared the Short Form Survey-12 (SF-12) and SGRQ with the 
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EQ-5D.The EQ-5D was found to be the best measure in terms of completeness 
and ease of use. However the authors reported a problem with the sensitivity of 
the score in relation to disease severity. At discharge the scoring led to an 
abnormally high level of participants declaring themselves to have full health on 
discharge. The problem with using this type of measure is that perception of health 
is based on our personal normal, and in chronic disease peoples’ perception of 
normal might be stable health and ill health may be exacerbation from that resting 
state. However as the preferred method of NICE it seemed beneficial to use it 
within this study (NICE, 2008). For the purpose of this feasibility study the 
descriptive questionnaire and EQ VAS were collated. The quantitative utility score 
was calculated but the economic cost/savings was not calculated for the purpose 
of the feasibility study. This outcome measure was completed after the HRQOL 
measures but before the breathlessness scoring was carried out. 
 
4.22.9 ActiCal Data 
The CE marked ActiCal (Philips-Respironics) was worn on a wrist strap and used 
to monitor activity expenditure and step count over 24 hours for three months post 
discharge.  
 
Figure 4.5 ActiCal Device 
The ActiCal is a motion sensor used to detect body movement and step count. It 
can be used to objectively quantify physical activity in daily life over a pre-
determined time period (Pita et al., 2006). It has been well validated, with clear 
information on the respective thresholds of activity in adults (Hooker et al., 2011; 
Wong et al., 2011). Hooker, et al. (2011) developed accelerometer thresholds to 
differentiate between light and moderate intensity physical activity in middle-aged 
and older adults. They evaluated non-obese participants aged between 45 to 64 
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years (n = 29), obese participants aged between 45 to 64 years (n = 21), and 
participants over 65 years (n = 23; of varying body composition). Participants 
completed laboratory-based sitting, household, and locomotive activities while 
wearing an ActiCal monitor. They concluded that for the ActiCal activity monitor, 
a point of 1065 (reflecting steps and motion activity) can be used to differentiate 
light and moderate intensity physical activity in people over 45 years of age. The 
ActiCal was put on the wrist rather than at the hip as many patients tend to wear 
hospital gowns as in-patients and loose clothing at home.  
The ActiCal was set up with the patient’s research ID and basic measures of age, 
height and weight. The ActiCal was applied at the point of discharge and 
participants were advised to continuously wear it for three months until the study 
finished. It is important to look at activity monitoring additionally to the 6MWT 
because research has shown that there is a difference between predicted activity 
from the 6MWT and the intensity and amount of activity a patient actually 
undertakes at home (Walker et al., 2008). The ActiCal was removed from the 
patient when they had finished the study or in the case of two participants at the 
time of death. The data were downloaded and analysed using Philips-Respironics 
Actiwear software.  
Basic pedometers have been suggested as a much cheaper device for recording 
step count and activity levels (Pita et al., 2005). Activity monitors are expensive,  
require technical knowledge and expensive software to interpret the data, 
however pedometers may not be useful in slow walkers (Hendelman et al., 2000; 
Pita et al., 2005). Therefore they were not used in this study involving relatively 
inactive patients with COPD. A known disadvantage of using any such device is 
that 20% of patients may not be concordant with wearing the device (Pita et al., 
2006; Kochersberger et al., 1996), therefore at the weekly phone check-ins and 
at the outcome measure assessments each patient was asked if they were 
wearing their ActiCal monitors to discuss and encourage concordance. 
4.22.10 Daily diary of symptoms and access to health care 
This participant reported diary was adapted from one used at the time of the study 
at the UHBristol (Appendix 11). It recorded the participants’ symptoms, for 
example, sputum colour. It also recorded access to medical health care 
professionals, hospital admissions and additional medication use. The patient 
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was issued with four weeks of diary pages at discharge and then at each 
additional outcome measure point. The records for the previous month were 
collected by the researcher at each visit for collation of measures. Each week the 
patient was reminded by telephone to complete the diary. Symptom diary cards 
were analysed by hand to record symptoms, healthcare access and medication 
use (Vijayasaratha and Stockley, 2008). 
4.22.11 Ventilator data 
The ventilator data were downloaded from the SD card using Direct View software 
on a double-encrypted password protected UHBristol hard drive. The data were 
assessed for concordance, time used, VT achieved and pressure used. This was 
used to assess if any patients used the device when not supervised and to confirm 
the intended use of high pressures during use of the NIV. These were downloaded 
at the end of each patient’s participation in the trial. 
4.22.12 Length of stay and therapy time 
The time that the researcher spent with each participant was calculated from the 
medical notes and statistical data that records therapy contact time at UHBristol. 
The initial length of stay was calculated for each participant from the Medway 
hospital patient data, which has a record of admission length. These were 
calculated at the end of the trial. All follow-up exercise sessions with the exercise 
on NIV in hospital and home group were recorded by the researcher. 
4.22.13 Mortality and morbidity data 
The six months before and after the trial were evaluated post trial for each 
participant. This was captured from the Medway computerised system which 
captured admissions data within UHBristol. It recorded all hospital admissions and 
captured date of death (where relevant). This indicated any overall differences 
between groups and captured the severity of the participant’s condition. 
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4.23 Data Analysis 
4.23.1 Feasibility analysis 
This was evaluated by the numbers recruited and retained, presented using the 
CONSORT diagram. The completion of the outcome measures assessed 
feasibility of their use. The overall valid completion of an outcome measure was 
assessed. The number of items missed per measure was not specifically 
analysed. The concordance of participants using the ventilator equipment was 
evaluated using ventilator downloadable data and researcher observation. The 
ability of participants to tolerate high PS ventilation during exercise was also 
demonstrated by ventilator data.  
4.23.2 SAEs 
The National Institute for Health Research (NIHR) (2014) defines a SAE as any 
AE that: 
1.  Results in death.  
2.  Is life threatening, or places the participant at immediate risk of death.  
3.  Needs or lengthens hospitalisation.  
4.  Causes persistent or significant disability or incapacity. 
5.  Results in congenital anomalies or birth defects.  
6. Is another condition which investigators judge to represent significant hazards.  
SAEs were also evaluated to assess potential difficulties of exercising this cohort 
with very severe lung disease. SAEs were reported to the Sponsor and the 
Hospital Trust Research and Development department within 24 hours of 
occurring. No SAEs required further reporting to the ethics committee. These were 
then evaluated by a research trial committee at Philips-Respironics (Sponsor) and 
the outcome emailed to the researcher. The outcomes were documented in the 
research study portfolio. At no point was the trial discontinued in relation to SAEs. 
Any participant that experienced an SAE that did not result in death continued in 
the study. No extra time was given to their inclusion in the trial. The intervention 
and exercise was adapted as previously described in section 4.11. 
205 
 
4.23.3 Outcome analysis 
The research evaluated three treatment limbs; Standard care; exercise on NIV in 
the hospital; and exercise on NIV in the hospital and home for a further three 
month period. The outcomes were measured at five time points; baseline (B); 
hospital discharge (DC); month one (M1); month two (M2) and month three (M3) 
following discharge. 
Data were recorded in Microsoft Excel version 13, selected and exported into 
SPSS version 17, (IBM: Chicago, Illinois, USA) for statistical analysis. Descriptive 
statistics were calculated for the baseline data and outcome measures and the 
data assessed for normal distribution. When the data were normally distributed a 
one-way ANOVA was carried out to assess for differences in the data between 
groups at each time point.  
When the data were not normally distributed non-parametric testing using 
Kruskall-Wallis was performed to assess for any differences between the groups. 
When the baseline data were not normally distributed median and interquartile 
range were calculated and non-parametric testing applied (Hazard, 2005). Any 
further statistical analysis was not possible because of the small sample size of 
each group.  
Due to the volume of data collated only a selection of baseline severity raw data 
was included in the Appendices. All of the complete specific tool outcome 
measure raw data was included in the Appendices. This was to allow for 
inspection of the individual data. The SAE, admission and participant diary raw 
data information was not included in the Appendix because of the sheer volume 
of data. 
4.24 Data Management 
All medical and personal information was treated as confidential. Data were 
anonymised as far as possible and as early as possible in the process. Data were 
stored in a locked filling cabinet within a safe locked location. Any data held on 
the researchers NHS Trust personal computer was protected by double encrypted 
password protection. Data were collected and retained in accordance with the 
Data Protection Act 1998. 
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4.25 Conclusion 
This chapter has described the quantitative research method used. It has 
discussed and justified the use of each outcome measure and explained how 
analysis was carried out. The next chapter describes the qualitative methods used 
to complete the mixed methods design. 
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Chapter 5 Qualitative Method 
 
5.1 Introduction  
The literature review demonstrated that the participants recruited to this study 
were likely to be a complex group of patients with severe lung disease. 
Quantitative clinical measures are useful to indicate an improvement in exercise 
capacity, dyspnoea and health status in line with PR guidelines (BTS, 2013), 
however there was a need to try to understand what impact, both positive and 
negative, the intervention had on the participants. The qualitative method used 
complemented the quantitative methods by providing the participant’s voice to add 
understanding and depth to the outcome measures used (Creswell and Clark, 
2007). 
5.2 Choosing the type of qualitative method 
There are many different methods that can be used under the umbrella term of 
qualitative methodology including focus groups; ethnographic methods and 
interviews. These have been discussed below. 
5.2.1 Focus group interviews 
A method often used in health care is focus group interviews. This method means 
that data can be collected from multiple participants simultaneously (Braun and 
Clarke, 2013). However focus group research was not appropriate in this study 
because the participants were often house-bound, and may have been wary of 
mixing with others because of the risk of acquiring infections. Group discussions 
may have proved challenging with the participants involved experiencing 
breathlessness. 
5.2.2 Ethnographic methods 
Ethnographers aim to become embedded in the field (Hammersley and Atkinson, 
1983), to understand the meanings people develop about their experiences 
(Bowling, 2009).  Participation and observation are often used for data collection. 
The strengths of this approach are that it provides rich naturally occurring data, 
which is useful to study under-researched groups (Hammersley and Atkinson, 
1983), although a criticism of this approach is that the presence of the researcher 
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may change the natural environment (Green and Thorogood, 2009). To use 
ethnography, the researcher would have to spend significant amounts of time with 
each patient to live the whole NIV experience with them which is unnatural, 
invasive and not achievable. Ethical approval may have been difficult to obtain as 
the participants may not be fully aware of the duration of time they would be 
observed and the implications of this. The material produced is large, hard to 
verify and difficult for the novice researcher to manage (Robson, 2011). Whilst 
ethnography may lead to understanding of the life experience of the participants, 
it can take time to capture. This research programme was time limited and this 
vulnerable patient group had a short life expectancy, meaning ethnographic 
methods were not appropriate.    
5.2.3 Interviews 
Individual semi-structured interviews were chosen as the method, with an 
interview guide using planned open-ended questions that the researcher built 
upon and which allowed for unplanned questions based on the participants’ 
responses (Robson, 2011).  This method was chosen because an in-depth 
method was required to explore the participants’ views and experience of COPD 
and an understanding of what participating in this research meant for them as an 
individual. A semi-structured method allowed for each interview to be 
individualised and allowed for more open-ended questions based on the study’s 
focus. Alternatively a fully structured interview would ensure each participant was 
asked clear questions which while it would have met the aims of the study it may 
have led to a lack of detail of the participants’ experiences (Fontana and Frey, 
2005). In comparison, although an unstructured interview may have yielded richer 
data it may have made achieving the aims of this study more challenging and 
comparisons across the entire data set may have been more difficult (DiCicco-
Bloom and Crabtree, 2006). 
Robson (2011) suggested that semi-structured interviews complement mixed 
methods studies well. They were useful in this study when the research was of a 
smaller scale and the researcher was also the interviewer. The researcher felt that 
often qualitative research is complex and needs years of experience to perfect. 
Although semi-structured interviews would prove challenging to the researcher, 
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the one-to-one nature of the interviews felt similar to the one to one consultations 
experienced when the researcher was in the role of physiotherapist.  
Braun and Clarke (2013) suggested that a researcher must have a qualitative 
sensibility with a critical and questioning interest in the process and meaning, not 
just the cause of effect. As a physiotherapist the researcher had to tailor 
treatments to meet the expectations and demands of individual participants, 
requiring in-depth understanding of the patients. There was a need to have good 
interactional skills and to allow for trust to develop between the interviewer and 
participant (Braun and Clarke, 2013).  
The researcher’s role as a physiotherapist often required trust and rapport 
between clinician and patient further enhancing the choice of interviews, however 
clinical interviews are arguably very different to research interviews. In a clinical 
interview the conversation is directed by the clinician to achieve the patient’s 
history to confirm or refute a diagnosis. The clinical interview is often concise and 
when patients deviate from specific physical health questions the clinician will 
guide the patient back to the topic. Clinical interviews are often time pressured 
and singularly directed by the clinician. The research interviews differed because 
they were focused on the participants enabling them to discuss their experiences 
and what was important to them. The interviewer, although guiding the interview 
in relation to aims of the research, was not dictating the course of the interview.   
5.3 Choosing the sample: Why interview only the hospital and 
home exercise on non-invasive ventilation (NIV) group? 
The interviews were only completed with those participants allocated to the 
exercise on NIV hospital and home group. This was because this group would 
provide the most information of the experience of being involved in the research 
and using the intervention. This was also partly because of the limited time and 
resources available to the researcher. Therefore the sample was purposive and 
suited the purpose of inquiry (Patton, 2002), which is quite common in qualitative 
research.  
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5.4 R & I Department approval 
The R & I department at UHBristol was informed of the changes to the research 
design and subsequent ethical approval of the amendment. The ethical 
amendment was discussed previously in Chapter 4 (‘Quantitative Results’), 
section 4.4 Ethical approval) 
Intellectual property was just as important an issue when undertaking the 
qualitative research as it was for the quantitative method. The participants could 
have expressed negative comments regarding the ventilator company’s 
equipment which meant that they may not want the data to be published. Thus 
the interview data were included in the intellectual property agreement between 
Philips-Respironics, UHBristol and UWE, (see Appendix 6, for the intellectual 
property contract). 
5.5 Designing the interview guide 
When designing the interview guide it was important to focus on the main aim of 
the research which was feasibility. The aim of the semi-structured interviews was 
to help contextualise the findings from the quantitative data, by providing insight 
into the lives of participants with severe COPD.  
The open question interview guide was to facilitate the participants in revealing 
their personal experience of the treatment and involvement in the study. The guide 
had a list of key areas that the researcher would focus on, but importantly allowed 
scope for the participant to raise issues that the researcher had not anticipated 
(Braun and Clarke, 2013). The interview guide included an introduction focusing 
on the participants’ general health and hospital stay, to relax them and introduce 
the topic areas with ease. Further sections focussed on the specifics of using the 
equipment, experience of the intervention, advice to others undertaking the study 
and clinicians carrying out the study, and closing with time for the participant to 
disclose any other information. The iterative and flexible design of the qualitative 
component meant that analysis began after the first interview. This influenced the 
guide questions as key themes or further questions emerged (DiCicco-Bloom and 
Crabtree, 2006). The interview guide was reviewed and altered in conjunction with 
supervisors during March 2013 to include more probing and open questions. The 
open ended questions were important because they encouraged the participants 
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to provide more detail in their responses and enabled time for the participants to 
discuss what was important to them not just the researcher agenda (Braun and 
Clarke, 2013). The final interview guide can be found in Appendix 19.  
5.6 Recording the interviews 
Audio recording the interviews allowed the researcher to focus on communicating 
with the participant rather than trying to write detailed notes (Legard, et al. 2003), 
however all participants were asked if this was acceptable prior to interview. None 
declined to be recorded. This produced a permanent record of the interview which 
enabled repeated analysis (Robson, 2011). It also permitted for more thorough 
analysis of what was said, as the researcher replayed excerpts repeatedly 
(Silverman, 2001).  The researcher then transcribed the interviews word for word. 
The recording device used was a Sony ICD-PX312-digital voice recorder-flash 
2GB-MP32. The batteries were checked at the beginning of each recording and 
a test statement about the weather was asked of the participant, to ensure a good 
quality recording was secured. 
5.7 UWE interview workshops 
The researcher attended a workshop provided by the graduate school at UWE on 
developing interview skills. This allowed her to practice interview skills upon other 
postgraduate students in October 2012 under the direction of an experienced 
qualitative researcher. This was followed up with a further session as part of the 
‘Qualitative research within clinical settings’ M-Level module undertaken by the 
researcher at UWE, November 2012.  
5.8 Pilot interviews 
The researcher was keen to involve patients in the research process as user 
involvement is important in qualitative research (Denzin and Lincoln, 2000). Pilot 
interviews are recommended in order to inform the full interview (Mason, 2002). 
The interview guide was piloted on three COPD patients who use NIV but were 
not study participants. They identified terminology that may not be understood and 
helped the researcher to improve interview skills (Robson, 2011). It also meant 
that the interview guide could be further improved. The researcher was also able 
to test the recording equipment and practice note taking during interview. Local 
support groups were consulted for the preferred format of interview. The 
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suggestions were that the key questions should be shown to respondents prior to 
the interview to ease anxiety. It was decided that the interviews should be 30-60 
minutes long to minimise potential for fatigue and breathlessness. All participants 
were offered a choice of telephone or face-to-face interviews, although no 
participant opted for a telephone interview. There is little data comparing 
telephone interviews with face-to-face interviews (Knox and Burkard, 2009), 
however the studies that have compared the two methods favoured face to face 
interviews because they were more advantageous in generating richer data (de 
Leeuw and Van der Zouwe, 1988; Jordan, Marcus and Reeder, 1980). Although 
telephone interviews are less inconvenient, safer for the researcher and less 
costly than a face-to-face visit, they may not last as long and contextual 
information would not be obtained (Shuy, 2003; Robson, 2011). It was 
recommended from the pilot interviews that the time and location should be the 
participant’s choice, however it was researcher preference to interview the patient 
in their home in keeping with the natural environment (Green and Thorogood, 
2009). Face to face interviews also offered observation of both the verbal and 
non-verbal data, which could add valuable information to the findings (Hiller and 
Diluzio, 2004), thus field notes were collated to capture the context of the 
interviews and expressions of the participants.  
5.9 Data storage 
All personal and medical information was treated as confidential. Data were 
anonymised as far as possible and as early as possible in the process. All data 
were transcribed solely by the researcher so as to avoid any confidentiality issues 
of bringing in a third person. Data were stored in a locked filing cabinet within a 
locked office in accordance with the Data Protection Act 1998.  
5.10 Personal safety 
In advance of planning the interviews the researcher needed to think through the 
aspects of their personal safety if they were visiting areas alone (Robson, 2011).  
Researcher safety was considered and a lone worker device used. This device 
enabled the researcher to detail location and time to a mobile alarm device which 
informed a security helpdesk at UHBristol. If the alarm was activated by the 
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researcher the police would be informed. The researcher re-informed the device 
when leaving a location. 
5.11 Qualitative analysis 
Data analysis is referred to as the most complex and mysterious phase of 
qualitative research (Thorne, 2000). However it is really important that it is done 
in a systematic and repeatable way to ensure rigour. Rigour is discussed further 
in section 6.16. Although this was a mixed methods study the researcher wanted 
the qualitative data to do more than just supplement or illustrate the quantitative 
data (Robson, 2011). The researcher wanted the qualitative data to give a voice 
to the participants to understand their experience of the research and intervention. 
Therefore ensuring that a detailed and structured analysis occurred was very 
important. 
5.12 Why Thematic Analysis (TA) was chosen? 
This section discusses why TA was chosen as a process of analysis. It describes 
the reasoning for the method and how it was undertaken (Hansen, 2006; 
Darlington and Scott, 2002; Thorne, 2000). TA identifies, organises, analyses and 
reports patterns within the data to allow rich description (Braun and Clarke, 2006), 
however it may also allow deeper interpretation of the research area (Boyatzis, 
1998). TA is not tied to any epistemological view so can be used for most 
philosophies, although it is often criticised as an anything goes approach (Antaki, 
et al. 2002), however if limited time and inexperience are an issue defenders of 
TA would argue it is better to use TA than use another method half-heartedly 
(Braun and Clarke, 2006). Critics of TA challenge flexibility as providing a lack of 
transparency (Mays, Pope and Popay, 2005). This is because TA can be 
commenced in many ways, for example inductive or deductive, led by theory 
and/or seek to be descriptive (Braun and Clarke, 2006).  
There is no fixed formula for analysing qualitative data with some researchers 
referring to analysis as an art form (Robson, 2011). There are several other 
methods of qualitative research and analysis. An alternative qualitative 
methodology Interpretive Phenomenological Analysis (IPA) provides an in-depth 
analysis seeking verification and layered analysis. It is not seeking to present one 
overarching theory but instead to give detailed description and interpretation to 
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make sense of the participant’s experience (Chapman and Smith, 2002). IPA uses 
reflexivity to continually assess what experience the researcher has brought to 
the analysis. Whilst IPA seemed to reflect the aims of understanding the patient 
experience, the research was not seeking to underpin the findings with a 
philosophical approach. The main focus of the research was to understand the 
participant experience. This research required a systematic, repeatable method 
of analysis that organised and labelled the data in rich detail. TA provided such a 
method, enabling interpretation within the qualitative component (Braun and 
Clarke, 2006). 
TA may give the insight needed to make sense of the subjective experience of 
this rare group, however, the researcher sought to address the criticisms of TA 
regarding transparency, which may discredit its findings, by following and 
documenting a detailed step by step approach (Braun and Clarke, 2006).  
5.13 The Analysis Process 
The researcher used the step by step guide of analysing with TA as described by 
Braun and Clarke (2006). Figure 5.1 illustrates the stages of analysis. 
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Figure 5.1 Phases of thematic analysis (TA) (Braun and Clarke, 2006) 
The researcher undertook two workshops at UWE on coding data. The researcher 
practiced coding as part of the M-Level module of ‘Qualitative research in clinical 
settings’. Additionally as part of the postgraduate workshops in May 2013, the 
researcher was able to practice the phases of analysis as described by Braun and 
Clarke (2006). The researcher also attended a two day course in May 2013 on 
using NVivo 10 to offer an alternative tool for data organisation. The researcher’s 
reflection of her analysis can be found in Chapter 8 (‘Reflexivity’) section 8.6 
Finding my role as an analyser. 
5.13.1 Phase 1: Familiarisation 
This phase was when the researcher became immersed in the data, Braun and 
Clarke (2013) describing this as the foundation of the analysis. The researcher 
had the advantage of collating the interview data herself therefore the 
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familiarisation of the data began at that point. The researcher also transcribed all 
of the interviews independently. The transcription occurred immediately after each 
of the interviews (see Appendix 20, for copies of all of the interview transcriptions). 
This was so the circumstances of each interview were recent in the mind of the 
researcher and so that they could inform the next interview. This was a time 
consuming process and took up to 6 hours for each interview.  
The researcher typed up the transcriptions using Microsoft Word 2013 and a 
transcription pedal and software (Sony Digital Voice Editor 3.3.1). This allowed 
for hands free replaying of the interviews. This was all completed on a double-
encrypted password-protected UHBristol computer. The transcription was typed 
‘verbatim’ word for word. The researcher then re-listened to the audio recording 
and checked for any mistakes. The researcher repeatedly read the transcript but 
in an active way, searching for meanings and patterns (Braun and Clarke, 2006). 
The researcher highlighted the data and made notes against the text. This was 
carried out on paper and electronically on NVivo 10, see section 5.13.2 phase 2 
for further discussion. 
5.13.2 Phase 2: Generating the initial codes 
The researcher at this point had created a list of ideas about the data. The next 
phase involved code creation. Codes have been described as evaluating the raw 
data using the simplest component (Boyatzis, 1998). Inductive “bottom up” 
approach and semantic “surface” coding were used because it was novel 
research, so there was limited pre-existing information (Braun and Clarke, 2006).  
The researcher wanted to code both manually and using NVivo 10. This was to 
allow for all possible tools to be used to ensure the fullest analysis of the data. 
NVivo is a practical, safe and time efficient way of keeping all the information 
together (Johnston, 2006). It is also easy for another researcher to follow and 
leave an audit trail to increase credibility (Robson, 2011). Criticisms of the 
software are that it could distance the researcher from the data (Fielding, Lee and 
Lee, 1998). However, whilst the software manages the data, the analysis process 
must still be carried out by the researcher (Johnson, 2006). 
Each interview was coded systematically initially soon after interview and then the 
whole data set was coded again when all the interviews were complete. When 
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preparing the data by hand the transcriptions were printed out several times and 
the highlighted annotated sections cut out and pieced together with similar 
themes. Care was taken to ensure all the data were coded. The copies of text 
enabled multiple codes to be applied to the same text. The transcription was also 
coded on NVivo where the transcriptions were saved and analysed on screen. 
The transcripts were blind coded for themes by a member of the supervision team. 
Multi-researcher analysis is important for ensuring findings are trustworthy 
(Silverman, 2001). 
5.13.3 Phase 3: Searching for themes 
When the researcher had coded all of the interviews, themes were considered. 
Themes house the meaning and content of the codes (Braun and Clarke 2006). 
The researcher used hand drawn mind maps and spider drawings to collate the 
codes into potential themes. When the researcher was unsure where to place a 
code it went into a mind map entitled ‘unsure’.  
Additionally the researcher used NVivo to move the codes (or ‘nodes’ as they are 
called) into family trees and then applied themes. The researcher also trialled 
Inspiration 8 software and Power Point 2013 to make mind maps. Ultimately the 
researcher preferred to hand draw mind maps and then recreated them on Power 
Point 2013. Some of the themes were made up from initial code names but other 
theme names were unique to the analysis process. At the end of this process the 
researcher had a group of potential themes and sub-themes in line with the 
procedure suggested by Braun and Clarke (2006). Each theme was given a name 
and a meaning by the researcher as some were similar in name but had 
completely different meanings. 
5.13.4 Phase 4: Reviewing themes 
The next stage of the analysis was re-evaluating the themes. Each coded 
transcript was evaluated to decide if some of the themes were part of the same 
over-arching theme and whether other themes needed to be split into separate 
themes. Then the researcher reviewed all the coded extracts of data to assess 
whether they fitted in with each chosen theme. At this point the researcher moved 
around some of the coded transcripts to new themes and some were put into a 
discarded pile. 
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The researcher then considered the themes in relation to the whole data set. 
Braun and Clarke (2006) refer to this as ensuring an accurate reflection of the 
meaning of the whole data set. This took quite a few attempts by the researcher 
and lots of re-structuring of the themes until the researcher felt comfortable that 
the themes reflected the content of all of the interviews. It was at this point that 
the clean interview transcripts were shared with one of the supervisors who had 
experience of analysing qualitative data for a blind TA. Confidentiality was 
ensured and at this point all of the interviewees had alternative names. The 
purpose of this was to increase the trustworthiness of the analysis, see section 
5.15, for further explanation. 
5.13.5 Phase 5: Defining and naming themes 
At this point the researcher had a thematic diagram of the data that was believed 
to be representative of the whole data set. Each theme was then reviewed for 
name and description of meaning. This stage was important because it 
encapsulated the substance of each theme and allowed for importance to be 
attached (Braun and Clarke, 2006). At this point the coding and themes that the 
supervisor produced were compared with those of the researcher. This was a 
positive experience because it strengthened existing themes. It also identified 
some additional themes and neglected some the researcher had identified. 
Therefore the researcher went back to Phase 4 to review the creation of themes. 
5.13.6 Phase 6: Producing the synthesis 
Once all the themes were identified they were sent to each of the interviewees to 
try to evaluate the extracted understanding of the patient experience. Originally 
the researcher had proposed to send each interviewee their transcript. However 
at the point of transcription it became evident that the way in which people talked 
inclusive of pauses and ‘erms’, may have been upsetting to see written down. 
Therefore a letter explaining the resulting themes was sent to each of the 
interviewees with the opportunity for them to feedback their comments.  
No confidential information was made available to the interviewees. None of the 
interviewees offered any feedback at this stage. Subsequently talking to the 
participants revealed that the participants agreed with what was said or, in the 
case of two participants, they felt ill-equipped to give feedback. Therefore the final 
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analysis was completed and a synthesis produced (Chapter 8). It was important 
to link back to the research questions and aims whilst ensuring that anything 
unique was also captured. The synthesis needed to demonstrate clear analysis 
of the findings not just a description of the data (Braun and Clarke, 2013). 
5.14 How rigour and trustworthiness were addressed 
5.14.1 Introduction 
There is much debate about if or how qualitative data should be assessed for 
quality (Meyrick, 2006: Lincoln and Guba, 1985). Some researchers believe that 
there are many truths and so there has to be more than one method for assessing 
quality (Meyrick, 2006). However the researcher felt that within the health care 
setting, where most research is quantitative, an explanation should be given as to 
how rigour and trustworthiness could be measured. It is important for the 
researcher to be aware of possible mistakes made within the methods used 
(Oakley, 2000). The researcher used the check list based on suggestions by Guba 
and Lincoln (1981) and Shenton (2004) to evaluate rigour within the method of 
this study. 
5.14.2 Sampling 
A random selection of participants may lessen researcher bias (Shenton, 2004; 
Preece, 1994). All the participants were randomised to groups. However in this 
study the sampling was purposive. Only participants in the treatment limb were 
interviewed due to time and the aim of the research which was to assess the 
feasibility of the project. 
5.14.3 Triangulation 
Triangulation involves the use of different methods to give strength to the findings 
(Shenton, 2004). The use of more than one method can compensate for their 
individual limitations and gain from their combined benefits (Brewer and Hunter, 
1989; Lincoln and Guba, 1985). Whilst the researcher did not use triangulation by 
using more than one qualitative method, she used a mixed methods design. 
Therefore the complementing of the qualitative and quantitative methods should 
add credibility to the findings (Robson, 2011). The mixed research design can 
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make up for the limitations in each of the paradigms, whilst exploiting the benefits 
(Bryman, 2006). 
5.14.4 Ensuring honesty 
All participants were given the right to withdraw from the study at any time or to 
opt out of the interview component. Therefore the study only collated data from 
participants who wanted to participate. This was to ensure an honest response 
from participants (Shenton, 2004), however by not including everyone who 
participated one might miss some important information about the experience. It 
may be that those who had a negative experience were less likely to want to 
discuss it, which could have affected the analysis of feasibility. Of the six 
participants, it was possible to interview four. Unfortunately two participants died 
during the study so their viewpoints were not obtained, which may have 
contributed to the eventual analysis of the participant experience. They both had 
previously expressed very positive views regarding the research process and this 
may have added to understanding the acceptability of the intervention, however 
this was beyond the control of the researcher. 
5.14.5 Frequent debriefing sessions 
There were regular meetings between the researcher and the supervision team 
to discuss the outcome of each interview. There were additional debriefing and 
discussion sessions with the supervisor with the most experience of qualitative 
research. This developed the researcher’s ideas through the experience of self 
and others, whilst maintaining confidentiality of the participants (Shenton, 2004). 
5.14.6 Researcher’s reflective commentary  
It has been suggested that in addition to evaluation from supervisors, the 
researcher should continually evaluate throughout the research process 
(Shenton, 2004). These reflections captured the effectiveness of interviewing, the 
researcher’s thoughts during the data collection period and developing thought 
processes of patterns and themes during analysis. Guba and Lincoln (1981) refer 
to this as “progressive subjectivity”, the evaluating of the researcher’s own ideas 
in a transparent way that others can process. For the full details of how the 
researcher reflected upon the research process refer to Chapter 6 (‘Reflexivity’). 
The introduction Chapter 1 Background, section 1.20 Motivations for undertaking 
221 
 
the study, and Chapter 6 Reflexivity, section 6.2 Separating the self, addresses 
the background, qualifications and experience of the researcher which can be 
considered to affect credibility (Patton, 1990). 
5.14.7 Credibility 
Credibility is one of Lincoln Guba’s (1985) criteria for assessing whether the study 
measures what it set out to (Guba, 1981). One method for assessing this is 
whether the method used has been used with previous studies (Merriam, 1998: 
Lincoln and Guba, 1985). The researcher used semi-structured interviews which 
have been previously used successfully in patients with severe COPD and end of 
life patients (Hasson et al., 2008; Jonsdottir and Jondsdottir, 2007; Fraser, Kee 
and Minick, 2006), however as this was novel research there had been no 
previous studies that interviewed participants who had exercised on NIV.  
The second method for assessing credibility is by developing an early familiarity 
with the culture of patients with COPD (Erlandson et al., 1993; Lincoln and Guba, 
1985). As a respiratory physiotherapist the researcher had spent many years 
caring for people within this disease group. Therefore the researcher already had 
good clinical insight into this group of patients, although to allow for a deeper 
understanding the researcher went to local Breathe Easy patients with COPD 
support group meetings prior to beginning the research. 
5.14.8 Member checks 
The sharing of information with the participants has previously been discussed in 
Phase 6 (See Section 5.13.6 Phase 6: Producing the synthesis). Many 
researchers value this process for adding credibility to the findings (Miles and 
Huberman, 1994; Lincoln and Guba, 1981). 
5.14.9 Examination of the research findings 
The researcher ensured that the synthesis and discussion included a detailed 
description of the experience of the participants to ensure that the account was a 
true reflection of the participant’s experience and not just the researcher’s 
(Shenton, 2004). The discussion also compared the findings to previous literature 
to assess their potential relevance within previous research (Silverman, 2005). 
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5.14.10 Transferability 
This method compares the study to other groups and assesses the ability to 
generalise (Merriam, 1998). However, to evaluate rigour in this way was not an 
appropriate method to use for this research because this research did not seek to 
generalise only to demonstrate feasibility and trends. In this qualitative research 
the researcher responsibility is transparency of the process of the study (Elman 
and Kapiszewski, 2014). Providing assistance to researchers for comparison 
regarding the process of research but simultaneously recognising that the 
researcher is the tool and no two studies will be identical. 
5.14.11 Dependability 
This again is a contentious issue as it could be argued that qualitative research 
values the individual, and if you performed the research in the same way you may 
not get the same results (Marshall and Rossman, 1999; Fidel, 1993). Guba and 
Lincoln (1981) suggested that “overlapping methods” can achieve dependability, 
however the researcher has used mixed methods research therefore any changes 
in QOL may be matched both in the interview data and also within the QOL 
questionnaires and walk test making the findings more dependable (Bryman, 
2006). The researcher has also clearly documented the methods and reflections 
appraised to ensure that the research was repeatable. This includes Shenton’s 
(2004) checklist of research design and its implementation, operational detail of 
data collection, reflective appraisal of the process. 
5.14.12 Confirmability 
This is to ensure that as far as was achievable the findings presented were the 
experiences and concerns of the participants rather than the values of the 
researcher (Shenton, 2004). However it has been commented that the bias of the 
researcher is unavoidable (Patton, 1990). Triangulation of methods is offered by 
researchers as a method to confirm findings (Shenton, 2004). Again the use of 
mixed methods helped to consolidate the research findings and ensured they 
accurately reflected the true experience of the participants. The reflections that 
the researcher made during the research process addressed researcher 
tendencies and allowed other researchers to assess how analysis decisions were 
made (Miles and Huberman, 1994). 
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Additionally Braun and Clarke’s (2006) 15 point check list of criteria for good 
thematic analysis (TA) (Table 5.1) was used to evaluate the method of TA. 
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Table 5.1 Adapted 15 point checklist of criteria for good thematic analysis (TA) (Braun and Clarke, 2006) 
Process No. Criteria How the criteria was achieved in this study. 
Transcription 1 Detailed transcription checked against audio-
recordings for accuracy. 
The researcher transcribed all of the interviews independently. 
Coding 2 All data has been given equal importance when 
coding. 
The entire transcript was coded for each participant.  
 3 Coding thorough and detailed to ensure themes 
are not generated from a few key examples. 
Coding included entire interviews, repeated to ensure thoroughness. 
 4 All the extracts for each theme were collected. Extracts were cut out and applied to each theme. 
 5 Themes are checked against all the data and 
each other. 
Themes checked for agreement within all the data set. 
 6 Themes are internally coherent, consistent and 
distinctive. 
Themes were repeatedly reviewed. Another reviewer from the 
supervision team ensured consistency. 
Analysis 7 Data has not just been described but analysed 
and made sense of. 
The data were made sense of through concepts discussed in Chapter 7. 
 8 The data must match up with the analysis. Clear examples from transcriptions are given in the findings, Chapter 7. 
 9 The analysis must be an organized story of the 
data and topic. 
 The themes reflect the participants’ voice and relate to the objectives of 
this study, see Chapter 1. 
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Process No. Criteria How the criteria was achieved in this study. 
 10 A good balance between analysis and extracts.  The Qualitative findings chapter reflect the voice of the participants and 
analysis, see Chapter 7. 
Overall 11 Enough time given to each stage of analysis.  External funding ensured analysis time, discussed in Chapter 4. 
Written report 12 The assumptions and approach to TA are clearly 
explained. 
Concepts regarding the aims of the thesis were used to synthesise the 
findings, see Chapter 7. 
 13 Described method and reported analysis are 
consistent. 
The method of analysis was clearly followed and described.  
 14 The language and ideas are consistent with 
epistemological position of analysis. 
A mixed methods approach met the aim of feasibility. Qualitative analysis 
completed the qualitative study component. 
 15 The researcher is active in the research process, 
themes do not just emerge. 
The researcher discussed clearly her role in analysis. 
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5.15 Conclusion 
This method chapter has demonstrated how the data collection and analysis for 
the qualitative component was carried out. Whilst providing a separate qualitative 
method in its own right, it also demonstrated how the qualitative methods 
complemented the quantitative methods to fulfil the mixed methods methodology. 
The next two chapters discuss the quantitative and qualitative results 
independently. The mixed methods will be combined and discussed together 
within the discussion chapter.  
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Chapter 6 Quantitative Results 
 
6.1 Introduction 
This chapter has 3 parts presenting the quantitative data: 
Part 1 Feasibility and Acceptability (Aim 1 and Aim 2): This presents the data 
relating to feasibility and acceptability. This includes the recruitment data, 
presenting the CONSORT diagram and feasibility of recruitment and retention. It 
includes the acceptability of the trial including completion of outcome measures 
and adherence to intervention. Additionally the SAEs are presented that occurred 
during the trial, hospital admission data and access to health care from the 
participants’ diaries and hospital database. 
Part 2 Presents the participant baseline information (Aim 1): Including the severity 
of disease and social circumstances. 
Part 3 Outcome measure results (Aim 4): Including the 6MWT; breathlessness 
scores - MMRC and MBORG; and the HRQOL questionnaires – SGRQ, LCADL 
and EQ-5D-5L. It also includes the ventilator settings used during the trial and the 
activity data recorded from the ActiCal device worn by the participants. 
6.2 Part 1 Feasibility and Acceptability 
6.2.1 Introduction 
The recruitment period of 11 months was from the end of January 2013 to the 
beginning of January 2014. The recruitment information is presented in the 
CONSORT diagram (Figure 6.1). 63 patients were screened for inclusion into the 
study. 30/63 patients met the exclusion criteria and were therefore not enrolled in 
the study. 
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Figure 6.1 The consort diagram 
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6.2.2 Exclusions 
30 patients met the exclusion criteria (see CONSORT diagram in Figure 6.1 and the reasons for the exclusions in Table 6.1).  
Table 6.1 Reasons for patient exclusions (n = 30) 
Reason Number Details 
1. Primary Diagnosis not COPD. 0 N/A 
2. Not had respiratory acidosis diagnosed 
through ABG analysis. 
0 N/A 
3. Not had NIV treatment. 0 N/A 
4. Under 25 years of age. 0 N/A 
5. Unable to follow commands or unable to 
consent. 
6 3 severe dementia, 2 unknown cause, 1 head injury. 
6. Known contraindication to NIV. 2 1 haemo-pneumothorax, 1 lung cancer: tumour main bronchus. 
7. Unable to tolerate acute hospital NIV. 8 4 unable to tolerate, 4 refusing to continue with acute NIV. 
8. Unable to or refused to comply with 
physiotherapy.  
6 1 safeguarding issue regarding home, 1 self-harmer, 1 patient 
interested but the hospital was in a critical bed state and the patient 
was discharged prior to consenting.1 initiating PR thus already in 
physio programme.1 four weeks into PR course, 1 non-concordant 
with physiotherapy 
9. Had an additional pathology that limited 
ability to mobilise. 
1 Avascular necrosis of the hip. 
10. Dying/receiving end of life care and not 
expected to survive hospital admission. 
7 1 ischaemic bowel, 1 bone metastases, 1 multiple MI, 4 Active 
treatment stopped. 
Abbreviation Key: ABG Arterial blood gas, COPD Chronic obstructive pulmonary disease, MI Myocardial infarction, NIV Non-invasive 
ventilation, PR Pulmonary rehabilitation 
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The most common reason for exclusion was that the participant could not tolerate 
acute NIV. The other two common reasons were that the patients were receiving 
end of life care or they were unwilling or unable to participate in the physiotherapy 
intervention. 
6.2.3 Acceptability and follow up 
Three patients declined to participate in the study, ten died and two lived out of 
area (see further details in table 6.2.) 
Table 6.2 Other reasons patients were not included (n = 15) 
Reason Number Details 
Patient declined. 3 1 worked fulltime. 
1 cared for grandchildren. 
1 disliked exercise. 
Died during admission. 10 6 acute acidosis. 
2 fractured neck of femurs led to 
pneumonia. 
1 gangrene sepsis. 
1 hypovolaemic cardiac arrest. 
Out of area. 2 1 lived in Wales. 
1 lived in Reading. 
 
Two of the three participants who declined to take part in the study cited time 
commitments as reasons for not taking part. One participant still worked as a 
seamstress and felt this took all her time and energy and the other looked after 
her grandchildren after school and felt she could not commit to the time needed. 
There was only one participant who disclosed a dislike of exercise as the reason 
for not taking part in the study. There were two patients who lived out of area this 
had not previously been considered when planning the exclusions as it was 
expected that most of the participants would live within the local Bristol area. Due 
to the lone researcher and time limitations of the PhD they could not be included 
in the study. An area inclusion zone would need to be considered in the future 
RCT. No participants refused to be randomised or withdrew because of the 
possibility of not receiving the intervention.  
During the study period three participants died. Their data were included in the 
evaluation of the results up to the last assessed outcome measure prior to the 
date of death. Of the participants who died one participant was in the standard 
care group and died during their initial hospital admission, thus only baseline data 
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were collated. The other two participants were both randomised to the group 
receiving exercise on NIV in hospital and home. Of those, one participant died 
one month following hospital discharge and one participant died two months after 
being discharged from hospital. The SAEs are explained within section 6.2.8 and 
the Chapter 9 Discussion chapter. There were no other participants who were lost 
to follow up, and all live participants completed the study (n = 15). 
6.2.4 Feasibility of the intervention 
It was feasible to exercise with NIV. Only one participant required nasal pillows to 
provide attachment to the NIV. All the others used a full face mask. There was no 
problem attaching the circuit and no disconnect occurred during supervised 
exercise. Some of the participants were able to carry the ventilator for the walking 
component of the exercise but some needed the clinician to carry the device 
during walking. There were no malfunctioning of equipment identified during the 
trial. Cycling, free weights, sit to stand, and step up’s were all able to be completed 
during the exercise. Seven NIV devices were required to be in use at the same 
time for this feasibility study. 
6.2.5 Ventilator data 
The mean EPAP used for all participants in both the exercise on NIV in hospital 
group and the exercise on NIV in hospital and home was 4cmH2O. It was feasible 
to exercise with a PS >10cmH2O. The mean PS end of study was 16cmH2O for 
the exercise on NIV in hospital and home group compared to 12cmH2O for the 
exercise on NIV in hospital group. Both groups received good PS, see table 6.3. 
Table 6.3 Ventilator settings (mean ±SD) used during the trial 
 Hospital exercise 
on NIV 
(n = 5) 
Hospital & home 
exercise on NIV 
(n = 6) 
Total 
(n = 11) 
Mean IPAPcmH2O 
start of trial ±SD  
 15.8 ±0.4 16.67 ±2.98 16.27 ±2.26 
Mean IPAPcmH2O 
end of trial ±SD 
16.4 ±0.8 
 
19.67 ±4.85 18.18 ±3.97 
Mean PScmH2O 
start of trial ±SD 
11.8 ±0.37 12.67 ±2.98 12.21 ±3.97 
 
Mean PScmH2O 
end of trial ±SD 
12.4 ±0.8 15.67 ±4.49 14.18 ±3.97 
 
Abbreviation Key: EPAP Expiratory positive airway pressure, IPAP Inspiratory 
positive airway pressure, PS Pressure support, SD Standard deviation. 
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6.2.6 Number of sessions prior to discharge 
The median number hospital of physiotherapy contacts, amount of hospital 
therapy time spent with each group and intervention days initiated from when the 
participant was medically stable (normal ABGs) are shown in Table 6.4. There 
was a trend for both the NIV treatment groups to have used NIV acutely for longer 
(in both days and hours) than the standard care group. There was also a trend for 
the exercise on NIV in hospital group to have had more physiotherapy contact (in 
both number of sessions and hours) than the other two groups. There was no 
significant difference between hospital stay and therapy contact. Therefore it was 
feasible to set up NIV and begin training with no extra time needed. 
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Table 6.4 Table of acute hospital treatment received data 
 Standard care 
(n = 7) 
Exercise on NIV 
in hospital (n = 5) 
 Exercise on NIV 
in hospital and 
home (n = 6) 
Total 
(n = 18) 
P = value 
ANOVA 
Hospital acute NIV use 
Median days any use 
(IQR) 
1 (1-4) 5 (3-6) 4 (1-8) 4 (1-6) 0.8 
Hospital acute NIV use 
Median hours used 
(IQR) 
13  
(5-60) 
92  
(69-98) 
52 (31-95) 48 (11-103)  0.6 
Median total number of 
physiotherapy sessions  
(IQR) 
7 (3-15) 13 (7-15) 7 (3-15)  9 (3-14) 0.9 
Median hours of total 
physiotherapy treatment time 
(IQR)  
4 (2-8) 
 
7 (4-7) 
 
4(2-11) 
 
6 (2-8) 0.9 
Median intervention days 
available (IQR) 
4 (3-12) 
 
10 (5-18) 
 
4 (3-9) 
 
5 (3-13) 
 
0.7 
Abbreviation Key: IQR Interquartile range 
 
234 
 
Following discharge the exercise on NIV hospital and home group had between 
eight and 24 exercise sessions. The four live participants at the end of the study 
all received 24 sessions of exercise on NIV following hospital discharge. There 
were two participants who were hospitalised during their planned intervention 
period. They continued with their supervised exercise in hospital once stabilised 
(cardiovascular observations stable and acidosis corrected). For one participant 
this involved one session in hospital and for the other participant it involved seven 
sessions in hospital because of an extended length of stay. For this participant 
the exercise intervention needed to be re-evaluated as their MBORG score was 
considerably higher so exercise intensity and intervention was less. No live 
participant missed any supervised exercise session.  
6.2.7 Feasibility of completion of outcome measures 
All of the outcome measures for 6MWT, HRQOL and Breathlessness scores were 
100% completed by all participants apart from in the three who died. There were 
no missing items. However, the ActiCal device was the only outcome measure 
that was incomplete not worn by 4 participants all of the time.  
One participant in the standard care group died in hospital before discharge and 
so was not issued a device. One of the exercise on NIV in hospital and home 
group participants died during the trial therefore only had the first month’s data 
available. There were four further participants who had incomplete data, see 
figure 6.2. The reasons for lost data were two patients misplaced the device, one 
patient took the device off for her son’s wedding and forgot to put it back on and 
one patient submerged the device in water and the data were lost. This included 
two patients from the standard care group and one from both the exercise on NIV 
in hospital group and exercise on NIV in hospital and home exercise groups. 
Therefore these participants were excluded from the median total number of daily 
steps. However, where complete data were available for month one, two or three 
this was included when calculating the monthly medians for each group. The raw 
data for Actical was not included in the Appendices because it was incomplete 
and large in volume. Medians were calculated because the data were not normally 
distributed.
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Figure 6.2 Bar chart of the number of concordance days with the ActiCal device across groups 
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Exercise on NIV hospital & home 1
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The outcome measures were all completed at the planned time points in live 
participants. The participants took between 30 to 45 minutes to complete the 
outcome measures. The outcome measures were carried out on a different day 
to the intervention.  
6.2.8 SAEs 
There were 17 SAEs within the sample during the study, see table 6.5. All three 
groups had participants that experienced SAEs. The standard care group 
experienced the most, at nine and exercise on NIV in hospital the least, at three. 
There were three participant deaths during the study. One participant died within 
the standard care group and two died within the exercise on NIV in hospital and 
home group. The participant who died in the standard care group only had 
baseline assessment, their condition deteriorated in hospital and they died from a 
combination of respiratory infection and heart failure. The other two participants 
were from the exercise on NIV in hospital and home group. One of these 
participants died in hospital after one month in the trial. This participant died of an 
acute infective exacerbation of COPD causing uncompensated type two 
respiratory failure and respiratory arrest. The second participant died at home 
after completing two months of the trial. They died in their sleep in the afternoon 
following a GP visit that day for acute breathlessness treated with morphine-based 
medication. None of the participants who died had been exercising with the 
intervention during the three days before death.  
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Table 6.5 SAEs for all three groups 
 Standard 
care 
(n = 7) 
Exercise on NIV 
in hospital  
(n = 5) 
Exercise on NIV in 
hospital and home 
(n = 6) 
Total 
(n = 18) 
SAE: Total 
number 
(mean ±SD) 
9 
(1.29 ±0.88) 
 
3 
(0.60 ±0.49) 
5 
(0.83 ±1.07) 
17 
(0.94 
±0.91) 
 
SAE: Number 
of Deaths 
(mean ±SD) 
1 
(0.18 ±0.38) 
0 
(0.00 ±0.00) 
2 
(0.14 ±0.15) 
3 
(0.17 
±0.37) 
Key: SAE Serious Adverse Event, SD Standard deviation 
 
All of the SAEs were reported via telephone and on standardised reporting forms 
to both the sponsor at Philips-Respironics and to the R & I department at 
UHBristol. The exact details of the events were documented, including the trial 
arm each participant was in, for scrutiny. Each of the SAEs were individually 
assessed by a research panel at Philips-Respironics and by the research safety 
officer at UHBristol. The researcher was then contacted by both Philips-
Respironics and the R & I department with a report regarding the outcome 
assessment for each SAE. This was then logged in the trial portfolio. 14 of the 
SAEs were participants hospitalised for an infective exacerbation of COPD. Eight 
hospital admissions were in the standard care group, three hospital admissions 
were in the exercise on NIV in hospital group and four hospital admissions were 
in the NIV on exercise in hospital and home group. All of the participants needed 
treating with antibiotics, steroids and nebulizers. Four of the admissions in the 
standard care group and two of the participants who had hospital admissions 
needed acute treatment of their uncompensated type two respiratory failure with 
NIV. All of the SAEs were evaluated as being related to the severity of the 
participants’ COPD. The trial was not stopped at any time because of SAEs. There 
were no incidents of equipment failure or breakages during the trial. At no time 
did any participants ask to stop the exercise or intervention. 
6.2.9 Hospital Admission data 
The hospital admission data were not normally distributed, therefore medians 
were used within the descriptive statistics. There was a trend that the standard 
care group and the exercise on NIV in hospital and at home group decreased their 
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hospital admissions from the six months before the trial to the six months after the 
trial, however there was an increase in admissions post trial for the exercise on 
NIV in hospital group (see table 6.6).  
Table 6.6 Median number of hospital admissions in all groups within the six months 
pre-trial, in-trial time and six months post-trial 
 Standard care Exercise on 
NIV in 
hospital 
Exercise on 
NIV in 
hospital & 
home 
Total 
Before study 
number of 
admissions 
(IQR)  
2 (0-5) 
 
(n = 7) 
0 (0-2) 
 
(n = 5) 
 
1 (0-2) 
 
(n = 6) 
1 (0-2) 
 
(n = 18) 
During study 
number of 
admissions 
(IQR) 
2 (0-3) 
 
(n = 6) 
0 (0-1) 
 
(n = 5) 
1 (0-2) 
 
(n = 5) 
1 (0-2) 
 
(n = 16) 
After study 
number of 
admissions 
(IQR) 
2 (0-5) 
 
(n = 6) 
1 (0-7) 
 
(n = 5) 
1 (0-3) 
 
(n = 4) 
1 (0-4) 
 
(n = 15) 
Abbreviation Key: IQR Interquartile range, n = number of participants. 
 
There was a trend for the exercise on NIV in hospital and home group to have the 
longest median length of stay (LOS) during the trial. There was a trend for the 
standard care group to have the longest median LOS within the 6 months 
following the trial, see table 6.7 for the admission length of stay data. 
Table 6.7 Median length of stay (days) of hospital admissions between groups 
within the six months pre-trial, in-trial time and within the six months post-trial 
 Standard care Exercise on 
NIV in 
hospital 
Exercise on 
NIV in 
hospital & 
home 
Total 
Before study 
LOS days of 
admissions 
(IQR)  
4 (2-7.5) 
 
(n = 7) 
1 (0-3) 
 
(n = 5) 
1 (0.25-7) 
 
(n = 6) 
2 (1-7) 
 
(n = 18) 
During study 
LOS of 
admissions 
(IQR)  
4 (1-10) 
 
(n = 6) 
3.6 (0-9) 
 
(n = 5) 
4.5 (1-25) 
 
(n = 5) 
4 (0-10) 
 
(n = 16) 
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 Standard care Exercise on 
NIV in 
hospital 
Exercise on 
NIV in 
hospital & 
home 
Total 
After study LOS 
of admissions 
(IQR) 
5 (1.25-9) 
 
(n = 6) 
2.5 (1-9.5) 
 
(n = 5) 
2 (0-18.5) 
 
(n = 4) 
4 (1-9) 
 
(n = 15) 
Abbreviation Key: IQR Interquartile range, LOS Length of stay, n = number of 
participants. 
 
6.2.10 Participant diary information  
These data were self-recorded during the trial.  It included information regarding 
medication use and access to health care. All participants successfully kept 
diaries and completed entries for each day of the trial.  
6.2.11 Medication use 
The record of medication use kept by the patients in their diary was not normally 
distributed, therefore the medians and Interquartile ranges (IQRs) were 
presented. There was a trend that the group that had the most days of antibiotic 
use was the standard care group at 38.5 median numbers of days compared with 
the exercise on NIV in hospital group that had the least at 22 median days use. 
There was a trend for the standard care group to have the most days of steroid 
use at median days of 33.5 compared with a median of 22 days of steroid use for 
participants in the exercise on NIV in hospital group and a median of 19 days use 
in the exercise on NIV in hospital and home group. 
The extra medication taken was calculated from the diaries. The participants 
marked on their diary all the medication taken that day and if they had used more 
than their normal dose, for example extra doses of bronchodilators. There was a 
trend for the standard care group to have documented the most median days of 
increased medication at 33 days, see table 6.8. 
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Table 6.8 The median days increase in total patient reported extra medication use 
between groups from hospital discharge over the three month trial period 
 Standard care 
(n = 7) 
Exercise on 
NIV in hospital 
(n = 5) 
Exercise on 
NIV in hospital 
& home (n = 6) 
Total 
(n = 18) 
Antibiotic use 
Median days 
(IQR) 
38.5 (9-45) 22 (8-43) 26 (0-48) 
 
25 (9-43) 
Steroid use 
Median days 
(IQR) 
33.5 (20-45) 22 (12-51) 19 (0-48) 24 (13-44) 
Increased 
dose/issues 
of prescribed 
medication 
Median days 
(IQR) 
33 (22-41) 22 (15-70) 11 (0-49) 25 (11-51) 
Abbreviation Key: IQR Interquartile range 
 
There was a trend for the exercise on NIV in hospital and home group to have 
documented the least median days of extra doses of medication.  
6.2.12 GP access from hospital discharge to month three 
Table 6.9 shows the differences in GP contacts between the groups. There was 
a trend that the exercise on NIV in hospital group had three times as many home 
visits compared to the exercise on NIV in hospital and home exercise group. One 
participant in the exercise on NIV in hospital group received 10 home visits from 
the GP within the three month follow up research period. 
Table 6.9 Table of GP access: Recorded by participants from hospital discharge to 
month three 
 Standard 
care 
(n = 6) 
Exercise on 
NIV in 
Hospital 
(n = 5)  
Exercise on 
NIV Hospital 
& home  
(n = 6) 
Total 
(n = 18) 
Number of visits to GP 
Practice  
 (IQR) 
0.5 (0-1.3) 
 
0 (0-2.5) 
 
0 (0-0.8) 
 
0 (0-2.5) 
 
Number of home visits 
by GP  
(IQR) 
1 (0-2) 
 
3 (0.5-6.5) 
 
0 (0.5) 
 
1 (0-2) 
 
Number of phone 
consults by GP 
(IQR) 
0 (0-1) 
 
0 (0-1) 
 
0 (0-2) 
 
0 (0-1) 
 
Abbreviation Key: GP General Practitioner, IQR Interquartile range. 
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6.2.13 Part 1 conclusions 
In summary a total of 18 patients were recruited and 15 completed the study. 30 
patients met the exclusion criteria, three declined to participate. The recruitment 
rate equates to 29% of those assessed (18/63) or 55% of those eligible for 
recruitment (18/33). A large proportion (30%) of those eligible died during 
admission (10/33) but only 9% (3/33) declined to participate. Randomisation after 
screening allocated seven to the standard care group, five to the exercise on NIV 
in hospital group and six to the exercise on NIV in hospital and home group. Three 
participants died and had incomplete follow up. There were no other reasons 
participants were lost to follow up. A mean of 5.72 patients were screened each 
month and 1.63 patients were recruited each month. Overall the consent rate of 
55% (of those eligible) was good, particularly considering how ill this population is 
and may be promising for recruitment into a future trial. 
The participant diaries were returned by all live participants. The standard care 
group demonstrated a trend for increased use of usual medication compared to 
the other groups. There was a trend for the exercise on hospital and home group 
to have accessed their GP less than the other two groups. 
 
6.3 Part 2 Participant Baseline Information 
6.3.1 Introduction 
The baseline characteristics of the sample consisted of descriptive information 
including ethnicity, gender and weight. Information on disease severity included 
smoking history, lung function and previous admissions. Social information is 
reported including factors of social isolation and deprivation. Further disease 
severity is expressed through ABG results and the calculation of BODE scores 
predicting mortality.  
6.3.2 Statistical Analysis 
Details of how data were recorded and analysed can be found in Chapter 4 
(‘Quantitative Methods’), section 4.23 Data Analysis. Missing data were caused 
by deaths of participants within the sample; there was no incomplete outcome 
measure data through researcher error or participant choice. The participants who 
242 
 
died were excluded from the analyses after their last data collection. 
Consequently one participant from the standard care group was excluded 
following baseline assessments and two participants from the exercise on NIV in 
hospital and home group were excluded, one after month one assessment and 
another after month two assessment respectively.  
Initially the descriptive statistics were calculated. All the outcome measure scores 
were normally distributed, with the exception of the ActiCal data and participant 
diary data. Not all of the baseline characteristics were normally distributed, 
therefore median and interquartile range were used to describe the data and non-
parametric testing were applied to the data (Kruskall-Wallis) to assess for any 
differences between the groups.  
The researcher analysed the data to identify any trends. Any further statistical 
analysis was not attempted because of the small sample size of each group.  
6.3.3 Differences in the Baseline Characteristics of the sample in each trial 
arm 
There were trends for differences in baseline characteristics between the exercise 
on NIV in hospital group and the other groups. The exercise on NIV group had a 
mean age of 73.4 years which is 11.2 years older than the mean age of 62.2 years 
in the exercise on NIV in hospital and home group and 8.1 years older than the 
standard care mean age of 65.3 years. The exercise in hospital group had more 
males but had a lower pack year history of smoking. The exercise on NIV in 
hospital group had a higher mean number of co-morbidities than the exercise on 
NIV in hospital and home group but not the standard care group. The exercise on 
NIV in hospital and at home group had a trend for more hospital admissions 
requiring acute NIV (see Table 6.10). However there were no significant 
differences between groups. 
 
A selection of the severity raw data (Age, FEV1% predicted, Pack year history) 
has been included in Appendix 21. This was to allow for a selection of individual 
and group data to be reviewed. All the raw data was not included due to the sheer 
quantity of data.
243 
 
Table 6.10 Baseline characteristics. Data are shown as mean ±SD (95% CI) or median (IQR range) 
 Standard care (n 
= 7) 
Exercise on NIV 
in hospital (n = 5) 
Exercise on NIV 
in hospital and 
home (n = 6) 
Total: 
(n = 18) 
p-value (ANOVA 
unless stated) 
Gender (% female) 71.4 40.0 66.6 55.5 0.22 Χ2 
Ethnicity (% white British) 85.7 80.0 83.3 88.2 0.40 Χ2 
Age (years) 
Mean ±SD 
65.3 ±6.5 73.4 ±19.3 62.2 ±6.1 66.5 ±11.6 0.28  
FEV1 (% predicted) 
Mean ±SD (95% CI) 
27.8 ±16.9 28.2 ±14.3 25.8 ±12.1 27.2 ±13.7 
(20.2, 34.3) 
0.96 
Pack year history (number 
of cigarettes smoked per day 
(20) × number of years smoked) 
Mean ±SD (95% CI) 
39.3 ±7.3 27.0 ±16.4 38.3 ±18.6 35.6 ±14.6 
(28.3, 42.8) 
 
0.32 
Previous admissions treated 
with NIV (number) 
Median (IQR)) 
0 (0-3) 0 (0-3) 1 (0-2.25) 0 (0-2.25) 0.85 
(Kruskal- 
Wallis) 
Co-morbidities (number) 
Mean ±SD 
(95% CI) 
5.9 ±3.6 5.0 ±3.1 4.2 ±1.7 5.1 ±2.9 
(3.6, 6.5) 
0.27 
Abbreviation Key: CI Confidence interval, IQR Interquartile range, SD standard Deviation. 
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6.3.4 Other severity factors 
There was a trend for the highest proportion of LTOT users to be in the exercise 
on NIV in hospital and home group at 83.3% presented in table 6.11. There was 
no significant difference between the groups for mean arterial pH and arterial 
pCO2 at initiation of medical treatment with acute NIV. 
 
Table 6.11 Other severity factors 
 Standard 
care 
(n = 7) 
Exercise 
on NIV in 
hospital (n 
= 5) 
Exercise 
on NIV in 
Hospital 
and home 
(n = 6) 
Total 
(n = 18) 
P- value 
Arterial pH at 
initiation of NIV 
Mean ±SD 
7.24 
 ±0.08 
7.23 
 ±0.11  
7.29  
±0.04 
7.26 
±0.08 
0.69 
Arterial pCO2 at 
initiation of NIV 
(kPa) 
 Mean ±SD 
11.14 ±2.52 10.42±2.59 10.47±1.97 10.70 
±2.41 
0.92 
LTOT user at 
Baseline 
(number (%)) 
3 (42.8) 2 (40.0) 5 (83.3) 10 (55.5) 0.28 
Abbreviation Key: LTOT Long term oxygen therapy, pCO2 Partial pressure of carbon 
dioxide in the arterial blood, SD Standard deviation. 
 
6.3.5 The BODE index score of predicted mortality 
The BODE index score was calculated at discharge for each of the participants. 
There was one participant within the standard care group who died prior to 
discharge so the BODE score was not calculated (see the quantitative method, 
section 4.21.1). The mean BODE score by group and percentage chance of 
mortality by 52 months is presented in table 6.12. 
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Table 6.12 Table of Mean BODE scores at baseline and % chance of mortality at 52 
months. Data are mean ±SD 
 Standard 
care (n = 
7) 
Exercise 
on NIV in 
hospital  
(n = 5) 
Exercise 
on NIV in 
hospital 
and home 
(n = 6) 
Total 
(n = 18) 
P-value 
(ANOVA) 
Baseline BODE 
score 
8.17 
±2.19 
8.40 
±1.20 
7.83 
±1.57 
8.12  
±1.74 
0.88 
Mortality at 52 
months (% 
chance) 
76.67 
±7.45 
80.00 
±0.00 
78.33 
±3.73 
78.24 
±5.13 
0.61 
All groups demonstrated high predicted mortality, in line with their known disease 
severity. 
6.3.6 Social History 
The table of smoking and illegal drugs users (Table 6.13) presents the intake of 
harmful substances within the sample. 
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Table 6.13 Smoking and illegal drug use within the group 
 Standard care (n = 7) Exercise on NIV in 
hospital (n = 5) 
Exercise on NIV 
hospital and home (n 
= 6) 
Total (n = 18) P-value (ANOVA) 
Current Smoker (n) 1 2 2 5 0.62 
Ex-smoker (n) 6 2 4 12 0.29 
Never smoker (n) 0 1 0 1 0.28 
Current drug user (n) 0 1 1 2 0.53 
Ex-drug user (n) 1 0 0 1 0.48 
Current alcohol abuser 
(n) 
1 0 1 2 0.69 
Ex-alcohol abuser (n) 2 2 0 4 0.28 
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6.3.7 Body Mass Index (BMI) 
There was no significant difference between the three groups in their BMI results. 
The weight distribution across the groups is presented in table 6.14. There was a 
trend for the exercise on NIV in hospital and home group to have an overweight 
BMI, with a mean BMI of 27.5Kg/m2, however there was no significant difference 
between the three groups in their BMI results.
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Table 6.14 Body Mass Index (BMI) of the groups (mean ±SD) (World Health Organisation (WHO), 2000) 
 Standard Care 
(n = 7) 
Exercise on NIV in 
hospital (n = 5) 
Exercise on NIV in 
hospital and home 
(n = 6) 
Total 
(n = 18) 
P value 
(ANOVA) 
BMI mean kg/m2 ±SD 
 
22 ±5 20 ±2 28 ±12 23 ±8 
 
0.33 
Underweight, n (%) 
< 18.5kg/m2 
2 (29) 3 (60) 2 (33) 7 (39) 0.56 
Healthy weight, n (%) 
18.5-25kg/m2 
2 (29) 1 (20) 0 (0) 3 (17) 0.42 
Overweight, n (%) 
25-30kg/m2 
3 (43) 0 (0) 1 (17) 4 (22) 0.22 
Obese, n (%) > 
30kg/m2 
0 (0) 1 (20) 3 (50) 4 (22) 0.10 
Abbreviation Key: BMI Body Mass Index, n number, SD Standard deviation. 
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6.3.8 Social Isolation 
Over a quarter of the total number of participants lived alone (38.9%) see 6.15 
table of isolation. Overall the group had poor activity levels and 72.2% of the 
sample were unable to climb stairs. 
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Table 6.15 Social Isolation 
 Standard care (n = 7) Exercise on NIV in 
hospital (n = 5) 
Exercise on NIV in 
hospital and home (n 
= 6) 
Total 
(n = 18) 
P value 
(ANOVA) 
Lives alone, n (%) 2 (28) 4 (80) 
 
1 (17) 7 (39) 0.08 
House bound, n (%) 4 (57) 2 (40) 2 (33) 8 (44) 0.71 
Unable to do stairs, n 
(%) 
4 (57) 4 (80) 5 (83) 13 (72) 0.56 
Uses walking aid, n (%) 4 (57) 1 (20) 2 (33) 7 (39) 0.45 
Unable to visit GP, n 
(%) 
4 (57) 2 (40) 4 (67) 10 (55) 0.71 
Unable to visit hospital, 
n (%) 
3 (43) 2 (40) 4 (67) 9 (50) 0.64 
Abbreviation Key: GP General Practitioner, n Number. 
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There was a trend for more participants within the exercise on NIV in hospital 
group to live alone, suggesting they may experience more isolation. There was a 
trend for more participants in the standard care group to be able to do the stairs 
and use a walking aid, suggesting they had higher activity levels than in the other 
two groups. 
6.3.9 Deprivation  
All three groups had participants living within socially deprived areas, see Table 
6.16 for details of social deprivation across the groups. There was a trend for the 
exercise on NIV in hospital group to have the greatest deprivation with 60% living 
in England’s worst 10% of deprived areas, 80% experienced any form of 
deprivation and 80% experienced crime deprivation. 
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Table 6.16 Table of deprivation 
 Standard care (n = 7) Exercise on NIV in 
hospital (n = 5) 
Exercise on NIV in 
hospital and home (n 
= 6) 
Total 
(n = 18) 
Area in top 10% of England’s overall deprived 
wards (2010), n (%) 
2 (28) 3 (60) 2 (33) 7 (39) 
Area within top 10% of England wards for crime 
deprivation, n (%) 
4 (57) 4 (80) 3 (50) 11 (61) 
Area in top 10% of England wards for education 
deprivation, n (%) 
3 (43) 2 (40) 1 (16) 6 (33) 
Living in a ward experiencing any form of 
deprivation, n (%) 
4 (57) 4 (80) 3 (50) 11 (61) 
Lives in council property, n (%) 5(71) 2(40) 4 (67) 11 (61) 
Receives paid benefit, n (%) 5 (71) 2(40) 4 (67) 11(61) 
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6.3.10 Part 2 Conclusion 
In summary there was a 55% consent rate for the study which may indicate good 
recruitment potential for a future study. There were no statistical differences 
between baseline characteristics of the three groups, although there were trends 
for differences. The exercise on NIV in hospital group were older, sicker and more 
isolated than the other groups. Interestingly both NIV groups remained unwell with 
decompensated acidosis requiring acute NIV for longer than the standard care 
group. 
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6.4 Part 3 Clinical Outcome results 
6.4.1 6MWT results 
The walking distance in six minutes for healthy individuals ranges between 400 
and 700m (Enright, 2003). This study is used a 30m change in distance as the 
MCID. Using SPSS version 17, (IBM: Chicago, Illinois, USA) the Kolmogorov-
Smirnov and Shapiro-wilk tests were used to assess the distribution of the data. 
The results demonstrated that data were normally distributed. It is clear from 
Figure 6.2 that there is a trend for improvement in mean walking distance for the 
home and hospital exercise on NIV treatment group from baseline over all time 
points. The mean and standard deviation are presented in full in Appendix 22. 
 
Figure 6.3 6MWT means of groups. (B-Baseline, DC-Discharge, M1-Month one, M2-
Month two, M3-Month three) presented with SDs. 
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There is a trend for improvement both in the exercise on NIV in hospital group 
and exercise on NIV in hospital and home group from baseline to discharge, 
however in contrast to the exercise on NIV in hospital and home group, both the 
standard care and exercise on NIV in hospital groups demonstrate a decline in 
walking distance following hospital discharge. Standard care and exercise on NIV 
in hospital and home groups both had one participant who walked further than 
other participants at baseline, 306m and 315m respectively, (see Appendix 22 for 
raw data). The individual participant results by group are presented in figure 6.4. 
This is presented to demonstrate the detail of the variability between participants 
and groups. 
256 
 
Figure 6.4 6MWT total scores measured over all time points, for all participants in the standard care group, exercise on NIV in hospital and home 
group and exercise on NIV in hospital and home group.  (B-Baseline, DC-Discharge, M1-Month one, M2-Month two, M3-Month three) 
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6.4.2 SGRQ results 
The SGRQ results are weighted from 0-100. The higher the score the worse the 
impairment. The average total score for healthy individuals is six (Ferrer et al. 
2002). There was a trend for improvement in total scores within the exercise on 
NIV in hospital and home group (see Figure 6.5). 
 
Figure 6.5 SGRQ results of the 3 groups mean score.  (B-Baseline, DC-Discharge, 
M1-Month one, M2-Month two, M3-Month three) 
The exercise on NIV in hospital group had minimal change from baseline (mean 
score = 74.27, 95% CI 100.28, 48.27) to discharge (mean score = 73.58, 95% CI 
96.40, 50.77), however there was a decline in impairment for this group at month 
1 (mean score = 80.17, 95% CI 94.95, 65.40) and month 3 (mean score = 80.11, 
95% CI 96.45-63.78). There was a trend for the exercise on NIV in hospital and 
at home group of an improved SGRQ total score from baseline (mean score = 
69.54, 95% CI 84.60, 54.48) to month 3 (mean score = 50.24, 95% CI 89.32, 
11.19). See Appendix 23 for the raw data SGRQ results. 
6.4.3 SGRQ Impact score 
The average impact score for healthy individuals has been reported as two (Ferrer 
et al, 2002). The hospital and home exercise on NIV participants demonstrated a 
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trend for the greatest mean improvement from baseline (mean score = 55.8, 95% 
CI 39.8, 71.8) to month three (mean score = 33.0 CI 9.68, 56.32), see figure 6.6. 
 
Figure 6.6 Graph demonstrating the mean SGRQ impact scores by group.  (B-
Baseline, DC-Discharge, M1-Month one, M2-Month two, M3-Month three) with SDs. 
6.4.4 SGRQ activity component 
The average activity score for healthy people was reported as nine (Ferrer et al, 
2002). There was a trend for both the standard care group and the exercise on 
NIV in hospital and at home group to have improved their activity scores by month 
1, however some of this improvement was lost by month two. Over all time points 
there was a trend for the standard care group to improve their mean score, from 
100 (SD 0.0) at baseline to 66 (95 % CI 44.46, 88.14) at month 3 , and the exercise 
on NIV in hospital and at home group from 89 (95% CI 81.38, 95.62) at baseline 
to 59 (95% CI 36.75, 80.45) at month three. See figure 6.7 for a comparison of 
results across the groups. 
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Figure 6.7 SGRQ mean activity scores across the groups. (B-Baseline, DC-
Discharge, M1-Month one, M2-Month two, M3-Month three) with SDs. 
6.4.5 SGRQ symptoms component score 
The normal score for symptoms in healthy people is 12 (Ferrer et al, 2002). The 
greatest trend for improvement in symptoms scores was in the exercise on NIV in 
hospital and home group. This improved from a baseline score of 79 (95% CI 
67.4, 89.8) to 59 (95% CI 36.75, 80.45) at month three; this can be seen in 
comparison to the other groups within figure 6.8.  
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Figure 6.8 SGRQ mean symptom score.  (B-Baseline, DC-Discharge, M1-Month 
one, M2-Month two, M3-Month three) with SDs. 
6.4.6 LCADL  
The LCADL total score is scored out of 75, the higher the score then the more 
likely the patient is unable to undertake a daily activity because of dyspnoea 
(Garrod et al, 2002). There was a trend that the exercise on NIV in hospital and 
home group had the greatest improvement in their LCADL score from baseline 50 
(95% CI 37.24, 62.36) to 41 (95% CI 27.18-54.42) at month three. The exercise 
on NIV in hospital group demonstrated a decline in their mean score from 47 (95% 
CI 38.67, 55.33) at baseline to 57 (95% CI 51.78, 61.42) by month three. See 
Appendix 24 for the raw data. The comparison between group means is 
demonstrated in figure 6.9. 
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Figure 6.9 Graph of LCADL results mean scores by group.  (B-Baseline, DC-
Discharge, M1-Month one, M2-Month two, M3-Month three) with SDs. 
6.4.7 Breathlessness scores 
The following sections consider the results of the breathlessness outcome 
measures of Modified Medical Research Council (MMRC) Dyspnoea score (0 – 
“not troubled by breathlessness” to 4 – “unable to leave the house because of 
breathlessness”), and MBORG scores (0 – “no breathlessness” to 10 – “maximum 
breathlessness”). 
6.4.7a Modified Medical Research Council (MMRC) Dyspnoea Score 
There was a trend for the standard care and exercise on NIV in hospital groups 
to both demonstrate deterioration in their mean MRC scores. At discharge there 
is a trend for the exercise on NIV in hospital group to have deteriorated from 3.20 
(95% CI 2.15, 4.25) to 3.6 (95% CI 3.16, 4.04), this deteriorates further to 4.0 (SD 
0) by month one. This is in contrast to both the exercise on NIV in hospital and 
home group (baseline 3.7 (95% CI 3.3, 4.1) to discharge 3.2 (95% CI 2.32, 4.08) 
and the standard care group (baseline 3.4 (95% CI 2.66, 4.14) to discharge 2.8 
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(95% CI 1.92, 3.68). For the exercise on NIV in hospital group the score increased 
from 3.20 (95% CI 2.15, 4.15) at baseline to 4.00 (SD 0) at month three. The 
exercise on NIV in hospital and home group demonstrated a trend for 
improvement from a mean score of 3.67 (95% CI 1.42, 3.58) at baseline to 2.50 
(95% CI 1.42, 3.58) by month three. The comparisons of means across groups is 
shown in figure 6.10. (See Appendix 25 for the raw data). 
 
 
Figure 6.10 MMRC Dyspnoea mean score by group. (B-Baseline, DC-Discharge, 
M1-Month one, M2-Month two, M3-Month three) with SDs 
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6.4.7b MBORG Score at rest 
There was a trend for improvement in all three groups from baseline to discharge, 
however only standard care improved their scores from discharge of 4.3 (95% CI 
2.46, 6.14) to month one 3.9 (95% CI 1.9, 5.9) compared with exercise on NIV in 
hospital at discharge 4.0 (95% CI 2.16, 5.84) to month one 4.8 (95% CI 1.9. 5.9) 
and NIV with exercise at home from discharge 1.6 (95% CI 0, 3.2) and to month 
one 2.5 (95% CI 1.86, 3.14). Over the complete time period there was a trend for 
improvement in both the standard care and exercise on NIV in hospital and at 
home groups from baseline 5.57 (95% CI 4.12, 7.08) (standard care), 2.50 (95% 
CI 0.5, 4.0) (exercise on NIV hospital and home) to month three, 3.25 (95% CI 
2.02, 4.58) (standard care) and 2.13 (95% CI 0.25, 4.45) (exercise on NIV hospital 
and home). The exercise on NIV in hospital group demonstrated a trend for a 
decline in BORG score from a baseline score of 4.3 (95% CI 2.02, 6.58) to a 
month three score of 7 (95% CI 5.2, 8.0). The difference in group means is 
demonstrated in figure 6.11. See Appendix 26 for the raw data. 
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Figure 6.11 Mean MBORG breathlessness scores at rest.  (B-Baseline, DC-
Discharge, M1-Month one, M2-Month two, M3-Month three) with SDs. 
6.4.10 European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Score 
A MCID is recognised as 0.03 for the utility score and 1.00 is regarded as best 
health (Brooks, 2003).  
6.4.10a EQ-5D-5L utility scores 
The mean utility scores demonstrated a trend for an improvement in the exercise 
on NIV in hospital and home group from 0.30 (95% CI 1.16, 0.64) at baseline to 
0.66 (0.5, 0.9) at month three (see Appendix 27 for the raw data). There was a 
trend for both the standard care group and the exercise on NIV in hospital group 
to report a worsening in their mean utility score from baseline to month three. 
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There was a trend for a large decrease in utility score for the standard care group 
between month one (0.46 95% CI 0.18, 0.82)) and month two (0.08 95% CI 0.04, 
0.44). A comparison of group mean utility scores can be seen in figure 6.12. 
 
Figure 6.12 EQ-5D-5L mean utility scores.  (B-Baseline, DC-Discharge, M1-Month 
one, M2-Month two, M3-Month three) with SDs 
6.4.10b EQ-5D-5L visual analogue scores (VAS) 
There was a trend for a deterioration in the exercise on NIV in hospital group from 
a mean score of 44 (95% CI 18.0, 69.95) at baseline to 39 (95% CI 25.24, 52.76) 
at month three. Both standard care and exercise on NIV in hospital and home 
groups demonstrated improvements from baseline with a mean score of 37 (95% 
CI 22.8, 51.92) (standard care) and 40 (95% CI 20.96, 59.04) (exercise on NIV in 
hospital and home) to month three scores of 39 (95% CI 20.96, 57.44) (standard 
care) and 58 (95% CI 43, 72) (exercise on NIV in hospital and home). See figure 
6.13 for the differences in mean VAS score between groups. 
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Figure 6.13 EQ-5D-5L mean group visual analogue scores (VAS) scores.  (B-
Baseline, DC-Discharge, M1-Month one, M2-Month two, M3-Month three) with SDs 
6.4.11 Activity monitoring 
The ActiCal collated three months’ worth of data from discharge. The data were 
evaluated and the total daily median step count for each group from all three 
months of data were calculated. Due to incomplete data the analysis included four 
participants from each group, see figure 6.14.  
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Figure 6.14 A box-plot graph to demonstrate the total daily step count between 
groups from discharge to month three 
Each available daily total has been plotted for Standard Care (n = 378 days), Exercise on NIV in 
Hospital (n = 336 days) and Exercise on NIV in Hospital and Home (n = 332 days). 
The exercise on NIV in the hospital and home group improved from 4020 steps at 
month 1 to 6017 by month 2. However by month 3 the step count declined. The 
standard care group had a much lower step count at month 1of 1009, but this 
continued to improve to 3843 at month 3. The exercise on NIV in hospital group, 
whilst beginning with a higher step count at 2515 than the standard care group, 
plateaued over the three months, see table 6.17. 
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Table 6.17 Median daily step count over the three months following discharge 
 Standard care Exercise on 
NIV in 
hospital 
Exercise on 
NIV in 
hospital and 
home 
Total 
 
Month one 
Median daily 
step count 
(IQR) 
1255 
(1009-4149) 
 
(n = 5) 
2515 
(2421-4274) 
 
(n = 5) 
4020  
(3606-7588) 
 
(n = 5) 
3606 
(2138-4519) 
 
(n = 15) 
Month Two 
Median daily 
step count 
(IQR) 
3442 
(1742-5234) 
 
(n = 4) 
2543 
(2374-2745) 
 
(n = 4) 
6017 
(2881-9569) 
 
(n = 4) 
2860 
(2587-5233) 
 
(n =12) 
Month Three 
Median daily 
step count 
(IQR) 
3843 
(2137-4931) 
 
(n = 4) 
2367 
(1937-4180) 
 
(n = 5) 
5843 
(2397-9660) 
 
(n = 4) 
2832 
(1931-5166) 
 
(n = 13) 
Abbreviation Key: IQR Interquartile range, n = Number of participants 
6.4.13 Conclusion 
The exercise on NIV in hospital and home group demonstrated a trend for 
improvement in all outcome measures. The exercise on NIV in hospital and home 
group was the only group to have improved outcomes for the 6MWT, LCADL, 
MRC and EQ-5D-5L.  A summary table of the outcome measures is presented in 
table 6.18. The ‘improved’ or ‘worse’ measures refer to a positive or negative 
change in excess of the MCID. ‘Unchanged’ represents a change below the 
established MCID. MMRC, BORG and total step count do not have a known 
MCID, therefore any improvement is classified as ‘improved’. 
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Table 6.18 Summary table of the outcome measure results in each group from 
baseline to month three 
 MCID Standard care Exercise on 
NIV in hospital 
Exercise on 
NIV in hospital 
and home 
6MWT 30m Unchanged Unchanged Improved 
SGRQ: Total 
score 
4 Improved Worse Improved 
SGRQ: 
Impact 
4 Improved Worse Improved 
SGRQ: 
Activity 
4 Improved Improved Improved 
SGRQ:  
Symptoms 
4 Improved Improved Improved 
LCADL 4 Unchanged Worse Improved 
MRC Not known Worse Worse Improved 
MBORG Not known Improved Worse Improved 
EQ-5D-5L: 
Utility Score 
0.03 Unchanged Worse Improved 
EQ-5D-5L: 
VAS score 
8 Unchanged Unchanged Improved 
Total step 
count 
Not known Improved Worse Improved 
Abbreviation Key: EQ-5D-5L European quality of life - 5 dimensions - 5 levels, LCADL 
London Chest activity of living questionnaire, MCID Minimum Clinically Important 
Difference, SGRQ St George’s respiratory questionnaire, 6MWT Six minute walk test. 
 
6.5 Overall Conclusions 
The quantitative results presented in this chapter demonstrated that the trial had 
a good recruitment and retention rate despite the disease severity of the 
population. This may offer positive information to inform a future trial. The study 
sample included a wide range of participants of variable, gender, age and 
ethnicity. They were reflective of the type of patients with severe unstable COPD 
seen in clinical practice, thus they seemed to represent the desired target 
population. The participants in the intervention limbs were able to exercise with 
NIV on the higher PS, recommended from the literature review. All outcome 
measures, except, the ActiCal data were collated, including the participant 
reported diary. A trend for improvement was demonstrated for the NIV on exercise 
hospital and home group in 6MWT, LCADL, SGRQ and EQ-5D-5L. Unexpectedly 
the exercise on NIV in hospital group demonstrated a trend for deterioration in 6/7 
of the outcome measures. The statistical analysis was limited because of the 
small sample size. A powered future trial may be able to address this problem. 
The recruitment success, outcome measure completion and trend for 
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improvement may suggest that a future trial is feasible, but it is also important to 
assess the acceptability of the intervention to the participants. This will be 
explored within Chapter 7 Qualitative Findings, analysis and researcher 
interpretation of the ‘participant experience’. These quantitative results will be 
combined with the qualitative findings and discussed together within the 
Discussion in chapter 9.  
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Chapter 7 Qualitative findings, analysis and researcher 
interpretation of ‘the participant experience’. 
 
7.1 Introduction 
This chapter presents the findings and analysis from the semi-structured 
interviews of the four surviving participants who were randomised into the hospital 
and home NIV arm of the study. They experienced both the use of exercise on 
NIV during their hospital stay and continued with exercise on NIV for a further 
three months at home. Three women and one man were interviewed and the age 
range was 52-65 years.  
The aim of this chapter is to enable the reader to hear the participants’ voices to 
enable a rich and true reflection of the interview material. The main themes were 
analysed and are discussed under the concepts of the experience of living with 
severe COPD, the feasibility of the study and directions for clinical practice. These 
concepts were developed from the aims of the study, researcher influence, 
literature review and the voices of the participants. This analysis meets the 
secondary aims of the research, Chapter 1 (‘Background’), section 1.21 Data 
Analysis. 
The researcher acknowledges that there is often overlap between samples of 
transcript. This is because the interviews were with human beings who do not 
speak in a unidirectional way and their thoughts often meant that conversation 
covered many areas. Therefore although an attempt has been made to identify 
specific themes to make sense of the data, these themes cannot truly be seen in 
isolation from one another. 
7.2 The interviews 
All four interviews took place within a week of the three months post discharge 
time period. The first interview took place on the 4/6/2013. The last interview took 
place on 24/3/2014. They all took place at the participants’ homes. Two of the 
participants needed rest breaks from the interview for breathlessness and fatigue 
management. The researcher’s reflection of undertaking the interviews can be 
found in Chapter 8 (‘Reflexivity’), section 8.5 finding my space as an interviewer. 
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7.3 The experience of living with severe COPD 
The themes that were identified under the experience of living with severe COPD 
are presented in figure 7.1. 
 
Figure 7.1 The experience of living with severe COPD 
The following sections will address each of the themes identified in Fig 7.1 
beginning with the participants’ voices and then followed by analysis and 
discussion. To allow greater understanding of the participant experience the 
discussion includes assimilation with other sources of literature, informal 
discussions with patients and observations. For clarity the researcher has 
differentiated in the text where thoughts are from her own observations or other 
interaction with the participants and not direct analysis of the transcription. The 
separation is to allow for the possibility that the researcher’s role as a clinician 
may have clouded some of these observations (see Chapter 8 Reflexivity). 
The Experience 
of living with 
severe COPD
Symptoms 
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exacerbation 
Impact on 
living: daily 
tasks
Time
Emotions
Isolation
Healthcare
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7.3.1 Symptoms and exacerbation 
The participants discussed the physical symptoms of having a diagnosis of COPD 
with particular emphasis upon their breathing and exacerbations: 
“…Bad...Breathing...Bad it was all bad…but then you don’t realise how bad 
you are til you go in there do you…” (Gert) 
“…things like the breathing problem and although you tell me my levels are 
fine for some reason they don’t feel fine and the confusion I’ve had and the 
light headedness and things like that…erm ones I cancelled oh what was it 
it’s hard for me to remember what it was it was see this is the (tut) memory 
problem I’ve got…” (Vanessa) 
 
Breathlessness was reported as the main symptom by participants, which is 
consistent with previous literature (Habraken et al., 2008; Elkington et al., 2004). 
Despite improved medication in the form of inhaled therapy this was still the 
overwhelming experience in this group.  In the literature breathlessness is often 
described vividly by COPD patients and compared to suffocation (Seamark et al., 
2004). None of the participants in the course of the study ever used these vivid 
descriptions. The participants in this study always spoke of breathlessness in 
relation to activity and tasks. 
For one participant her memory was affected. Cognitive loss has been reported 
to be present in 77% of patients with COPD and hypoxaemia (Grant et al., 1982). 
Cognitive deficit may also worsen over time, memory and attention problems can 
increase in presentation during an exacerbation and this is heightened in patients 
who have received hospital NIV (Hung et al., 2009; Kirkil et al., 2007; Ambrosino, 
2002).  Cognitive symptoms developed during a severe exacerbation can last up 
to 6 months following the hospital admission (Ambrosino et al., 2002).  In an 
alternative study fatigue was the participants’ main concern (Lewko et al., 2014) 
however most of the other symptoms experienced were not referred to during the 
interview but in every day conversation with the researcher. Whilst some were 
specific to COPD respiratory symptoms (for example, wheeze, sputum and 
fatigue), others were not specific to COPD (for example low back pain, leg 
oedema and knee pain). Whilst COPD is acknowledged to be a multi-component 
disorder (Agusti, 2005), these symptoms may be because of the age and co-
morbidities of the participants.   
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7.3.2 Impact on living: daily tasks 
The participants emphasised the daily struggle of completing their activities of 
daily living and the balancing act between task, time and breathing: 
“…mainly because I think I I’m struggling too much just to get through each 
day erm doing the main things I need to do you know like eating and clearing 
up and things like that…” (Vanessa) 
“…I mean I couldn’t tell you it was probably about eight months ago that I 
walked around the supermarket with a trolley…cause a lot of people…even 
this morning said where’s your scooter…” (Elsie) 
“…whereas I used to sit in the chair and let him (nodding at husband) do 
everything…” (Gert) 
“… I was struggling to perhaps go to the shops that type of thing and stopping 
off…” (Neil)  
 
The participants describe the struggle of carrying out daily tasks (for example, 
shopping). Through analysis of their descriptions it would seem that the 
participants have developed coping strategies to function including: slowing down 
either the speed of an activity or by having rests during the activity (for example 
Neil continually stopping for breaks); adaptation of the daily task (for example 
Elsie using a scooter for shopping); and activity avoidance (for example Gert 
letting her husband take on her role). This is supported by the studies carried out 
by Habraken et al. (2008) and Wortz et al. (2012).  They undertook interviews of 
patients with end stage COPD and participants reported that they modified their 
activities, took breaks between activities or avoided activities altogether. These 
methods of coping with breathlessness were also supported by researcher 
observations throughout the study. An example of slowing down tasks was to 
allow longer for tasks and to break them up with rest (for example, walk to the 
next lamp post or stop for coffee). An example of changing tasks was ironing in 
sitting or using the microwave to heat coffee. An example of avoidance was one 
participant who only dressed in pyjamas to avoid the activity of dressing and 
changed their pattern of sleep to wake later in the day so as not to have to make 
breakfast or deal with people calling at the door. 
Whilst the impact of breathlessness on daily activities is widely reported in the 
literature, from a clinical perspective I had failed to realise the impact on every 
small task, leading to adaptation and avoidance. 
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As a clinician I had witnessed these patients when they were at their sickest, bed 
bound, attached to a tight fitting mask, and often unable to communicate fully. 
Then if the patient improved there followed brief 30 minute treatment sessions 
e.g. transfer out of bed, onto commode, mobilise to the toilet and then at this point 
they are often deemed medically fit and to have reached the minimal status for 
discharge home. This brief interaction is carried out in a safe hospital environment 
with an adapted environment (for example, hospital bed, raised toilet and O2 or 
assistance if indicated), with all daily needs met (for example, cup of tea brought 
to bed). There are no life interruptions such as the doorbell or environmental 
hazards (such as stairs) to negotiate. As a physiotherapist it is important to be 
able to be patient centric and focus on patient led goals to adapt treatment to the 
needs of the patient however, it is easy to forget that hospital is not home and the 
symptoms experienced by patients are not just one off events but ongoing, multi-
dimensional and they affect every aspect of living. What seemed surprising was 
just how limited their lifestyle was, whilst for the participants it seemed normal.  
This was reflected by Habraken et al. (2008) who concluded that because COPD 
patients spend a long time in end stage illness, unlike other pathologies, they have 
time to modify to each deterioration and time to become used to their limitations. 
Therefore, life with limitations becomes normal. This is a problem as positive 
social relationships and social support are linked with better QOL and personal 
integrity (Nicholson and Anderson, 2003; Leidy and Haase, 1999). 
 
7.3.3 Time 
The theme of time was identified in many aspects of the transcripts: 
“…erm that was in order to do my hair I had to have my arms lifted up above 
my head for quite a few minutes it took me about twenty minutes to half an 
hour to do my hair and that was quite tiring on my arms and my shoulders so 
by the time I’d finished doing my hair yeah my arms and shoulders were quite 
tired and sore…” (Vanessa) 
“…in the last three months I think before I was struggling...” (Neil) 
…not being able to sort the oxygen quick enough if I’m not getting…” 
(Vanessa) 
“…I was out Christmas time but I don’t think I went out after that…it always 
seem like Christmas time that I go down…sighs…” (Elsie) 
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The participants focused on time by assessing how long they have been unable 
to perform tasks well. They discussed the anxiety around doing tasks quickly (for 
example attaching oxygen). Strang, Ekberg-Jansson and Henoch (2014) reported 
that anxiety often materialises in combination with dyspnoea in patients with 
COPD. There appeared to be little documented about how patients with COPD 
perceive time. Environmental factors seemed to define activity, with winter months 
being seen as challenging for one participant and linked with exacerbations. 
Habraken et al. (2008) supported this with his findings that sometimes patients 
did not leave the house for months due to bad weather. 
7.3.4 Emotions 
“… cause before then I was just I was miserable...I gotta admit...and things 
was worrying me as well…” (Gert) 
There was also anxiety attached to having an exacerbation: 
“...No not worried I just think about...Is it every time I get a cold will I end up 
in hospital…yeah...I mean I’ve got my tablets…” (Elsie) 
For one participant it felt that there were no treatment options left: 
“...No...No and this is where you come in (tearful)…I really appreciate it… 
Erm...sighs well…there was no other choice really because I just want to get 
better…sighs…” (Elsie) 
In this research study during the informal discussions with the researcher the 
participants often spoke of being depressed and anxious. The participants spoke 
of loss in terms of not being able to do previous activities. This is similar to findings 
from the literature. Wortz, et al. (2012) carried out in-depth interviews that 
identified loss as a major theme in relation to loss of normal functioning, loss of 
independence, loss associated with co-morbidities and loss of social contact. 
7.3.5 Isolation 
The participants commented on a feeling of isolation: 
“…They haven’t seen it (the ventilator)...I don’t get a lot of people up 
here...so...it’s just as well really there aren’t a lot of people that come up 
here...” (Gert) 
“…Erm… it can be I mean I’ve got loads of friends but I just don’t see them 
now... I mean I had a friend we used to go out in the car and we used to go 
shopping and everything together but I don’t even ask now and she doesn’t 
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ask me sometimes you can feel very cut off I mean the girls I used to work 
with before at work you know in a job you keep in touch for a while and then 
everything wears off and you don’t hear anything for a while…a couple of 
people on Facebook…that I used to work with and all that...but you can get 
very lonely…very lonely…” (Elsie) 
One participant discussed the opinions of others regarding her own responsibility 
for causing her disease: 
“… Oh Burt’s attitude, that’s my son, his attitude very much is that most of 
what’s happened to me I deserve because I haven’t completely given up 
smoking so he tends to fluctuate between feeling that there’s no point in 
having any treatment at all while I still smoke and making use of treatment 
that will help and that if it helps enough maybe it will help me give up smoking 
if you understand that…” (Vanessa)  
 
During the informal discussions had with the researcher participants discussed 
the stigma they felt by both health care professionals and family towards their 
condition.  The literature suggests that the loss of social support leads to being 
isolated from society and stigmatisation of their symptoms and disability. Blame 
from others and self-blame can lead to poor self-esteem (Nicholson and 
Anderson, 2003; Toms and Harrison, 2002). Interviews carried out by Halding et 
al. (2010) suggested that people with COPD were judged by society because their 
disease was perceived as being self-inflicted. This was spoken of by one 
participant (Vanessa) and her son’s attitude of her not deserving treatment. 
Participants suffered from negative emotions and the urge to apologise. Of the 
four participants interviewed two were still current smokers. Researcher 
observations throughout the study had observed that, whilst one participant was 
apologetic for smoking and had expressed the blame by relatives, the other 
participant felt no guilt and blamed boredom and no other pleasure as the reason 
for continuing with smoking. Halding, et al. (2011) supported this by demonstrating 
that the interviewees revealed actions to diminish strain from stigmatisation and 
self-blame such as non-disclosure of smoking habits and pointing out excuses. 
Interestingly throughout this research study the participants were observed by the 
researcher as often referring to others as more deserving of care and considering 
them to be worse off. This related to other patients seen on the wards, often 
unbeknown to the patient but with less severe disease.  
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The participants spoke of losses, which is supported in the literature by the 
interview findings of a study (Seamark et al., 2004) where participants described 
losses in relation to jobs, tasks around the garden and growing dependence on 
carers. Most of the participants discussed a loss of activity around the home and 
growing dependence on others to do tasks from washing up to withdrawing 
money. One of the participants, who was the only one still working at the start of 
the study, had to drop his hours considerably by the end of the study and was 
considering retiring. 
The researcher’s personal perspective is that the isolation experienced was a 
direct result of not being able to participate in social activities due to activity 
avoidance worsened by hospitalisation, however research by Halding et al. (2010) 
suggested that patients no longer felt that they were full members of society right 
from the point of diagnosis. 
7.3.6 Healthcare 
The participants often discussed their past experiences of healthcare. Hospital 
care was mentioned directly and in terms of the inevitability of admission: 
“...I gotta be…the hospital…they do treat you well I gotta say they they did 
everything for me in there without them I wouldn’t be here I don’t think ….but 
they are good…” (Gert) 
“...erm...sighs well…there was no other choice really because I just want to 
get better…sighs…” (Elsie) 
They often had negative preconceptions about NIV: 
“…reminds me of that I had in hospital of the mask that’s what it reminds me 
of and I didn’t like that either…” (Gert) 
“…It would have frightened me…Yeah I was thinking about the other one 
laughs...yeah...alright in the beginning with the other one I was scared...erm 
and I...No I think it was just having that over my face and it was very hard to 
get to sleep with it because it was the way it was going and I think I must 
have just given in and just laid down to it and that was it...but it seemed to be 
like I was fighting it for some reason but I started going through the night then 
with with it ok…And… erm… it’s as I said it’s not because the thing is you 
breathe with that one the other one does the breathing for you…” (Elsie) 
One participant had preconceptions about PR and being sedentary: 
“…I turned it (PR) down quite a few times…Because people had told me they 
are very pushy…Force you to do things…the worse thing you can do is just 
sit there as with this illness…” (Elsie) 
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Regardless of the fact that the participants often have a long time living with their 
symptoms it was unanticipated that exacerbations still surprised them. There is a 
government push for the public to avoid using A&E in favour of GP or walk in 
centres (NHS England, 2014), however for this group of patients A&E is still 
frequently utilised. An exacerbation of COPD is the second biggest cause of 
admission to hospital in the UK (one in eight admissions) (Healthcare 
Commission, 2006). For this group despite having had frequent exacerbations 
and having suffered with COPD for many years an exacerbation was still 
unexpected. One participant waited for some time with symptoms trying to avoid 
hospitalisation, however this may potentially have led to a more severe 
exacerbation. There was much emphasis by the participants on self-
management, self-monitoring of symptoms and self-prescription. It was also clear, 
however, that ultimately there was an acceptance that they would have to go into 
hospital.  
The interview findings suggested that there will always be a need for this group of 
patients to access hospital care. Whilst self-monitoring was important, 
exacerbations were still unpredictable and their severity will inevitably lead to 
admission. 
7.4 Acceptability: The participants experience of being involved in 
the study 
This section will present the concept of acceptability of the research to the 
participants. The themes that underpin this concept are illustrated in figure 7.2. 
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Figure 7.2 The acceptability of the research and intervention 
7.4.1 Impact 
This concept relates directly to the aim of the thesis (see Chapter 1 Background, 
Section 1.22 Aims of the Research and Thesis). This theme encompasses the 
possible impact the intervention has had on each participant both physically and 
emotionally. They found the intervention contributed to physical changes: 
“…From going in erm I feel about 70% better but now as the time has gone 
on now it’s escalated…” (Elsie)   
There was a physical improvement often described by participants in terms of 
daily activities:  
“…yeah definitely Oh yeah I can walk a little bit better than what I did...and I 
do feel a little bit better I gotta say...” (Gert) 
“… erm small amount of additional strength in my limbs especially my legs 
err you know where which is what we worked on mainly…” (Vanessa) 
 “…Erm I think in the last three months I I think before I was struggling to to 
perhaps go to the shops that type of thing and stopping off I just presumed 
that type of condition but since I have exercised and so forth erm you know I 
was able to walk to my shops and back without stopping…” (Neil) 
“…Erm I can walk round the shops, I go up and down the stairs, I walk out to 
the front with the oxygen obviously erm I’ve been out a few times...been to 
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the hospital...been to the doctors...been to my cousins…went out for a meal 
which is something I haven’t done for a long long time..” (Elsie) 
Fatigue was described as being counterproductive:  
“…I suppose my main feeling is that I haven’t really been physically up to it 
that I haven’t had such as much benefit from... from the sessions as I could 
have had because of being unable to erm do any exercises on my own in the 
daytime when you haven’t called…mainly because I think I I’m struggling too 
much just to get through each day erm doing the main things I need to do 
you know like eating and clearing up and things like that…difficulties in 
exercising?...” (Vanessa) 
The participants expressed how the intervention affected them emotionally: 
  “…Oh yeah definitely Oh yeah I can walk a little bit better than what I 
did...and I do feel a little bit better I gotta say...cause before then I was just I 
was miserable...I gotta admit...and things was worrying me as well but at the 
Yeah I was really down and yeah I was but at the moment no I’m 
alright…moment now I’m fine...I’m much better now I do say…” (Gert) 
“…I was lying (laughs)… erm… oh did I do that (laughs)… I don’t know what 
to say erm… well yeah it did seem to have a good effect on my mood and 
my feeling physically even though I was a bit tired afterwards and needed a 
little sleep or nap… erm… generally speaking I did feel better…” (Vanessa) 
“…laughs erm yeah I suppose my stress levels improved mainly because 
you were as good as your word that I didn’t feel pressured that I had to do 
anything I didn’t want to do…” (Vanessa) 
(Interviewer) “…So now you’ve finished this research...are you feeling a bit 
more positive about life?” “(tearful) very much...very much (laughs) but I’ll tell 
you why I’m laughing I’ll tell you soon…” (Elsie) 
Confidence levels were commented on as improving: 
“…erm actually confidence that my breathing is better than I realised by 
having the machine the little thing showing me every time you came that my 
sats levels were good and stuff…” (Vanessa) 
 “…don’t know because you talked to me about it I’ll be honest with you it 
seems to give you the will to try things erm you know you sort of done it with 
that and then you think let me try it without it and its surprising…” (Elsie) 
(Post interview Elsie said the other main change she wanted to thank me for was 
increasing her confidence and making her feel like the old Elsie again…making 
her feel human. But she didn’t want to say this on tape because she knew she 
would get upset but was happy for me to document this.) 
 
The participants described a feeling of fear and dread regarding the intervention: 
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“…Very difficult (laughs) cause I didn’t like using it without you being here 
mind...cause I was frightened that I was going to break it or I was gonna do 
something that’s why I never ever used it but erm once…” (Gert) 
“…I don’t dread you coming so much as the purpose of your visit that’s what 
I dread really… erm… I suppose it’s the thought of having to do the exercise 
erm... use the mask erm… and the worst bit is taking the mask off afterwards 
and getting my breath back…” (Vanessa) 
 “...erm a little bit daunting initially (laughs)...” (Neil) 
 
Guilt, blame and regret were recognised by the participants:  
“…I suppose my main feeling is that I haven’t really been physically up to it 
that I haven’t had such as much benefit from... from the sessions as I could 
have had because of being unable to erm do any exercises on my own in the 
daytime when you haven’t called…” (Vanessa) 
“… I don’t want to let you down…” (Vanessa) 
“… erm no I just wish that I wasn’t so that my condition wasn’t so poor to start 
with a year or two ago I’d have probably benefited much more than this than 
I am doing now…” (Vanessa)  
 “…erm Jason (son) and Sam (nephew) think it’s great they think that erm I 
should make more use of it and they are happy to help me use it if I want 
to...Oh Burt’s attitude, that’s my son, his attitude very much is that most of 
what’s happened to me I deserve because I haven’t completely given up 
smoking so he tends to fluctuate between feeling that there’s no point in 
having any treatment at all while I still smoke and making use of treatment 
that will help…” (Vanessa) 
The participant’s commented on the negative effects of the exercise programme 
and outcome measures: 
“…the walk tests erm I did find difficulty with them sometimes because I 
would put quite a lot into it erm and obviously the nurse would monitor me 
erm how I was and so forth but when doing a full exercise and then you know 
going to work I did find it it did take quite a lot out of…” (Neil) 
 “…Aching limbs ((laughs)) yeah but that could have been the stairs as well 
though mind…” (Elsie) 
 
The participants divulged the potential benefit of the device, although for some 
their thoughts were contradictory: 
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 “…Well It’s obviously a positive thing otherwise I wouldn’t be using it would 
I? So it is obviously positive but err… some things you get used to and some 
things you don’t do you? And that I didn’t get used to…” (Gert) 
“…I expect it has been a positive experience yes. Well it does I think it does 
help you with your exercise erm I think that’s the positive thing because I 
realised pretty early on that I erm that you need to do some sort of exercise 
to stabilise your condition and erm help you in future years…”.(Neil) 
 “…erm I’ll say positive overall (laughing) even though I hate to admit that 
(laughing)…” (Vanessa) 
 “…Its improved on my breathing erm it doesn’t make me want to stop and 
overall it is a good thing for like people in my condition to use…” (Elsie) 
 “…When you’ve actually got it on it can feel quite relaxing…” (Vanessa) 
 
The clinician within the researcher had not appreciated the reality that some of 
the participants felt that they had to choose between activities due to fatigue. For 
one participant choosing to put her hair up (a weekly task) meant she would not 
be able to exercise that day. 
For another participant it was the assessment of the 6 minute walk test in 
combination with the exercise and still working which was tiring. 
It would seem that the adaptations the participants had made, with their daily 
activities of living, carried over to include the exercise regime. Therefore fatigue 
and graded exercise may need to be considered in future studies. 
 
7.4.2 Equipment/Logistics 
The participants expressed difficulties with both application of the mask and the 
claustrophobia it created: 
 “…no I don’t know I don’t think so although I’m quite nervous about using it 
and putting it on and stuff… yeah I don’t find that easy to put on plus as well 
because I have to take my glasses off then I can’t see properly so that makes 
me nervous not being able to see properly if I am doing it on my own…” 
(Vanessa) 
“…Well if I was sort of on it most of the time I don’t think I would have liked it 
because obviously the glasses and it’s not very nice...this one’s ok but the 
bipap with false teeth…” (Elsie) 
“…Ok the only thing that I did find difficult at times was putting the mask on 
to be quite honest with you erm again I think it’s the claustrophobic aspect to 
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it and also I don’t know which brought on a little bit of a what we discussed 
just now a little bit of a panic err to so you know so you were probably 
breathing more heavily which you know is not natural…” (Neil) 
The participants discussed the equipment dimensions specifically: 
“…because it’s light… the designs alright in it...it’s just a matter of putting it 
on the floor really so yeah that’s alright…” (Gert) 
“…I find the weight of the equipment heavy to lift but then that can be put in 
place you know it’s not too heavy for me to move I could put it in place first 
and then put the equipment on and stuff you know at the side of the bed erm 
…” (Vanessa) 
“…No because I charged it once since I’ve come out of hospital…” (Elsie)  
“…No...because it’s compact...very compact... and I mean everything’s in the 
bag so you haven’t got to oh where I put that and where is that...it’s all 
there…” (Elsie) 
The participants focused on the practicalities of using the NIV at home to exercise: 
“…I could walk alright with it…” (Gert) 
 “…erm connecting it up properly and you know not having….yeah to the 
oxygen and not being able to sort the oxygen quick enough if I’m not 
getting…yeah I don’t find that easy to put on plus as well because I have to 
take my glasses off then I can’t see properly so that makes me nervous not 
being able to see properly if I am doing it on my own…” (Vanessa) 
 “...erm a little bit daunting initially (laughs) but once you use it and you 
experience it you get very much used to it and erm it is no problem at all 
really so you know you find it well the whole equipment and so forth  you find 
useful really…” (Neil)  
Overall the participants rated the equipment as compact and a good weight, 
although one participant felt the device was too heavy to move. However most of 
the participants tended to position the ventilator on the floor and exercise around 
it. This meant that the exercises used needed to be adapted for this. However the 
researcher had already considered this and most of the exercises were easily 
achieved with the ventilator on the floor. However walking and stair climbing could 
only be carried out with the assistance of the researcher because of the weight of 
the device. Therefore there is a need to develop a more portable device to allow 
participants to wear it for activity. However within this very severe disease group 
most exercises may initially be in sitting. The home environment may additionally 
impinge on the space required for exercising so portability of the device may be 
redundant in the house-bound patient. 
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Similarly to many nocturnal home ventilator users the mask was a concern. All of 
the participants reported claustrophobia associated with the mask particularly on 
initial use. There was also an issue involving participants who wore glasses but 
needed the full face mask as this meant they were unable to wear them during 
the exercise sessions. This also caused difficulty when donning the mask. One 
participant reported difficulties with loose dentures although this was more with 
the hospital acute NIV than the NIV during the study. Since the completion of the 
study new mask technology has been developed. There are now full face masks 
without a head strap which glasses can be worn over to avoid the problems 
experienced by the participants in this study. One participant was able to use a 
nasal mask but this was not tolerated by other participants. Some participant’s 
experienced dry mouth after using the NIV device. This is a common side effect 
of home NIV often cured by a full face mask or adding a humidifier. A humidifier 
is a heated water bath that the air runs through prior to reaching the mask. Adding 
a humidifier may increase resistance in the circuit changing, inspiratory flow and 
pressure to the patient. Thus the addition of a humidifier into the study would need 
further investigation. 
7.4.3 Ventilator settings 
The participants discussed the sensation of the positive pressure from the 
ventilator which for one of them was an unpleasant sensation: 
“…Yeah...I tell you Roger I don’t like it up your nose...it’s the air going through 
your nose… because if it’s too high obviously it covers your breathing and it 
reminds me of that I had in hospital of the mask that’s what it reminds me of 
and I didn’t like that either (laughs)…” (Gert)  
“…I didn’t like the pressure on it either… no...I didn’t …no…” (Gert) 
 But for others it provided relief: The sensation of the pressure from the ventilator 
was for some of the participants an unpleasant sensation but for others it provided 
relief: 
“…It wasn’t so overpowering on the face and the mask didn’t feel half as 
bad…” (Elsie) 
“…And… erm… it’s as I said it’s not because the thing is you breathe with 
that one the other one does the breathing for you…Erm…if… if…you don’t 
work with it you get all the noise the bubbling…it’s just concentrating on using 
it and using it the right way…No…No cause you’d already talked me through 
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it erm as I said if you don’t use it in the right sequence it doesn’t work properly 
does it…” (Elsie) 
 “…It helps you breathe a little bit better with it on it does...when you’re 
exercising….otherwise you’re out of breath so bloody quick that did help… 
but other than that …no…” (Gert) 
“…the worst bit is taking the mask off afterwards and getting my breath 
back…” (Vanessa) 
“…I feel it actually gives me dry mouth which I don’t I don’t like very much 
and I don’t like taking it off because of you know the transition back to you 
know the normal oxygen machine…” (Vanessa) 
Only the participant using a nasal mask commented on the pressure being an 
unpleasant sensation. This was given as a reason why the participant did not use 
the ventilator often without supervision. More time could be spent titrating 
pressures and exploring mask interfaces as this patient may have benefitted from 
an alternative mask type to assist distribution of pressure. One of the participants 
found the pressures easier to tolerate than those provided by acute ventilation 
devices. This may be a reason as to why the participants in this study were 
concordant with ventilation use because they had already experienced much 
greater pressures acutely. It is clear from the response of participants that they 
valued lots of explanation and reassurance from the researcher on the use of the 
ventilator. 
7.4.4 Outcome measure choice 
The outcome measures were specifically mentioned: 
“…Yeah I… I the diaries are useful erm the walk tests erm I did find difficulty 
with them sometimes because I would put quite a lot into it erm and obviously 
the nurse would monitor me erm how I was and so forth but when doing a full 
exercise and then you know going to work I did find it it did take quite a lot 
out of me err not that I was thinking it would take a lot out of me but erm it I 
did actually find that it did a little bit…” (Neil) 
 “…Well diaries and questionnaires I absolutely hate in any form for anything 
so erm that’s something that I would have struggled to do you know anyway 
erm…” (Vanessa) 
“…Yeah I think over the weeks it starts to build up more and more and more 
...the last time was twenty seven times weren’t it... I mean I couldn’t believe 
I done that many and then we done steps you know I think it’s progression 
you done that and then you think oh I’ll achieve this or that the next time I 
just go for it…” (Elsie) 
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Only one participant commented on strongly disliking completing questionnaires 
or diaries, however despite stating this all patient reported outcome measures 
were completed by this participant. Most participants actually sought comfort in 
the outcome measures as proof of their health improvement. Therefore the 
specific timing of the outcome measures needs to be considered for a future 
study. The researcher had anticipated the 6MWT as being fatiguing to patients 
and that it would probably mean that the exercise session would not take place. 
The researcher had not considered that the questionnaires would be considered 
as tiring and for some participants these had to be carried out in isolation to 
exercise. Therefore the type and length of completion of outcome measures does 
need to be considered carefully for a further trial. 
 7.4.5 Exercise sessions 
The participants differed in their views between using the ventilator to exercise 
and unsupported exercise: 
“…I mean the exercising that’s alright I don’t mind things like that...it was just 
that... (looking at the ventilator) but other than that yeah it was alright. Well it 
helped you didn’t it when you did your exercises...it does help you…It helps 
you breathe a little bit better with it on it does...when you’re 
exercising….otherwise you’re out of breath so bloody quick that did help… 
but other than that …no…” (Gert) 
(Interviewer) “Did you find it easy exercising in your home?” 
“Yeah I did yeah...I did. What without it…Oh yeah you don’t get the same 
benefit do you? If you haven’t got it on you don’t get the same 
benefit...so...yeah having it on did make a lot of difference...” (Gert) 
“…Ok the only thing that I did find difficult at times was putting the mask on 
to be quite honest with you and then I’d try try and try sometimes I have used 
it a couple of times erm and then you think oh blow it I’ll just do the exercises 
without using the equipment so that’s the only down side I mean I would have 
used it if I could you know fit it on better... to be quite honest with you I didn’t 
see a lot of difference from using the ventilator to erm there were a couple of 
times where we didn’t use it and erm I didn’t see any difference between 
actually using it and erm doing it without the  ventilator…” (Neil) 
“…No…because I that can be a lot easier than to do it without it…Its 
improved on my breathing erm it doesn’t make me want to stop and overall 
it is a good thing for like people in my condition to use…Yeah…yep…I mean 
I can do it with or without I could do it with or without it but as I was supposed 
to be using it I carried on using it… even if you don’t do the full amount like 
you were doing on that at least you are doing something and that is the way 
I looked at it as well I did try as much as I could but obviously I done more 
with that…” (Elsie) 
288 
 
There was anticipation that the exercise would be a negative experience: 
“…I don’t dread you coming so much as the purpose of your visit that’s what 
I dread really… erm… I suppose it’s the thought of having to do the 
exercise… because I know that what I dread well it isn’t as bad as the 
sessions gonna be what I dread really… erm… I suppose it’s the thought of 
having to do the exercise…” (Vanessa) 
 “…the exercise did...it’s like you said if you are not used to it you will you will 
feel it…” (Elsie) 
The participants discussed their experience of exercising on NIV without 
supervision: 
“…Very difficult (laughs) cause I didn’t like using it without you being here 
mind...cause I was frightened that I was going to break it or I was gonna do 
something that’s why I never ever used it but erm once…” (Gert)   
“…I suppose my main feeling is that I haven’t really been physically up to it 
that I haven’t had such as much benefit from... from the sessions as I could 
have had because of being unable to erm do any exercises on my own in the 
daytime when you haven’t called…” (Vanessa) 
 “…No...No...I mean you are not here every day so you know you’ve helped 
me...so what I’ve done every day is like a pattern every day right eleven 
o’clock it’s time to do this and I got myself into that (laugh’s) I mean you gotta 
have a timetable or a you know obviously if I had doctors or anything...but I 
still done it not said oh well I’m going to the doctors so I won’t...or I can’t be 
bothered with that today…I done it…” (Elsie) 
“…Erm it was just getting used to it and I as you know I didn’t really walk with 
it it was only with you that I walked with it erm but it was…” (Elsie) 
The timing and frequency of the intervention was discussed: 
“…erm no I just wish that I wasn’t so that my condition wasn’t so poor to start 
with a year or two ago I’d have probably benefited much more than this than 
I am doing now…” (Vanessa) 
“…erm only maybe very marginally simply because I haven’t been able to 
make full use of you know the opportunity to do the exercises I think if I’d 
have managed to do it more times in the week then I think I would have 
benefitted quite significantly…” (Vanessa) 
 “…No...no...it seems ...how many weeks have we done this now… (So 
twelve (Interviewer))…Yeah that’s surprising isn’t it…” (Elsie) 
 
Some of the participants reported they were unable to use the device 
unsupervised. As previously mentioned this may have been to do with difficulties 
applying the mask and connecting the O2. Another participant felt unable to use 
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the device because of the weight of the equipment when trying to physically move 
it around the property. Others spoke of a lack of motivation and fatigue as 
preventing independent exercise. One of the participants voiced that extra 
supervised sessions would have been useful as part of the programme. One of 
the participants felt that different exercise could be achieved when supervised (for 
example, walking on the ventilator). 
7.4.6 Research feedback 
They discussed their experience of being involved in the research: 
“Because it… well there’s always changes and you’ve probably come up with 
and another person’s probably come up with something that would be more 
helpful as well I really, really appreciated what you have done… Well I’d just 
like other people to take part it would make a lot of difference for yourselves 
and it would help the people cause I’ve seen what it done to me…” (Elsie) 
“…No as far as I was aware I would think that this is doing a cross section as 
to you you to erm I presume help people in in the future really that’s the way 
I read it…” (Neil) 
They also had some advice to others embarking on the research intervention: 
“… erm well just basically to go for it that it’s not as bad as you think it’s gonna 
be (laughing)…” (Vanessa) 
“…Don’t bother (laughs) don’t bother no it is a good thing when you it is... if 
you...you know  it is if you need something like that it is a good thing for 
people to use…” (Gert) 
“…It’s really helped. Its improved on my breathing erm it doesn’t make me 
want to stop and overall it is a good thing for like people in my condition to 
use…Go ahead and use it…don’t be afraid because it will help. Do as you’re 
told (laughs) and push on through...” (Elsie) 
 “…Err I think the only thing is erm…I think is the keep up what you are being 
told by the nurse erm because it will only help you really you know I think that 
the advice the advice that you’re given really you’ve got to take on board 
because the stronger you are the more exercise is going to help your 
condition and help prolong your life which is what it’s all about really I 
suppose…” (Neil) 
 
Overall the participants felt that being involved with the research was a positive 
experience. They wanted the opportunity to take part in new research and would 
recommend taking part to others. They reported an initial fear but their anxiety 
was eased with clear explanations and physiotherapy. One participant 
appreciated the feedback during and at the end of the research. She had 
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previously been involved in a research trial and after it finished she was not told 
whether she had received a placebo or a real drug. This was a source of anxiety 
for her and put her off participating in other research until this study. 
The participants experienced positive physical changes. They reported increased 
activity levels both in being able to carry out household tasks and wider social 
activities. The participants reported that the intervention gave them confidence in 
their abilities to be able to do activities. They reported a relief from dyspnoea on 
exercise that allowed them to train harder and for a longer period of time. They 
reported an improvement in upper and lower limb strength. One participant 
reported she had achieved weight loss from carrying out the exercise. The 
participants also experienced improvements in their mood and stress levels. 
 
7.5 Directions for clinical practice 
This concept relates to the themes discussed that direct clinical practice. The 
themes that underpin this concept are illustrated in Figure 7.3. 
 
Figure 7.3 Directions for clinical practice 
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7.5.1 Value placed on monitoring 
The participants were concerned with their O2 levels and placed importance upon 
this when self-evaluating their health: 
 “…Yeah…yeah… and another help has been me getting a sats machine as 
well because I can monitor…because if my sats go down then I know that 
there’s something wrong and then it’s not advancing more…” (Elsie) 
“…erm actually confidence that my breathing is better than I realised by 
having the machine the little thing showing me every time you came that my 
sats levels were good and stuff…” (Vanessa) 
Value was placed on the monitoring carried out by the physiotherapist during the 
research period: 
“…in general I think it’s a good thing to come round like this...I never knew 
people would come round like this but yeah…” (Gert) 
“…I don’t really know I just thought  erm I mean it has been helpful obviously 
in the fact that you know erm that somebody is I presume is you know is 
coming round to monitor you and erm discuss your medication and discuss 
your ongoing health I suppose…” (Neil) 
There was much emphasis on self-management, behaviour change, self-
monitoring of symptoms and self-prescription within the health-care literature and 
current clinical practice, however, one of the novel findings from the interviews 
was that the participants valued monitoring. The participants, whilst keen to carry 
out their own monitoring, really valued professional monitoring. They were 
enthused to know if their outcome measures were any better or worse, particularly 
the walking tests. 
This finding suggested that face to face contact was important to these 
participants and demonstrated how community visits were perceived as valuable. 
This research may support the role of community matrons and community 
physiotherapy. 
The participants seemed fixated with their O2 levels and their monitoring and what 
this could mean clinically. A big change has occurred in the last few years in 
regard to self-management. One possible cause is easier access for patients to 
purchase their own monitoring equipment on the internet e.g. O2 saturation 
machines, however whether this is advantageous is unclear. Whilst the 
participants felt reassurance in having this device it is not a full assessment of 
their condition. I feel as a clinician that I had been trained to complete a full 
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respiratory assessment. I was taught not to focus on O2 saturations but I have 
undergraduate students who do so, seeing this as a quick and easy measure of 
respiratory status. 
7.5.2 Time: set up/removal 
The participants described the intervention as something that takes time to get 
used to: 
“…It’s the beginning that’s the worse once you’ve got it on you are alright 
cause you’ve got to get used to it…..but it is the beginning puts you right 
off....but once you’ve got it on you’re alright…” (Gert) 
 “…Yeah…it got better as time went on…yeah…” (Elsie) 
“...erm a little bit daunting initially (laughs) but once you use it and you 
experience it you get very much used to it and erm it is no problem at all 
really so you know you find it well the whole equipment and so forth you find 
useful really err initially not no erm it took several goes actually when I say 
several probably about two to three err goes before erm I got used to it 
really…” (Neil) 
The participants identified that there is a recovery period after the intervention: 
“…I don’t dread you coming so much as the purpose of your visit that’s what 
I dread really… erm… I suppose it’s the thought of having to do the exercise 
erm... use the mask erm… and the worst bit is taking the mask off afterwards 
and getting my breath back and I don’t like taking it off because of you know 
the transition back to you know the normal oxygen machine…” (Vanessa) 
The participants reported it took them quite a long time to get used to the NIV. 
This should be taken into consideration for both acute patients and home NIV 
patients. It is also a consideration for taking exercise on NIV forward into clinical 
practice. Adequate time must be given to ensuring patients feel confident with the 
device. Not all of the participants felt confident enough to exercise on their own 
with the device. More time could have been spent by the researcher encouraging 
independent use rather than just focusing on an exercise session. More time was 
needed to demonstrate connection of additional O2 to the ventilator as this 
increased anxiety in one participant. 
At the other end of the spectrum patients also found their work of breathing 
increased on removal of NIV. This could have deterred them from using NIV. 
Certainly in clinical practice home ventilation patients often describe a period of 
breathlessness in the morning when they first wake up and take off the ventilator. 
It may be that a longer time is needed to rest on the ventilator when stopping 
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exercise to restore breathing back to pre-exercise levels.  More research is 
needed to assess the optimum time for NIV removal post exercise.  
7.5.3 Hospital management of NIV 
The participants commented on their experience of having NIV acutely in 
comparison to the NIV experienced in the study: 
“…reminds me of that I had in hospital of the mask that’s what it reminds me 
of and I didn’t like that either…” (Gert) 
 “…It wasn’t so overpowering on the face and the mask didn’t feel half as 
bad…” (Elsie) 
“…It would have frightened me…Yeah I was thinking about the other one 
laughs...yeah...alright in the beginning with the other one I was scared...erm 
and I...No I think it was just having that over my face and it was very hard to 
get to sleep with it because it was the way it was going and I think I must 
have just given in and just laid down to it and that was it...but it seemed to be 
like I was fighting it for some reason but I started going through the night then 
with with it ok…And… erm… it’s as I said it’s not because the thing is you 
breathe with that one the other one does the breathing for you…” (Elsie) 
 
The participants expressed lots of anxiety around their acute NIV experience. 
Fear of whether they would ever come off the ventilator and discomfort from the 
mask were their main concerns. More explanation from health care staff about 
NIV, how it works and how long the treatment may be on for, may all have relieved 
anxiety in these participants. Equally spending more time fitting the acute NIV 
mask and introducing the ventilator slowly may also have benefited this patient 
group. However within the acute setting where time is important a leisurely 
approach may not be available. 
7.5.4 Other uses of NIV: pacing 
“…Yeah...erm… you...you obviously you’ve got to work with the machine 
you’ve got to work with the machine but you’ve got to concentrate on what 
you are doing as well otherwise it would just be a waste of time…” (Elsie) 
“…It’s been a good teacher…very good teacher...” (Elsie) 
Another novel finding from this study was the role NIV may play in pacing of 
breathing during exercise. One of the participants described the ventilator as a 
teacher that taught the patient how to slow and correct breathing.  Traditional 
respiratory physiotherapy encompasses pacing and positions of ease to improve 
294 
 
breathlessness. However time limitations in the acute environment often make 
this management strategy less frequently taught to patients. 
It could be that NIV is used clinically to assist the patient in pacing activities. 
Additionally the NIV could be used for activities of daily living (for example put on 
for hoovering or bed making to allow for paced breathing and decrease work of 
breathing). There is a need to look further at the role of NIV and more portable 
devices may increase the possibilities for use. 
The participants reported that the NIV felt relaxing and had a re-training role. NIV 
could be useful clinically in reducing the work of breathing post exercise and in 
supporting exercise to assist recovery. 
 7.5.5 On-going care: including information 
The interaction and information from the clinician was discussed: 
“…laughs erm yeah I suppose my stress levels improved mainly because 
you were as good as your word that I didn’t feel pressured that I had to do 
anything I didn’t want to do…” (Vanessa) 
“…Yeah…yeah…cause I thought I was gonna be on it all the time...I think it 
was when you came round talking to me and told me it was just when I 
needed it at night and whatever…” (Elsie) 
The method of initiating NIV was considered: 
 “…No…No cause you’d already talked me through it erm as I said if you 
don’t use it in the right sequence it doesn’t work properly does it your blowing 
back into it so you are breathing it in as it is giving it to you and then out 
again…” (Elsie) 
“…No because you explained everything ...you explained to me in hospital 
and then when we got together the first time you showed me and you 
explained all that it does and you said like you can turn it up you can adjust 
it an everything which is good…” (Elsie) 
“…And talked more about it as well...cause they don’t really tell you what they 
are actually doing all they say is that we’ve got to put a mask on you and 
that’s…” (Elsie) 
There was a feeling of being given one chance for health care: 
“…Yeah...yeah cause once well obviously once you’re discharged from the 
hospital from the doctor you know you just report back to your doctor if you’re 
not well but again that worries me if I went to the doctors with a chest infection 
will it automatically mean back in hospital cause I mean is he going to give 
you a chance to see if you come out of it...and that is one thing that worries 
me or don’t worry me I think about I mean...” (Elsie) 
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“No I’d had a letter to go but that was cancelled by the hospital cause it was 
snow then the next one I had my aunty had died and it was her funeral so I 
rang and then I had another letter saying that cause I hadn’t been to 5 
appointments which wasn’t true it was 2 appointments they closed…the book 
on me and they were going to write to my doctor and if anything my doctor 
would have to refer me back…” (Elsie)   
The participants wanted to have the opportunity to experience other treatment 
options and having access to treatment: 
“…No...No and this is where you come in (tearful)…I really appreciate it. 
Everything…everything it has opened my eyes more knowing that there is 
something else out there that will help…” (Elsie) 
“…do like the idea of having access to it even though I haven’t used it on my 
own if I didn’t have so many other things stressing me out (laughs) then I’d 
probably put more effort into having a go and using it on its own cause I think 
that.. I think it would help me… with some of the erm daily problems I’ve 
had…” (Vanessa)   
 “…monitor you and erm discuss your medication and discuss your ongoing 
health I suppose…” (Neil) 
“…There probably is… if you look around but who do you contact….. I know 
there is a phone number for the British Lung foundation and all that but 
there’s nothing is there now really… (Sighs and yawns)…” (Elsie) 
“…I turned it (PR) down quite a few times…Because people had told me they 
are very pushy…Force you to do things…but I’ve learnt now you shouldn’t 
listen to other people (coughs)… I read it this time in a booklet from the 
hospital I came away with the other day…they won’t force you to do anything 
you don’t want to do (laughs)…” (Elsie) 
The participants valued the time spent explaining the therapy and improvements 
seen. One participant felt more time should be spent on planning treatment with 
the patient and explaining the treatment options in response to individual health 
care needs. Understanding and trust from health personnel can positively impact 
the lives of patients with COPD (Leidy and Haase, 1999). Non-supportive health 
care encounters generated feelings of discredit, self-blame and guilt (Haldine et 
al., 2010). 
The findings suggested that participants felt that they were discharged from 
hospital care back to their GP because there was nothing more that could be done 
for them. They also reported that they were often discharged from hospital care if 
they could not make outpatient appointments. In the literature Seamark, et al. 
(2004) described the desire for patients to go to clinics but the exhaustion of 
getting there made it distressing. Some patients in this research study spoke of 
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negative comments from receptionists when they were unable to make their 
appointments. In this study the participants were unsure of the benefit of having 
a nurse visit who was a stranger but for carers it was reassuring. Although the 
participants did value more frank, open communication and monitoring there was 
anxiety experienced that GP care would not be as good and would lead to hospital 
admission. This is similar to the findings of Habraken et al. (2008) where patients 
were told by physicians that their lungs would only get worse and nothing more 
could be done. 
The participants wanted to have the opportunity to access health care even if they 
choose not to accept. As previously stated chronic patients may not be re-offered 
therapy (for example smoking cessation and PR) if they have previously declined. 
Mann and Stuenkel (2006) suggest that health care professionals should be 
aware of the problems of stigma and should examine their own values, although 
they may be difficult to change. The participants wanted knowledge of new 
treatments and research to optimise their care.  
7.5.6 The need for home exercise sessions 
“… erm I feel that I should you know which we discussed earlier that I should 
keep up some of the exercises which I think are important I think that is really 
about it…” (Neil) 
The participants felt the benefit of having an exercise plan at home. They reported 
that they would benefit from having PR and exercise classes explained to them in 
full. One participant would have liked knowledge of other groups that meet and 
alternative exercise groups.  
7.6 What did they not say that I had expected them to? 
No participant openly expressed that they felt the NIV added a burden to their life. 
Some participants were ambivalent about the benefit of the device. O2 has 
previously been expressed as both a lifeline and a restriction (Elkington et al., 
2004). I had wondered if the acceptability of the device would be poor and whether 
another piece of medical kit in their home would not be viewed positively. 
However, in this instance the participants were only using NIV for a short period 
of time and they always knew that the NIV use was temporary. There have been 
conflicting reports as to whether or not home nocturnal NIV improves the QOL of 
patients with COPD (McEvoy et al., 2009; Meecham Jones et al., 1995).   
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Despite the severity of their lung disease not one participant discussed dying. On 
personal reflection their proximity to death was well known to the researcher from 
researched statistics and clinical practice. Thus that is why it maybe seemed 
strange to me as the clinician and researcher that they did not discuss this either 
formally or informally, however the literature demonstrated a lack of 
understanding by COPD patients about the severity of disease and eventual death 
(Sorenson, 2013; Horton et al., 2013). This is potentially because health care 
professionals do not discuss dying with patients (Lau et al., 2010) and palliative 
care provision remains inferior to that offered for other pathologies (du Covedic et 
al., 2012). Perhaps their abstaining from discussing death is not surprising 
because I did not ask them a direct question concerning it.  
 
7.7 Overall experience 
Overall the interviews have provided new knowledge on the acceptability of the 
research into exercise on NIV in patients with COPD. Existing literature has been 
further enhanced by in-depth rich finding about the experiences of an under 
researched group of patients with severe COPD. 
It is clear that the participants wanted active treatment. One possible solution is 
that this should be carried out in tandem with palliative care. Most literature 
focuses on the lack of palliation and lack of advanced decision making, which can 
be difficult to initiate in COPD because it is difficult to predict death. A difficulty 
arises when patients are told that they are dying and then stop being active or 
stop certain treatments but then do not actually die in the subsequent few months. 
Then the patient ends up in limbo, receiving neither active nor palliative care. 
The participants found being involved in research a positive experience and were 
keen to have the opportunity to be involved in further research. The participants 
all found the intervention beneficial. They felt that the NIV relieved breathlessness, 
allowing them to exercise more and they gained physical and emotional benefits 
from being involved in the study. 
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7.8 Summary 
The main themes have been presented through the voices of the four participants. 
Although sometimes the participants’ comments were repetitive it was still 
important that they were heard and considered under the different themes. This 
chapter has presented an analysis of the research findings and discussed the 
main concepts which developed from the themes of the findings. It has addressed 
the secondary aim of the research project and discussed the experience of the 
participant. The chapter has also discussed the acceptability of the research and 
intervention to the participants. The integration of the qualitative synthesis and the 
qualitative results is presented within the discussion chapter (Chapter 9 
Discussion). 
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Chapter 8 Reflexivity 
 
8.1 Reflexivity: finding the ‘me’ in the research process 
This section of the chapter will be written in the first person as it is a direct 
reflection of the research process. A core part of qualitative research is to 
embrace reflexivity. Whilst quantitative methods seek to be as objective as 
possible, qualitative researchers accept that the researcher is an active participant 
in the research process and shapes methods and analysis (Robson, 2011). Some 
key researchers (Silverman, 2001) try to identify and separate subjectivity. 
However, whilst I sought to identify what personal factors may have influenced 
the research I also chose to embrace them within a reflexive diary, which other 
qualitative researchers have considered useful, as an account of my relationship 
with the research process (Banister, 1994).  
Reflexivity is the ability to critically reflect on the research process and the 
individual’s own role as researcher (Maso, 2003; Finlay 2002) and recognises that 
researchers bring their own emotions, intuitions, values, commitments, 
perspectives, prejudices and personal agendas to research. This chapter of my 
reflexivity should allow me to be open about how this has impinged and shaped 
the research process thus improving the integrity and trustworthiness of this 
research (Finlay, 2002). 
Initially I found the qualitative concept of embracing subjectivity as challenging, 
possibly because I was so used to reading and reviewing professionally with 
scientific objectivity. In contrast the process of reflection felt more familiar. Within 
physiotherapy it is a very common process initiated at undergraduate level, 
nurtured with compulsory documented continued professional development 
(CPD) and has become so ingrained in my professional practice that almost all 
my clinical decisions were reflective. In contrast Finlay and Gough (2003) 
suggested that reflection is thought after the event, whereas reflexivity is an 
instant, vigorous, non-stop, consciousness. 
For the purpose of this chapter key stages from my reflective diary have been 
selected and discussed. This is to help the reader understand the importance of 
my values and beliefs, and how they may have influenced this piece of research. 
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As part of the qualitative component of my mixed methods design I understood  
that it was important to use reflexivity to resonate these values and beliefs at all 
phases of the research process to allow for credibility of my research findings 
(Pope and Mays, 1999; Wellington and Austin, 1996). 
8.2 Separating the self 
It is important to understand the many roles that I had and how they may have 
influenced the research I chose. Within the research I was going to be 
physiotherapist, researcher and an interviewer. Each of these roles is very 
different but I questioned how far I would really be able to separate them.  I also 
questioned whether realistically the participants would separate me into three 
different roles. Additionally to these roles I am a mother and wife and thus my 
personhood is affected by these influences. Equally would I as a researcher be 
able to separate the patient, from the participant, from the individual? I decided 
from the beginning to wear my uniform for all clinical exercise sessions. When I 
was undertaking outcome measures I wore a white shirt and black trousers. When 
I carried out the interviews I wore jeans and casual clothes. On reflection I felt this 
would help me and the patients to differentiate roles, however I was not naive to 
think that I could filter out the other roles but I thought it may allow the patients to 
think of me differently for each task. 
This section is a snapshot of what makes up my personhood, although, all roles 
overlap and influence each other. This helped me to clearly see who I was and 
gave insight into my role in this research. 
At the time of the research I had been a respiratory physiotherapist for 10 years. 
My enjoyment of respiratory physiotherapy came from the problem based 
assessment and thus appropriate treatment selection. I enjoyed the 
multidisciplinary team approach and comradery when working with a team. On 
reflection I recognised that I was a practical person who likes practical solutions 
to problems. I think this was why it was important for the research to be something 
relevant and easily slotted into clinical practice. Unlike other colleagues within 
respiratory care, who focused on treatment for sputum retention, it was always 
rehabilitation that interested me. In particular the careful clinical balance required 
when weaning patients from ventilation and progressing rehabilitation.  
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I considered myself to be quite bossy and I like to lead, again this often influenced 
my physiotherapy practice. I wondered how this desire to lead may influence my 
role as interviewer in the research, when I needed to ensure it was the 
participant’s experience captured and not my own. I was passionate about social 
injustice. I had a concern for the ‘underdog’ stemming from childhood. My mother 
recounts stories of how I would always ask her to buy the teddy in the shop no 
one wanted (for example the bear with no eye). This developed to stray animals 
and befriending children at school that no one else liked. I was though, unclear as 
to what was the trigger for this concern, however, this concern extended into my 
role as a physiotherapist.  
On completion of my junior rotations I shunned the desirable outpatient specialty 
in favour of respiratory care, an area that was considered then as a less desirable 
speciality. When delving into my thoughts about this. I realised this went further. I 
did not choose surgical respiratory or ITU but chose the even less desirable 
Medical care speciality. I did not choose the well-funded and more desirable area 
of Cystic Fibrosis but patients with COPD. Again I thought of myself as the 
underdog champion, working with a group of patients with less funding and 
equipment than other groups and with a stigma of blame related to their smoking. 
Through this reflective process I can see how my interest in this group came about 
and how the research question developed. Although it was beneficial to sum up 
the history behind the research, I was concerned about how my sympathy for this 
group of patients might have affected the research. 
8.3 How I chose the question? 
In order to fully appreciate how I would interact with the research process, I 
needed to be clear as to my subjective investment in the research question (See 
Chapter 1 Background, section 1.21.1 Personal Perspective). I needed to think 
about what had influenced my decisions. Why did I consider research into this 
chosen patient group to be so important and why did I want to do this piece of 
research?  
Maso (2003) suggested that the research question should be personally relevant, 
provoke passion and initiate a meaningful research endeavour. I spent 
considerable time reflecting upon these questions. As a result of this reflection, I 
302 
 
concluded that the true research question was actually to confirm if what I was 
already doing in clinical practice (for example exercising patients with severe 
COPD on NIV) was actually beneficial to the patient. I was concerned that it may 
just seem like it is better. I was also aware that junior staff may see me as 
hypocritical when I questioned them on the evidence behind their treatment, when 
there was limited information on the treatment I was advocating. 
8.4 Reflecting on reflecting 
As a physiotherapist I am used to reflecting on my clinical practice in regard to 
applying evidence as part of my CPD. This is a very structured process often 
involving models of reflection which I have undertaken since my undergraduate 
studies, however I had not necessarily reflected on my own personal feelings and 
influences. Thus initially reflexivity did not come easily to me. Over the research 
period I kept a reflective diary of my thoughts and feelings. Initially it was quite 
factual and structured but over the course of the research my notes became more 
reflective and less descriptive by including my thoughts and feelings not just 
actions and events. Overall reflexivity seemed to be a skill that was dynamic and 
changed throughout the research process (Finlay and Gough, 2003). Towards the 
end of the research period I became aware of reflecting on reflections. The 
following section details key reflection points within the research period. 
8.4.1 Tension between researcher and physiotherapist 
Initially, when carrying out the 6MWT I became conscious that I was possibly 
encouraging the standard care group more than the other two groups. Even 
though there was a SOP that I was following, I was anxious to not favour the two 
treatment groups. Then I reflected whether by doing this I was covertly 
disadvantaging these participants.  However by the time the discharge outcome 
measures were assessed I reflected that my physiotherapy role had taken over. 
On reflection I realised that the physiotherapist in me wanted each patient to 
succeed and improve. Again there was the conflict of keeping the researcher 
collating the outcome measures separate to the physiotherapist wanting 
improvement. It was interesting to reflect on how I seemed to have two separate 
roles but yet was one person, although from one diary entry it would seem that I 
felt there were multiple roles: 
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 25th May 2013 
 “It would seem that I have 3 different characters that I play one is the 
researcher keen to extract data and remain aloof, one is the physiotherapist 
keen for the patient to progress and to do well, one is the concerned 
empathiser who seeks to comfort and agree with the participants”. 
Over the course of the research I was surprised at the success of the completion 
of questionnaires. There was only one participant who did not automatically give 
me her diary cards each month and needed prompting. I had reflected on 
watching the participants complete the questionnaires at hospital discharge and 
wondered if any of them would continue with such a time consuming task. I 
reflected on the wisdom of evaluating completion of outcome measures as part of 
the feasibility aim.  
I felt that less bias was introduced by not evaluating any of the questionnaires or 
ActiCal data until the end of the study. It was only through the 6MWT that I was 
aware I could possibly see the progress of participants, however it was a month 
between tests so I could not always remember previous events. Despite my best 
efforts to reduce bias in the outcome measures, the participants were always keen 
to tell me how they had fared. 
22nd October 2013 
“I was feeling pleased today that despite the challenge of keeping the 
researcher role separate to the physiotherapy role, I really could not 
remember the distance Neil (pseudonym) had walked at last assessment, 
thus I was unlikely to influence this result today. However no-one told Neil 
today that I was keeping my roles distinct and he disclosed full distance 
measure of last assessment a few seconds before initiation of the 
assessment. I had forgotten the participants are an added complication when 
separating the self…” 
Additionally I had reflected upon the challenge of using the mixed methods design. 
As a researcher within the quantitative method I needed to remain objective and 
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unbiased. However within the qualitative methods my personal involvement was 
an integral component of analysis. 
8.5 Finding my space as an interviewer?  A reflection  
There was a tension through being clinician, researcher and interviewer. As a 
physiotherapist I thought I would be quite good at conducting the interviews. I had 
prided myself as having good communication and felt I was skilled at getting a 
patient history to create a diagnosis and problem list. However, I am also used to 
curtailing patients who are poor historians and move away from the facts. Within 
qualitative methods it is important to be able to let the participants dictate to a 
certain extent the direction of conversation to ensure that their experience can be 
truly understood (Braun and Clarke, 2013). With qualitative research there was a 
need to step outside of physiotherapy or what Braun and Clarke (2013) refer to 
as cultural membership. This was the ability to put aside my own assumptions. 
I wrote in the reflective diary after each interview and during the analysis. I found 
it useful to make field notes as I interviewed. In the first interview I wrote very little 
as I engaged in questions and focused on the interview guide. However my ability 
to reflect within the interview improved with each interview. I also made sure I 
spent time after each interview reflecting on the environment, the participants and 
also my immediate reaction to the interview responses.  
30th May 2013 
“Throughout the interview I found my mind drifting. I was aware that I 
experienced a conflict between being a non-judgemental NHS 
physiotherapist, to a judgemental person and to a researcher. For example 
in my physiotherapy thoughts on the participant still smoking, to a researcher 
wanting the patients to have found the experience beneficial and also as a 
person who wanted to offer the participant comfort.” 
I also reflected upon times within the interviews when I disagreed with the 
participant and how this may have shaped the interview. Further to this I even 
wondered if I even liked the participant. This was even harder for me to express. 
The professional physiotherapist within me would suggest they were challenging 
or non-concordant. It was a relief to actually say “I don’t like that person” in my 
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diary after interview. Although, yet again I had to evaluate how my dislike may 
have shaped the research and interview.   
In contrast to this another reflection related to wondering if a patient had given 
good feedback to try and please me. I recall one participant explaining that she 
never cancelled a session because she did not want to let me down. My diary 
reflected on my thoughts that I wondered if I had somehow unintentionally 
communicated my desire for the research to work and to complete the PhD onto 
the participants. I debated whether this was something that all patients 
experienced. That patients felt they had to please health care professionals in 
return for continued treatment and involvement. Yet again, these thoughts made 
me change my behaviour as a researcher. I endeavoured further to not knowingly 
put my own or the research agenda on individuals. I found benefit from discussing 
with my supervisors my initial reaction to the interviews and immediate reflections 
on how I undertook them. This de-brief after each interview was really important 
as it helped me to see how others interpreted the environment and interview 
content. It helped me to reflect on why I may have thought and reacted as I did. It 
helped me to identify how my thought processes shaped the rest of the interviews. 
All these reflections during the interview were challenging for me in my role as 
researcher. It was difficult to be able to listen to what was being said by the 
participant and to also reflect on this to guide further conversation. Braun and 
Clarke (2013) referred to this as being able to have double consciousness. 
I felt that the final interview produced the most in-depth and revealing data. I think 
this was because of a combination of factors. The final interviewee was an 
outspoken Bristolian female who enjoyed conversation. Overall the research 
study had been a positive experience for her and this therefore made conversation 
flow easily. I knew from discussion with other post graduate students that often 
the majority of information can come from one key interviewee, the ‘golden 
participant’ as we referred to them at postgraduate study days. I reflected that I 
am pretty sure that the fourth interviewee was my golden participant 
 
28th April 2014 
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“Yippee…That went so well…it works…my research made her better…I think 
I have some real good nuggets of information…finally I relaxed enough to 
get the full patient experience” 
I was also aware that the better content of the last interview may have been the 
result of my improved skills as an interviewer. I felt that as I knew it was the final 
interview I relaxed. I finally heeded the advice of my supervisors to become freer 
with the interview guide. I became less conscious of time and the need to meet 
the aims of the research and researcher agenda. I allowed more time for the 
participant to lead the conversation and to discuss the experience of living with 
COPD. I also felt that I had learnt from the previous interviews and was able to 
ask questions at opportune moments and allow for silence when waiting for a 
response. 
8.6 Finding my role as analyser 
Braun and Clarke (2006) suggested that the researcher needs to ensure that they 
have ongoing reflexive discussion with themselves through the process of 
analysis. Therefore the reflective diary was continued during this process to assist 
with decisions.  
8.6.1 Transcribing 
It was at this stage that I decided to give participants names with the same letter, 
associated with the same age and economic circumstances.  
3rd July 2013 
“Writing an allocated ID number on top of the transcription seems very cold, 
objective and too quantitative. I want to still be able to picture the participant 
and apply a human face to them rather than just a number” 
During transcription I became aware of my views on each of the comments said 
by the interviewee. Especially if it was positive about the study it made me feel 
happy that the research worked, equally I worried I was potentially dismissing the 
negative comments. I had to think how this may influence my interpretation of 
what was said. 
Transcribing was a frustrating and slow process the participants often speaking in 
Bristolian tones making for difficult transcribing. Being a part time researcher it 
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was difficult to find enough time to immerse myself in the transcription. Initially 
learning to use the transcription pedal was frustrating. At some low points it did 
feel like a waste of time especially as some postgraduate peers had outsourced 
their transcriptions. It was also difficult to ensure the tone and mood was captured 
throughout. The tedium of transcription has been reported by other authors 
(Reissman, 1993), however because there were only four interviews I felt that 
transcription, although tedious, was manageable and essential to allow for full 
immersion into the data (Braun and Clarke, 2013). As transcription became easier 
I was able to reflect upon my immediate thoughts as I re-heard the interview. This 
included reflecting upon my own interaction with the participants. I reflected on 
the way I had asked questions and meaningful pauses. These all helped me to 
reflect on how I may have influenced responses and allowed for deeper insight 
into what a participant may have actually been saying. 
8.6.2 Coding 
When undertaking the initial coding it was difficult not to focus on specific words 
but this often meant that the context was lost. Bryman (2001) commented on the 
importance of keeping the surrounding data to ensure it is meaningful. It was also 
difficult to not just focus on the aims of the research and feasibility of the 
intervention. The researcher had to remember to just code as seen initially then 
move onto what this may mean as part of the production of themes and analysis. 
After piecing all the codes together to form themes I was beginning to have a 
sense of what I felt were the more important ones and also which met the 
feasibility aim. I tried to distance myself again from the aims of the project to make 
sure that I had captured the patient experience within the themes. What I may 
consider an important theme others (including the participants) may not. I also 
found that the ‘golden participant’ quotes were frequently appearing. I reflected 
on whether this was because I thought that what she said was valuable or just 
because her interview was the longest. Braun and Clarke (2006) suggested that 
coding needs to be thorough and not just from a few key examples. This was 
challenging when there were only four participants and one talked for much longer 
than the others. 
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8.6.3 The findings  
This was difficult as I was not sure how this should look. Whilst my primary 
concern was addressing the aims of the research I also wanted to capture the 
patient experience. It was difficult as the last interviewee produced the longest 
data set and so often had the most quotes to use. It was challenging to ensure 
coded quotations were included from all four interviewees. Another challenge was 
avoiding too much duplication as often the same piece of data were used for 
multiple themes. On reflection and discussion with my supervisors I 
acknowledged that overlap is a natural consequence of being human and 
thoughts are not distinct from one another. I therefore decided to embrace the 
repetition and overlap within the findings. Nevertheless there needed to be 
enough data within the synthesis to evidence the themes. Braun and Clarke 
(2006) suggested that it is important to avoid repetition but still ensure a full story 
is explained. The researcher used mind maps to illustrate the separate themes 
and to break up the chosen quotes. A narrative was used to explain each of the 
themes. 
8.7 The integration of the qualitative findings with the quantitative 
results 
One of my aims of using a mixed methods methodology was to ensure true 
integration of qualitative and quantitative research methods, however I also 
wanted to ensure enough detail was given in the thesis to the outcome of each 
method. There was a lack of evidence in the literature as to how qualitative and 
quantitative data could be integrated as part of a mixed methods approach 
(Bryman, 2006; Ivankova, Cresswell and Stick, 2006). Therefore to achieve this 
both the quantitative results and qualitative analysis were presented separately 
but they would be discussed together in the overall discussion chapter. 
8.8 Conclusion 
In this chapter I have focused on my reflective journey encompassing the 
important attribute of qualitative research in reflexivity. I have reflected on why the 
research question was chosen, my interaction within the research process from 
development of the research question, to carrying out the data collection and 
interviews, and the analysis.  By presenting my reflections throughout the 
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research I hoped to inform the reader of my interaction with the process and 
improve the credibility of my research findings. The next chapter combines the 
mixed methods results and discusses them in relation to the aims of the feasibility 
study. 
  
310 
 
Chapter 9 Discussion 
 
9.1 Introduction 
This chapter reflects on the aims and objectives of the research and how well they 
were achieved. It discusses how the study met the aim of feasibility (Aim 3 and 
Aim 4). It discusses the combined quantitative results of the research and briefly 
compares this with the existing literature on exercising on NIV (Aim 2). It also 
reflects on the experience of patients with COPD of participating in the research 
process relating to the acceptability of the trial (Aim 1 and Aim 2). Furthermore it 
unites the quantitative and qualitative findings from the research. In addition this 
chapter summarises the main findings of the study and considers the contributions 
it has made to new knowledge. It evaluates the strengths and limitations of the 
research and discusses possible alternative methods and direction of future 
research.  
9.2 Research Aim: Feasibility and Acceptability 
9.2.1 Recruitment sample 
From the mixed methods results it can be concluded that it seemed feasible and 
acceptable to undertake a RCT exercising participants with severe COPD on NIV. 
The participants were recruited and retained in the study from baseline 
assessment to three months following hospital discharge. The research process 
was acceptable to participants and they commented that they would repeat the 
experience and recommend it to others. No participants expressed concern 
regarding randomised allocation and this was not given as a reason for patients 
not participating. It seems feasible and acceptable to participants to undertake 
exercise on NIV from hospital to home following an acute admission for an 
exacerbation of COPD. The participants completed the training course of exercise 
on NIV and found relief from the sensation of dyspnoea possibly allowing them to 
train harder and for a longer duration. The sample size obtained for this study (n 
= 18 split into three groups: n = 7, n = 6, n = 5) is similar to that used in previous 
studies investigating exercise on NIV with sample numbers ranging from two to 
twelve participants in the NIV treatment group (Dyer et al., 2011; Borghi Silva et 
al., 2010; Reuveny et al., 2005; Costes et al., 2003).  
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Recruitment of patients with COPD into research studies is considered 
challenging. In a contemporary Cochrane review of NIV for exercise training in 
COPD six RCTs recruited sample sizes of 18-32 participants (Menadue et al., 
2014). When presenting this research at conference (European Respiratory 
Conference, 2014; BTS Conference-winter 2014) the researcher was commonly 
asked how it was achievable to recruit and retain participants into this type of 
study. The possible reasons for successful recruitment were that the present 
study looked at a specific group of patients post acidosis, who are not routinely 
picked up by discharge schemes and generally have a longer hospital stay this 
may have allowed the patients to get used to the NIV device. Another possibility 
is that often this group is overlooked to take part in research because they are 
excluded, considered palliative or perhaps it is assumed that they do not want to 
take part. An alternative view is that feasibility studies in patients with conditions 
considered as palliative are very important (Hagen et al., 2011). There were 17 
SAEs and three deaths that took place during this study thus demonstrating the 
potential challenges of retaining patients with severe COPD into a RCT.  
The successful recruitment may be because it is critical in studies of this type for 
the patient to have confidence in the researcher. The researcher was a respiratory 
physiotherapist who may have instilled confidence in the patients, thereby 
influencing their participation. This research has demonstrated that it is feasible 
to recruit into and retain participants into this type of study, but because of the 
small numbers recruited and increased possibility for participants to die a 
definitive multi-centre trial over a longer recruitment period would be necessary. 
This group of patients all had severe lung disease, demonstrated by their lung 
function results on discharge from hospital. They all had a large number of co-
morbidities indicating overall general poor health. All groups presented a poor 
predicted mortality based on their BODE score.  The group would seem to be a 
good representation of the type of patients seen clinically.  There were no 
significant differences in the characteristics of the groups, which is important 
because it means that they were broadly homogenous and group differences were 
unlikely to have affected outcome. There were more LTOT users within the 
intervention hospital and home exercise on NIV group. This could be indicative of 
the worsening severity of this group. However O2 use may be a compounding 
312 
 
factor as discussed in the limitations in section 9.6 Problems and limitations of the 
research. Therefore the inclusion and documentation of O2 use in a future study 
may be important. 
9.2.2 Inclusion/exclusion criteria 
One of the objectives (objective 5) was for this research to be useful and relevant 
to clinicians. Often research is explanatory in design evaluating the effectiveness 
of an intervention in a controlled laboratory environment compared to a pragmatic 
trial that seeks to test effectiveness of the intervention in the clinical environment 
(Zwarenstein et al., 2008). Often explanatory trials are only useful within the 
controlled laboratory conditions in which they were undertaken. Explanatory trial 
results can be difficult to generalize and apply to clinical practice (Patsopoulos, 
2011). An example of this is that most patients with COPD have co-morbidities 
and are an elderly population. It would be extremely difficult to control for this and 
exclusions often used in explanatory studies may lead to the study being not 
representative of the patients seen clinically. The inclusion and exclusion criteria 
used in this trial seem sensible for a future study. The exclusion criterion 
surrounding mental capacity represented a challenging decision as to whether 
this should be reviewed for a future trial. It may have been possible to exercise 
and train patients with mental capacity issues on NIV but it possibly would have 
been more time consuming and may not have been possible in the time frame 
required. Therefore this may need to be considered in a larger RCT because this 
group is often excluded from research (Parker, Penhale and Stanley, 2010). There 
were two patients who lived out of area this had not previously been considered 
when planning the exclusions as it was expected that most of the participants 
would live within the local Bristol area. Due to the lone researcher and time 
limitations of the PhD they could not be included in the study. An area inclusion 
zone would need to be considered in the future RCT. Multi-site research would 
capture different post code areas. 
9.2.3 Access to health care 
There was a trend that overall the hospital and home exercise on NIV group 
accessed less health care than the standard care group. This was demonstrated 
with medication use, including antibiotics, steroids and existing medication. This 
group had less access to their GP and number of hospital admissions in-trial and 
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post-trial. However the length of stay in-trial was greater than standard care, 
although this was considerably less than standard care in the post-trial 
admissions. This trend is important as, if replicated in an RCT, it could lead to 
considerable health benefits for patients and economic benefits for the NHS. 
9.2.4 Physiotherapy input 
During the hospital admission there was no extra physiotherapy time or treatment 
sessions needed for the hospital and home exercise group than those offered to 
the standard care group. Therefore this demonstrates that it is feasible to set up 
NIV and begin the training with no extra time needed. However the researcher is 
an experienced specialist in NIV so it is unclear if it would be more time consuming 
for a less experienced staff member. Most of the home patients experienced 24 
sessions of approximately one hour with a senior physiotherapist. This is 
considerably more than the once a week for six weeks that is often allocated for 
community physiotherapy caseload, although this extra cost may be worthwhile if 
the trend for decreased hospital length of stay post trial and decrease in extra 
medication use is upheld in an RCT. So a rigorous economic analysis within a 
future RCT is required to assess whether the extra cost required to carry out the 
intervention is beneficial long term to both the patient but also economically in 
terms of health and societal costs. It seems feasible to collect the data required 
to inform, including resource use and the EQ-5D-5L. 
9.2.5 Acceptability 
Only three participants refused to participate in the trial therefore the suggestion 
of the research seems acceptable to patients. There were no drop outs of live 
participants in the trial supporting that the research design is acceptable to 
patients. The participants in the exercise on NIV in hospital and home group were 
asked to comment on the research process including intervention and completion 
of outcome measures and although fatigue was mentioned for both the 
intervention and completion of outcome measures, no one expressed that they 
would not take part, or that they did not want to complete the measures and all 
would recommend the trial to others. The completion of all measures, except the 
ActiCal, and concordance with all supervised intervention provide strong evidence 
that the research design and intervention was acceptable to participants. 
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9.3 Research Aim: Outcome measures and combined results 
It seems feasible to carry out the majority of the outcome measures used in the 
study. All of the patient reported measures were completed. The only data which 
was incomplete was the ActiCal data. Any challenges and difficulties associated 
with the collation of this data is discussed later within the limitations. A trend for 
improvement was demonstrated for the NIV on exercise hospital and home group 
in 6MWT, LCADL, SGRQ and EQ-5D-5L. Unexpectedly the exercise on NIV in 
hospital group demonstrated a trend for deterioration in six out of seven of the 
outcome measures. If the outcomes of this study were replicated in a larger study 
it could establish that NIV on exercise is an important intervention. 
9.3.1 How do the results of the outcome measures compare to the existing 
literature. 
9.3.1a Walking and Activity 
The exercise on NIV in hospital and home group improved their mean walking 
distance by 220m (311% increase) from baseline to month three compared to 4m 
(8% increase) and 9m (53% increase) in the standard and exercise on NIV in 
hospital groups respectively. In comparison an updated Cochrane analysis of the 
6MWT following a course of PR found a mean treatment effect of 44m from a 
meta-analysis of 38 studies (McCarthy et al., 2015).  Despite there being a 
clinically important difference in the exercise on NIV in hospital and home group, 
the final walking distance was less than 334m which is the distance proven to 
predict an increased risk of death and hospital admission (Polkey et al., 2013). 
Equally all three groups demonstrated an improvement, which is important 
because research has suggested that a 30m decline in 6MWT is associated with 
worsening clinical status (Pinto-plata et al., 2004). The participants in this study 
were much more deconditioned but still able to achieve a much greater 
improvement in 6MWT than other studies with greater effects on walking distance 
than PR, LVRS and AOT (McCarthy et al., 2015; Criner et al., 1999; Leach et al., 
1992).  
The exercise on NIV in hospital and home group improved from 4,020 steps at 
month one post discharge to 6,017 by month two but by month three the step 
count declined. The standard care group had a much lower step count at month 
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one of 1,009, but this continued to improve to 3,843 at month three. The exercise 
on NIV in hospital group, whilst beginning with a higher step count at 2,515 than 
the standard care group, plateaued over the three months. However there was 
incomplete data from this measure. 
The existing literature demonstrated that in patients with COPD who have not 
undergone PR their daily physical activity levels decrease over time (Donaldson 
et al., 2005). One study measured step count in men with COPD and concluded 
that the average step count for mildest lung disease, GOLD 1 was 5856 
decreasing to 3707 with the most severe stage of disease, GOLD IV (Moy et al., 
2012). The exercise on NIV in hospital and at home in the current study ended 
their average daily step count at 5843, considerably more than their equal disease 
severity from the previously mentioned study. 
In COPD, a higher daily step count, when objectively measured, has been linked 
with lower mortality in COPD, independent of lung function. Physical activity was 
the best predictor of all-cause mortality (Waschki et al., 2011). In this prospective 
cohort study patients with COPD who survived 48 months had a mean daily step 
count of 6,424 compared with the patients who did not survive who had a mean 
daily step count of 3,006. (Waschki et al., 2011). 
If the data had been complete it would have been useful to study the energy 
expenditure of the participants. Energy expenditure is the total amount of calories 
burnt each day, therefore it is the amount of energy a person needs each day to 
carry out their activities from breathing to walking (Crouter, Churilla and Bassett, 
2006). The ActiCal device may not be the most advanced device for this because 
it does not address isometric exercise, carrying of loads or hill walking (Spierer et 
al., 2011). Therefore there may be a cost element to using a device that more 
accurately measures energy expenditure. The ActiCal was the only incomplete 
outcome collated therefore in the future RCT it may be necessary to consider an 
activity questionnaire. This would be low in cost and easily completed, however 
there is often a low completion rate and recall bias when documenting activity 
(Lissner et al., 2004). The activity may need to consider lower level activities 
because of how deconditioned the participants are. A SR of activity assessment 
in chronic disease including COPD suggested that the LCADL is a useful 
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assessment of activity for patients completing PR (Williams et al., 2012). This was 
included in this trial and may be relevant to use in the planned RCT. 
 
9.3.1b QOL questionnaires  
There was a trend for an improvement in excess of the MCID (4 units) in the 
SGRQ in the hospital and home exercise on NIV group. The standard care group 
also demonstrated an improvement in QOL by 7 units from baseline to month 
three but this was not as great as the 19 unit improvement found in the exercise 
on NIV in hospital and home group. The exercise on NIV in hospital group 
demonstrated a clinical worsening with an increase in score by 6. At discharge 
after the use of NIV during the hospital stay there was an improvement in total 
score of 2 units but it did not reach the MCID.  
A Cochrane review examining the effect of PR on QOL in patients with COPD 
found that the mean effect of PR exceeded the MCID of 4 units (McCarthy et al., 
2015). The most recent review meta-analysis of 19 studies demonstrated a mean 
improvement of 7 units in the total SGRQ score in participants who underwent PR 
(McCarthy et al., 2015). However the improvement in SGRQ differed from the 
results of the review into the use of NIV for exercise training in COPD, which 
demonstrated that total scores failed to reach the MCID (Menadue et al., 2014). 
This may have been because it considered only two studies and there were 
methodological limitations. A study researching home PR demonstrated a 
significant improvement in SGRQ total score by 10 units (p < 0.001). Activity 
improved by 9 units (p < 0.008) and impact scores by 14 units (p < 0.001) and 
these were also significantly greater than in the control group (Pinto et al., 2014), 
however symptom scores were not significantly different. 
The exercise on NIV in hospital and at home group were the only group to 
demonstrate a MDC (4 units) in LCADL total score from baseline (mean score 50 
units) to three months (41 units). MDC is not the same measure of change as 
MCID and has limitations because although it may signify statistical significance 
this is not the same as being clinically meaningful to patients or clinicians. The 
patients may not be able to perceive the benefit and clinicians may not change 
their management or treatment dependent on the results of MDC (Crosby, 
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Kolotkin and Williams, 2003). The exercise on NIV in hospital group demonstrated 
a worse LCADL score by 10 units. None of the existing studies of exercise on NIV 
used LCADL as an outcome measure, however a home exercise programme for 
patients with COPD also demonstrated an improvement in total LCADL score of 
3 units. Although that change was significantly different from the control group, it 
was not a MDC (de Sousa Pinto et al., 2014). Therefore it would seem that this 
measure of activities of daily living designed for patients with severe COPD 
detected a greater change in the present study’s exercise on NIV in hospital and 
home group than other studies, supporting the potential value of the intervention 
to this patient group (de Sousa Pinto et al., 2014; Garrod et al., 2000) 
This study only demonstrated an improved QOL score on the EQ-5D-5L in 
exercise on NIV in hospital and home group (+ 0.27 utility score). This research 
is novel as no other studies evaluating exercise on NIV have used the EQ-5D-5L 
measure. One study reviewing the effects of PR found that QOL decreased at 
eight and twenty weeks following PR despite improvements in other outcome 
measures (Egan et al., 2012).  
9.3.1c Breathlessness measures  
In this research study there was a trend for improvement in MBORG in both the 
standard care and exercise on NIV in hospital and at home groups from a baseline 
of 5.57 units (standard care) and 2.50 units (exercise on NIV hospital and home) 
to month three, 3.25 (standard care) and 2.13 units (exercise on NIV hospital and 
home). The exercise on NIV in hospital group demonstrated a trend for an 
increase in MBORG score from a baseline score of 4.3 units to a month three 
score of 7 units.  
Garrod, Paul and Wedzicha (2000) demonstrated that NIV on exercise decreased 
BORG scores from 6 to 4 units.  
A study carried out by Egan et al., (2012) demonstrated a statistical improvement 
(p = 0.008) in modified MRC dyspnoea score from baseline to week 20 following 
a course of 7 weeks PR, although when rounded to complete scores there was a 
small change in score number (week 0 = 2.3 to week 20 = 2.1). However there 
was no control group for comparison. The researcher could find no other studies 
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looking at modified MRC as an outcome. Mostly it is used as an inclusion criterion 
similar to age and lung function. 
The numerical breathlessness scores are important but more important are the 
words used to describe each score. The mean exercise on NIV in hospital and 
home group rating changed from being ‘too breathless to leave the house or I am 
breathless on dressing’ to ‘I stop for breath after walking about 100 yards or a few 
minutes on level ground’ suggesting a very positive improvement. 
9.3.2 Summary 
It was feasible to collate the majority of the outcome measures (only the ActiCal 
device had missing data). It was acceptable for participants to complete the 
questionnaires and diaries, but one of the interviewed participants did feel that 
they were tiring to complete. Exercise on NIV in hospital and home improved 
physical objective measures of the 6MWT and activity levels compared to 
standard care. Exercise on NIV in hospital and home improved patient reported 
QOL measures. These improvements were supported by the participants’ voice 
in being able to walk further outside of the home, carry out more daily tasks and 
reports of both physical and emotional benefits following the study. 
9.4 What might the findings and results mean? 
Overall there was a trend for improvement in the hospital and home exercise 
group in both patient reported and objective measures. The greatest surprise to 
the researcher was just how poorly the exercise on NIV in hospital group did 
compared to the standard care group and the exercise on NIV in hospital and 
home group. Although there was no statistical difference in baseline 
characteristics, this group did spend longer on NIV in hospital, suggesting a 
prolonged recovery from exacerbation.  
9.4.1 What may have contributed to this trend for improvement in quantitative 
results and qualitative findings? 
The main symptom expressed at interview was breathlessness. Therefore the 
intervention possibly relieved breathlessness to allow the participants to exercise. 
There are a few possible theories as to how it may have achieved this. The 
literature revealed that NIV may offload respiratory muscles and improve DLH or 
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change the provision of blood supply to the peripheral limbs allowing exercise at 
a greater intensity (Aliverti and Macklem, 2008; O’Donnell and Webb, 2008). This 
research study used higher pressures than previous studies (mean PS = 16cm 
H2O), however this research did not measure diaphragm fatigue or respiratory 
muscle action. Therefore it is difficult to know whether this was the mechanism for 
improvement. 
Alternatively the increased monitoring the patient received throughout the 
research process may have contributed to the trend in improvement in outcome 
measures. The interview findings suggested that the participants found monitoring 
beneficial. However all participants experienced increased monitoring and access 
to a health care professional. 
Another contributing cause could be a placebo effect from using the ventilator. 
This trial did not use blinding of participants with the use of a sham device due to 
the severity of the patients and the researcher had concerns that breathing 
suboptimal pressures would be detrimental to the participants.  
The sample characteristics used may also have influenced the trend for 
improvement. They were a group with severe COPD. Menadue et al., (2011) 
reported positive results in patients with more severe lung disease. The timing of 
the intervention may have provided an opportune moment for rehabilitation. The 
literature demonstrates success with PR post exacerbation (Puhan et al., 2011).  
Additionally selecting sicker patients on NIV had the advantage of spending longer 
time in hospital allowing for greater adjustment to NIV on discharge. By bridging 
the intervention from hospital to home it allowed patients to continue with a 
rehabilitation programme in their own home and avoid the problems of accessing 
outpatient based rehabilitation. 
9.5 Strengths of the study 
One strength of this study was that it trialled a new intervention producing novel 
results. There were no other studies that trained patients with severe COPD 
following an acidotic exacerbation of COPD requiring hospitalisation and 
treatment acutely with NIV. There were no other studies that exercised from the 
acute to community setting over a three month period of time using high ventilator 
pressures. This study was developed from a clinical idea so has direct relevance 
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to clinical practice. It was further developed from the existing literature and used 
the learning points of these previous studies to develop the intervention package. 
Through the process of developing the clinical question into a research project 
other clinicians may feel empowered to develop their own clinical questions into 
research ideas. 
A strength specifically related to the study design was that it was a feasibility 
study. This means that it will help to contribute to the success of a further study. 
As discussed in Chapter 3 (‘Methodology: Justification’),  section 3.7 Justification 
of change of primary outcome to feasibility  it is important that adequate time is 
given to test that an intervention works as it is supposed to (MRC, 2008). By 
choosing the research aim of feasibility it means that any parts of the research 
study which were unclear, or if doubt was cast as to whether or not certain aspects 
would work, they could be assessed before a more costly larger study was 
embarked on (Feeley, 2009).  However, it is also important that the research and 
intervention are acceptable to patients and clinicians (Feeley, 2009). The 
feasibility study design allowed for the researcher to study a difficult to research 
group, notoriously difficult to recruit into studies, a sick group, across both the 
acute and community setting. 
Another design related strength was the successful execution of a mixed methods 
study enabling evaluation of both feasibility and acceptability. The usefulness of 
the qualitative approach was that it also gave a voice to an under researched 
group of patients with severe COPD. Contributions to the literature of their 
experience of living with COPD and their involvement in the study have been 
made. The use of semi-structured interviews allowed for a depth and complexity 
in the qualitative data gathered. The detail of the easy to follow qualitative method, 
analysis and reflexivity have added to the evaluation of trustworthiness and rigour 
throughout the research process.  
The quantitative methods produced novel research because it is the first study to 
use activity as an outcome measure for the intervention of hospital and home 
exercise on NIV in severe COPD. The limitation of this measure was that the data 
were incomplete, so future studies would need to consider how they ensure use 
of activity devices by participants. This is an important outcome measure gaining 
more use within research and an essential part of a future research study.  
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The pragmatic study design was a key strength to avoid unnecessary exclusion 
of participants, using equipment and methods similar to clinical practice. The 
research took place in realistic clinical settings from the busy medical assessment 
unit to cluttered homes. This met one of the methodological objectives of 
producing real world research that is directly relevant to applied settings and 
clinical practice.  
An additional strength of the study is that it investigated a topical area and 
contributed to developing a research base in NIV, COPD and physiotherapy. 
Since the study was undertaken, exercising on NIV has been a focus at two key 
respiratory conferences (ERS conference 2014 and Journees Internationals De 
Ventilation A Domicile (JIVD) 2015). The research is therefore topical and further 
knowledge seems keenly desired within the respiratory professions.  
9.6 Problems and limitations of the research 
This feasibility study had a number of challenges and limitations. Despite being a 
major strength that this study was a feasibility study, it was also a limitation. The 
small sample means that statistical significance was not able to be demonstrated 
due to the low statistical power. However there were positive trends in results 
observed. 
One of the areas which proved challenging was in recruitment. It was challenging 
trying to recruit on a busy medical assessment unit. It was also difficult as often 
the patients flagged up for potential recruitment died. There was a need to ensure 
recruitment could take place every day (including at weekends) to maximise the 
time available to initiate therapy within the hospital environment. Although the total 
sample used was small, it was not dissimilar to other research studies. This 
knowledge is useful because it demonstrates to other researchers that it is 
feasible to recruit patients with severe lung disease into such trials. However it 
also determines the necessity for a multi-centre RCT. The researcher had two 
initial refusals to participate in the research, which may have been because of the 
inexperience of the researcher in recruitment. The timing of recruitment was also 
different for each participant as they were required to be improving medically and 
have a stable pH level on ABG. They also had different lengths of hospital stay 
leading to different lengths of treatment time within the hospital. However methods 
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to resolve this issue are not immediately apparent in this acutely unwell group. 
One possible solution could be to have a total time of inclusion in the study or set 
a number of sessions but this also has limitations. An additional limitation of 
recruitment is that it only occurred at one hospital site. Therefore it is difficult to 
predict if the research would be feasible within a different hospital or location. 
A further limitation is that the researcher considered behaviour change within the 
literature retrospectively and the research protocol had already been designed 
and initiated. This was possibly because at the time of initiating the research idea 
behaviour change was not commonly considered in clinical physiotherapy 
practice and unfamiliar to the researcher. Behaviour change techniques have 
been successfully applied in smoking cessation, manging chronic low back pain 
and pelvic floor weakness (Hay-Smith, McClurg, Frawly and Dean, 2016; Bartlett, 
Sheeran and Hawley, 2014; Harman et al., 2014). Therefore behaviour change 
techniques could be advantageous when using an exercise intervention with 
patients with COPD. 
There were limitations with the method because the study was unblinded, 
although this is difficult to achieve with a single researcher. This may have meant 
that bias was introduced into the trial. It is also challenging to issue a sham device 
in this group as sham devices are poorly researched and may increase the work 
of breathing in the sham group, affecting outcome. However the researcher did 
use randomisation to allocate participants to different groups and used sealed 
envelopes to try to decrease possible bias associated with group allocation. 
Documented SOPs for measuring the 6MWT ensured equal instructions were 
issued to the participants independent of group. 
Another limitation was that AEs were not reported. This was because the patients 
were not specifically asked about a checklist of symptoms. The feasibility study 
was reliant on self-reporting. All of the SAEs were reported as planned and this is 
further reflected upon in section 9.8. This limitation would be addressed in the 
future RCT and a specific checklist of AE questions would be asked of all the 
participants and they would keep a copy for daily/weekly reporting. 
One potential confounding factor could have been the use of O2 with NIV. The 
study by Dreher et al. (2009) demonstrated PaO2 increased by 14.0 ±16.66mm 
Hg following the walk with NIV and O2 compared to just O2 alone (p < 0.003) 
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unfortunately there was no NIV alone group, or NIV and double dose O2 entrained 
for comparison. Interestingly the distance walked was less with NIV and O2 (555 
±227m) compared with usual O2 (619 ±210m) and double dose O2 (622 ±215m) 
(p < 0.024). Five of the six participants had LTOT and thus used O2 entrained to 
their NIV.  
In this current study two of the five participants of the Exercise on NIV in hospital 
group and three of the five participants in the Standard care group and five of the 
six participants in the Exercise on NIV in hospital and home group were receiving 
LTOT. All three participants that died were on LTOT. There was one participant 
in the exercise on NIV group who did not have O2 entrained when exercising with 
NIV but still achieved an improvement in their 6MWT of 179m. None of the 
participants undertook their 6MWT on NIV so the weight of device could not have 
reduced the 6MWT distance in this instance (no O2 users carried their cylinders 
either). However, whether those on LTOT and thus walking on O2 were able to 
walk further because of the O2 is unknown. The amount of O2 entrained with NIV 
may need consideration in a future study. AOT is still an area of current debate 
(BTS, 2015). As further research is carried out into which patients may benefit 
from ambulatory AOT this may help inform further studies involving exercising on 
NIV. Another potential problem is with the inclusion of participants on home NIV. 
There may be some benefit from using additional nocturnal NIV in patients with 
hypercapnic COPD. However there were no participants on nocturnal home NIV 
during this study. 
There were difficulties with the collation of outcome measures. When assessing 
the 6MWT it was difficult to ensure the area was clear of people within the hospital 
environment. Within the home environment it was difficult to find an area big 
enough and so often the garden or street was used. This was not ideal in the 
winter in poor weather conditions. These challenges were very helpful in planning 
a subsequent trial as they need careful review and planning, given the disease 
severity of the participants. The outcome measures were time consuming to 
complete and additional days to exercise days were needed just to complete the 
outcome measures. These issues have implications for staffing a successful RCT. 
It was challenging being a part-time researcher and balancing clinical duties with 
research. A particular challenge was during the trial when the needs of the clinical 
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service required the research to be undertaken on two consecutive days. This 
took lots of negotiation to change because it was not acceptable to patients to 
exercise on two consecutive days because of fatigue. 
Another consideration of this trial is that it was sponsored by a commercial 
company and this may be viewed negatively by other researchers. However 
because the researcher retained intellectual property of the research data and 
freedom to publish negative results it should offer balance to the criticism. 
Furthermore if the equipment and back fill time had not been funded this research 
would not have been able to occur. The study’s commercial sponsor meant that 
intellectual property rights had to be negotiated which was time consuming and 
eroded the recruitment period. 
One of the biggest limitations to this study is that it did not include a group just 
receiving exercise training at home (i.e. it did not compare exercise with exercise 
on NIV for three months). The findings of Pinto et al.’s (2014) home PR study were 
similar to this study because they showed an improvement in health status. This 
may cause conflict as it could be that home exercise is a confounding factor and 
the participants in this study may have done well just with exercise and not NIV 
on exercise. However the changes in health status observed by Pinto et al. (2014) 
were not as great as those observed in the present study (10 units improvement 
for total SGRQ score compared with 19 units in the current study). However it 
does suggest a future RCT may benefit from having an exercise at home only arm 
for comparison. 
The aim of this study was feasibility of an RCT and it was not clear at the outset 
if recruitment would be possible. Initially it was thought there may be value from 
just exercising the patients on NIV during their time in hospital. Therefore this was 
one of the researched groups. At the time of the study development of home 
exercise for COPD was a novel area of research and some of the initial studies 
were negative. However further research produced more positive results allowing 
justification for inclusion of a hospital and home exercise group, although the 
inclusion of another limb would impact upon study recruitment numbers and future 
research. 
With regard to the qualitative methods it would have been insightful to have 
interviewed all participants from all groups, but the time limitations of being a 
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single researcher did not allow for this. It would have also been useful to have 
interviewed on more than one occasion. This would have assisted identification 
of time points for improvement and captured information from participants who 
died later in the trial.  
On reflection I regret that there was no opportunity to discuss the themes in person 
with the participants, however the time taken for analysis meant it was completed 
a considerable time after the last interview which would have made it disjointed. 
Posting out the themes to participants was less invasive but may have contributed 
to the lack of response. 
9.7 Implications of findings for further research 
It is clear there is a need for a multi-centre RCT with a large number of participants 
comparing exercise to exercise on NIV for three months post discharge. A sample 
size calculation (Fieller, 2007) for a future definitive trial was made using data 
collected as part of this feasibility trial. The 6MWT at three months following 
discharge was chosen as the primary outcome, with a clinically relevant difference 
of 30m, a SD of 73.25 (the SD of the standard care group at 3 months), alpha = 
0.05 and 80% power. Based on three independent groups a prospective sample 
size of n = 127 per group would be required. A trial including just two independent 
groups would need a prospective sample size of n = 95 per group. This would 
determine if there is any significant benefit on 6MWT from using NIV on exercise 
in patients with severe COPD following an acidotic exacerbation resulting in 
hospitalisation and NIV use. Initially the researcher had wanted to preserve the 
three group model because of wanting to review any benefit for the current 
practice of exercising whilst in hospital on NIV but on reflection this finding can be 
extracted from the discharge outcome measure timing, therefore only two groups 
are required potentially meaning less research centres are required or a shorter 
length of trial. There would be no standard care group but on reflection there are 
multiple studies that look at the morbidity and mortality of this group that could be 
used as comparison with the future RCT findings. An outline of the research 
protocol for the proposed RCT is included in section 9.10. 
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9.8 Implications of findings for clinicians now 
Clinically there was a trend for improvement in 6MWT and QOL measures. Sadly 
two of the participants died in the NIV on exercise in hospital and at home group 
and one participant in the standard care arm. These SAEs did not occur whilst 
using the intervention or within three days of an exercise session. They were all 
formally investigated and the trial was not discontinued. Additionally ten patients 
died prior to approaching for inclusion into the study. There was also a large 
number of SAEs. All of this reflects just how unwell this group was and 
demonstrates a realistic representation of patients with end stage COPD. 
Therefore in a future trial reporting of SAEs and AEs will be important to fully 
assess the safety of exercising patients with severe COPD and its use in clinical 
practice. Examining the data from the two participants who died in the exercise 
on NIV in hospital and at home group there was a trend for improvement in their 
6MWT at their last recorded measure thus suggesting benefit.  Therefore a 
suggestion from this research is that clinicians continue to use NIV as an adjunct 
for exercise in those who seem to benefit, particularly if this can be continued at 
home. 
9.9 Implications for patients 
This study has provided more evidence into the potential benefits of NIV in 
patients with severe COPD. Therefore it has given patients another choice of 
intervention. It has given this severe disease group a voice and added to the 
literature on the experiences of patients with severe COPD. The research has 
demonstrated that patients with severe COPD wanted to be involved in research 
and wanted to exercise. This study may influence other researchers to research 
this sample group. For the participants in the study they were all referred to PR 
and may now have been able to access this outpatient service. 
 
9.10 Clear vision of the future RCT 
This feasibility study has demonstrated the value and possibility for a successful 
RCT.  This intervention was complex because it was involving a complex patient 
group who are severely unwell, the intervention spans complex organisations 
(both primary and secondary care) and the intervention had to be adjusted for the 
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individual in terms of both exercise and ventilation settings (MRC, 2008). This 
feasibility study has fulfilled MRC complex intervention requirements because it 
has allowed the researcher to be confident that the intervention can be used as 
intended. It has allowed for the rates of recruitment and retention to be fully 
evaluated to enable a sample size calculation to be completed for planning a 
further RCT (MRC, 2008).  The future multi-centre trial research process is 
presented in Figure 9.1 
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Figure 9.1 Diagram of the future RCT 
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9.11 Outline of the future research protocol and justification 
provided by feasibility study 
One of the aims of this feasibility study was to inform a future trial. The researcher 
has been able to plan an outline of the proposal for a future trial. A full protocol is 
beyond the scope of this thesis and would need further planning to complete. This 
outline protocol is based on the WHO (2016) recommended format for a research 
protocol.  
9.11.1a Study Ethics and procedure 
 Full NHS ethical and R&I permissions will be sought for the trial. The trial will be 
registered as an RCT. Full ethical and R & I protocol will be followed in line with 
good research clinical practice including the keeping of a trial portfolio. 
9.11.1b Justification 
There are no anticipated or unknown ethical issues based on the feasibility study. 
9.11.2 Study objective and null hypothesis 
9.11.2a Study objective 
Do patients walk further when exercised on NIV following a hospital admission 
with an exacerbation of COPD with uncompensated type II respiratory failure on 
NIV compared to exercise alone? 
9.11.2b Null hypothesis 
That there is no difference in outcome in exercising patients with severe COPD 
following a hospital admission with an exacerbation of COPD with 
uncompensated type II respiratory failure on NIV to exercise alone. 
9.11.3 Study Design 
9.11.3a Design  
A multi-centre randomised controlled trial. 
9.11.3b Justification 
This trial is multi-centre to allow for recruitment of a greater sample size. This is 
because the sample size calculation demonstrated that a sample size of n = 95 
330 
 
per group (total sample size n = 190) would be needed to identify a clinically 
significant difference between groups in the 6MWT as statistically significant. 
Therefore five centres would need to be involved for a trial period of two years. 
There would be one group for supervised exercise hospital and home and one 
group supervised exercise on NIV hospital to home. This would mean 38 
participants per centre, at a rate of n = 1.5 participants per month. Additional 
participants would need to be considered if participants dropped out. 
9.11.4 Research Team 
Research team required at all 5 centres:  
0.25 Full Time Equivalent (FTE) Researcher for screening and consenting 
0.5 (FTE) Band 6/7 Physiotherapist for intervention 
0.25 (FTE) Band 5/6 Physiotherapist for outcome measure assessment 
Research team main centre: 
0.5 (FTE) Researcher for data entry and analyser 
0.5 (FTE) Health Economist 
0.25 (FTE) Statistical Analyser 
9.11.4a Justification 
This staffing is based upon the feasibility study which identified that different 
clinicians and researchers blinded to group were needed for undertaking the 
intervention, outcome measures and data analysis. The Physiotherapy time is 
derived from the feasibility of one year 0.5 (FTE) Band 7 required to do all the 
research tasks. The exact cost of the staff required would need to be considered 
at the timing of grant or commercial funding application as this will be dependent 
on location of centre and pay inflation. The role of a health economist inclusion 
into the study has been reflected upon. For the purpose of the proposed study this 
would be included but cost effectiveness of the intervention would be a secondary 
outcome. 
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9.11.5 Equipment 
There would need to be 10 NIV devices per centre. This would mean a loan or 
purchase of 50 NIV devices. These cost £3,500 per NIV device and additionally 
there are consumables and maintenance. Therefore if purchased the cost of 
equipment would be £35,000. It would be preferable to seek an agreement for 
borrow or loan of the ventilators, each NIV device will last from five to eight years 
to make this a viable option. 
9.11.5a Justification 
Commercial funding was sought and granted for the feasibility trial. Commercial 
providers of NIV frequently offer NIV equipment on loan for trials. 
9.11.6 Recruitment   
9.11.6a Screening   
All Patients admitted to hospital following an acute exacerbation of COPD 
requiring treatment with NIV. 
9.11.6b Location 
A & E, Assessment Medical Unit and acute respiratory wards of the five acute 
hospital centres. 
9.11.6c Inclusion/exclusion criteria:  
Inclusion: All Patients admitted to hospital following an acute exacerbation of 
COPD requiring treatment with NIV. 
1. Exclusion: Primary diagnosis not COPD 
2. Not had a respiratory acidosis diagnosed through ABG analysis 
3. Not had NIV treatment 
4. Under 25 years of age 
5. Unable to follow commands or unable to consent  
6. Known contraindication to NIV (Royal College of Physicians, 2008) 
7. Unable to tolerate acute hospital NIV 
8. Unable to or refused to comply with physiotherapy  
9. Patients already attending PR 
10. Patient home environment unsafe for lone researcher 
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11. Had an additional pathology that limited ability to mobilise 
12. Dying/receiving end of life care and not expected to survive hospital 
admission 
13.  Do not live more than one hour from the hospital 
 
9.11.6d Justification 
There would be no changes to the inclusion criteria used in the feasibility study. 
The exclusion criteria would be more detailed and patient unable to or refused to 
comply will be separated out. There will be three extra exclusion criteria 9, 10 and 
13 in regards to PR, home safety and home location.  
9.11.7 Outcomes 
Primary outcome: 
6MWT 
Secondary outcomes: 
SGRQ for HQOL assessment  
EQ5D-5L and economic evaluation 
MBORG 
ActiCal: Step count, energy expenditure and LCADL 
Extra measures 
Spirometry will be undertaken at baseline and BODE score calculated at hospital 
discharge to capture disease severity data. Other baseline data will mirror that 
obtained in the feasibility data including age, BMI, smoking history, social status, 
hospital admission history, acute NIV use and LOS. This will ensure that the 
baseline characteristics are assessed for homogeneity. 
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9.11.7a Justification 
The trial would use 6MWT as the primary outcome because it was easily collated 
in the feasibility study from the acute to community environment and is meaningful 
to both clinicians and patients. 
Activity is still an important outcome to assess as the impact of NIV on exercise 
in activity in patients with COPD is unknown. During the feasibility study the 
ActiCal was the only measure incomplete. Additionally to step count data it may 
be beneficial to review energy expenditure of the participant when collating the 
ActiCal data. It would also be beneficial to have an additional activity 
questionnaire in case there is missing data and the ActiCal is not worn by enough 
participants. LCADL can present some details about activities but not the amount 
or quantity. Further discussion and piloting of an activity questionnaire with expert 
patient groups may be needed to decide upon an activity questionnaire to 
supplement the ActiCal device.  
The other area still undecided upon would be the role of qualitative methods. 
There is a tension between wanting to fully capture the voice of the participant in 
their experience of NIV and impact on QOL and balancing this with understanding 
the financial cost of including interviews in the final study. For the feasibility study 
it was essential to include qualitative methods to completely understand the 
acceptability of the trial and to truly understand the participants’ experience of the 
research. The qualitative findings show that the trial is acceptable and a positive 
experience to the participants. Therefore in the proposed RCTs skeleton study 
protocol the interviews have been omitted. The QOL measures assessed should 
offer insight into participants’ perceived benefits. The qualitative findings 
suggested that breathlessness is the main symptom that they experienced 
therefore MBORG is chosen as a secondary outcome. There may be a need to 
record symptom reported diary information which was successfully collated during 
the trial and this may be dependent on the health economic requirement of the 
trial. 
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9.11.7bTiming 
The baseline measurements will be taken in hospital on the ward within 24 hours 
of consent following stability of cardiovascular system and respiratory acidosis.  
The discharge measurements will be taken on morning of discharge on the ward. 
The month one, two and three measurements will be taken in the participant’s 
home at four weeks, eight weeks and twelve weeks following discharge. These 
will be undertaken at the same time and location for each individual participant. 
The outcome measures will not be assessed on the same day as an intervention 
session. The outcome measures will take between 30-45 minutes to complete. 
This will allow for rest time following the 6MWT to allow the participants to recover 
from breathlessness. A standardised SOP for each of the outcome measures will 
be completed for example 6MWT SOP will be based on Appendix 18. 
The order of the assessment of the outcome measures will be: 
1. 6MWT 
2. SGRQ 
3. EQ5D-5L 
4. LCADL 
5. MBORG 
ActiCal monitoring (Is a continuous measure that will be applied at hospital 
discharge). The ActiCal monitor will be downloaded at the end of the trial. The 
ventilator data will be downloaded at the end of the trial.  
9.11.8 Randomisation and Blinding 
Randomisation of participants to groups would be decided prior to the trial starting 
in sealed envelopes or via a clinical trials unit randomisation service to reduce 
selection bias. Bias would also be reduced by having a different therapist 
performing the outcome measures and the interventions. The physiotherapist 
assessing outcomes would be blinded to how the patients had been randomised. 
The quantitative analysis would also be carried out by a researcher blinded to 
group allocation. It is not possible to blind the clinician providing the intervention 
or the participant as there is no known sham NIV. 
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9.11.9 Intervention 
9.11.9a NIV 
NIV using the Trilogy 100 (Philips-Respironics), with a minimum PS target of 
16cmH2O. Set up will be based on the SOP in Appendix 13. 
The circuit will be single limb with a leak valve in the mask. The mask will be full 
face mask but if a patient is claustrophobic an alternative nasal mask will be 
considered. No humidifier will be put into the circuit.  
O2 will be entrained into the NIV circuit if the patient uses LTOT and if the patient 
desaturates to <90% SpO2 during exercise. 
NIV will be initiated at rest at the PS used during the acute exacerbation unless 
patient reports unable to tolerate this then it will be decreased by 2cmH2O every 
5 minutes until patient is able to tolerate. The NIV will then be titrated during 
exercise in-line with patient feedback, SpO2 <85% and asking the participant the 
MBORG score. If the MBORG score increases by one unit score on the MBORG 
scale the pressure is increased by 2cmH2O. 
9.11.9b Exercise 
This will follow PR guidelines (BTS, 2013). This will consist of pedal cycling, 
walking, step ups and the use of free weights. The same exercise will be 
undertaken in both groups. The same exercise will be used during the hospital 
stay and at home. This will be based on the SOP in Appendix 12. MBORG will be 
used to increase or decrease the exercise intensity in both groups. The exercise 
will be stopped at a participant’s request, if SpO2 falls below 85% or persisting RR 
>40 breaths per minute despite upward titration of PS.  
9.11.9c Sessions 
 The sessions will be supervised twice weekly for a maximum of 30 minute of 
exercise time. No additional sessions will occur in either group. If the participant 
is admitted to hospital during the trial the training sessions will continue as 
planned once their condition has stabilised in both cardiovascular observations 
and resolved respiratory acidosis. No extra sessions will be offered to participants 
if sessions are missed for any reason. 
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9.11.9d Justification 
The exercise used will be based on the exercise in the feasibility study. Due to the 
extent of the deconditioned patients recruited the intensity of training suggested 
by PR guidelines and within the exercise SOP was not initially possible. Therefore 
further consideration of this is required. To clarify this future work may need to 
occur on deciding how to progress the patients with very severe COPD to 
optimised PS on NIV and exercise training duration and intensity. A focus group 
of professionals who rehabilitate with NIV or rehabilitation patients with very 
severe COPD would be useful as there is currently no standardised method. 
Further discussion of clinical criteria of when to stop the exercise session would 
also be sought. 
9.11.10 Safety 
9.11.10a SAEs and AEs 
The SAEs and AEs will be reported as to the requirements of the individual NHS 
R & I centres and/or Sponsor. The participants will be individually asked about 
specific AEs and SAEs at each intervention session and outcome measure 
assessment. Contact details of the principal researcher at each of the centres will 
be provided to each of the participants to report any concerns. This will be 
available for participants for three months after they have completed the trial. 
9.11.10b Intervention 
The participant will be monitored with pulse oximetry for SpO2 and HR throughout, 
RR and MBORG will be evaluated every two minutes and patient feedback 
obtained. If RR >40 breaths per minute or SpO2 stays < 85% despite optimising 
NIV the session will be stopped. The session will be discontinued at the 
participant’s request. Any NIV equipment failure means the session will be 
terminated and the NIV equipment replaced prior to the next session and the AE 
recorded and reported to trial Sponsor. 
9.11.10c Justification 
A shortcoming of the feasibility trial was that AEs were not routinely sought via a 
check list. Thus this will be rectified for the RCT. The SAEs will be clearly reported 
as there were three deaths within the feasibility study and 14 hospital admissions. 
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These should therefore be fully evaluated to ensure the intervention or 
unsupported exercise is not the cause. Further discussion at a focus group of 
experts who rehabilitate patients with very severe COPD would add to the 
decision making within the protocol for clinical signs/methods to assess the 
cessation of an exercise session. 
9.11.11 Data Analysis 
Formal standardised outcome measure data collection sheets will be used at all 
of the sites, participants will only identifiable on the sheets by their participant 
number. All forms will be collated at one research site and collated by the research 
assistant who is blinded to participant group. The forms data will be recorded in 
Microsoft Excel version 13, selected and exported into SPSS version 20, (IBM: 
Chicago, Illinois, USA) for statistical analysis. Descriptive statistics will be 
calculated for the baseline data and outcome measures and the data will be 
assessed for normal distribution. When the data is normally distributed a one-way 
ANOVA will be carried out to assess for differences in the data between groups 
at each time point. Further statistical analysis will be provided by a statistician. All 
medical and personal information will be treated as confidential. Data will be 
anonymised as far as possible and as early as possible in the process. Data will 
be collected and retained in accordance with the Data Protection Act 1998. 
9.11.12 Expected outcome 
If the results of the study prove that NIV enables participants to exercise and gain 
benefits enabling them to walk further NIV could prove a useful adjunct to both 
PR and acute hospital rehabilitation. It may offer an alternative treatment for 
patients with very severe lung disease who only have palliative treatments 
available currently. 
9.11.13 Dissemination 
The aim for the dissemination of the RCT would be to publish the results in the 
scientific journals of Thorax or European Respiratory Journal. The results will also 
be fed back to other health care professional at conferences of the British Thoracic 
Society, European Respiratory Society and Chartered Society of Physiotherapy. 
The results would be disseminated in written form to any participants who would 
like to receive a summary of the trial results. 
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9.14 Conclusion 
This chapter has demonstrated how the research aims and objectives were met. 
It reflected on the feasibility of the research trial, the clinical outcome results and 
interview synthesis. This chapter has also compared the findings of this study with 
existing literature.  It has united the results of the quantitative and qualitative data. 
The chapter has discussed the strengths and the limitations of the feasibility study, 
revisiting alternative methodology and methods that could have been used. It 
concludes with a protocol outline that could be implemented as the basis of the 
future RCT.  
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Chapter 10 Conclusions 
 
10.1 Introduction 
This final chapter re-examines the original aims, objectives and research question 
considering the degree that they have been achieved. It then concludes with 
implications of the findings for future research and concludes with the contribution 
to new knowledge the doctoral research has made. 
10.2 Revisit the research aims and objectives 
This theses has sought to answer these aims:  
10.2.1 Aim 1:  
To evaluate the acceptability of applying non-invasive ventilation (NIV) during 
exercise in both the hospital environment and at home to patients with severe 
COPD who have been hospitalised for an acute exacerbation with acidotic 
respiratory failure.  
The research has successfully achieved this aim by presenting the attrition rates, 
concordance with outcome measures and qualitative interview data from the 
participants regarding their experience of the research. 
10.2.2 Aim 2: 
To gather qualitative data to aid understanding of the patient experience of 
participation in the intervention arm of the research trial to enhance quantitative 
acceptability data. 
The qualitative research enabled the acceptability of the research intervention to 
be fully understood through the patient experience. The themes identified from 
the interview material revealed the intervention to be a positive experience for the 
exercise on NIV in hospital and home group. Therefore the qualitative information 
identified that the research and intervention was acceptable to this group. 
Acceptability is an important component of concordance and thus the feasibility 
of the research. 
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10.2.3 Aim 3:  
To evaluate the feasibility of a randomised controlled trial design including: 
 Ability to complete the design in clinical environment with available 
resources 
 Availability of the participant sample pool 
 Recruitment numbers and recruitment time period 
 Randomisation process and acceptability 
 Participant retention in the trial, dropout rate and reasons 
The quantitative results enabled evaluation of the feasibility of the trial design by 
presenting an evaluation of recruitment and retention in the consort diagram, 
figure 6.1. The design was evaluated for completion within a clearly described 
clinical environment, timing required and the available resources documented. 
 
10.2.4 Aim 4: 
To evaluate the feasibility of collating and completion of the quantitative outcome 
measures. To inform a future trial of the potential primary outcome and secondary 
outcomes. These measures included:   
 Six minute walk test (6MWT) 
 St George’s respiratory questionnaire (SGRQ) 
 European Quality of Life - 5 Dimensions - 5 Levels (EQ-5D-5L): Utility score 
and visual analogue score 
 The London Chest Activity of Daily Living Questionnaire (LADL) 
 Modified BORG (MBORG)breathlessness score 
 Modified Medical Research Council (MMRC) dyspnoea score 
 Activity levels: assessed by ActiCal activity monitor 
 Self-reported medication use, access to healthcare and hospital 
admissions 
The feasibility of collation and participant completion of the quantitative 
outcome measures was evaluated. The NIV on exercise in hospital and home 
intervention package generated a trend for improvement in the outcome 
measures with the most obvious improvement seen in the 6MWT, this was 
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selected as the primary outcome in the outline of the protocol for a future trial. 
This outcome was used to calculate the sample size required for statistical 
significance in the future trial. 
10.3 Final conclusions 
This doctoral research investigated the feasibility of exercising patients with 
severe COPD on NIV from hospital to home over three months. 
This study demonstrated a contribution to new knowledge in this area by 
demonstrating that it is feasible and acceptable to patients with severe COPD to 
exercise on NIV. It demonstrated that this can be carried out in both the hospital 
and home environment. This study demonstrated that this type of study can be 
recruited into but to achieve sufficient numbers and to ensure reduced bias a 
multi-centre trial would be required. This study successfully took a mixed-methods 
approach and successfully balanced the methods with comprehensive 
integration. This work was important because it demonstrated that patients with 
severe COPD wanted to be actively treated, including engaging in exercise, and 
wanted to be involved in research. The trend for improvement in outcome 
measures and positive experiences expressed by participants at interview 
strengthen the existing literature on exercise on NIV in patients with COPD. Future 
research is needed in the form of a multicentre randomised trial to assess whether 
the findings have any statistical significance, clinical significance and are cost 
effective. 
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Appendix 7 Philips-Respironics Trilogy 100 specification 
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Appendix 8 Preliminary Trilogy CPET 
This is the data download from the Trilogy 100 ventilator to demonstrate the data 
of the CPET. It presents wave forms of respiratory data over the time of the 
exercise. The ventilator flow rate was maintained throughout the exercise test. 
This can be seen on the top wave form graph. The second graph demonstrates 
the RR, third graph the PS used, fourth graph inspiration to expiration ratio and 
final graph is VE.  
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This graph demonstrates the numerical average of the ventilator data. The 
average minute ventilation of the exercise test (top graph) was 39.22L/min. The 
average RR was 17 breaths per minute (third graph). The average IPAP was 
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19.44cmH2O and EPAP 3.51cmH2O (sixth graph). The average mask leak was 
61.89L/min (bottom graph). 
 
This image demonstrates the time and date of use. 
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Appendix 16 Modified Borg dyspnoea scale 
 
0 Nothing at all 
 
0.5 Very, very slight (just noticeable) 
 
1 Very slight 
 
2 Slight 
 
3 Moderate 
 
4 Somewhat severe 
 
5 Severe 
 
6 
 
7 Very severe 
 
8 
 
9 Very, very severe (almost maximal) 
 
10 Maximal 
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Appendix 17 MMRC Dyspnoea scale 
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Appendix 19 Interview Guide 
Introduction questions 
1. Can you give me a snap shot of your experience in using the equipment for the last 
three months? 
2. How would you describe using the equipment to someone who has never seen the 
equipment? 
3. Has the ventilator influenced your life? 
 
Using the equipment 
4. Overall has the ventilator been a positive or a negative experience for you? 
5. Did you find it easy exercising on the ventilator? 
6. Were there any difficulties of exercising on the ventilator? 
7. Were there times when you chose not to use the equipment? 
8. Is there anything you would change about the design of the equipment used? 
Experience 
9. Have you experienced any physical changes over the last 3 months? 
10. Have you experienced any other changes? 
11. What do your family and friends think of the equipment? 
12. Did anything surprise you about the study? 
13. Did anything surprise you about the equipment?  
Advice 
14. Do you have any advice for a person who is about to take part in the research? 
15. Do you have any advice for health professionals who set patients up on this 
equipment? 
16. Do you have any advice for health professionals carrying out this type of research? 
Extra information 
17. Is there anything you would like to add about your experience of using the 
equipment? 
18. Is there anything else you would like to add about your experience of the study? 
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Appendix 20 Interview transcriptions 
Interview 1: Vanessa 
Tuesday 18th June Interview: 3.30pm in the kitchen of the home of NIV1:3 on stool 
and interviewer sitting opposite by window, can hear gentle chug of oxygen 
concentrator and birds singing outside the open window, faint smell of cigarettes is 
present. The participant asked for lots of prompts and breaks for breathlessness.  
Interviewer: “Alright…ok…so first question you said on more than one occasion 
that you dread my visits can you tell me about this?” 
Vanessa: “erm…erm…well… obviously it’s I don’t dread you coming so much as 
the purpose of your visit that’s what I dread really… erm… I suppose it’s the thought 
of having to do the exercise erm... use the mask erm… and the worst bit is taking 
the mask off afterwards and getting my breath back.” 
Interviewer: “yeah but I have the knowledge that you rarely cancelled a visit why 
was this?” 
Vanessa: “erm…crumbs this is really off putting can we have a break” 
Interviewer: “let’s have a break for a minute (turned off recorder at patients 
request)” 
Vanessa: “what was the question again?” 
Interviewer: “so even though you dreaded my visits “ 
Vanessa: “oh I haven’t cancelled” 
Interviewer: “you rarely cancelled an attendance, why was this?” 
Vanessa: “because I know that what I dread well it isn’t as bad as the sessions 
gonna be and I don’t want to let you down erm and I know that some good’ll probably 
come of it the session afterwards anyway” 
Interviewer: “probably?” 
Vanessa: “probably erm yeah” 
Interviewer: “what good?” 
Vanessa: “erm that the exercise will probably do some good physically and yeah 
probably be helpful in the long run “ 
Interviewer: “ok... could you give me a snapshot of your experiences of using the 
equipment over the last 3 months?” 
Vanessa: “(pause) I suppose my main feeling is that I haven’t really been physically 
up to it that I haven’t had such as much benefit from.. from the sessions as I could 
have had because of being unable to erm do any exercises on my own in the 
daytime when you haven’t called” 
Interviewer: “why was that do you think?” 
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Vanessa: “mainly because I think I I’m struggling too much just to get through each 
day erm doing the main things I need to do you know like eating and clearing up 
and things like that” 
Interviewer: “How would you describe using the equipment to someone whose 
never seen it?” 
Vanessa: “what the machine? You mean erm laughs I don’t know what I’d say 
laughs” 
Interviewer: “ok how would you describe how it feels?” 
Vanessa: “erm when you’ve actually got it on it can feel quite relaxing” 
Interviewer: “mmm” 
Vanessa: “I feel it actually gives me dry mouth which I don’t I don’t like very much 
and I don’t like taking it off because of you know the transition back to you know the 
normal oxygen machine” 
Interviewer: “has the ventilator influenced your life, do you think?” 
Vanessa: “erm I do like the idea of having access to it even though I haven’t used 
it on my own if I didn’t have so many other things stressing me out (laughs) then I’d 
probably put more effort into having a go and using it on its own cause I think that.. 
I think it would help me… with some of the erm daily problems I’ve had” 
Interviewer: “can you give me some examples of what you think it might help with?” 
Vanessa: “things like the breathing problem and although you tell me my levels are 
fine for some reason they don’t feel fine and the confusion I’ve had and the light 
headedness and things like that “ 
Interviewer: “overall has the ventilator been a positive or negative experience for 
you?” 
Vanessa: “erm I’ll say positive overall (laughing) even though I hate to admit that 
(laughing)” 
Interviewer: “why do you hate to admit that?” 
Vanessa: “because my attitude doesn’t suggest that…sorry I need a rest now” 
Interviewer: “yes let’s have a rest (recorder turned off)” 
Interviewer: “ok so we are starting the tape again I’m just going to check that he’s 
working which he is…Ok did you find it easy exercising on the ventilator?” 
Vanessa: “erm...yeah I suppose yeah” 
Interviewer: “were there any difficulties in exercising?” 
Vanessa: “difficulties in exercising?” 
Vanessa: “no not especially I suppose the main thing was… was how easily tired it 
made me erm yeah my limbs erm” 
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Interviewer: “did it feel any different to when you have exercised without the 
ventilator?” 
Vanessa: “erm Oh I don’t know...I can’t remember particularly I don’t think so” 
Interviewer: “can you remind me of the time, when the exercise plan we were going 
to do was changed because your arms were aching because you’d been brushing 
your hair? You felt unable to do the weights” 
Vanessa: “erm that was to in order to do my hair I had to have my arms lifted up 
above my head for quite a few minutes it took me about twenty minutes to half an 
hour to do my hair and that was quite tiring on my arms and my shoulders so by the 
time I’d finished doing my hair yeah my arms and shoulders were quite tired and 
sore” 
Interviewer: “can you remember and explain some of the reasons why you did 
cancel a few of the sessions?” 
Vanessa: “erm ones I cancelled oh what was it it’s hard for me to remember what 
it was it was see this is the (tut) memory problem I’ve got” 
Interviewer: “it’s ok you’re fine.. your’e fine.. was one to do with not feeling well?” 
Vanessa: “yeah” 
Interviewer: “tiredness?” 
Vanessa: “oh there’s that but wasn’t there one where I’d hurt my leg or something 
or” 
Interviewer: “ there was one where your leg was aching but that was after we’d 
done an exercise session and I think one may have been when the council was 
telephoning or coming to visit to sort out your heating” 
Vanessa: “(shrugs) yeah” 
Interviewer: “that’s ok we can come back to that erm is there anything you would 
change about the design of the equipment?” 
Vanessa: “erm ..(shakes head)” 
Interviewer: “anything about the actual ventilator or mask or hose or the way we 
connect the oxygen?” 
Vanessa: “no I don’t know I don’t think so although I’m quite nervous about using it 
and putting it on and stuff” 
Interviewer: “ what are you nervous about?” 
Vanessa: “about….erm connecting it up properly and you know not having….” 
Interviewer: “to the oxygen?” 
Vanessa: “yeah to the oxygen and not being able to sort the oxygen quick enough 
if I’m not getting it right” 
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Interviewer: “so do you think you need to be quite quick when you use it?” 
Vanessa: “mmm” 
Interviewer: “Anything about the size of the equipment or weight or mask?” 
Vanessa: “I find the weight of the equipment heavy to lift but then that can be put 
in place you know it’s not to heavy for me to move I could put it in place first and 
then put the equipment on and stuff you know at the side of the bed erm “ 
Interviewer: “can you put the mask on easily?” 
Vanessa: “yeah I don’t find that easy to put on plus aswell because I have to take 
my glasses off then I can’t see properly so that makes me nervous not being able 
to see properly if I am doing it on my own” 
Interviewer: “rest or you ok?” 
Vanessa: “yeah I could do with a rest” 
(Tape recorder paused)” 
Interviewer: “Ok we are starting the recorder again...yeah? Do you think you’ve 
experienced any physical changes over the last three months?” 
Vanessa: “erm only maybe very marginally simply because I haven’t been able to 
make full use of you know the opportunity to do the exercises I think if I’d have 
managed to do it more times in the week then I think I would have benefitted quite 
significantly” 
Interviewer: “ok just describe how you think you have marginally changed?” 
Vanessa: “erm small amount of additional strength in my limbs especially my legs 
er you know where which is what we worked on mainly.” 
Interviewer: “Did you experience any other changes?” 
Vanessa: “erm actually confidence that my breathing is better than I realised by 
having the machine the little thing showing me every time you came that my Sat’s 
levels were good and stuff” 
Interviewer: “any other experiences sort of your emotions or stress levels….” 
Vanessa: “laughs erm yeah I suppose my stress levels improved mainly because 
you were as good as your word that I didn’t feel pressured that I had to do anything 
I didn’t want to do” 
Interviewer: “On a couple of visits you did admit to feeling slightly better having 
done the exercise the next couple of days can you tell me about that?” 
Vanessa: “I was lying laughs erm oh did I do that laughs I don’t know what to say 
erm well yeah it did seem to have a good effect on my mood and my feeling 
physically even though I was a bit tired afterwards and needed a little sleep or nap 
erm generally speaking I did feel better” 
Interviewer: “what do your family or friends think of the equipment?” 
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Vanessa: “erm Burt (son) and Ernie (nephew) think it’s great they think that erm I 
should make more use of it and they are happy to help me use it if I want to..” 
Interviewer: “cause initially you did say to me erm that they thought it was a waste 
of money could you elaborate on that?” 
Vanessa: “Oh Burt’s attitude, that’s my son, his attitude very much is that most of 
what’s happened to me I deserve because I haven’t completely given up smoking 
so he tends to fluctuate between feeling that there’s no point in having any treatment 
at all while I still smoke and making use of treatment that will help and that if it helps 
enough maybe it will help me give up smoking if you understand that” 
Interviewer: “I do” 
Vanessa: “so I need to rest” 
Interviewer: “yes you’ve done really well” 
(Tape recorder paused)” 
Interviewer: “right restarting the recorder. Did anything surprise you about the 
study?” 
Vanessa: “erm in what way?” 
Interviewer: “was there anything you weren’t expecting” 
Vanessa: “erm I don’t know I don’t think so I didn’t really know what to expect” 
Interviewer: “Did anything surprise you about the equipment?” 
Vanessa: “erm” 
Interviewer: “cause you’ve used hospital NIV how did it compare to this” 
Vanessa: “well I didn’t really use it myself did I at the hospital it was always a nurse 
you know to operate things so I suppose I suppose I was surprised at just how much 
I lacked confidence in using it erm yeah” 
Interviewer: “ok do you have any advice for person about to take part in the 
research study “ 
Vanessa: “erm well just basically to go for it that it’s not as bad as you think it’s 
gonna be (laughing)” 
Interviewer: “Have you got any advice for health professionals setting up patients 
on this equipment?” 
Vanessa: “erm no not really I’m happy with the way its been used on me and yeah” 
Interviewer: “Is there anything else you’d like to add about your experience of using 
the equipment?” 
Vanessa: “erm…..” 
Interviewer: “Anything you hated anything you loved?” 
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Vanessa: “erm no I just wish that I wasn’t so that my condition wasn’t so poor to 
start with a year or two ago I’d have probably benefited much more than this than I 
am doing now “ 
Interviewer: “So you think that you may have liked to have a go of exercising on 
the ventilator sooner?” 
Vanessa: “yeah” 
Interviewer: “What about, anything else you want to add about the whole 
experience of being involved in the research? And all the outcome measures things 
like the walking test the questionnaires “ 
Vanessa: “laughs” 
Interviewer: “the diary” 
Vanessa: “well diaries and questionnaires I absolutely hate in any form for anything 
so erm that’s something that I would have struggled to do you know anyway erm “ 
Interviewer: “How about the walking test?” 
Vanessa: “yeah the walking test I found quite good because it gave ma an idea of 
just how far I can walk unaided sort of thing so” 
Interviewer: “what about the actical, did that feel alright?” 
Vanessa: “the what?” 
Interviewer: “the device on your wrist” 
Vanessa: “oh yeah that’s been fine that’s still there” 
Interviewer: “was there anything else you would have liked to have done… different 
exercises? Or…” 
Vanessa: “like I say I just wish I could have done more exercises longer... more in 
the week” 
Interviewer: “Is there anything I could have changed to make you feel more 
confident to use the machine on your own” 
Vanessa: “no” 
Interviewer: “or to exercise more?” 
Vanessa: “no I think you did everything you could against my lack of confidence” 
Interviewer: “Is there anything else you’d like to add” 
Vanessa: “no not really (laughs)” 
Interviewer: “That’s great” 
(Interview time 1hour, actual talking time 25 minutes due to dyspnoea) 
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Interview 2: Neil 
In lounge participant sitting next to researcher on couch in lounge of the ground 
floor flat. Kitten is playing on the floor with the tubing of the ventilator. 
Interviewer:  “So yep we are recording.  Can you give me a snapshot of your 
experience of the study over the last 3 months?” 
Neil:  “Erm...a snapshot erm……” 
Interviewer:  “Your experience…?” 
Neil:  “Erm I don’t really know I just thought  erm I mean it has been helpful 
obviously in the fact that you know erm that somebody is I presume is you know 
is coming round to monitor you and erm discuss your medication and discuss your 
ongoing health I suppose” 
Interviewer:  “Ok how would you describe the equipment to somebody who has 
never seen the equipment?” 
Neil:  “erm a little bit daunting initially (laughs) but once you use it and you 
experience it you get very much used to it and erm it is no problem at all really so 
you know you find it well the whole equipment and so forth  you find useful really” 
Interviewer:  “How would you describe how it feels?” 
Neil:  “Erm... initially quite erm you might find it a little bit erm as I did err a little 
bit claustrophobic erm which I have done with using masks erm recently in the 
last six months I’ve found very very claustrophobic but err certainly you get used 
to and obviously it is there to to help you” 
Interviewer:  “Did it differ from the machine you used at the hospital?” 
Neil:  “Erm...not really only in the shape of the mask I think was the only difference 
that I can remember” 
Interviewer:  “Has the ventilator influenced your life?” 
Neil:  “Has it influenced my life erm probably not (laughs)I don’t know not 
personally it hasn’t sort of changed my life (laughs)you know (laughs) it’s not like 
having children or marriage you know (laughs)” 
Interviewer:  “Overall has the ventilator been a positive or negative experience 
for you?” 
Neil:  “I expect it has been a positive experience yes…” 
Interviewer:  “Why is that?” 
Neil:  “Well it does I think it does help you with your exercise erm I think that’s the 
positive thing because I realised pretty early on that I erm that you need to do 
some sort of exercise to stabilise your condition and erm help you in future 
years….” 
Interviewer:  “Did you find it easy exercising on the ventilator?” 
Neil:  “Err initially not no erm it took several goes actually when I say several 
probably about two to three err goes before erm I got used to it really…” 
Interviewer:  “Why was that?” 
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Neil:  “Erm again I think it’s the claustrophobic aspect to it and also I don’t know 
which brought on a little bit of a what we discussed just now a little bit of a panic 
err to so you know so you were probably breathing more heavily which you know 
is not natural..” 
Interviewer: 
“Were there any difficulties when you exercised on the ventilator?” 
Neil:  “No none what so ever no” 
Interviewer:  “You only used the equipment on the days I visited could” 
Neil:  “I have used them no I have used it on other occasions sat over there and 
erm used it there as well...” 
Interviewer:  “How did you find that?” 
Neil:  “Ok the only thing that I did find difficult at times was putting the mask on to 
be quite honest with you and then I’d try try and try sometimes I have used it a 
couple of times erm and then you think oh blow it I’ll just do the exercises without 
using the equipment so that’s the only down side I mean I would have used it if I 
could you know fit it on better” 
Interviewer:  “Ummhmm is there anything you regret about the study?” 
Neil:  “No none whatsoever” 
Interviewer:  “Is there anything you were expecting or hoping the study would do 
that hasn’t happened?” 
Neil:  “No as far as I was aware I would think that this is doing a cross section as 
to you you to erm I presume help people in in the future really that’s the way I read 
it” 
Interviewer:  “Is there anything you would change about the design of the 
equipment used?” 
Neil:  “Yeah the mouthpiece (laughs) obviously because I’ve stated (laughs) “ 
Interviewer:  “Ok... Have you experienced any physical changes over the last 
three months?” 
Neil:  “Erm I think in the last three months I I think before I was struggling to to 
perhaps go to the shops that type of thing and stopping off I just presumed that 
type of condition but since I have exercised and so forth erm you know I was able 
to walk to my shops and back without stopping”  
Interviewer:  “Ok have you experienced any other changes?” 
Neil:  “erm…” 
Interviewer:  “feelings or emotions or changes to your mental health?” 
Neil:  “No not really no” 
Interviewer:  “What do your family and friends think of the equipment and 
neighbours?” 
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Neil:  “Erm I don’t think any of them have particularly seen it erm no I mean the 
only people that see and the neighbours do see is the nebulizers and that doesn’t 
worry me at all so” 
Interviewer:  “Did anything surprise you about the equipment or study?” 
Neil:  “Erm no not really erm I don’t think no” 
Interviewer:  “Have you got any advice for a person who is about to take part in 
the research study?” 
Neil:  “Err I think the only thing is erm erm I think is the keep up what you are 
being told by the nurse erm because it will only help you really you know I think 
that the advice the advice that you’re given really you’ve got to take on board 
because the stronger you are the more exercise is going to help your condition 
and help prolong your life which is what it’s all about really I suppose” 
Interviewer:  “Do you have any advice for health professionals who set patients 
up on this equipment?” 
Neil:  “Erm no I think my only concern erm is is the design of the mask really that 
that really is and I think you know because I’m still working and I’m still reasonably 
active you know I think for anybody that’s older and a little bit more not so perhaps 
as able as I am I would think they’d find that very very quite difficult to actually 
implement and use really” 
Interviewer:  “Do you think there was enough time in hospital to get used to the 
equipment before you went home?” 
Neil:  “Yes Yes Yes” 
Interviewer:  “Do you have any advice for health professionals carrying out this 
type of research?” 
Neil:  “Erm not really no” 
Interviewer:  “Did you find the walk tests, the questionnaires and the diaries?” 
Neil:  “Yeah I I the diaries are useful erm the walk tests erm I did find difficulty 
with them sometimes because I would out quite a lot into it erm and obviously the 
nurse would monitor me erm how I was and so forth but when doing a full exercise 
and then you know going to work I did find it it did take quite a lot out of me err 
not that I was thinking it would take a lot out of me but erm it I did actually find that 
it did a little bit” 
Interviewer:  “Did you find that on the days that when we exercised on the 
machine as well?” 
Neil:  “Erm yes that as well especially the leg exercise“ 
Interviewer:  “Anything you would like to add about your experience of using the 
equipment? You have said to me you thought it helped” 
Neil:  “Yep” 
Interviewer:  “And that you thought it helped you walk further to the shops in what 
way di the ventilator help with the exercise?” 
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Neil:  “Erm... to be quite honest with you I didn’t see a lot of difference from using 
the ventilator to erm there were a couple of times where we didn’t use it and erm 
I didn’t see any difference between actually using it and erm doing it without the 
erm ventilator” 
Interviewer:  “Ok Anything else you would like to add?” 
Neil:  “no not really erm I feel that I should you know which we discussed earlier 
that I should keep up some of the exercises which I think are important I think that 
is really about it.” 
 
Interview 3: Gert 
Took place 18/11/12 at 11am in the living room (the walls are stark as the 
wallpaper has been stripped off some time ago but not replaced), participant is 
sitting on the sofa in her tracksuit with the oxygen on via nasal specs and 
researcher is sitting on the opposite sofa, participants husband and daughter 
wandering in/out. There is a faint smell of cigarette smoke present, the audible 
chug of the oxygen concentrator can be heard and the television initially blaring 
out on 24 hour Christmas films channel. 
Interviewer:  “Ok so I’m starting the tape recorder…lovely he’s recording….and 
now on with the questions” 
Gert:  “I ain’t no good at talking and this sort of thing you know that...” 
Interviewer: “So tell me about your hospital admission just before you started this 
research programme?” 
Gert:  “It was alright actually...I gotta be…the BRI…they do treat you well I gotta 
say they they did everything for me in there without them I wouldn’t be here I don’t 
think ….but they are good……” 
Interviewer:  “And how were your general activity levels and health, before you 
came in, do you think?” 
Gert:  “Before I went in to hospital? “ 
Interviewer:  (Nods) 
Gert:  “Bad...Breathing...Bad it was all bad…but then you don’t realise how bad 
you are til you go in there do you? I always concentrated on the breathing but it’s 
not always that is it so it’s just as well I did go in when I did.” 
(Husband enters lounge and takes remote control to turn up television…) 
Interviewer:  “Hi Roger…we are just doing the interview at the moments that’s 
why the Telly’s turned down...ok...” 
Roger:  “Oh right…” (Laughs) 
(Roger sits down at the table) 
Interviewer:  “So when we are talking about the study can you tell me your 
experience of using the equipment for the last three months?” 
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Gert:  “Well I gotta say…I don’t...I didn’t like using it I gotta say and the thing that 
goes in your nose...I don’t like that sort of thing...but in general… yeah...I think it’s 
a good thing actually...I think it’s a good thing...I  just didn’t like that part (looks at 
Roger)” 
Roger:  “No? What the thing up your nose...” 
Gert:  “Yeah...I tell you Roger I don’t like it up your nose...it’s the air going through 
your nose… because if it’s too high obviously it covers your breathing and it 
reminds me of that I had in hospital of the mask that’s what it reminds me of and 
I didn’t like that either (laughs) but no in general I think it’s a good thing to come 
round like this...I never knew people would come round like this but yeah…” 
Interviewer:  “So was it the actual pillows that you...” 
Gert:  “Yeah...yes...yeah well if you got to use it you got to use it haven’t you but 
in general it was alright….” 
Interviewer:  “What about the pressure?” 
Gert:  “I didn’t like the pressure on it either… no...I didn’t …no” 
Interviewer:  “Was there anything worse about it at the beginning or…?” 
Gert:  “It’s the beginning that’s the worse once you’ve got it on you are alright 
cause you’ve got to get used to it…..but it is the beginning puts you right off....but 
once you’ve got it on you’re alright” 
Interviewer:  “Did it change over the 3 months or you didn’t enjoy...?” 
Gert:  “I didn’t enjoy any of it...no, no” 
Interviewer:  “How would you describe using the equipment to someone who has 
not used it before?” 
Gert:  “Very difficult (laughs) cause I didn’t like using it without you being here 
mind...cause I was frightened that I was going to break it or I was gonna do 
something that’s why I never ever used it but erm once..  I think once they you’ve 
shown them properly a couple of times they should be alright shouldn’t they…” 
Interviewer:  “How would you describe it to them?” 
Gert:  “Oh (laughs) I don’t know, I don’t know how to describe it...but then I’m not 
that sort of person so….” 
Interviewer:  “What would you say it feels like?” 
Gert:  “What doing it yourself?...No…I didn’t like it at all I gotta admit……….” 
Interviewer:  “Was it similar to anything you could describe or felt…?” 
Gert:  “No...No I haven’t ever felt it so I don’t know” 
Interviewer:  “Or could you describe it to someone?” 
Gert:  “No…no ...I haven’t ever felt it so I don’t know……” 
Interviewer:  “So would you say overall the ventilator has been a positive or a 
negative experience for you?” 
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Gert:  “Well It’s obviously a positive thing otherwise I wouldn’t be using it would 
I? So it is obviously positive but err… some things you get used to and some 
things you don’t do you? And that I didn’t get used to” 
Interviewer:  “What did you get used to? Was there anything we did that you got 
used to?” 
Gert:  “I mean the exercising that’s alright I don’t mind things like that...it was just 
that...(looking at the ventilator) but other than that yeah it was alright………….” 
Interviewer:  “Did you find it easy exercising on the ventilator?” 
Gert:  “Yeah I did yeah I did find it easy...yeah” 
Interviewer:  “In comparison to when you did it without did you find any 
differences?” 
Gert:  “What without it……..Oh yeah you don’t get the same benefit do you? If 
you haven’t got it on you don’t get the same benefit...so...yeah having it on did 
make a lot of difference...” 
Interviewer:  “In what way?” 
Gert:  “Well it helped you didn’t it when you did your exercises...it does help 
you…..so” 
Interviewer:  “I’m going to push you…in what way?” 
Gert:  “I don’t know………..don’t ask me that…” 
Interviewer:  “So you said it was better using the machine…how did it do that?” 
Gert:  “It helps you breathe a little bit better with it on it does...when you’re 
exercising….otherwise you’re out of breath so bloody quick that did help… but 
other than that …no” 
Interviewer:  “Did it help during or after for recovery or both?” 
Gert:  “No… during…during………..” 
Interviewer:  “So what was the hardest bit about it?” 
Gert:  “Erm…” 
Interviewer:  “The mask….the” 
Gert:  “It is the mask…yeah…” 
Interviewer:  “And I know you said you used it when I was here but you didn’t use 
it when I?” 
Gert:  “Once…I used it once when you weren’t here…” 
Interviewer:  “And how did you find that?” 
Gert:  “I couldn’t get on with it...cause it was only the once...and it was the 
pressure…I couldn’t get the pressure right…the thing is if you’re not using it all 
the time you don’t know do you so…that is why I never used it again without you 
being here...cause I couldn’t get it right….” 
Interviewer:  “The mask fit or?…” 
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Gert:  “No the mask fitted…no it did fit…it was just getting the pressures right on 
it…” 
Interviewer:  “The pressures?” 
(Silence) 
Interviewer:  “Ok was everything else ok...the hose...etc.” 
Gert:  “Yes everything was fine…everything was fine” 
Interviewer:  “Is there anything you’d change about the design of the equipment?” 
Gert:  “Yeah the whole lot (laughs)...nah... it’s alright if you...I mean if you’ve gotta 
use it you’ve got to use it haven’t you the designs alright in it...it’s just a matter of 
putting it on the floor really so yeah that’s alright.. I mean you wouldn’t have it any 
other way really are you cause that’s about right” 
Interviewer:  “So you’ve said to me you don’t like the mask…what would you 
change about that?” 
Gert:  “It’s at... the nose really...it’s the pressure…but then that gotta be there...so” 
Interviewer:  “So do you think it would be better if the machine started with a 
lower…?” 
Gert:  “Yes definitely lower...put it on low…let it increase and then you get used 
to that…” 
Interviewer:  “Is that what was hard about doing it on your own was you couldn’t 
get the pressure right?” 
Gert:  “Yes because I couldn’t get the pressure right…Yeah...otherwise I would 
have used it…”. 
(Silence) 
Interviewer:  “Erm do you think you’ve experienced any physical changes over 
the last 3 months?” 
Gert:  “No” 
Interviewer:  “No?” 
(Silence) 
Interviewer:  “Have you experienced any benefit from using it?” 
Gert:  “No I can’t say I have I gotta be honest…no I haven’t” 
Interviewer:  “Were there any negatives of using it?” 
Gert:  “No not really...no” 
(Silence) 
Interviewer:  “What do your family and friends think about it?” 
Gert:  “They haven’t seen it...I don’t get a lot of people up here...so...it’s just as 
well really there aren’t a lot of people that come up here...so” 
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Interviewer:  “What does your husband think about it?” 
Gert:  “He’s alright with it...in’t it Roger...” 
Roger:  “Yeah” 
Gert:  “That machine” 
Roger:  “Umhmm” 
Gert:  “He thought it was good” 
(Silence) 
Interviewer:  “Did anything surprise you about doing the study or using the 
equipment?” 
Gert:  “No not really...no” 
(Silence) 
Interviewer:  “Have you got any advice for a person who’s about to take part in 
it?” 
Gert:  “Don’t bother (laughs) don’t bother no it is a good thing when you it is... if 
you...you know  it is if you need something like that it is a good thing for people to 
use” 
Interviewer:  “Why do you think it’s a good thing?” 
Gert:  “Well it ain’t no good to me I... I didn’t use it but it would help with your 
breathing I suppose wouldn’t it…” 
Interviewer:  “Do you think you got any benefit from the sought of twice a week 
sessions you did with me?” 
Gert:  “No I just enjoyed somebody coming to be honest... It was just somebody 
turning up…..and... cause I don’t get nobody up here anyway...so company as 
well as you know…..” 
Interviewer:  “Do you think it had any impact on your walking or?” 
Gert:  “I could walk alright with it” 
Interviewer:  “Or your weight …?” 
Gert:  “The weight it didn’t but…not at the moment no ……It might have done 
actually cause I am losing it, I am losing it…this at the moment... I aint this is what 
I got but I am losing the weight I gotta admit” 
Interviewer:  “There were a couple of sessions where you mentioned that you 
thought your tummy had …?” 
Gert:  “Gone...Yeah it went down but…this is different (pointing at stomach) this 
will go in a couple of days” 
Interviewer:  “What about sort of getting out and about?” 
Gert:  “I do get out and about yeah I do get out and about...I ain’t saying I walk 
that far but I don’t but I do get out and about” 
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Interviewer:  “Can you see any difference in how you were before you went in to 
hospital to how you are now?” 
Gert:  “Oh yeah definitely Oh yeah I can walk a little bit better than what I did...and 
I do feel a little bit better I gotta say...cause before then I was just I was 
miserable...I gotta admit...and things was worrying me as well but at the moment 
now I’m fine...I’m much better now I do say so” 
Interviewer:  “So before your admission you were feeling anxious and down?” 
Gert:  “Yeah I was really down and yeah I was but at the moment no I’m alright” 
Interviewer:  “Good…Have you got any advice for a health professional setting 
up patients on this equipment?” 
Gert:  “No not really cause I ain’t no good at that sort of thing...so...I ain’t no good 
at speaking to people anyway...so...” 
Interviewer:  “Well you have given me advice...you’ve said how you would start 
the pressure on low then turn it up” 
Gert:  “Oh yeah...you gotta do that...yeah...but it is a good thing for anybody to 
use” 
Interviewer:  “How about the mask?... how could we make that better… how 
could we change it?” 
Gert:  “You can’t really can you…the mask is the mask in it” 
Interviewer:  “All right erm did you think that the exercising each week on the 
ventilator might have…might have erm…” 
Gert:  “Helped?...yeah It did help yeah it did I get in and out a little bit more I’ve 
got to say...whereas I used to sit in the chair and let him (nodding at husband) do 
everything but not now I do’s get up...and do washing and that sort of thing so…” 
Interviewer:  “Do you think it was worth it?” 
Gert:  “Yeah I think so...yeah yeah it was worth it” 
Interviewer:  “Anything else that you want to add?” 
Gert:  (Groans) 
Interviewer:  “About the exercising...the ventilator...anything you found hard?” 
Gert:  “Well I didn’t find anything hard really…I mean that sort of thing would be 
alright for old people as well wouldn’t it...because it’s light…” 
Interviewer:  “Yep…did you find it easy exercising in your home?” 
Gert:  “Yeah I did yeah...I did but we’ll after Christmas start back at the school 
(local gym group)” 
Interviewer:  “That’s good to hear...Anything else you want to add?” 
Gert:  “No” 
Interviewer:  “Feel happy?” 
Gert:  “Yep” 
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Interviewer:  “Thank you…I know it’s difficult and you didn’t like doing it but you 
did really well” 
Gert:  “I hate doing things like that” 
(Recorder turned off) 
 
Interview 4: Elsie 
Took place in Elsie’s council flat, faint smell of cigarettes, lots of cats present and 
chug of oxygen concentrator present. 
Interviewer:  “So I’ll just check the recorder is working...testing...lovely. 
Alright...so...I’ll sit this side so you can see me facing you...Ok so this is just to 
recap of it all really where am I best to sit here so I’m facing you?” 
Elsie:  “no you’re fine there” 
Interviewer:  “It’s a recap of the whole project and you using the ventilator and 
your experiences. So just a few general questions that I’ll ask you and then some 
more specific ones...but it’s more for you to do most of the chatting to me which I 
know you like talking so...(laughs)...that’s always good” 
Elsie:  (Laughs) 
Interviewer:  “So to start with if you just tell me a little bit about the run up to the 
project and how it’s been the actual experience of having COPD?” 
Elsie:  “It’s a horrible thing to have because it does stop you from doing a lot of 
things...erm...” 
Interviewer:  “Like what….?” 
Elsie:  “Things you used to be able to do like a lot of cleaning things which I’ve 
managed to overcome which I do erm but not in a fast speed I just started slowing 
down on everything” 
Interviewer:  “Anything else it’s stopped you doing?” 
Elsie:  “No… not… well I’m not as active as I used to be but I try to keep it at a 
level” 
Interviewer:  “So prior to coming into hospital what were your main symptoms 
would you say?” 
Elsie:  “What this time...or...?” 
Interviewer:  Nods 
Elsie:  “Erm... just couldn’t breathe very well” 
Interviewer:  “Anything else?” 
Elsie:  “I don’t know If I did I can’t remember if I did have a cough … I just didn’t 
feel well..” 
Interviewer:  “And was it a gradual thing...or did you...something that happened 
suddenly?” 
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Elsie:  “About three or four days it start...sort of built up but then I mean  I was 
only on one Litre of oxygen I mean when I went into hospital they put it up to 3 
and my sats and everything went up” 
Interviewer:  “And how had your health been the year before coming into 
hospital?” 
Elsie:  “I was fine for a year... yep… cause I’d been in hospital the year before 
and everything was fine but it was that Christmas sort of when you’re  rushing 
around everywhere cause it always seem like Christmas time that I go 
down...sighs” 
Interviewer:  “Ok...and tell me a bit about sort of...how you came to come into 
hospital?” 
Elsie:  “Erm... I was feeling unwell and the doctor… came out and he said to me 
that he would get some nurses in every day...every evening they would come and 
look at me and monitor me and everything...erm. they done it for about two or 
three days and the third day things weren’t changing so they rang and spoke to 
the doctor and the doctor said arrange for an ambulance...me sats just wouldn’t 
come up” 
Interviewer:  “And how did you feel at that moment coming into hospital?” 
Elsie:  “Erm...sighs well…there was no other choice really because I just want to 
get better…sighs” 
Interviewer:  “And what were your symptoms coming in to hospital?” 
Elsie:  “Erm the breathing as I said I don’t think I did have a cough...I just felt tired 
and my breathing” 
Interviewer:  “And what was your activity levels just prior to coming in?” 
Elsie:  “Erm all over the Christmas I was fine it was  like a couple of days after 
Christmas I started to sort of feel worn out...it was like I couldn’t bring myself back 
up I was just going down and down” 
Interviewer:  “Had you been able to leave the house?” 
Elsie:  “I was out Christmas time but I don’t think I went out after that” 
Interviewer:  “Ok erm... can you tell me a bit about your hospital experience and 
how that was?” 
Elsie:  “Erm... a bit frightening in the beginning...erm...” 
Interviewer:  “What was frightening about it?” 
Elsie:  “Cause I was sort of had to wear a mask...erm...” 
Interviewer:  “Tell me about that, what did that feel like?” 
Elsie:  “Well I’m a bit claustrophobic and I sort of can’t stand anything around my 
head...erm...but if it got me better then obviously you know erm...but I didn’t stay 
in bed which I never do if I’m ill I’m I want to get out of bed and sit in the chair and 
I was glad when you came along and took me for walks and talking to me” 
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Interviewer:  “Ok great...so how much better did you feel sort of the day you left 
hospital from coming in?” 
Elsie:  “From going in erm I feel about 70% better but now as the time has gone 
on now it’s escalated” 
Interviewer:  “Great” 
Elsie:  “So I was still a bit shaky when I came home weren’t I” 
Interviewer:  “Shaky in what way...weak?” 
Elsie:  “Nervous” 
Interviewer:  “What were you nervous about?” 
Elsie:  “Erm I think it was everything like you said I was weak erm unsteady on 
my feet aswell erm” 
Interviewer:  “That’s fine...ok so tell me about your experience of exercising on 
the ventilator if you think about it from the beginning to now?” 
Elsie:  “It’s really helped...” 
Interviewer:  “Ok in what way?” 
Elsie:  “It’s improved on my breathing erm it doesn’t make me want to stop and 
overall it is a good thing for like people in my condition to use” 
Interviewer:  “Did it feel very different to using the ventilator in hospital?” 
Elsie:  “Yeah a lot different” 
Interviewer:  “I’m going to push you as to why...?” 
Elsie:  “It wasn’t so overpowering on the face and the mask didn’t feel half as 
bad………” 
Interviewer:  “Do you think it helped that you’d experienced it acutely sort of in 
hospital?” 
Elsie:  “Yeah...yeah...” 
Interviewer:  “So if I’d come to you before and said I’m going to try the ventilator 
on...?” 
Elsie:  “It would have frightened me” 
Interviewer:  “It would have frightened you?” 
Elsie:  “Yeah...yeah...yeah” 
Interviewer:  “Cause it did frighten you a little bit in the beginning when I came to 
talk to you?” 
Elsie:  “Yeah I was thinking about the other one laughs...yeah...alright in the 
beginning with the other one I was scared...erm and I...” 
Interviewer:  “What made you scared? Was it how unwell you were?” 
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Elsie:  “No I think it was just having that over my face and it was very hard to get 
to sleep with it because it was the way it was going and I think I must have just 
given in and just laid down to it and that was it...but it seemed to be like I was 
fighting it for some reason but I started going through the night then with with it 
ok” 
Interviewer:  “Did you see the ventilator and maybe you didn’t? But as 
deterioration is that why you were anxious about it?” 
Elsie:  “Yeah…” 
Interviewer:  “So like with home oxygen that was another step?” 
Elsie:  “Yeah…yeah…cause I thought I was gonna be on it all the time...I think it 
was when you came round talking to me and told me it was just when I needed it 
at night and whatever” 
Interviewer:  “Was it was  it a different way of introducing the mask that helped 
so obviously when you were in hospital it’s put on in a different way obviously it’s 
quite urgent because you’re poorly?” 
Elsie:  “Yeah” 
Interviewer:  “Did it seem different…?” 
Elsie:  “What this one here” 
“Yeah yeah very much different it was slowly introduced “ 
Interviewer:  “Yep” 
Elsie:  “And… erm… its as I said it’s not because the thing is you breathe with 
that one the other one does the breathing for you” 
Interviewer:  “So the claustrophobia you got with the machine in hospital you 
didn’t seem to get with this one?” 
Elsie:  “I did but not as bad…yeah” 
Interviewer:  “More to begin with is it something that got better?” 
Elsie:  “Yeah…it got better as time went on…yeah” 
Interviewer:  “Ok good and erm how does it feel this ventilator when you’re using 
it how would you describe it to someone that’s not seen it before?” 
Elsie:  “Don’t know...erm...what the use of it?” 
Interviewer:  “Yeah what does it feel like?” 
Elsie:  “Erm... helpful in the way that you don’t seem to get out of breath like you 
do if you do one without it” 
Interviewer:  “So you spoke about the hospital one being a timing thing and 
fighting with it why doesn’t this one feel like that, did this one ever feel like that in 
the beginning?” 
Elsie:  “No I was just scared in the beginning…yeah………….” 
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Interviewer: “How does it feel…would you be able to describe the sensation to 
anyone...what it feels like...the pressure?” 
Elsie:  “Erm…if… if…you don’t work with it you get all the noise the bubbling…it’s 
just concentrating on using it and using it the right way…………” 
Interviewer:  “Sort of how long do you think it took you to get used to it?” 
Elsie:  “Couple of days” 
Interviewer:  “Were you anxious about using it on the days I wasn’t here?” 
Elsie:  “No…No cause you’d already talked me through it erm as I said if you don’t 
use it in the right sequence it doesn’t work properly does it your blowing back into 
it so you are breathing it in as it is giving it to you and then out again” 
Interviewer:  “Did you find there was anything tricky about setting it up?” 
Elsie:  “No…no” 
Interviewer:  “No problems with connecting the oxygen...or?” 
Elsie:  “I did did once erm and the masks quite easy...what I did was I kept it as it 
was...I didn’t undo any of it…” 
Interviewer:  “Did you find it quite easy exercising with the ventilator?” 
Elsie:  “Yeah…yep…I mean I can do it with or without I could do it with or without 
it but as I was supposed to be using it I carried on using it” 
Interviewer:  “Did it make you feel more confident to do exercise without it then 
as well?” 
Elsie:  “Yeah…very much so...” 
Interviewer:  “Why do you think that was?” 
Elsie:  “I don’t know because you talked to me about it I’ll be honest with you it 
seems to give you the will to try things erm you know you sort of done it with that 
and then you think let me try it without it and its surprising..” 
Interviewer:  “In a good way?” 
Elsie:  “Yeah because you haven’t got that you know when like you’re up and 
down you haven’t got that going with you even if you don’t do the full amount like 
you were doing on that at least you are doing something and that is the way I 
looked at it as well I did try as much as I could but obviously I done more with that” 
Interviewer:  “Did you find it took much power and it was expensive to run?” 
Elsie:  “No because I charge it once since I’ve come out of hospital” 
Interviewer:  “Right…..now I’m just going to remember a few things you have said 
about it and one negative was you couldn’t wear your glasses with it?” 
Elsie:  “No” 
Interviewer:  “Was that an issue?” 
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Elsie:  “Well if I was sort of on it most of the time I don’t think I would have liked it 
because obviously the glasses and it’s not very nice...this one’s ok but the bipap 
with false teeth” 
Interviewer:  “Right ok...so this one was fine with your dentures...?” 
Elsie:  “Yeah...yeah” 
Interviewer:  “But the one in the hospital was not?” 
Elsie:  “Yeah” 
Interviewer:  “Was that the shape of the mask in hospital or?” 
Elsie:  “I think what it was was crunching your teeth what with them being loose 
and they were sort of going out” 
Interviewer:  “Ok but you never experienced that with this…” 
Elsie:  “No No” 
Interviewer:  “Interesting…and how was it when you were trying to walk on it?” 
Elsie:  “I didn’t like that” 
Interviewer:  “Interesting…Ok why not?” 
Elsie:  “Don’t know…” 
Interviewer:  “Because you couldn’t see?” 
Elsie:  “Yeah it it as I said to you in hospital it sort of throws you off and I wasn’t 
actually walking in a line I was whether it was cause as you said the vision sort of 
thing it was sort of blocking vision” 
Interviewer:  “But all the other exercise were easy to do on it?” 
Elsie:  “Yeah” 
Interviewer:  “Did you find it heavy to move around?” 
Elsie:  “No” 
Interviewer:  “Quite light?” 
Elsie:  Nods 
Interviewer:  “Did it pack up alright?” 
Elsie:  “Yeah” 
Interviewer:  “Clean alright” 
Elsie:  “Yeah…everything’s in there anyway so” 
Interviewer:  “Great…so...erm… how was it being involved on the research?” 
Elsie:  “It was very helpful…you were very understanding...and you were very 
helpful” 
Interviewer:  “Is it something you have done before?” 
Elsie:  “No” 
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Interviewer:  “Is it something you would do again?” 
Elsie:  “Yeah” 
Interviewer:  “That’s good why do you say that?” 
Elsie:  “Because it er well there’s always changes and you’ve probably come up 
with and another person’s probably come up with something that would be more 
helpful as well I really really appreciated what you have done…” 
Interviewer:  “Thankyou...I’m going to check through my list...is there anything 
else you want to add before I go through some more specific questions?” 
Elsie:  “No...no...it seems ...how many weeks have we done this now..” 
Interviewer:  “So twelve” 
Elsie:  “Yeah that’s surprising isn’t it” 
Interviewer:  “Gone quick?” 
Elsie:  “Yeah...the only ...well...the only thing that upset me in the beginning...was 
the weather and not being able to go out...and I think I was getting very 
depressed...because it was four walls and that was the only thing I feel was a let-
down the whole three months...we were talking about six weeks weren’t we when 
I never went out..” 
Interviewer:  “Cause of winter?” 
Elsie:  “mmm...and I think since the weather has changed...alright it’s not very 
nice today but I think since the weather changed it has brightened me up as well” 
Interviewer:  “Do you think if you hadn’t have had this you would have done any 
of the exercises?” 
Elsie:  “I would have done some because I can remember…but not it’s more 
advance what you’ve done now with this” 
Interviewer:  “So sort of having severe lung disease...did you feel there was much 
more that could be done for you?” 
Elsie:  “No...No and this is where you come in (tearful)…I really appreciate 
it………..” 
Interviewer:  “Did you feel forgotten?” 
Elsie:  “Yeah...yeah cause once well obviously once you’re discharged from the 
hospital from the doctor you know you just report back to your doctor if you’re not 
well but again that worries me if I went to the doctors with a chest infection will it 
automatically mean back in hospital cause I mean is he going to give you a chance 
to see if you come out of it...and that is one thing that worries me or don’t worry 
me I think about I mean..” 
Interviewer:  “Do you worry about coming back into hospital?” 
Elsie:  “No I don’t worry it’s just the fact that is it every time I’ve got a cold I got to 
go in? Cause I can’t see that I mean you can probably answer that?” 
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Interviewer:  “So you are worried…I’m not sure I’m understanding what you are 
worried about?” 
Elsie:  “No not worried I just think about...Is it every time I get a cold will I end up 
in hospital…yeah...I mean I’ve got my tablets…” 
Interviewer:  “Your antibiotics and steroids” 
Elsie:  “Yeah yep and I have been told the steroids for a cough now I was always 
told the antibiotics” 
Interviewer:  “The antibiotics if it is a productive cough” 
Elsie:  “Mmm” 
Interviewer:  “No not necessarily… I guess because you were so unwell they are 
not going to mess around it might be that you only need to come in for twenty 
hours…what it doesn’t mean is that you are ultimately going to have the machine 
on and I think that’s the important thing to reassure you…what they will do is take 
a blood test quickly to decide and that’s the thing because it’s better that you go 
in and are sorted out quickly and you might only need to stay a couple of days as 
opposed to a week” 
Elsie:  “Yeah…mm…yeah” 
“I and I know when we’ve talked about stuff and general health and wellbeing you 
did say that the past year you’d been doing less than previously?” 
Elsie:  “No for eleven months “ 
Interviewer:  “So really it was the last month?” 
Elsie:  “It was like in the December after Christmas I’d been well from Christmas 
to the new year New Year’s eve I started to feel unwell” 
Interviewer:  “And had you had any contact with the hospital in that last year?” 
Elsie:  “No I’d had a letter to go but that was cancelled by the hospital cause it 
was snow then the next one I had my aunty had died and it was her funeral so I 
rang and then I had another letter saying that cause I hadn’t been to 5 
appointments which wasn’t true it was 2 appointments they closed the book on 
me and they were going to write to my doctor and if anything my doctor would 
have to refer me back” 
Interviewer:  “Do you find it difficult to get to appointments?” 
Elsie:  “What the hospital…no…no over there its brilliant BRI it’s a bit different but 
that’s handy over there yeah and my GP’s just down the road” 
Interviewer:  “How would you describe using the equipment to someone that’s 
not used it before?” 
Elsie:  “Go ahead and use it…don’t be afraid because it will help” 
Interviewer:  “Any advice top tips?” 
Elsie:  “Do as you’re told (laughs) and push on through...” 
Interviewer:  “So how has it influenced your life would you say?” 
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Elsie:  “It’s been a good teacher…very good teacher...” 
Interviewer:  “Do you mean in terms of pacing?” 
Elsie:  “Yeah...erm… you...you obviously you’ve got to work with the machine 
you’ve got to work with the machine but you’ve got to concentrate on what you 
are doing as well otherwise it would just be a waste of time…am I answering all 
your questions alright?” 
Interviewer:  “Yes it’s good I want to hear from you so its fine I’d rather you just 
chat on... 
Erm so would you overall say it’s been a positive or negative experience?” 
Elsie:  “Positive” 
Interviewer:  “Was there anything challenging about it?...I guess the 
claustrophobia in the beginning was?” 
Elsie:  “Erm it was just getting used to it and I as you know I didn’t really walk with 
it it was only with you that I walked with it erm but it was……..” 
Interviewer:  “Was all the instructions on it easy? The ons...offs …the 
connections?” 
Elsie:  “Yeah, yeah” 
Interviewer:  “And did it feel like an extra burden having another piece of kit in 
your house...not just that but the exercise equipment as well taking up more 
room?” 
Elsie:  “No... No... No” 
Interviewer:  “It didn’t make you feel like you’d progressed a bit or changed?” 
Elsie:  “Well no because probably you probably had all this equipment before but 
nobody had sort of only you have come out...I don’t know I mean is it new to you?” 
Interviewer:  “Erm...it’s not new to me in that I’ve worked with it for a long time 
but this obviously using it for exercise is quite a new idea particularly in people 
that sort of have more advanced COPD that have come into hospital and been 
unwell…yeah that’s a new thing…erm were there times when you chose not to 
use it or not to exercise?” 
Elsie:  “Only…my back today…” 
Interviewer:  “That’s fine...but was there at time when you couldn’t be bothered 
or?” 
Elsie:  “No I done it and I done the stairs and I done the steps” 
Interviewer:  “Was it an effort to do it on some days?” 
Elsie:  “No…because I that can be a lot easier than to do it without it” 
Interviewer:  “So you can achieve more with it?” 
Elsie:  “Yeah...yeah…” 
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Interviewer:  “If you did do an exercise session did that mean you could still do 
your daily tasks?” 
Elsie:  “Yes...yeah” 
Interviewer:  “Would you change anything about the design of the equipment?” 
Elsie:  “No...because it’s compact...very compact... and I mean everything’s in the 
bag so you haven’t got to oh where I put that and where is that...it’s all there” 
Interviewer:  “So I know you’ve used nebulisers before and you’ve used oxygen 
concentrators how does it compare to that in terms of set up…?” 
Elsie:  “About the same, it’s only like the fact that you unplug this put it in the 
side…you put the tube in for your mask and you’ve got your switches” 
Interviewer:  “Are you going to miss it?” 
Elsie:  “Probably will…yeah...yeah but as I said I want to go forward and say well 
I’ve done this on my own or I done that on my own” 
Interviewer:  “So have you experienced any physical changes over the past few 
months?” 
Elsie:  “I’ve got stronger a lot stronger…” 
Interviewer:  “Are we talking emotional strength…or physical strength?” 
Elsie:  “Everything…everything it has opened my eyes more knowing that there 
is something else out there that will help…” 
Interviewer:  “Any other physical changes?” 
Elsie:  “I don’t know I……” 
Interviewer:  “Do you think you’ve lost weight?” 
Elsie:  “About the same…well I’m a little bit lower than I was about 4 to 5lb lower 
but it is keeping active really does help cause I think probably by now I’d of 
probably have put more on…” 
Interviewer:  “Because of being at home?” 
Elsie:  “Yep….” 
Interviewer:  “Have you experienced any other changes? 
So sort of feelings…emotions… or mental health?” 
Elsie:  “Well I’m not as depressed as I was because I’ve got something to occupy 
me as you said when I’m not using it and I’m sat there I get up every ten to fifteen 
minutes and I walk into the kitchen or walk the hallway and I come back in I don’t 
stay in one place “ 
Interviewer:  “So it’s changed your…” 
Elsie:  “Attitude towards exercise” 
Interviewer:  “And being sedentary?” 
Elsie:  “Yes” 
539 
 
Interviewer:  “That’s great to hear…what do any friends who have seen you use 
it...what do they think about it?” 
Elsie:  “I’ve only one friend see me…but I have had lots of comments about how 
well I look…” 
Interviewer:  “That’s good...and what did they think about the equipment?” 
Elsie:  “My friend said it’s amazing...what they can do for people now...” 
Interviewer:  “Did anything surprise you about the study?” 
Elsie:  “No because if it helps other people I don’t really mind because I done one 
for breast cancer on the tablet and it wasn’t until the end of the five year survey 
that you knew what you were taking in fact I didn’t know for about ten years and 
it turned out I was taking termazepam…not temazepam…tamoxafin…and not 
placebo...but that was only because they rang me to ask me to do another trial 
and I said well no not really because I didn’t have the results of the last one and 
then the next day they rang to say I was on tamoxifen…” 
Interviewer:  “Has it been time consuming for you?” 
Elsie:  “No...No...I mean you are not here every day so you know you’ve helped 
me...so what I’ve done every day is like a pattern every day right eleven O’clock 
it’s time to do this and I got myself into that (laugh’s) I mean you gotta have a 
timetable or a you know obviously if I had doctors or anything...but I still done it 
not said oh well I’m going to the doctors so I won’t...or I can’t be bothered with 
that today…I done it” 
Interviewer:  “That’s great. Did you have any side effects from using it? Did you 
notice?” 
Elsie:  “Aching limbs ((laughs)) yeah but that could have been the stairs as well 
though mind” 
Interviewer:  “Anything from a respiratory point of view...did you get a dry mouth?” 
Elsie:  “That does dry your mouth out but as soon as you take it off you are 
alright...but erm...the exercise did...it’s like you said if you are not used to it you 
will you will feel it (laughs)” 
Interviewer:  “Erm do you have any advice for people who set this up on 
people...so particularly the people who do the acute hospital stuff...if they had put 
it on you differently would it have changed your perception of it?” 
Elsie:  “And talked more about it as well...cause they don’t really tell you what 
they are actually doing all they say is that we’ve got to put a mask on you and 
that’s it...” 
Interviewer:  “So you don’t think they explained properly what it was?” 
Elsie:  “No…no” 
Interviewer:  “Did you know about it before?” 
Elsie:  “Yeah” 
Interviewer:  “Had you had it before?” 
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Elsie:  “No” 
Interviewer:  “What was your understanding of it before you had it?” 
Elsie:  “Erm that it did help to take out some of the enzymes in your body and that 
is what it does isn’t it…” 
Interviewer:  “Had you seen any one use it before?” 
Elsie:  “I’ve seen quite a few people…my sister had it…I think...but she wasn’t on 
it all the time and they wouldn’t let her have it..” 
Interviewer:  “Did that influence what you thought about it?” 
Elsie:  “No...No cause I saw the difference in her look” 
Interviewer:  “Have you got any advice for someone like me who sets this up on 
patients at home…anything I could change?” 
Elsie:  “No because you explained everything ...you explained to me in hospital 
and then when we got together the first time you showed me and you explained 
all that it does and you said like you can turn it up you can adjust it an everything 
which is good” 
Interviewer:  “That’s good to hear. So is there anything else about using the 
equipment or the study that you would like to talk about or add?” 
Elsie:  “Well I’d just like other people to take part it would make a lot of difference 
for yourselves and it would help the people cause I’ve seen what it done to me…” 
Interviewer:  “Just give me an idea of what you can do now...what you couldn’t 
do before?” 
Elsie:  “Erm I can walk round the shops, I go up and down the stairs, I walk out to 
the front with the oxygen obviously erm I’ve been out a few times...been to the 
hospital...been to the doctors...been to my cousins…went out for a meal which is 
something I haven’t done for a long long time.. I mean I couldn’t tell you well it 
was probably about eight months ago that I walked around the supermarket with 
a trolley...cause a lot of people… even this morning said oh where’s your scooter” 
Interviewer:  “That’s great and you’re back doing stairs” 
Elsie:  “Yep…” 
Interviewer:  “Is that something you hadn’t done?…” 
Elsie:  “Yep...Erm I haven’t done it today obviously but I done it the last few days 
but I will make up for it honestly... I will do it” 
Interviewer:  “But it’s something you haven’t been able to do for a while? You’d 
been getting the lift?” 
Elsie:  “Hmm… I mean I won’t go down all the flights of stairs...but I must admit I 
went over there this morning and if I didn’t have the trolley before  I would have 
had to have stayed on the bike...scooter” 
Interviewer:  “The next stage is to go on to pulmonary rehab which is fantastic” 
Elsie:  “Ummhmm” 
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Interviewer:  “Was that something you would have thought about before?” 
Elsie:  “I turned it down quite a few times” 
Interviewer:  “Why was that?” 
Elsie:  “Because people had told me they are very pushy” 
Interviewer:  “In what way?” 
Elsie:  “Force you to do things…but I’ve learnt now you shouldn’t listen to other 
people (coughs)” 
Interviewer:  “And is that the only reason that you turned it down?” 
Elsie:  “Yeah” 
Interviewer:  “Did anyone explain to you that this might not be the case?” 
Elsie:  “I read it this time in a booklet from the hospital I came away with the other 
day…they won’t force you to do anything you don’t want to do (laughs)” 
Interviewer:  “So now you’ve finished this research...are you feeling a bit more 
positive about life?” 
Elsie:  “(tearful) very much...very much (laughs) but I’ll tell you why I’m laughing 
I’ll tell you soon” 
Interviewer:  “Ok...and do you feel a bit more positive about your condition?” 
Elsie:  “Yeah...yeah” 
Interviewer:  “And obviously you still get breathless do you feel in control of it 
now?” 
Elsie:  “Yeah yep and I’ll be honest with you Kate I know like with the oxygen… 
erm I said to you about cold sores...if you know anyone that is the best thing 
(pointing to lip salve)not Vaseline…they are gone 
Erm what was the question you asked me” 
Interviewer:  “Erm do you fell more in control?” 
Elsie:  “Yeah…yeah… and another help has been me getting a sats machine as 
well because I can monitor the doctor…but they are expensive for some people 
that was £24 “ 
Interviewer:  “So self monitoring is important to you?” 
Elsie:  “Yeah…when I saw them a while ago they were sixty nine pounds and 
when the doctor took hers out last week it’s exactly the same as the one I got 
(laughs)cause I said to her I bought one and she said very good idea” 
Interviewer:  “Why is it important for you to know what your oxygen levels are?” 
Elsie:  “Because if my sats go don then I know that there’s something wrong and 
then it’s not advancing more” 
Interviewer:  “And how did you feel doing the monitoring stuff…so the 
questionnaires and walk tests” 
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Elsie:  “Brilliant because it’s all a kick up the bum (Laughs)” 
Interviewer:  “So you never resented it…” 
Elsie:  “No” 
Interviewer:  “And the walk tests because I know that’s something you had talked 
about disliking before” 
Elsie:  “I did pretty well” 
Interviewer:  “Amazing” 
Elsie:  “Yeah I think over the weeks it starts to build up more and more and more 
...the last time was twenty seven times weren’t it... I mean I couldn’t believe I done 
that many and then we done steps you know I think it’s progression you done that 
and then you think oh I’ll achieve this or that the next time I just go for it…” 
Interviewer:  “What do you think the worst thing about COPD is?” 
Elsie:  “Breathlessness…frustration of not being able to alright I don’t hoover I 
use the little hand held erm I do everything...I clean windows and everything but 
in moderation I don’t go berserk with it I cooked a lovely dinner yesterday…I 
washed up…everything...but it’s just that as I‘ve said to you before I am one that 
used to walk fast do everything pretty fast and it’s the learning to slow down and 
it does help…you still get breathless but not as bad” 
Interviewer:  “So you have had to completely change…” 
Elsie:  “Your way of life...yeah” 
Interviewer:  “Do you feel...I mean I know you get out and about now but Would 
you say it was quite lonely having COPD?” 
Elsie:  “Erm… it can be I mean I’ve got loads of friends but I just don’t see them 
now... I mean I had a friend we used to go out in the car and we used to go 
shopping and everything together but I don’t even ask now and she doesn’t ask 
me sometimes you can feel very cut off I mean the girls I used to work with before 
at work you know in a job you keep in touch for a while and then everything wears 
off and you don’t hear anything for a while…a couple of people on Facebook…that 
I used to work with and all that...but you can get very lonely…very very lonely…” 
Interviewer:  “Do you think there is much support for people with COPD?” 
Elsie:  “There probably is Kate if you look around but who do you contact….. I 
know there is a phone number for the British Lung foundation and all that but 
there’s nothing is there now really… (Sighs and yawns)” 
Interviewer:  “So let’s finish the interview on a positive…so my understanding of 
what you have told me is the research has been a very good experience for you?” 
Elsie:  “Very very good” 
Interviewer:  “It has changed your perception of the ventilator?” 
Elsie:  “Yeah” 
Interviewer:  “Its changed your perception of exercise?” 
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Elsie:  “Yep” 
Interviewer:  “And you are able to do a lot more than you were?” 
Elsie:  “Yeah” 
Interviewer:  “You are not afraid of exercise?” 
Elsie:  “No” 
Interviewer:  “And it has also improved your feeling down/depression?” 
Elsie:  “Yeah” 
Interviewer:  “Would you say there is anything else or is it all?” 
Elsie:  “Captured...I mean there’s nothing else really… I could kick myself now for 
having this (Elsie injured her back loading the washing machine)but it doesn’t stop 
me walking a slow pace but not too far... I don’t say to myself I can’t do that so 
every 10 to 15 minutes even if it’s only out there and come back in at my own 
pace I done it cause the worse thing you can do is just sit there as with this illness 
and with what I got wrong with me now,” 
Interviewer:  “Anything else you want to add?” 
Elsie:  “No so is there any contacts?” 
Interviewer:  “There is the breathe easy groups so the BLF have the contacts for 
your nearest group...now there used to be one in Whitchurch but that had shut for 
a bit the BLF will be able to update you...they meet monthly and all stages of 
disease go and they do social activities…bingo...etc...the one I have attended is 
in North Bristol...that would be my preference...but also when you go to Pulmonary 
rehabilitation they do a fololow up group so they do a maintenance group so once 
you’ve completed the 6 week coursed you can still continue…if there isn’t a 
breathe easy group they need someone like you to start one up” 
Elsie:  “Yeah…yeah…” 
(Stopped recorder) 
(Post interview Elsie said the other main change she wanted to thank me for was 
increasing her confidence and making her feel like the old Elsie again…making 
her feel human. But she didn’t want to say this on tape because she knew she 
would get upset but was happy for me to document this.) 
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Appendix 21 Baseline severity data 
Age 
Standard care Exercise on NIV in 
hospital 
Exercise on NIV in 
hospital and home 
ID Age ID Age ID Age 
NIV  2.1 69.0 NIV 4.2 97.0 NIV 1.3 52.0 
NIV  5.1 66.0 NIV 6.2 64.0 NIV 3.3 65.0 
NIV  7.1 72.0 NIV 8.2 46.0 NIV 9.3 66.0 
NIV 12.1 52.0 NIV 11.2 78.0 NIV 10.3 59.0 
NIV 15.1 65.0 NIV 13.2 82.0 NIV 14.3 69.0 
NIV 16.1 64.0 Mean 73.4 NIV 18.3 62.0 
NIV 17.1 69.0 SD 17.3 Mean 62.2 
Mean 65.3 CI 15.1 SD 5.5 
SD 6.0   CI 4.4 
CI (95%) 4.4     
 
FEV1% predicted 
Standard care Exercise on NIV in 
hospital 
Exercise on NIV in 
hospital and home 
ID FEV1% ID FEV1% ID FEV1% 
NIV  2.1 Deceased NIV 4.2 51.0 NIV 1.3 16.0 
NIV  5.1 17.0 NIV 6.2 24.0 NIV 3.3 40.0 
NIV  7.1 19.0 NIV 8.2 14.0 NIV 9.3 25.0 
NIV 12.1 28.0 NIV 11.2 32.0 NIV 10.3 38.0 
NIV 15.2 17.0 NIV 13.2 20.0 NIV 14.3 9.0 
NIV 16.1 61.0 Mean 28.2 NIV 18.3 27.0 
NIV 17.1 25.0 SD 12.8 Mean 25.8 
Mean 27.8 CI 11.2 SD 11.0 
SD 15.4   CI 8.8 
CI (95%) 12.3     
 
Smoking History (Pack years) 
Standard care Exercise on NIV in 
hospital 
Exercise on NIV in 
hospital and home 
ID Pack 
years 
ID Pack 
years 
ID Pack 
years 
NIV 2.1 40.0 NIV 4.2 0.0 NIV 1.3 30.0 
NIV 5.1 40.0 NIV 6.2 40.0 NIV 3.3 40.0 
NIV 7.1 50.0 NIV 8.2 40.0 NIV 9.3 60.0 
NIV 12.1 40.0 NIV 11.2 25.0 NIV 10.3 25.0 
NIV 15.1 40.0 NIV 13.2 30.0 NIV 14.3 60.0 
NIV 16.1 40.0 Mean 27.0 NIV 18.3 15.0 
NIV 17.1 25.0 SD 14.7 Mean 38.3 
mean 39.3 CI 12.9 SD 17.0 
SD 6.8   CI 13.6 
CI 5.0     
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Appendix 22 6MWT Raw data 
 
Raw Data for the 6MWT (m): Standard Care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
2.1 0.0     
5.1 306.0 357.0 270.0 162.0 216 
7.1 2.0 30.0 112.0 15.0 30 
12.1 0.0 9.0 6.0 8.0 16 
15.1 8.0 8.0 14.0 10.0 12 
16.1 4.0 4.0 8.0 14.0 20 
17.1 22.0 40.0 0.0 0.0 22 
Mean 48.9 74.7 68.3 34.8 52.7 
SD 105.2 126.9 98.1 57.1 73.3 
95% CI 77.9 101.6 78.5 45.7 58.6 
 
Raw data for the 6MWT (m): Exercise on NIV in hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
4.2 38.0 37.0 40.0 14.0 21.0 
6.2 2.0 4.0 1.0 5.0 5.0 
8.2 24.0 37.0 100.0 20.0 10.0 
11.2 0.0 145.0 60.0 12.0 24.0 
13.2 20.0 90.0 12.0 80.0 70.0 
Mean 16.8 62.6 42.6 26.2 26.0 
SD 14.2 49.6 35.4 27.3 23.1 
95% CI 12.5 43.4 31.0 23.9 20.2 
 
Raw data for the 6MWT (m): Exercise on NIV in hospital and home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
1.3 56.0 40.0 70.0 56.0 84.0 
3.3 315.0 321.0 470.0 423.0 493.5 
9.3 2.0 82.0 79.0 92.0  
10.3 30.0 30.0 140.0 217.0 238.0 
14.3 0.0 71.5 99.0   
18.3 22.0 90.0 305.0 338.0 348.0 
Mean 70.8 105.8 193.8 225.2 290.9 
SD 110.8 98.6 146.7 140.2 149.9 
95% CI 88.6 78.9 17.3 122.9 146.9 
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Appendix 23 SGRQ Raw data 
The raw data for SGRQ: Total scores for Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 90.7     
NIV 5.1 72.3 49.7 50.8 55.8 60.9 
NIV 7.1 73.0 49.9 45.9 53.8 59.6 
NIV 12.1 90.1 83.1 84.2 83.5 83.9 
NIV 15.1 88.9 88.9 88.4 82.7 82.8 
NIV 16.1 83.0 83.0 55.7 83.6 97.1 
NIV 17.1 69.4 64.8 58.1 75.3 59.1 
Mean 81.1 69.9 63.8 72.5 73.9 
SD 8.6 16.0 26.4 12.8 14.8 
95% CI 6.4 12.8 13.1 10.3 11.8 
 
The raw data for SGRQ: Total scores for Exercise on NIV in hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 85.3 61.4 66.2 72.7 74.0 
NIV 6.2 91.0 90.7 92.2 94.4 97.9 
NIV 8.2 91.9 93.1 93.1 79.8 88.8 
NIV 11.2 54.2 72.1 74.1 76.0 75.3 
NIV 13.2 49.0 50.7 75.3 64.8 64.6 
Mean 74.3 73.6 80.2 77.5 80.1 
SD 18.7 16.4 10.6 9.8 11.8 
95% CI 16.4 14.4 9.3 8.6 10.3 
 
The raw data for SGRQ: Total scores for Exercise on NIV in hospital and home 
group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 81.4 82.9 83.1 78.4 79.5 
NIV 3.3 60.1 50.2 53.7 55.7 57.8 
NIV 9.3 89.2 70.7 62.7 75.8  
NIV 10.3 67.5 67.5 41.6 46.6 42.4 
NIV 14.3 69.7 70.8 55.5   
NIV 18.3 49.3 49.3 29.3 18.0 21.3 
Mean 69.5 65.2 54.3 54.9 50.3 
SD 13.1 12.0 16.8 22.0 21.3 
95% CI 10.5 9.6 13.4 19.3 20.8 
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The raw data for SGRQ: Impact scores for Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 90.3     
NIV 5.1 57.8 36.2 38.4 28.4 44.0 
NIV 7.1 66.6 29.4 28.3 34.1 38.8 
NIV 12.1 85.5 75.4 81.5 74.7 72.3 
NIV 15.1 81.7 81.7 89.1 73.0 96.0 
NIV 16.1 78.2 78.2 31.9 73.7 48.5 
NIV 17.1 55.4 54.7 36.6 69.7 20.3 
Mean 73.7 59.3 51.0 58.9 62.4 
SD 12.8 20.7 24.6 19.7 20.3 
95% CI 9.4 16.5 19.7 15.8 16.2 
 
The raw data for SRGQ: Impact scores for the Exercise on NIV in hospital 
group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 73.4 42.0 51.9 57.2 57.8 
NIV 6.2 85.0 85.8 88.0 91.7 100.0 
NIV 8.2 89.8 92.2 92.2 65.5 86.5 
NIV 11.2 50.2 50.2 54.0 60.5 62.3 
NIV 13.2 14.8 25.3 61.5 34.9 44.0 
Mean 62.6 59.1 69.5 62.0 70.1 
SD 27.6 25.8 17.1 18.2 20.3 
95% CI 24.2 22.6 15.0 15.9 17.8 
 
The raw data for SGRQ: Impact score for the Exercise on NIV in hospital and 
home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 73.3 81.5 73.5 74.2 67.4 
NIV  3.3 38.7 28.7 26.7 42.5 42.3 
NIV 9.3 86.1  43.7 62.5  
NIV 10.3 59.0  18.3 17.3 14.9 
NIV 14.3 51.3  37.5   
NIV 18.3 26.6 26.6 20.8 7.3 7.3 
Mean 55.8 50.5 36.7 40.7 33.0 
SD 20.0 18.8 18.7 25.5 23.8 
95% CI 16.0 15.0 14.9 22.4 23.3 
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The raw data for SGRQ: Activity score for Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 100.0     
NIV 5.1 100.0 85.3 49.4 76.7 43.2 
NIV 7.1 100.0 59.3 39.4 29.0 52.0 
NIV 12.1 100.0 91.0 77.2 81.7 84.1 
NIV 15.1 100.0 91.9 64.9 81.1 97.5 
NIV 16.1 100.0 66.6 47.5 97.5 94.9 
NIV 17.1 100.0 46.9 47.5 47.4 26.0 
Mean 100.0 73.5 54.3 68.9 66.3 
SD 0.0 17.0 12.7 23.3 27.3 
95% CI N/A 13.6 10.2 18.6 21.8 
 
The raw data for SGRQ: Activity scores for Exercise on NIV in hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 100.0 66.4 63.9 84.1 79.3 
NIV 6.2 100.0 89.6 91.1 92.5 87.1 
NIV 8.2 100.0 83.5 83.5 88.2 89.6 
NIV 11.2 46.2 91.1 91.1 82.0 71.5 
NIV 13.2 92.5 86.5 74.2 96.0 79.4 
Mean 87.7 83.4 80.7 88.6 81.4 
SD 21.0 8.9 10.5 5.2 6.4 
95% CI 18.4 7.8 9.2 4.5 5.6 
 
The raw data for SGRQ: Activity scores for Exercise on NIV in hospital and at 
home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 92.5 69.6 95.3 64.0 78.9 
NIV  3.3 79.7 78.5 79.0 82.2 79.7 
NIV 9.3 100.0 77.9 79.9 74.2  
NIV 10.3 92.5 49.4 33.1 63.9 49.7 
NIV 14.3 92.5 93.5 45.6   
NIV 18.3 73.8 77.1 28.4 31.9 26.3 
Mean 88.5 74.3 60.2 63.2 58.6 
SD 8.9 13.2 25.6 17.1 22.3 
95% CI 7.1 10.6 20.5 15.0 21.8 
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The raw data for SGRQ: Symptom scores for Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 74.8     
NIV 5.1 68.5 85.3 49.4 76.7 43.2 
NIV 7.1 44.2 59.3 39.4 29.0 52.0 
NIV 12.1 85.8 91.0 77.2 81.7 84.1 
NIV 15.1 91.9 91.9 64.9 81.1 97.5 
NIV 16.1 66.6 66.6 47.5 97.5 94.9 
NIV 17.1 56.3 46.9 47.5 47.5 26.0 
Mean 69.7 73.5 54.3 68.9 66.3 
SD 15.2 17.0 12.7 23.3 27.3 
95% CI 11.3 10.2 10.2 20.4 21.8 
 
The data for SGRQ: Symptom scores for the Exercise on NIV in hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 95.2 66.4 63.9 84.1 79.3 
NIV 6.2 93.5 89.6 91.9 92.5 87.1 
NIV 8.2 83.4 83.5 83.5 88.2 89.6 
NIV 11.2 81.7 91.1 91.1 82.0 71.5 
NIV 13.2 78.9 86.5 74.2 96.0 79.4 
Mean 86.5 83.4 80.7 88.6 81.4 
SD 6.6 8.9 10.5 5.2 6.4 
95% CI 5.8 7.8 9.2 4.5 5.6 
 
The raw data for SGRQ: Symptoms scores for the Exercise on NIV in hospital 
and home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 86.0 69.6 95.3 64.0 78.9 
NIV  3.3 93.0 78.5 79.0 82.2 79.7 
NIV 9.3 79.2 77.9 79.9 74.2  
NIV 10.3 49.4 49.4 33.1 63.9 49.7 
NIV 14.3 86.7 93.5 45.6   
NIV 18.3 77.1 77.1 28.4 31.9 26.3 
Mean 78.6 74.3 60.2 63.2 58.6 
SD 14.0 13.2 25.6 17.1 22.3 
95% CI 11.2 10.6 20.5 15.0 21.8 
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Appendix 24 LCADL Raw data 
Raw data for the LCADL: Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 62.00     
NIV 5.1 28.0 32.0 25.0 29.0 47.0 
NIV 7.1 66.0 42.0 37.0 48.0 44.0 
NIV 12.1 67.0 64.0 65.0 65.0 65.0 
NIV 15.1 56.0 57.0 63.0 63.0 49.0 
NIV 16.1 43.0 43.0 58.0 50.0 59.0 
NIV 17.1 49.0 48.0 46.0 60.0 46.0 
Mean 53.0 47.7 49.0 52.5 51.7 
SD 13.1 10.4 14.5 12.3 7.7 
95% CI 9.7 8.3 11.6 10.7 6.7 
 
Raw data for the LCADL: NIV on exercise in hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 54.0 66.0 63.0 64.0 62.0 
NIV 6.2 57.0 57.0 54.0 58.0 55.0 
NIV 8.2 53.0 44.0 52.0 62.0 64.0 
NIV 11.2 35.0 45.0 51.0 53.0 50.0 
NIV 13.2 36.0 43.0 57.0 47.0 52.0 
Mean 47.0 51.0 55.4 56.8 56.6 
SD 9.5 9.1 4.3 6.2 5.5 
95% CI 8.3 7.9 3.8 5.4 4.8 
 
Raw data for the LCADL: NIV on exercise in hospital and home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 50.0 49.0 53.0 56.0 59.0 
NIV  3.3 29.0 32.0 37.0 35.0 31.0 
NIV 9.3 67.0 53.0 45.0 55.0  
NIV 10.3 59.0 56.0 47.0 43.0 49.0 
NIV 14.3 65.0 61.0 58.0   
NIV 18.3 29.0 56.0 20.0 18.0 24.0 
Mean 49.8 51.2 37.3 41.4 40.8 
SD 15.7 9.3 12.3 19.5 13.9 
95% CI 12.6 7.4 9.9 17.1 13.7 
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Appendix 25 MMRC Dyspnoea score 
MMRC Raw data: Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 4.0     
NIV 5.1 1.0 1.0 1.0 3.0 3.0 
NIV 7.1 4.0 2.0 3.0 3.0 3.0 
NIV 12.1 4.0 4.0 4.0 4.0 4.0 
NIV 15.1 3.0 3.0 4.0 4.0 4.0 
NIV 16.1 4.0 4.0 4.0 4.0 4.0 
NIV 17.1 4.0 3.0 3.0 4.0 3.0 
Mean 3.4 2.8 3.2 3.7 3.5 
SD 1.0 1.1 1.1 0.5 0.5 
95% CI 0.8 0.9 0.9 0.4 0.4 
 
MMRC Raw data: Exercise on NIV in hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 4.0 4.0 4.0 3.0 4.0 
NIV 6.2 4.0 4.0 4.0 4.0 4.0 
NIV 8.2 4.0 4.0 4.0 4.0 4.0 
NIV 11.2 3.0 3.0 4.0 3.0 4.0 
NIV 13.2 1.0 3.0 4.0 4.0 4.0 
Mean 3.2 3.6 4.0 3.6 4.0 
SD 1.2 0.5 0.0 0.5 0.0 
95% CI 1.0 0.4 N/A 0.4 N/A 
 
MMRC Raw data: Exercise on NIV in hospital and home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 4.0 4.0 4.0 4.0 4.0 
NIV  3.3 3.0 1.0 1.0 1.0 2.0 
NIV 9.3 4.0 3.0 3.0 4.0  
NIV 10.3 4.0 4.0 3.0 3.0 3.0 
NIV 14.3 4.0 4.0 4.0   
NIV 18.3 3.0 3.0 3.0 3.0 1.0 
Mean 3.7 3.2 3.0 3.0 2.5 
SD 0.5 1.1 1.0 1.1 1.1 
95% CI 0.4 0.9 0.8 1.0 1.1 
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Appendix 26 MBORG Raw data 
MBORG raw data: Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 8.0     
NIV 5.1 2.0 2.0 2.0 3.0 3.0 
NIV 7.1 4.0 4.0 0.5 1.0 0.5 
NIV 12.1 6.0 7.0 8.0 8.0 6.0 
NIV 15.1 6.0 7.0 6.0 7.0 3.0 
NIV 16.1 5.0 5.0 4.0 4.0 4.0 
NIV 17.1 8.0 1.0 3.0 10.0 3.0 
Mean 5.6 4.3 3.9 5.5 3.3 
SD 2.0 2.3 2.5 3.1 1.6 
95% CI 1.5 1.8 2.0 2.5 1.3 
 
MBORG raw data: Exercise on NIV in hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 0.5 2.0 2.0 0.0 5.0 
NIV 6.2 8.0 7.0 8.0 4.0 9.0 
NIV 8.2 4.0 2.0 5.0 4.0 5.0 
NIV 11.2 3.0 3.0 6.0 7.0 8.0 
NIV 13.2 6.0 6.0 3.0 3.0 6.0 
Mean 4.3 4.0 4.8 3.6 6.6 
SD 2.6 2.1 2.1 2.2 1.6 
95% CI 2.2 1.8 1.9 2.0 1.4 
 
MBORG raw data: Exercise on NIV in hospital and home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 1.0 0.5 2.0 2.0 2.0 
NIV  3.3 3.0 1.0 2.0 2.0 0.0 
NIV 9.3 4.0 1.0 3.0 4.0  
NIV 10.3 7.0 6.0 2.0 4.0 6.0 
NIV 14.3 0.0 1.0 4.0   
NIV 18.3 0.0 0.0 2.0 2.0 0.5 
Mean 2.5 1.6 2.5 2.8 2.1 
SD 2.5 2.0 0.8 1.0 2.4 
95% CI 2.0 1.6 0.6 0.9 2.3 
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Appendix 27 EQ-5D-5L: Raw data 
EQ-5D-5L utility score raw data: Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 0.1     
NIV 5.1 1.0 1.0 1.0 0.6 0.4 
NIV 7.1 0.7 0.6 0.8 0.5 0.6 
NIV 12.1 -0.6 0.1 0.1 0.0 0.1 
NIV 15.1 0.1 0.2 0.2 0.0 0.2 
NIV 16.1 0.1 0.1 0.0 -0.4 -0.2 
NIV 17.1 0.3 0.3 0.7 -0.3 0.3 
Mean 0.2 0.4 0.5 0.1 0.2 
SD 0.5 0.3 0.4 0.4 0.3 
95% CI 0.3 0.3 0.3 0.3 0.2 
 
EQ-5D-5L utility score raw data: Exercise on NIV hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 0.6 0.5 0.4 0.2 0.2 
NIV 6.2 0.1 0.5 0.1 0.1 0.0 
NIV 8.2 0.6 0.8 0.6 0.3 0.5 
NIV 11.2 0.6 0.7 0.3 0.6 0.5 
NIV 13.2 -0.1 0.6 -0.2 0.0 0.0 
Mean 0.4 0.6 0.2 0.3 0.3 
SD 0.3 0.1 0.3 0.2 0.2 
95% CI 0.3 0.1 0.2 0.2 0.2 
 
EQ-5D-5L utility score raw data: Exercise on NIV hospital and home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 0.7 0.4 0.3 0.3 0.4 
NIV  3.3 0.5 0.6 0.9 0.7 0.5 
NIV 9.3 -0.2 -0.2 0.8 0.5  
NIV 10.3 0.1 0.1 0.6 0.7 0.8 
NIV 14.3 0.3 0.4 0.7   
NIV 18.3 0.8 0.8 0.8 0.9 0.9 
Mean 0.4 0.3 0.7 0.6 0.7 
SD 0.3 0.3 0.2 0.2 0.2 
95% CI 0.3 0.1 0.1 0.2 0.2 
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EQ-5D-5L VAS raw data: Standard care group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 2.1 25.0     
NIV 5.1 50.0 40.0 80.0 0.0 80.0 
NIV 7.1 40.0 70.0 90.0 50.0 50.0 
NIV 12.1 10.0 20.0 9.0 30.0 10.0 
NIV 15.1 20.0 20.0 20.0 20.0 20.0 
NIV 16.1 40.0 40.0 40.0 40.0 30.0 
NIV 17.1 75.0 95.0 48.0 55.0 45.0 
Mean 37.1 47.5 47.8 32.5 39.2 
SD 20.0 27.0 29.3 18.7 22.8 
95% CI 14.8 21.6 23.5 14.9 18.2 
 
EQ-5D-5L VAS raw data: Exercise on NIV in hospital group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 4.2 35.0 50.0 50.0 30.0 25.0 
NIV 6.2 10.0 30.0 40.0 25.0 45.0 
NIV 8.2 20.0 30.0 35.0 35.0 25.0 
NIV 11.2 65.0 60.0 60.0 10.0 30.0 
NIV 13.2 90.0 70.0 80.0 80.0 70.0 
Mean 44.0 48.0 53.0 36.0 39.0 
SD 29.6 16.0 16.0 23.5 15.7 
95% CI 25.9 14.0 14.0 20.6 13.7 
 
EQ-5D-5L VAS raw data: Exercise on NIV in hospital and home group. 
Participant Baseline Discharge Month 1 Month 2 Month 3 
NIV 1.3 50.0 30.0 40.0 40.0 60.0 
NIV 3.3 55.0 65.0 70.0 65.0 40.0 
NIV 9.3 0.0 50.0 50.0 50.0  
NIV 10.3 35.0 50.0 80.0 80.0 50.0 
NIV 14.3 25.0 45.0 80.0   
NIV 18.3 75.0 75.0 80.0 80.0 80.0 
Mean 40.0 52.5 66.7 63.0 57.5 
SD 23.8 14.4 16.0 16.0 14.8 
95% CI 19.0 11.5 12.8 14.0 14.5 
 
